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Abstract 
 
Tumour metastasis to the brain is a common and deadly development in certain cancers; 
18-30% of breast tumours metastasise to the brain. The contribution that gene silencing 
through epigenetic mechanisms plays in metastasis to the brain is not well understood.  
To identify epigenetic drivers of brain metastasis, a combined candidate gene screen 
using literature review, bioinformatics analysis of 450K methylation data of primary 
breast tumours from The Cancer Genome Atlas (TCGA) and Genome-wide methylation 
analysis of metastatic brain tumors that originated from primary breast tumours were 
carried out.  
A candidate gene approach identified two genes (BNC1 and CCDC8) dysregulated in 
breast to brain metastases (BBM) from a screen of 78 genes. Similarly, bioinformatic 
analyses of TCGA data identified GALNT9 and an independent comparison of genome-
wide methylation profiles in brain metastases identified 7 genes including non-coding 
RNA genes dysregulated in BBM. Taken together, these 10 genes identified are 
metastatic suppressor or promoter genes, which include novel regulatory elements non-
coding RNA (ncRNAs) genes such as microRNAs, long intergenic non-coding RNAs 
(lincRNAs) or non-protein coding genes such as pseudogenes derived from their 
parental gene. Methylation analyses in BBM and their associated primary tumours from 
individual patients have revealed that identified genes are dysregulated either early or 
late in tumour evolution due to aberration in DNA methylation. In addition, methylation 
status of these genes in BBM correlates to serum DNA methylation in individual 
patients, which suggests that these genes could be used as a panel of prognostic markers 
or as therapeutic targets for BBM.  
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CHAPTER 1 
Introduction 
 
1.1 Cancer as a disease 
1.1.1 Global incidence of cancer  
One in seven deaths in the world are caused by cancer (American Cancer Society, 
2015); a disease comprised of more than 100 subtypes, these subtypes originate from 
most of the different cell types found in adults and children (Stratton et al., 2009). The 
incidence of cancer is rising, factors such as ageing populations, urbanization and other 
lifestyle factors such as smoking, obesity and changes in reproductive patterns are 
believed to contribute to the rise in cancer cases globally (Torre et al., 2015). In 2012, 
there were 6.7 million new cases of cancer in females and 7.4 million cases in males 
making a total of 14.1 new cases of cancer globally (Cancer Research UK, 2015). As of 
2012, lung cancer remained the major cause of deaths in males globally; breast cancer is 
the second biggest cause of global deaths, the majority of these deaths occurring in 
women (Torre et al., 2015).  The cancer incidence and deaths by major cancer types in 
males and females are illustrated in figure 1.1.  
 
 
 
 
 
 
 
 
2 
 
 
 
Figure 1.1: The global cancer incidence and deaths in 2012. The major cause of 
deaths by cancer worldwide is cancer of the lungs including bronchial and tracheal 
cancers in males and breast cancer in females. The types of cancer causing the 
most deaths in both men and women are lung, liver, breast, stomach, colon and 
rectal, oesophagus, pancreas and leukaemia. The figure is taken from (Torre et al., 
2015). 
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1.1.2 Genetic and cellular basis of Cancer 
 
Cancer is characterised by uncontrolled cellular proliferation (American Cancer Society, 
2015) followed by metastasis to different organs. The role of gene aberrations in cancer 
was first suggested when unusual chromosomal abnormalities were observed in 
dividing cancer cells under the microscope in the late nineteenth century (Hansemann, 
1890). This observation paved the way to the conclusion that a tumour is a mass of 
abnormal clones with aberrations in genetic material (Hungerford & Nowell, 1962). 
More recently, different types of genetic abnormalities such as mutations, translocations, 
and genomic rearrangements became evident and specific aberrations such as mutations 
in specific positions such as G to T transition (as in HRAS gene) was identified (Reddy 
et al., 1982).  Hence, cancer arises due to a series of genetic aberrations that follows the 
process of Darwinian evolution within the microenvironment among cellular 
populations. These genetic alterations provide selective advantages to the tumour cells 
enabling them to grow and proliferate more effectively compared to their neighbouring 
cells (Stratton et al., 2009).  The genetic aberrations that occur in cancer cells could 
either be cancer drivers or passengers; a driver mutation contributes to the 
transformation of normal cell into a cancer cell whereas a passenger mutation does not 
obviously contribute to tumorigenicity (Schinzel & Hahn, 2008). In addition to classical 
mutation, epigenetic programing is also dysregulated in tumours, such that errors result 
in aberrations in chromatin structure and gene expression patterns  (See section 1.2). 
Therefore, the origin of cancer or tumorigenesis is a result of a series of genetic and 
epigenetic changes that lead to defects of cellular growth, proliferation and 
differentiation (Schinzel & Hahn, 2008).  
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1.2 The Role of Epigenetics in Cancer 
 
The term epigenetics, which refers to the heritable changes in the pattern of gene 
expression not directly mediated by alterations in the primary nucleotide sequence, was 
first used by Conrad Waddington to explain the interactions between the genes and their 
environment (Jones & Baylin, 2007; Dwivedi et al., 2011). The study of epigenetics has 
developed into one of the most promising fields of biomedical research from its 
beginning in 1940, epigenetic regulation is now known to be associated with many 
human diseases including human cancers (Rodriguez-Paredes & Esteller, 2011). 
Various crucial cellular mechanism that regulate gene silencing such as imprinting and 
X-chromosome inactivation are essential during development and such mechanisms are 
required for stable cell proliferation and growth (Jaenisch & Bird, 2003). Epigenetic 
mechanisms such as DNA methylation, RNA-mediated gene silencing and histone 
modification lead to changes in chromatin dynamics that mediate cellular 
reprogramming necessary for development and cellular identity (Herceg & Vaissiere, 
2011). Dysregulation of these epigenetic processes contribute to aberrations in gene 
expression giving tumour cells a selective growth advantage that contributes to cancer 
development (Tsai & Baylin, 2011). 
 
1.2.1 The role of DNA methylation  
1.2.1.1 Origin of DNA methylation and its maintenance in cells 
DNA methylation refers to the addition of methyl groups (CH3) to cytosine residues 
resulting in the formation of 5-methyl cytosine (5mC) (Bird, 2002). DNA methylation is 
primarily associated with silencing of the genes, which are necessary to be silenced for 
normal cellular development. Such gene silencing is important during embryonic 
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development (Okano et al., 1999), genomic imprinting (Li et al., 1993), inactivation of 
X-liked genes (Loyn, 1961) as well as silencing of DNA sequences such as mobile 
genetic elements (retroposons or transposons) and endogenous retroviruses (Kass et al., 
1997). DNA methylation in mammals (cytosine methylation) is carried out by DNA 
methyltransferases (DNMT) 1, 2 and 3 (Bird, 2002; Schaefer et al., 2008) among which 
DNMT1 is the most abundantly present DNA methyltransferase that maintains 
methylation during DNA replication by methylating hemimethylated CpG dinucleotides 
(Okano et al., 1999). Similarly, tRNA methyltransferase activity is maintained by 
DNMT2 (Schaefer et al., 2008) whereas DNMT3 family carries out de novo 
methylation during embryonic development. The DNMT3 family includes DNMT3A 
and DNMT3B; DNMT3A mediates genomic imprinting through methylation during 
gametogenesis whereas both DMNT3A and DNMT3B mediate methylation on 
repetitive sequences (Okano et al., 1999). CpG dinucleotides are present throughout the 
mammalian genome; however, the presence of CpG rich regions at the 5’end of the 
gene, which are termed CpG islands (CGI), is one of the remarkable features of the 
eukaryotic genome.  By definition, CGI is a region with more than 50% CGs, covering 
a minimum length of 200 base pairs (Gardiner-Garden & Frommer, 1987). It has been 
observed that the majority of the CGIs around promoter region of the genes are 
unmethylated during embryonic development and a significant portion becomes 
methylated during development resulting into stable gene silencing (Antequera & Bird, 
1993). In addition, the majority of CGIs outside the promoter region and other CpG 
dinucleotides remain methylated in normal somatic cells (Deaton et al., 2011). In germ 
cells and peri-implantation stages of development in mammals, the DNA methylation is 
erased and reprogrammed by DNMT3A and DNMT3B (de novo methyltransferases), 
which are also needed to maintain original patterns of DNA methylation during early 
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development (Monk et al., 1987; Kafri et al., 1992). Similarly, the maintenance 
methylation is mediated between the successive generations by DNMT1 that effectively 
copies the methylated and unmethylated CpGs in the newly formed daughter DNA 
strands during semiconservative replication of DNA (Pradhan et al., 1999). Therefore, 
in normal somatic cells, de novo methylation established by de novo methyltransferases 
DNMT3A and DNMT3B is maintained by maintenance methyltransferase DNMT1 
between the successive generations.  
 
 
1.2.1.2 The mechanisms of gene silencing and activation by DNA methylation 
 
There are two principal mechanisms by which DNA methylation mediates 
transcriptional gene silencing. First, the repression of transcription is brought about by 
preventing binding of transcriptional factors on gene promoters as exemplified by 
transcription factor N-Myc binding on CGI of its target gene (Perini et al., 2005).  
Second, gene silencing due to methylation is mediated by recruiting methyl DNA 
binding proteins (MDBPs). The Kaiso like family of proteins, the SRA (SET- and 
RING-associated) domain proteins and methyl binding domain family of proteins 
(MDBs) are the three classes of MDBPs, of which MBDs are the most common and 
biggest players in gene repression (Yoon et al., 2003). The recruitment of MDBPs 
results in recruitment of additional repressor proteins that in turn recruit histone 
modification complexes such as histone deacetylases (HDACs) leading to chromatin 
modifications (Zhang et al., 1999). Four classes of MDBs namely MDB1, MDB2, 
MDB3 and MDB4 (Roloff et al., 2003) and another two classes of MBDs MeCP1 and 
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MeCP2 (Lewis et al., 1992) have been identified that play roles in transcriptional 
repression in a similar manner (Cihák, 1974).  
 
1.2.1.3 The role of DNA methylation in cancer 
 
Aberrant DNA methylation change is one of the most widely studied epigenetic 
mechanisms in cancer, characterised either by global DNA hypomethylation or 
hypermethylation or by hypomethylation at a localised region of the gene.  
A global loss of methylation or hypomethylation can lead to the activation of repeat 
sequences, which otherwise remain silenced in the genome, resulting in chromosomal 
rearrangement and genomic instability (Xu et al., 1999). It has been observed that the 
global hypomethylation in repeat elements such as Alu and LINES elements has led to 
genomic rearrangement and activation of these transposable genetic elements 
(Weisenberger et al., 2005). In addition, analysis of chromosome 11 in mice that 
contain a hypomorphic Dnmt1 allele, an allele with a partial loss of Dnmt1 function 
(Dnmt+/-) and single copy of TP53 and NF1 has shown genomic instability due to 
hypomethylation (Eden et al., 2003).  
 
In addition, gene specific hypomethylation can occur, activating proto-oncogenes which 
otherwise would remain silenced (figure 1.2). A study on salivary gland adenoid cystic 
carcinoma has showed that 8 genes were overexpressed due to loss of methylation 
(Shao et al., 2011). Promoter hypermethylation of common tumour suppressor genes 
(figure 1.2) and their subsequent inactivation or down regulation was observed in many 
cancers such as RB1 in retinoblastoma (Greger et al., 1989; Sakai et al., 1991), VHL in 
renal cell carcinoma (Herman et al., 1994)  and CDKN2A (cyclin-dependent kinase 
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inhibitor 2A) in multiple tumour types (Herman et al., 1995). In several cases, 
downregulation or complete silencing of the tumour suppressor gene is the principal 
mechanism of dysregulation in cancer, as is evident in RASSF1A inactivation in various 
cancers such as lung, breast, glioma, colorectal and Renal Cell Carcinoma (RCC) 
(Hesson et al., 204; Dammann et al., 2000; Dammann et al., 2001; Morrissey et al., 
2001; van Engeland et al., 2002) and HIC1 inactivation in leukemia and breast cancer 
(Issa et al., 1997; Fujii et al., 1998; Melki et al., 1999). Similarly, hypermethylation and 
downregulation of tumour suppressor gene may be a second hit as evident in CHD1 
hypermethylation in various cancers (Grady et al., 2000). Aberrant DNA methylation 
has now been identified in hundreds of genes and in most cancer types such as 
childhood acute lymphoma (Dunwell et al., 2009b), glioma (Kim et al., 2006; Patel et 
al., 2008), and other CNS tumours (Muhlisch et al., 2006; Margetts et al., 2008), bone 
(Rao-Bindal & Kleinerman, 2011), breast (Miyamoto et al., 2003; Yuan et al., 2003; 
Thakur et al., 2007; Moelans et al., 2011; Park et al., 2011; Zeng et al., 2012), lungs 
(Miyamoto et al., 2003; Shames et al., 2006a; Hsu et al., 2007; Han et al., 2009; 
Paliwal et al., 2010),  colorectal (Miyamoto et al., 2003), pancreas (Miyamoto et al., 
2003), renal (Morris et al., 2005; Morris et al., 2008; McRonald et al., 2009; Morris et 
al., 2010; Morris et al., 2011)  and melanoma (Hoon et al., 2004; Marini et al., 2006; 
Liu et al., 2008; Koga et al., 2009; Schinke et al., 2010; Bonazzi et al., 2011). The large 
number of genes dysregulated in cancer may contribute to tumorigenicity (driver 
events), however some are likely to be passenger events dysregulated as a consequence 
of genome-wide epigenetic dysregulation.  
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Figure 1.2: Mechanism of DNA methylation on gene silencing and genomic 
dysregulation of regulatory elements. CpG island promoter regions are generally 
unmethylated in tumour suppressor genes in normal cells (A), which when 
hypermethylated (B), results in the transcriptional silencing in cancer. In contrast, 
tumour promoter genes are kept silenced due to promoter methylation in normal 
cells (B), which when hypomethylated, results in the transcriptional activation in 
cancer cells (A). Similarly, aberration of DNA methylation 
(hypomethylation/demethylation) of intragenic region of regulatory elements 
results in genomic instability.  
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1.2.2 Role of histone modifications in cancer 
 
A eukaryotic genome consists of double stranded DNA complexed with histones 
forming a repeating subunit called the nucleosome, which further condenses to form 
chromatin. Each nucleosome consists of two subunits of each histone H2A, H2B, H3 
and H4 forming a complex with another linker histone H1 (Kornberg, 1974). In a 
normal cell, the chromatin being a highly packaged, condensed architecture, either 
remains in a repressive state (heterochromatin) or in a less condensed state 
(euchromatin), which is accessible to the transcriptional machinery for gene expression 
(Grunstein et al., 1995).  
Histone modification refers to the various types of histone modifications that are 
reported to be involved in normal cellular physiology and in cancer. These include 
acetylation, methylation, phosphorylation, ubiquitination, sumoylation, ADP-
ribosylation, deamination, proline isomerism and propionylation (Sawan & Herceg, 
2010) which either keep chromatin in a repressive or active state regarding 
transcriptional regulation.  A great deal of work is ongoing to elucidate the complex 
nature of these modifications (Thurman et al., 2012). However, the role of histone 
acetylation and methylation in cancer is reasonably well understood: In a normal cell 
physiology, one or more types of histone modifications maintain the chromatin state 
either as accessible (euchromatin) or less accessible state (heterochromatin) to 
transcriptional machinery to promote or to inhibit expression of genes (Quina et al., 
2006). For instance, chromatin can be made accessible to DNA by histone acetylation 
removing the positive charge at lysine residues on the histone tail that weakens the 
DNA-histone or nucleosome- nucleosome interactions; HATs and Histone deacetylases 
HDACs are the two enzymes governing histone acetylation and deacetylation 
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respectively, which are reported to be involved in cancer (Leroy et al., 2013) (figure 
1.3).  
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Figure 1.3: The basic epigenetic mechanism such as DNA methylation and histone 
modifications in normal cells and in cancer.  In normal cell, the majority of CpGs 
in DNA are unmethylated and the chromatin is transcriptionally active 
(euchromatin) due to histone acetylation governed by histone acetylates (HATs) 
where as in cancer cells the majority of CpGs are methylated due to DNA 
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methyltransferases (DNMTs), that recruits methyl binding proteins (MBDs). 
MBDs further recruit histone deacetylases (HDACs) turning chromatin into 
transcriptionally inactive (heterochromatin). In addition, there are other 
modifications regulating chromatin dynamics such as histone methylation 
governed by histone methyltransferases (HMTs) and phosphorylation. The 
epigenetic modifications leading to gene silencing due to DNA methylation and 
histone modification can be reversed by epigenetic drugs (therapy) such as 
demethylating agents that could reactivate the silenced genes (The figure has been 
taken from Yoo and Jones, 2006) (Yoo & Jones, 2006).    
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Dysregulation of various HDACs has been reported in various cancers as exemplified 
by the upregulation of HDAC2, 3, 6, 8 and 7 in childhood Acute Lymphoblastic 
Leukemia (ALL) (Moreno et al., 2010), overexpression of HDAC1, 2 and 3 in ovarian 
cancer (Hayashi et al., 2010), overexpression of HDAC6 in breast cancer and oral 
squamous cell carcinoma (Sakuma et al., 2006) and over expression of HDAC2 in 
numerous cancers (Jin et al., 2008; Adams et al., 2010; Langer et al., 2010; Mutze et al., 
2010) .  
Another crucial type of histone modification, histone methylation is catalyzed by 
histone methyltransferases that occurs at an arginine which is tri-methylated or at lysine 
residues which is mono-, di- or tri- methylated. These histone modifications marks are 
associated with either repressive or active chromatin states. For instance, mono 
methylation on lysine resides on different histone subunits are associated with 
transcriptional activation (H2BK5, H3K4, H3K9, H3K27, H3K79 and H4K20) (Barski 
et al., 2007; Benevolenskaya, 2007; Steger et al., 2008). Similarly, di- or tri-
methylations on lysine residues are associated with either activated (H3K4m2, H3K4m3 
and H3K79m2) (Koch et al., 2007; Steger et al., 2008) or repressive (H2BK5m3, 
H3K9m2, H3K9m3, H3K27m2, H3K27me3) (Barski et al., 2007; Rosenfeld et al., 
2009) state. Interestingly, tri-methylation at lysine residues on H3 (H3K79m3) is 
associated with either as active (Steger et al., 2008) or repressive state (Benevolenskaya, 
2007), which could be due to the activity of different effector proteins. Methylation at 
arginine residues on H3 and H4 (H3R17, H3R23 and H4R3) is associated with 
transcriptional activation (Berger, 2007). An example of dysregulation of a histone 
demethylase is LSD1 (lysine (K)-specific demethylase 1A) upregulated in bladder cancer 
(Hayami et al., 2011), estrogen receptor negative breast cancer (Lim et al., 2010) and 
neuroblastoma (Schulte et al., 2009). In addition, evidence for the importance of histone 
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modifications is provided by mutations in PBRM in renal cell carcinoma (Varela et al., 
2011a) and ARID1A  in ovarian cancer (Jones et al., 2010). It has been observed that 
inhibition of LSD1 results in growth inhibition of cells where as its upregulation is 
associated with upregulation of various growth regulatory genes as well as the genes 
involved in chromatin remodeling (Lim et al., 2010; Hayami et al., 2011).    
1.3 Cancer metastases 
1.3.1 Dissemination of tumour cells from the primary tumours  
 
Cancer metastases refers to the formation of new tumours in a distant site due to the 
dissociation of tumour cells from the primary tumour (Chambers et al., 2002).  The 
majority of the cancer related deaths (90%) is credited to metastases to distant organs 
(Nguyen & Massague, 2007; Rodenhiser, 2009) which, to a greater extent, is due to the 
resistance to the existing therapy that can eradicate most primary tumours (Valastyan & 
Weinberg, 2011; Neman et al., 2014). The ability to detect metastatic tumours early, as 
opposed to once they have metastasised, appears to be a difficult hurdle to overcome in 
the treatment of disease (Chambers et al., 2002). The complex nature of the interactions 
between Disseminating Tumour Cells (DTCs) and microenvironment could drive 
treatment resistance (Valastyan & Weinberg, 2011). It is well established that metastatic 
cells disseminate from the primary tumours by invading the lymphatic vessels and then 
only some cells with aggressive metastatic potential are capable of entering in to the 
blood circulation (intravasation) (Fernández-Periáñez et al., 2013). In this case, 
metastatic colonisation may take in different organs from the same primary tumour 
(synchronous seeding) or spread metastatic tumour cells from one secondary site to 
another may occur (metachronous seeding) (Fernández-Periáñez et al., 2013). 
Occasionally the metastatic tumour cells return back to the primary site, this is termed 
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self-seeding (Nguyen & Massague, 2007). The presence of undetectable 
micrometastases or latent metastatic lesions running parallel to the malignant 
progression of primary tumours or their occurrence a long time after primary tumours 
diagnosis makes prognosis and treatment of metastatic diseases difficult (Holmgren et 
al., 1995). In addition, it has been observed in many instances that the development of 
the malignant tumours from the adenoma (adenocarcinoma) is a slower process than the 
development of the metastatic tumours from it, which suggests that the metastatic 
tumour formation takes place in parallel with the malignant tumour (Klein, 2009).   
 
Metastases exert an organ specific pattern in terms of final colonization in distant 
organs (Figure 1.4) such as breast tumours often metastasise to bone, lungs, brain, liver 
and more infrequently to adrenal glands (Chambers et al., 2002). 
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Figure 1.4 Metastases exhibit a pattern of organotropism, for instance, breast 
cancer metastasises frequently to the bone, lung, brain and liver and less 
frequently to adrenal glands (green arrows) whereas lung tumours metastasise to 
bone, brain, adrenal glands and pancreas (red arrows). Similarly, melanoma 
metastasises to brain, bone and kidney (blue arrows) whereas both adrenal glands 
and pancreas metastasises to the liver (black arrows). 
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Cancer metastasis always follows a multistep process regardless of the distant organs 
involved for metastatic evolution (Rodenhiser, 2009; Talmadge & Fidler, 2010; Cock-
Rada & Weitzman, 2013) in which a tumour cell invades the extracellular matrix, 
disseminates to the blood stream (intravasation), survives in the circulation and invades 
(extravasation) the distant tissues and finally evolves (colonisation) as a metastatic 
lesions (Chambers et al., 2002; Minn et al., 2005b; Hu et al., 2009; Rodenhiser, 2009; 
Zhang & Yu, 2011). Colonisation of DTCs in a distant sites consists of the metastatic 
events such as extravasation in the new niche, formation of micrometastases, survival in 
a new environment, induction of a latent period and evolution into a macrometastases 
(Vanharanta & Massague, 2013).  Cancer can progress into distance sites of the body 
and may undergo a latent period for many years before developing into a more deadly 
and recurrent metastatic disease (Aguirre-Ghiso, 2007).  
 
1.3.2 Seed and soil theory of cancer metastases 
 
A British surgeon Stephen Paget in 1889 (Paget, 1889), after examining 700 cases of 
patients with breast cancer, postulated that cancer metastasis is not a random incident. 
Rather, it is the results of possible interaction between the tumour cells (seed) with the 
distant organs (soil) to which the tumour cell metastasises (Chambers et al., 2002; 
Talmadge & Fidler, 2010; Zhang & Yu, 2011). The seed and soil hypothesis further 
clarifies that the seed may only be able to grow in the right soil even though it may 
spread in varying directions (Fidler & Poste, 2008; Talmadge & Fidler, 2010), in which 
a seed may be a progenitor cell, a cancer stem cell (CSC), metastatic cell or a tumour 
initiating cell that may be able to grow only in the suitable distant microenvironment 
(soil) (Talmadge & Fidler, 2010). Therefore, in addition to the neoplastic cells, 
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metastasis depends on the nature of the microenvironment to which metastatic cells tend 
to colonize (Fidler, 2003). In this regard, metastasis is a result of interaction between the 
tumour cells and their microenvironment including various factors such as angiogenesis, 
migration, invasion and cell proliferation (Fidler, 2003). This implies that the seed and 
soil theory, in principle, consists of the microenvironment of the distant organ and a 
heterogeneous population of neoplasm (primary tumour).  In these regards, only some 
of the cells from each subpopulations may be able to complete some of the initial stages 
of the metastatic cascades (Klein, 2009). Therefore, it is possible that only very few 
cells, derived from a single cell, may be able to eventually colonise the distant niche 
which suggest that the metastatic tumour is of clonal origin and derived from a single 
tumour cell (Talmadge & Fidler, 2010).  The cross talk between the soil (the 
microenvironment) and the homeostatic mechanism (Mendoza & Khanna, 2009) results 
into the metastatic development that when a seed (tumour cell) metastasises into a new 
and unique biological microenvironment (soil) i.e. specific distant organs (Paget, 1889; 
Talmadge & Fidler, 2010).  
 
1.3.3 Metastatic cascades  
 
In order to colonize distant sites, tumour cells from the primary tumours need to acquire 
genetic and epigenetic changes to overcome the sequential events, which are termed as 
the metastatic cascades. The first step in the metastatic cascades is a local invasion in 
which a cancer cells should be able to invade extracellular matrix (ECM), and penetrate 
(intravasate) the blood vessel (Chambers et al., 2002; Coomber et al., 2003 ) The blood 
microenvironment is different to the original primary tumour environment; cancer cells 
need to acquire the ability to resist the selective pressure of the blood vasculature such 
20 
 
as lack of adhesion, unfavourable conditions and immune responses. In the blood 
vasculature, it is necessary for tumour cells to adhere to the endothelial surface in the 
lumen of the blood vessels from which they migrate (extravasate) into the target organs 
(Coomber et al., 2003 ). Tumour cells may remain dormant for several years attached to 
the surface of the blood vessel or the lymph vessel until they acquire additional layers of 
genetic and epigenetic dysregulation necessary to resume their progress, leading to the 
eventual colonisation of a new niche and the continued evolution into a distant site 
micrometastases (Nguyen et al., 2009). Due to the sequential selection pressure, each 
stage in the metastatic cascade is rate limiting and the process of metastasis is regarded 
as inefficient through which only a few tumour cells will succeed to complete the 
process (Talmadge & Fidler, 2010).  It has been demonstrated that some of the clones in 
a genetically and phenotypically heterogeneous population of primary tumour have a 
metastatic phenotype or factors influencing metastatic potential such as migration, 
invasion, survival, proteolysis and angiogenesis (Joyce & Pollard, 2009). Cancer 
metastasis, therefore, is a non-random, highly specialised process as postulated in the 
seed and soil hypothesis, in which the tumour cells capacity to proliferate in a specific 
distant site is either predetermined before the initial step or is determined during the 
process of metastatic cascade (Coomber et al., 2003 ; Psaila & Lyden, 2009). In this 
regard, the metastatic phenotype, which is a result of the genetic and epigenetic 
dysregulation necessary for metastatic competence is similar to a higher-grade 
malignant phenotype due to the stepwise progression through a metastatic cascade 
(Nguyen & Massague, 2007).  Therefore, the genetic or epigenetic changes responsible 
for the metastasis could possibly be predictable either in primary tumours as an early 
event or be able to be detected as the late event after the tumour progresses through the 
circulating tumour cells in the blood vasculature (Psaila & Lyden, 2009). Some of the 
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predictable early markers for tumour metastases include p53 mutations in advanced 
colorectal cancer (CRC) and amplification of HER2 in metastatic breast cancer 
(Coomber et al., 2003 ). However, it is likely that many more are yet to be identified. 
 
1.3.4 Biological mechanisms underlying metastatic dormancy 
 
A cancer cell, which has escaped from the primary tumour is regarded as a disseminated 
tumour cell, which after leaving the primary tumour site may undergo dormancy for 
years, some remain dormant for decades (Klein, 2009). The treatment of the primary 
tumour may lead to the DTCs persisting in the body as minimal residual tumours 
(Aguirre-Ghiso, 2007), which, with a favourable microenvironment, may develop into 
metastases. Another possibility is a dissemination of primary tumour cells to the 
distance site before the primary tumour reaches a state of malignancy in which a 
metastatic tumour grows in parallel with the primary tumour (Rocken, 2010). The 
genetic dysregulation in primary tumours is thought to provide genetic fitness or 
selective advantages to the tumour cells to metastasise as an early or a late event of the 
cancer progression (Aguirre-Ghiso, 2007; Cock-Rada & Weitzman, 2013). In an early 
event (parallel progression model), the successive rounds of genetic dysregulation 
provides the DTCs with the ability to exhibit more aggressive phenotypes to grow as 
metastatic tumours along with the primary tumours (Klein, 2009) (Figure 1.5A) 
whereas in late event (linear progression model), the tumours cells acquire genetic 
changes or epigenetic changes at a later stage of the primary malignant tumours to be 
able to invade the surrounding cells to enter into the metastatic cascades (Aguirre-Ghiso, 
2007; Klein, 2009) (Figure 1.5B). The long time periods for a tumour cells to proliferate 
and to grow in to a metastatic lesions after the disseminations explains the period of 
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dormancy (Rocken, 2010), however, the mechanism of dormancy in different cancers is 
still elusive. Hence, in all cancers, the period of dormancy is attributed to the slow and 
steady accumulation of genetic aberrations such as loss of TP53, RB1, P16, RAS/BRAF 
activating mutations, ERBB2 amplifications etc. required for transformation and 
immortalization of the tumour cells during carcinogenesis (Aguirre-Ghiso, 2007).  
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Figure 1.5: The two models of metastatic colonization. In a linear progression 
model (A), primary tumours progresses into a more aggressive malignant form 
from which the tumour cells disseminated to colonise distant organs whereas in a 
parallel progression model (B), tumour cells may disseminate early from early 
stage primary tumours and grow into a micrometastases along with the 
progression of the malignant primary tumour eventually forming a metastases. 
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1.3.5 Interaction between the microenvironment and the tumour cell 
 
The new niche encountered by an invading tumour cell is not a natural environment to 
grow and proliferate. Tumour cells may be able to grow if the niche or a 
microenvironment is conductive for their growth. However, an unaccommodating 
microenvironment may significantly hinder the tumours growth capacity (Aguirre-
Ghiso et al., 2004). The choice between growth arrest and proliferation of the tumours 
is decided by the deregulation of the interaction between the tumours and their 
microenvironment. Tumours cells may remain dormant if they have a capacity to 
remain in a differentiated state (Aguirre-Ghiso, 2007). Cross talk between the tumour 
cell and the DTCs was observed in head and neck carcinoma where the growth of the 
tumour was stimulated by metastasis associated urokinase receptor (uPAR) by 
activating α5β1 integrins (Gohji et al., 1997). This complex propagates mitogenic 
signals by an association with RAS and extracellular signal regulating kinase (ERK) by 
recruiting focal adhesion kinase  (FAK) and EGF receptor (EFGR) (Aguirre-Ghiso, 
2007). Similarly, inhibition of RAF-MEK-ERK signaling pathway by ERK signaling in 
vivo resulted in dormancy of tumour cell and G0-G1 arrest of the dormant cells 
(Aguirre-Ghiso et al., 2004). Likewise, the growth arrest or the dormancy of the tumour 
cells is favored by activation of P38 MAPK signaling due to the disruption of uPAR. 
Hence, high ERK activity contributes to sustain tumour growth where as the P38 
activation contributes to tumour dormancy by upregulation of P53 and downregulation 
of c-JUN (Adam et al., 2009). 
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1.3.6 The role of metastatic suppressors in dormancy of disseminated tumour cells 
 
Over 99% of DTCs are thought to die in a new microenvironment; the main hurdle that 
DTCs must overcome to enable their evolution into metastatic tumours is the 
deactivation of tumour suppressor genes (Aguirre-Ghiso, 2007). Tumour suppressor 
genes inhibit metastases by promoting apoptosis. For example, KSS1 is thought to 
inhibit metastases by elongating the dormancy of DTCs, CD82, a tetraspanin protein 
inhibit metastases of mouse melanoma cell by binding to CD234 (Aguirre-Ghiso, 2007; 
Rodenhiser, 2009). In addition to melanoma metastases, a reduced level of KSS1 is 
implicated in breast cancer brain metastases (Rodenhiser, 2009). Similarly, RAS 
signalling is inhibited by NM23, which is expressed in non-metastatic cells. MKK4 is 
silenced in both prostate and ovarian cancer by activation of JNK and P38 respectively 
(Chambers et al., 2002). Interestingly, a study using a mouse model has shown that the 
metastatic efficacy of the host depends on F1 parents suggesting the role for the genetic 
make up of the host on the ability to supress metastases (Crawford et al., 2006; Aguirre-
Ghiso, 2007).  
 
1.4. Cellular and molecular basis of metastasis  
1.4.1 Epigenetic regulation in cancer metastases 
 
The success of the metastasising cell to complete the metastatic cascades leading to 
eventual colonisation depends on the interactions of tumour cells with host 
microenvironment at various stages of metastatic evolution. In these regards, the 
epigenetic regulation of microenvironment as well as the epigenetic dysregulation in 
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tumours cells contributes significantly to metastatic evolution (Coomber et al., 2003 ). 
The basic epigenetic mechanism includes DNA methylation and histone modifications 
in which the various post-translational modification such as methylation and acetylation 
regulate chromatin dynamics, activating and inhibiting of gene expression (Rodenhiser, 
2009).  The process involves recruitment of enzymes for histone modification, which, 
either promotes or removes such modifications (Rodenhiser, 2009; Cock-Rada & 
Weitzman, 2013). A large number of histone modifying enzymes have been identified 
which regulate the metastatic phenotypes in primary tumours through their target genes 
(Cock-Rada & Weitzman, 2013). The epigenetic regulatory networks includes changes 
in the gene expression due to alterations in methylation, acetylation, and other processes 
which further contributes to various processes such as ECM degradation, post 
translational activation, changes in the adhesive properties of the cells, activation of 
coagulation signalling and activation of other enzymatic environment contributing to 
metastases (Coomber et al., 2003 ). In addition, various factors such as growth factor 
availability, hypoxia, hormonal influences and metabolic stress, composition of ECM, 
inflammatory reaction and immune response are part of the epigenetic network which 
contribute to tumour progression and metastatic evolution of the primary tumour cells 
(Coomber et al., 2003 ).  
 
1.4.2 Role of angiogenesis in metastatic evolution 
 
One of the crucial elements of the metastatic pathway is the formation of new blood 
vessels, or angiogenesis, that enables tumours to escape from their primary site and 
enter into the blood circulation (Zetter, 1998). Each stage in the metastatic cascades i.e. 
local invasion, intravasation, survival in the vasculature, extravasation and eventually 
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colonization of the metastasising cells is related to angiogenesis. Various factors 
contribute to angiogenesis, notably the overexpression of vascular endothelial growth 
factor (VEGF) (Ellis & Fidler, 1996). Endothelial cell migration is an essential step in 
angiogenesis which is further governed by actin, its major cytoskeleton component, 
which can be remodeled into different structures such as filopodia (long filamentous 
structures), lammellipodia (cytoplasmic protrusions) and stress fibers (actin filaments 
with inverted polarity) contributing to endothelial cell motility (Theriot & Mitchison, 
1991; Disanza et al., 2005). In this regard, endothelial cell migration is characterised by 
chemotaxis mediated by VEGF and basic fibroblast growth factor (bFGF), directional 
migration towards ligand (haptotaxis) activated by integrins binding to ECM and 
migration due to shear mechanical forces (mechanotaxis) mediated by adhesive forces 
(Senger et al., 1996; Li et al., 2002). VEGF is a major potent angiogenic factor that 
promotes proliferation and migration of endothelial cells (Rousseau et al., 2000). 
Furthermore, VEGF binds to membrane tyrosine kinase receptors VEFGRs (VEGFR1, 
VEFGR2 and VEGFR3) mediating to downstream signals migratory pathways of 
endothelial cells (Olsson et al., 2006). In addition, autophosphorylation and activation 
of p38 pathways contributes to lammellipodia formation (Lamalice et al., 2004) 
whereas activation of PI3K by VEGFR2 further activates AKT/PKB (protein kinase B) 
contributing to EC motility promoting angiogenesis (Bernatchez et al., 2001). Likewise, 
VEGF promotes reactive oxygen species (ROS) production by activating NADPH 
oxidase through activation of VEGFR2/PIK3/AKT/PKB that further promotes 
angiogenesis (Dimmeler et al., 2000; Ushio-Fukai et al., 2002). In addition, tumour 
suppressor genes, oncogenes and factors that contribute to epigenetic networks such as 
hypoxia, hypoglycemia and cytokine stimulation are known to influence angiogenesis 
in tumour metastases (Coomber et al., 2003 ).  
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Moreover, formation of new blood vessels for nutrient supply by tumours cells on their 
own is regarded as a hallmark of cancer (Hanahan & Weinberg, 2000). An experiment 
carried out by Weidner et al (Weidner et al., 1991) using endothelial cells from invasive 
breast carcinoma patients to examine the formation of blood vessels showed that 
numbers of and density of blood vessels correlates with the outcome of metastatic 
disease. An in vivo study of angiogenesis in gyanaecological leiomysarcoma has shown 
that tumour cells capable of disseminating into a chick embryo showed a strong 
angiogenic response (Alias et al., 2015) providing further evidence of angiogenesis in 
the metastatic potential of primary tumours regardless of their site of origin. 
 
1.4.3 Role of tumour hypoxia in invasion and metastasis 
 
Tumour cells often adapt themselves to hypoxia, which is associated with metastasis 
(Mendoza & Khanna, 2009). Hypoxia is known to induce various events in tumours that 
contribute to angiogenesis, invasion and metastasis increasing the malignancy of 
tumours (Zhong et al., 1999; Coomber et al., 2003 )A hypoxic microenvironment is 
associated with two of the very prominent characteristics of solid tumours, glycolysis 
and angiogenesis which promotes metastasis and invasion in tumours (Zhong et al., 
1999). The HIF1α subunit regulates the transcriptional activity of HIF1, which activates 
VEGF (resulting in an angiogenic response) and genes involved in glucose transporter 
and glycolytic enzymes (altering the metabolic nature of the tumour cells) (Webster, 
1987; Lin et al., 2004a).  Previous studies (Zhong et al., 1999; Mendoza & Khanna, 
2009) have shown that HIF1α expression was higher in metastatic breast tumours (69%) 
compared to its expression in primary breast tumours (29%) which suggests that the 
increased expression of HIF1α contributes to cancer metastases (Zhong et al., 1999).  
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1.4.4 Tumour microenvironment 
 
One of the key determinants of the fate of metastasising tumour cells is the tumour 
microenvironment, which can change the behaviour and gene expression patterns of the 
cancer cells influencing their ability to grow and proliferate. The gene expression 
patterns, level of various proteolytic enzymes expressed and resistance to chemotherapy 
may differ if the same cancer cells are grown in two different microenvironments 
(Nakajima et al., 1990). In addition, a microenvironment may be more selective to a 
type of tumour cells and may be more supportive to other types suggesting the 
preference of different tumour cells to different microenvironments influencing 
different metastatic outcome (Kuo et al., 1995). The status of p53 in cancer cells may be 
a determinant for anti-angiogenic therapy and growth whereas the expression of soluble 
cytokines like IL-6, and adhesion molecules could be a contributor for 
microenvironment mediated chemotherapeutic and apoptotic response (Lowe et al., 
2014). Similarly, the metastatic ability of the tumour cells in secondary organs are 
supressed by metastatic suppressor genes, which do not in general, contribute to 
regulation or suppression of primary tumours. Likewise, expression of chemokine 
receptors by tumour cells plays a role in supporting lymphocytes and other tumour cells 
in specific organs suggesting a role in organ specific metastases, in which both the 
tumour microenvironment and the metastasising tumour cells express the identical 
chemokine receptors (Müller et al., 2001). For instance, experimental models in animals 
has shown that breast cancer cells with increased levels of CXCR4 and CCR7 
metastasise to the lungs, breasts, liver and bone were increased levels of CXCR12 and 
CCL21 (Müller et al., 2001). In contrast, inhibition of CXCR4 expression is found to 
suppress breast cancer metastasis in these sites (Burger & Kipps, 2006). Similarly, 
30 
 
activated RAS mutations favours the metastatic growth and is associated with 
maintaining micrometastases and increased growth potential of the metastasised cells in 
secondary sites (Nomoto et al., 1998).  
 
1.4.5 Epithelial-Mesenchymal Transition (EMT) 
 
An important group of molecules contributing to the process of metastasis are 
transcription factors such as Slug, Snail, Twist and ZEB1 which are highly expressed in 
metastatic cells and play important roles in EMT (Beltran et al., 2008; Talmadge & 
Fidler, 2010; Taube et al., 2010). EMT, a concept developed from embryonic 
development, is defined as the reversible changes in a cellular phenotype resulting in a 
loss of epithelial characteristics and a gain of mesenchymal characteristics (Thiery & 
Sleeman, 2006; Kalluri & Weinberg, 2009) which includes stem cell properties (Mani et 
al., 2008; Polyak & Weinberg, 2009) (Figure 1.6).  Loss of adhesion and polarity of the 
epithelial phenotype and gain of increased motility through ECM of the mesenchymal 
phenotype contributes to migration and invasion that lead to increased metastases 
(Talmadge & Fidler, 2010). In addition, the process of EMT is associated with reduced 
expression of epithelial markers such as E-cadherin, cytokeratin and claudins leading to 
increased expression of mesenchymal markers such as N-cadherin and vimentin (Cates 
et al., 2008). Various lines of evidence have been reported regarding involvement of 
EMT in tumour progression leading to invasion and metastases. (Acevedo et al., 2007) 
reported that the overexpression of fibroblast growth factor receptor 1 in a mouse led to 
a tumour progression into adenocarcinoma through EMT. Similarly, a microarray based 
histochemical study of 479 invasive breast carcinoma samples showed the 
overexpression of mesenchymal markers and reduced expression of epithelial markers 
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in basal like subtypes (Sarrio et al., 2008). In addition, micrometastatic cells from the 
bone of a breast cancer showed expression of mesenchymal phenotype with reduction 
of epithelial phenotype, which was also detected in primary breast tumours with 
aggressive phenotype in vivo (Willipinski-Stapelfeldt et al., 2005). Moreover, EMT 
resulted from aberration in DNA methylation and histone modifications at genes 
associated with alterations in the signalling components and pathways such as reduced 
autophosphorylation of EGFR, increased oxidative phosphorylation, induced tumour 
cell chemotaxis and increasing survival signalling (Thomson et al., 2011).  In addition, 
genome-wide epigenetic reprogramming such as alterations in histone modification 
mark is identified in EMT driven chemoresistance and migration in mouse hepatocytes 
(McDonald et al., 2011).  Likewise, epigenetic and genetic dysregulation of microRNAs 
are reported to contribute to or suppress the process of EMT (Davalos et al., 2012). 
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Figure 1.6: A process of Epithelial mesenchymal transition (EMT) in which 
epithelial cells characterised by adhesion, basal layer and lack of motility may be 
transformed into mesenchymal cells characterised by motility, lack of adhesion 
and degradation of basal layer or ECM resulting in an increase in migratory, 
invasive and metastatic behaviour and gain of stem cell properties. A number of 
factors such as mutation, DNA methylation, histone modification (such as 
alterations in histone methylation marks) and microRNA dysregulation 
contributes to EMT that results in change in epithelial markers to mesenchymal 
markers.  
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 1.5 The Brain metastases 
1.5.1 Patterns of brain metastases 
 
Brain metastases, like any other tumour metastases, are not an exception to the seed and 
soil hypothesis, which has become a theoretical basis of cancer metastases (Zhang & Yu, 
2011). Brain metastases account for up to 40% of all secondary tumours, with an 
estimated 27,000 new cases every year in the United Kingdom (Soffietti et al., 2002; 
Gavrilovic & Posner, 2005). Current estimates suggest that 18-30% of patients with 
breast cancer eventually develop brain metastases (Weil et al., 2005; Gori et al., 2007; 
Kennecke et al., 2007; Tosoni et al., 2008). The prognosis of the brain tumours is very 
poor and both morbidity and mortality are high; the median survival of patients with 
brain tumour is 2 months without treatment and 12-15 with treatment (Subramani et al., 
2013), and overall the approximate median survival is 7 months (Sperduto et al., 2010). 
The treatment for brain metastases generally includes whole brain radiotherapy 
(WBRT), surgery and chemotherapy (Zhang & Yu, 2011).  
 
The underlying mechanisms of this organotropism towards specific secondary sites such 
as the brain are still poorly understood. Although the genetic basis of primary tumour 
formation is becoming increasingly clear (Stratton et al., 2009) it is still unclear which 
of the many hundreds of tumour-associated alterations found in primary breast cancer 
(Curtis et al., 2012; TCGA, 2012) contribute to metastasis and moreover, metastasis to 
specific secondary sites such as the brain.  
 
One of the challenging hurdles in treating brain metastases is the failure of 
chemotherapy to cross through the tight junctions in blood brain barrier (BBB) 
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containing brain endothelial cells, arranged in a basement membrane including other 
supporting cells such as pericytes and astrocytes (Sugiyama et al., 1999). In this regard, 
one of the intriguing questions is the period of latency between the presence of early 
circulating cells in the blood and appearance of well-developed brain metastases as a 
result of an ability of circulating tumour cells to cross the BBB (Riethdorf et al., 2007). 
However, due to the leaky nature of the BBB, the drug resistance, to some extent, is 
attributed to expression of the membrane protein, P-glycoprotein which serves as a drug 
efflux pump in tight junctions. Moreover, the extravasated tumour cells, which are 
surrounded by activated astrocytes in the brain microenvironment are resistant to 
chemotherapy (Subramani et al., 2013) 
 
1.5.2 The brain microenvironment  
 
The brain microenvironment (BME) consists of different types of neurons and glial 
cells such as astrocytes, microglia and other similar cells (oligodendroglia and satellite 
cells) (Zhang & Yu, 2011). In this regards, the BME is highly heterogeneous containing 
cells with drastically diverse biological functions maintaining homeostasis 
(Teschemacher et al., 2015). The endothelial cells are present in the tight junctions in 
BBB that provides barrier to circulating molecules to enter into the brain, astrocytes 
provide nutrients maintaining homeostasis whereas microglia are resident macrophages 
that play roles as phagocytic cells in the BME (Wei et al., 2013). Brain ventricles that 
separates the brain parenchyma (meninges) consists of Cerebrospinal fluid (CSF) 
maintaining a buffer system (Zhang & Yu, 2011). Hence, the BME represent the 
leptomeningeal space and a major site for the tumours extravasated to the brain, which 
is separated from the blood circulation by the tight junctions containing endothelial cells. 
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These prevents the entry of circulating molecules that otherwise would be allowed to 
pass through the blood vessel wall (Zhang & Yu, 2011). The presynaptic neurons 
release different neurotransmitters which activate the receptors on the postsynaptic 
neurons which require endogenous growth factors called neurotrophins such as nerve 
growth factors, brain-derived neurotrophic factors (BDGF), NT-3, NT-4 (Termini et al., 
2014). Interestingly, upregulation of neurotransmitters such as γ-amino butyric acid 
(GABA) has been reported in brain metastases, the GABA is catabolised by metastatic 
tumour cells through the GABA shunt to utilize it to form nicotinamide adenine 
dinucleotide (NADH). This suggests that the neurotransmitters may provide 
proliferative advantage to the metastatic tumour cells in the brain (Neman et al., 2014). 
The tight junction in the BBB presents an obstruction for treatment of brain metastases 
and any tumours growing in the BME (Nakagawa et al., 2009). Moreover, BBB may be 
leaky in the brain in comparison to the blood tumour barriers, which could be a reason 
for being resistant to chemotherapy (Fidler et al., 2010). It has been suggested that a 
glioblastoma stem like cell may differentiate into endothelial cells to promote blood 
supply to the tumours. Moreover, the expression of VEGF and its regulation by 
integrins in activated tumour cells favours the tumour outgrowths in the brain 
microenvironment (Lorger et al., 2009). The brain is also characterised by an ample 
supply of nutrients and oxygen and has a highest rate of glucose and oxygen 
metabolism, which is possible due to dense blood vessel networks. However, it has been 
observed that the cancer cells mainly depend on lactate production in aerobic conditions 
as an alternative source of energy (Teschemacher et al., 2015), suggesting an alternative 
way of deriving energy to survive and to proliferate.  
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1.5.3 Role of brain microenvironment in brain metastases  
 
Brain metastases account for up to 40% of all solid tumours and are extremely difficult 
to treat (Lorger & Felding-Habermann, 2010; Subramani et al., 2013).  It has been 
revealed that the BME primarily consists of endothelial cells, microglia and astrocytes 
as its resident cells in which circulating tumour cells invading brain first interact with 
the endothelial cells at the BBB (Lorger & Felding-Habermann, 2010). The endothelial 
cells at the BBB that acts as the barrier for arresting tumour cells later supports its 
growth. However, the mechanism by which circulating tumour cells negotiates with the 
endothelial cells and invades through the BBB maintaining it intact still remains elusive. 
Similarly, the BME, that is highly selective for any foreign cellular entity, consists of 
reactive astrocytes and re-localizes to associate with the incoming tumour cells (Klein et 
al., 2015). The astrocytes are mainly housekeeping cells to supply nutrients and 
maintain homeostasis in the BME by playing a key role in maintaining concentration of 
extracellular glutamate, ions, pH as well as providing metabolic substrates for neurons 
(Marchetti et al., 2000). Moreover, any foreign or tumour cells stimulate astrocytes to 
become reactive, which are otherwise non proliferating and quiescent cells in the brain 
(Termini et al., 2014). It has been shown that the reactive astrocytes secrete cytokines, 
heparanase, neurotrophic factors such as transforming growth factors, stromal cell 
derived factor 1 (SDF-1), sphingosen-1 phosphate and further activate MMP9, which 
promotes the growth of the tumour cells (Hoelzinger et al., 2007). MMP9 is a pro-
angiogenic factor that promotes tumour cell proliferation and invasion by secreting 
growth factors from the extracellular matrix (Du et al., 2008). Similarly, microglia are 
phagocytic cells and are resident macrophages capable of presenting antigen, which are 
overcome by tumour cells by production of immunosuppressive factors (Murata et al., 
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1997). Microglia stimulates angiogenesis, tumour proliferation and invasion by 
promoting immune suppression and secretion of various growth factors, cytokines and 
enzymes (Lorger & Felding-Habermann, 2010). However, the role of microglia in 
exhibiting cytotoxic effects in lung cancer metastases in the brain suggests its diverse 
and varying roles in different stages and heterogeneity of the brain metastases (Lorger 
& Felding-Habermann, 2010). Subramani, et. al. (Subramani et al., 2013) co-cultured 
astrocytes with melanoma, breast and lung tumour cells to investigate a unique 
interaction of tumour cells with the brain microenvironment in brain metastases and 
observed that the astrocytes promotes survival and chemo-protection to the tumour cells. 
Likewise, it is possible that the tumour cells which have an ability to utilize nutrients 
and signalling cascades to overcome the natural barrier are selected by the BME 
(Termini et al., 2014). Furthermore, overexpression of BMP-2 by metastatic cells 
promotes neural stem cells (NSCs) to differentiate into astrocytes, which in turn 
promotes tumour survival as a micrometastases or as dormant cells by cytokine 
stimulation (Neman et al., 2013). Initial survival of these metastatic cells with support 
from astrocytes allow them to acquire more genetic and epigenetic dysregulation to 
develop neural phenotypes giving them selective advantages to further growth 
(Subramani et al., 2013; Termini et al., 2014).  
 
1.5.4 Breast to brain metastases (BBM) 
 
CNS metastases from breast tumours comprise of 78% multiple brain metastases, 14% 
solitary brain metastases and 8% leptomeningeal brain metastases (Lin et al., 2004b). 
Patients’ younger age, premenopausal status, ER-, PR – and HER2- (triple negative) 
status are associated with increased frequency of CNS metastases (Tham et al., 2006). 
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The nodal HER2 status, tumour size and high tumour grade are also associated with 
CNS metastases (Pestalozzi et al., 2006). 
Experimental evidence indicating that tumours originating in specific organs favour 
certain sites of metastasis has existed for over fifty years (Sugarbaker, 1952) However, 
the underlying mechanisms of this organotropism towards specific secondary sites such 
as the brain are still poorly understood. Although the genetic basis of primary tumour 
formation is becoming increasingly clear (Stratton et al., 2009), it is still unclear which 
of the many hundreds of tumour-associated alterations found in primary breast cancer 
(Curtis et al., 2012; TCGA, 2012) contributes to metastasis and moreover, metastasis to 
specific secondary sites such as the brain. 
The common long lag-time between primary tumour diagnosis and recurrence of a 
detectable secondary tumour in ER+ve breast tumours suggests that cells from these 
tumours undergo a period of dormancy (Aguirre-Ghiso, 2007; Lim et al., 2012). These 
dormant cells are often found as micrometastases in bone marrow. However the 
presence of these micrometastases is not in itself a strong prognostic indicator for later 
metastatic disease (Klein, 2003; Pantel et al., 2008). Recent trials of long-term 
tamoxifen treatment suggests that ER signaling inhibition is capable of suppressing 
proliferation of dormant cancer cells but is not capable of killing them (Davies et al., 
2013; Zhang et al., 2013). 
Disseminated ER+ve tumour cells must acquire further adaptive changes to enable 
intracranial growth. Tumour cells that infiltrate the brain may enter a state of 
micrometastatic growth where the rate of proliferation is counterbalanced by cell death 
(Demicheli, 2001). During this period of metastatic latency the general instability of the 
tumour genome can result in the evolution of cells capable of proliferating within the 
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microenvironment of the brain parenchyma. Alternatively, this evolution may occur in a 
different organ, most likely bone marrow (Zhang et al., 2013) and the resulting cells 
make a second migration to the brain. 
Primary breast tumour cells after disseminating from their original niche evolve into 
metastases through two possible routes. They may reach the lung capillaries, through 
the heart to reach to the systemic circulation (Pestalozzi, 2009). Therefore, breast cancer 
cells need to invade the barrier of lung capillaries to reach the blood from where they 
will extravasate to the distant organs. Alternatively, it is possible that the breast tumour 
cells may reach a lymph node through the invasion of lymphatic vessel, where the 
tumour cells either grow into lymph node metastases or will enter into the blood vessel 
(Chambers et al., 2002). The tumour cells either enter into the blood directly or through 
the newly formed blood vessel from which they will eventually colonise into the brain.  
 
One of the most intriguing factors underlying BBM is an adaptation of neural properties 
by primary breast tumour cells after they extravasated to the brain (Neman et al., 2014). 
This neural-like phenotypic change may be a necessary adaptive change driven by the 
selection pressure of the neural niche (Van Swearingen et al., 2014). It has been shown 
that the human brain exerts higher concentration of GABA as a neurotrophic factor, 
which play roles in cellular proliferation, migration, neural differentiation and death, 
which is catabolized into succinate to release NADH to fulfill a nutritional requirement 
(Neman et al., 2014; Termini et al., 2014). Interestingly, GABA is reported to be an 
alternative metabolite in various primary cancers such as gastric, colon, ovarian and 
breasts tumours including BBM from HER2+ and triple negative breast tumour cells 
when the TCA cycle and normal cellular metabolism is not favorable to them (Neman et 
al., 2014). In addition, various proteins involved in GABA metabolism such as GABA 
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transaminase, glutamate decarboxylase, GABA transporter, reelin and parvalbumin are 
expressed by BBM tumour cells (Van Swearingen et al., 2014). Moreover, a subset of 
GABAergic neurons expresses the protein reelin, which in association with HER2 is 
involved in motility and maintaining cytoskeleton by activating PI3K, which further 
elicits AKT and other downstream signaling molecules resulting in actin skeleton 
activation (Chai et al., 2009). Furthermore, ENAH/HMena, a regulator for actin 
cytoskeleton is overexpressed in metastatic HER2+ cells, this is stabilized in the brain 
microenvironment by reelin and HER2, which further helps to modify cytoskeleton to 
promote tumour-stromal interaction in the extracellular matrix (Neman et al., 2014).  
 
1.6 The biology of breast tumour 
1.6.1 Primary breast tumour and its subtypes 
 
Breast cancer, a leading cause of cancer death in less developed countries, is also a 
common malignancy and a second leading cause of cancer deaths in women in the 
western world (Cianfrocca & Goldstein, 2004; Torre et al., 2015) with estimated global 
deaths of 521900 in 2012 alone (Torre et al., 2015). It originates from normal epithelial 
cells, characterised either as precursor lesions called atypical ductal hyperplasia (ADH), 
flat epithelial atypia (FEA), and ductal carcinoma in situ (DCIS) or more invasive 
phenotype invasive ductal carcinoma (IDC) (Park et al., 2011). DCIS is a pre invasive 
form of breast cancer characterised by a proliferation of epithelial layers without 
invading it (Moelans et al., 2011). 20% of patients carry DCIS, which are in general 
curable except for a minority of patients who go on to develop invasive ductal 
carcinoma (IDC) (Moelans et al., 2010). It has been observed that the high and low 
grade IDC is derived from the high and low grade DCIS respectively (Moelans et al., 
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2010). Genetic profiling of breast tumours has revealed that the majority are derived 
from luminal epithelium or their progenitors suggesting that they are from an epithelial 
origin (Park et al., 2011). High survival rates (~90%) of breast cancer patients following 
early detection suggests that this is crucial for effective treatment and survival of the 
patients (Tommasi et al., 2009).  
 
Other than the histological origin, breast tumours have been classified into subtypes 
based on gene expression profiling and genomic alterations such as DNA methylation in 
normal breast (epithelial) tissues and primary breast tumours. Five major subtypes of 
breast cancer have been reported based on gene expression studies i.e. basal like, HER2 
enriched (ERBB2), luminal A, luminal B and normal breast like with distinct disease 
phenotype entities (Sorlie et al., 2003). Exome sequencing of 103 patients with different 
subtypes has uncovered 4,985 candidate mutations in total, with frequent C to T 
transitions in CpG dinucleotides (Banerji et al., 2012). Similarly, investigation of 
somatic mutations and copy number changes using exome sequencing in the genomes 
of 100 patients have further revealed mutations in 40 cancer genes including driver 
mutations in some genes not reported previously to be involved in breast cancer such as 
AKT2, ARID1B, CASP8, CDKN1B, MAP3K1, MAP3K13, NCOR1, SMARCD1 and 
TBX3, which suggests an extreme genetic heterogeneity of primary breast tumours 
(Stephens et al., 2012). This study identified 7,241 somatic point mutations that 
included single base substitutions, missense, nonsense, indels (insertions and deletions) 
and frameshift mutations. Analyses of DNA methylation variable regions (MVRs) of 
estrogen receptor alpha (ESR1) gene in ER positive and negative cell lines have 
identified that the ESR1 promoter was unmethylated and intragenic regions were 
methylated in ER+ cells, whereas ESR1 promoter was methylated and intragenic 
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regions were unmethylated in ER- cells (Shenker et al., 2015). This revealed that there 
is a correlation between the ESR expression in intragenic methylation in homogenous 
cell populations further suggesting the significant differences between in vivo and 
heterogeneous tumour microenvironment. This further highlights the importance of 
looking in to the possibility of alterations in intragenic methylation in tumours 
contributing to epigenetic dysregulation of genes. Ronneberg et al (Ronneberg et al., 
2011) reported a cluster on myoepithelial origin and two clusters on luminal epithelial 
origin based on DNA methylation profiling. Interestingly, breast tumours subtypes with 
a similar genetic or gene expression profiling showed different epigenetic profiling. 
Histological and clinicopathological features of breast tumours samples have identified 
triple negative tumours as having poor prognosis and disease free survival (Haffty et al., 
2006; Onitilo et al., 2009). Interestingly, BRCA mutations were commonly associated 
with triple negative tumours (Haffty et al., 2006). Similarly, a previous study (Neve et 
al., 2006) identified different patterns of copy number changes in breast cancer subtypes. 
Likewise, luminal B was found to have the highest percentage of lymph node 
metastases compared to other subtypes including luminal A (Inic et al., 2014). HER2+ 
/ER- are associated with poor outcome due to the presence of residual tumours (Carey 
et al., 2007) and ER+ tumours are noted to have metastatic dormancy for many years 
(Zhang et al., 2013). An integrated genomic and transcriptomics profiling of 2000 
breast cancer patients with a clinical follow up including copy number changes and 
SNPs identified various intermediate subgroups. ER+ subgroups had higher mortality 
risks and driver mutations, luminal A subgroups with low genomic instability. Luminal 
B subgroups showed frequent genomic translocations and basal like tumours had high 
genomic instability and good patient outcome (Curtis et al., 2012).   
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1.6.2 Evolution of the metastatic breast tumour   
Breast cancer spread to other distant organs takes place in an organized fashion, first 
through the lymphatic system and then through the blood.  The micrometastatic 
paradigm states that micrometastatic lesions may already exist in breast cancer patients 
at the time of primary breast cancer diagnosis and that these will later develop as 
metastatic disease (Cianfrocca & Goldstein, 2004). It has been shown that breast 
tumours may lose their tissue architecture due to aggressive and disorganized 
proliferation. Hence, inhibition of EGF signaling due to loss of 1-integrins and EGF 
may lead to the aberration of these structures (Aguirre-Ghiso, 2007). The tumour 
heterogeneity in terms of DNA methylation patterns in primary and metastatic breast 
tumours have identified aberrant DNA methylation of BMP6, BRCA1 and CDKN2A in 
lymph node metastases that may evolve as a distant metastases in the future (Barekati et 
al., 2012).  Moreover, analyses of single cell progenies from a population of metastatic 
breast cancer cells from an immunodeficient mouse has showen that the different cell 
progenies favor metastases to different distant organs suggesting a different requirement 
for metastases to different secondary sites (Minn et al., 2005b). Likewise, genomic 
hypomethylation and hypermethylation events in some important genes such as CDH1, 
CST6, EGFR, SNAI2 and ZEB2 are associated with EMT leading to metastasis to 
different secondary sites (Rodenhiser et al., 2008). This suggests that breast tumours 
could possibly possess an inherent capacity to metastasise to different organs (Weigelt 
et al., 2005).  
 
 
44 
 
1.6.3 Prognostic and predictive indicators for breast tumour recurrence 
1.6.3.1 Tumour phenotype, patients’ age/ethnicity and vascular/lymphatic status  
The presence of breast tumour in axillary nodes i.e. tumour size and the number of 
lymph nodes involved are prognostic factors for distant recurrence of breast tumours. 
The number of lymph nodes and tumour size are independent to each other. However, 
both of these factors together increase the chances of distant metastases. Moreover, 
distant recurrence of breast tumours increases with the tumour size and the median time 
to develop distant metastases decreases as the tumour size increases (Carter & Allen, 
1989). Similarly, tumour grade that ranges from 1 to 3 is calculated based on the total 
score for its mitotic index, differentiation and pleomorphism for which the score ranges 
from 1 to 3. Well differentiated tumours (grade 1) have scores from 1 to 3, moderately 
differentiated tumours have scores from 6-7 (grade 2) where poorly differentiated 
tumours have scores from 8-9 (grade 3). Tumours grades are more important especially 
for lymph node negative patients who have borderline tumour size (Cianfrocca & 
Goldstein, 2004). Furthermore, African American and Hispanic women have reduced 
survival rate in comparison to American women, this is attributed to several factors 
such as lack of clinical care (Daly et al., 1985). Breast cancer patients younger than 35 
years of age generally show worse prognosis (Albain et al., 1994). The presence or 
absence of breast tumour in axillary lymph node is a very important prognostic indicator 
for early stage breast cancer, the risk of breast cancer recurrence is directly associated 
with the number of axillary lymph nodes involved. Based on the number of axillary 
lymph node involvement breast cancer patients are classified as negative lymph nodes, 
1-3 lymph nodes, 4-9 lymph nodes and more than 10 lymph nodes. Long term follow up 
of breast cancer patients have shown a high risk of breast cancer related death or tumour 
recurrence due to breast cancer micrometastasis in lymph nodes (Saez et al., 1989). 
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Similarly, local and distance metastasis of breast cancer increases with vascular 
invasion of lymphatic vessel. Vascular invasion has been associated with recurrence 
risk and is more important in terms of decision-making in breast cancer patients with 
borderline tumours size and without lymph node metastasis (Cianfrocca & Goldstein, 
2004). 
1.6.3.3 Hormone receptor (ER/PR/HER2) Status 
The presence of ER and PR is a crucial predictive factor in patients to assess the 
likelihood of benefitting from tamoxifen (an antagonist of estrogen receptor) treatment 
(Cianfrocca & Goldstein, 2004; Park et al., 2011). Statistically, ~10% of the patients are 
ER/PR/HER+, ~70% are ER/PR+, HER-, and ~13% are triple negative (Onitilo et al., 
2009). This shows that, regardless of HER status, around 80% of the patients are 
ER/PR+. ER+ breast tumours can remain dormant or not detected for many years after 
the diagnosis of the primary tumour suggesting that the cancer cells may proliferate 
with a slow rate during the period of latency (Zhang et al., 2013). Moreover, early stage 
breast cancer may eventually metastasise after a long period of time, even decades after 
a diagnosis of primary tumours (Zhang et al., 2013). In contrast, recurrence of ER- 
breast tumours takes place within three years from the initial diagnosis and generally the 
recurrence rate decreases after five years. Therefore, ER+ breast tumours pose a 
substantial challenge (Hilsenbeck et al., 1998). Similarly, overexpression of the HER2 
gene denotes the aggressiveness of the diseases with reduced disease free and overall 
survival of breast cancer patients (Slamon et al., 2001). In patients that develop 
resistance to therapy the HDAC I inhibitor SNDX-275 (an epigenetic modulator) is 
observed to increase the ability of the patients to respond to herceptin therapy (Huang et 
al., 2011). Similarly, combination therapy using a HDAC II inhibitor with tamoxifen 
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has been effective in hormone therapy resistant patients (Munster et al., 2011).  
1.6.4 Mechanisms of dormancy of disseminated breast tumour cells 
Comparative Genomic Hybridization (CGH) in primary breast cancer has shown that 
the evolution of micrometastases or dormancy may depend on genetic dysregulation of 
genes in primary tumours leading to continued progression and systemic microevolution 
of tumours (Aguirre-Ghiso, 2007). Several components that regulate cancer cell 
viability and self-renewal mechanisms contribute to dormancy, this is probably 
controlled by cross talk between the dormant cells and their microenvironment (Zhang 
et al., 2013).  
It is possible that the tumour cells, which remain dormant in a new niche, may be 
tumour initiating cells or cancer stem cells, which have the capacity to reinitiate the 
tumour. However, is not clear if the cells that reinitiate metastasis in bone are the same 
cells that contribute to tumorigenesis in primary tumours (Marsden et al., 2012). It has 
been shown that tumour initiating potential of breast micrometastases in the lung is 
suppressed by BMP2 signaling. Furthermore, metastasis in lung is driven by Coco 
expression by terminating metastatic dormancy (Zhang et al., 2013). WNT and Notch 
pathways are activated to maintain tumour-initiating cells by the ECM protein TNC 
(Tenascin C).  
 
1.6.5 Detection of micrometastases and late occurrences 
Only micrometastases more than 300 μm in diameter can be detected by MRI 
spectroscopy (Zhang et al., 2013). Therefore, other techniques will be required to 
identify the majority of micrometastases. One promising technique to detect the 
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presence of micrometastases is the examination of tumour DNA in peripheral blood 
using suitable molecular methods (Weigelt et al., 2005).  It is believed that the 
circulating tumour cells (CTCs) and tumour DNA in patients could signify the present 
of micrometastases in distant sites (Giuliano et al., 2011). Similarly, the presence of 
micrometastases could be examined by the presence of tumour free circulating DNA in 
the blood based on the DNA released by the micrometastases into the blood (Zhang et 
al., 2013). Histopathological features and gene expression profiles are used to predict 
early relapses (less than five years) with reasonable accuracy (Wang et al., 2005). 
Unlike late occurrences, early relapses may be a result of rapid proliferation of tumour 
cells. However, it has been extremely difficult to predict late occurrences, which 
generally are not correlated to rapid proliferation of the tumours (Cardoso et al., 2012).   
A comparison of gene expression profiling of primary tumours and late reoccurring 
tumours has been used to identify gene expression signatures for late occurrences 
(Mittempergher et al., 2013). The results of this study suggest that there may be specific 
epigenetic and genetic changes that occur over a long evolutionary process where the 
distant site microenvironment provides a distinct selective pressure to that applied to the 
primary tumour. Therefore, it is important to examine primary tumours and lately 
recurred metastases to identify unique genetic and epigenetic dysregulation responsible 
for late recurrences of the primary tumours.  
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CHAPTER 2 
Aims and Objectives 
 
2.1 The Project Background 
 
The aim of this project was to identify epigenetic alterations contributing to metastatic 
growth, which provides potential for tumour cell dissemination and infiltration to a new 
niche. We hypothesised that epigenetic silencing of BBM associated genes would either 
occur as  
a) Early events, in which the epigenetic alterations occur early in the primary 
tumours that contribute to local invasion and intravasation. These early events 
may be required for specific distant site metastasis and also contributes to 
primary tumour development (Figure 2.1). 
b) Late events, in which the epigenetic alterations occur late in BBM. These play 
no significant role in the initial evolution of the primary tumour but contribute to 
the development of the secondary brain metastasis, either by promoting invasion 
or improving the capacity for these foreign cells to survive in the new 
microenvironment of the brain (Figure 2.1). 
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Figure 2.1: The possible genomic alterations in cancer metastasis to the brain 
during metastatic cascade. The genomic alterations that occur in primary tumours 
(early events) in a malignant phenotype may provide a selective advantage to 
tumour cells to invade the surrounding tissues and enter the blood vasculature, 
(intravasation), which eventually reaches the brain (extravasation).  Similarly, 
additional genomic alterations that occur in the brain microenvironment (late 
events) may provide a selective advantage to metastasised tumours cells to grow 
and to evolve into the malignant brain metastases.  
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In this regard, the project intended to identify those genes which are dysregulated either 
early in primary tumours (early events) that provided these cells a selective advantage to 
metastasise to the brain or late in the metastasised cells in the brain (late events) that 
provided potential to those cells survive against the selective pressure in order to grow 
and to proliferate in the brain microenvironment.  
 
 
2.2 Identifying genes dysregulated in BBM i.e. genes frequently methylated in 
brain metastases.  
The first step was to identify genes dysregulated in BBM. This was achieved as follows.  
2.2.1 A broad literature search to screen genes frequently methylated in one of the 
tumour types that metastasises to the brain 
Given that lung, breast, melanoma, colorectal and renal cancers are the most frequent 
ones metastasising to the brain, there may be some genomic alterations common 
between them (chapter 4). There may be a possibility that at least in part, genomic 
alterations that drive tumour formation in these primary organs provide the potential for 
colonization of a distinct subset of primary tumours in secondary sites. In order to 
choose candidate genes that are uniquely dysregulated in BBM but not in primary breast, 
the initial screenings included only those genes, which are either methylated in lung 
(figure 2.2, gene B), melanoma (Figure 2.2, gene C), or RCC (Figure 2.2 gene D). 
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Figure 2.2: Screen of dysregulated genes in BBM. The candidate genes methylated 
in all primary tumours that readily metastases to the brain contribute to primary 
tumours including breast (Gene A). Initial screening included the genes, which are 
methylated either in lung (Gene B), melanoma (Gene C) or RCC (Gene D) but not 
in primary breast. However, some genes with their unknown methylation status in 
primary breast (such as Gene B) were also chosen. A good candidate would be 
methylated in one of the tumour types that readily metastasises to the brain such 
as lungs, melanoma and RCC but not methylated in breast (from the initial 
literature search), and frequently methylated in BBM samples identified by 
laboratory analyses (such as gene C, D).  
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2.2.2 A broad literature search for screening of genes downregulated in EMT 
 
The process of EMT is involved in metastasis and invasion (section 1.4.5). We 
hypothesise that the genes that are downregulated in the process of EMT may provide a 
selective advantage to cells to attain mesenchymal phenotypes increasing their motility 
suitable for invasion and metastases. In order to extend the list of candidate genes 
dysregulated in BBM, those genes downregulated in EMT process were selected. The 
genes downregulated in EMT included occludins, claudins, keratins and tumour 
suppressor microRNAs (chapter 4).  
 
2.2.3 Bioinformatic analysis of The Cancer Genome Atlas (TCGA) data 
 
We hypothesized that gene methylation that may contribute to BBM will occur 
commonly in primary lung tumours, as these often metastasise to the brain in a short 
time period relative to initial diagnosis.  These metastasising breast tumours may have 
genomic alterations common to lung tumours that are responsible for BBM. Therefore, 
the genes that are infrequently methylated in non-metastasising breast tumours and 
frequently methylated in primary lung tumours (that readily metastasis to the brain) may 
be found to be commonly methylated in metastatic brain tumours that derive from both 
lung and breast tumours. In order to identify such novel candidate genes that contributes 
to BBM, analyses of genome wide 450K methylation array data was carried out.  
(chapter 5, figure 2.3) 
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Figure 2.3: The bioinformatics analysis of the Infinium BeadChip 450K 
methylation array data for primary breast and lung tumours from TCGA. The 
frequent genomic dysregulation (X) in a genome (XXXX) responsible for primary 
lung tumours may also be common and frequent in lung to brain metastases brain 
metastases (LBM) and BBM, which, however, may be infrequent but common in 
primary breast tumours. Additional genomic dysregulation (X) may occur in the 
genome of BBM tumour (XXXX) inside the brain microenvironment that may 
contribute to survival of brain micrometastases and to the eventual development of 
macrometastases.   
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2.3 Investigation of methylation status of candidate genes and their expression 
primary breast tumours and BBM 
 
The methylation status of candidate genes obtained from a literature search and TCGA 
data analysis were investigated using Combined bisulphite and restriction analysis 
(CoBRA) in BBM samples. The candidate genes frequently methylated in BBM were 
further investigated in an independent cohort of primary breast tumours. Furthermore, 
those candidate genes which were differentially methylated in primary breast tumours 
and BBM samples were analysed for their expression in BBM samples to ensure that 
the genes were silenced due to promoter hypermethylation (chapter 4 and 5). The 
summary of the methodology is illustrated in figure 2.4. 
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Figure 2.4: Graphical overview of methodologies used in screening and experimental validation of genes dysregulated in BBM. The 
candidate metastatic suppressor genes screened from a literature review to identify those genes that are methylated in lung, 
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melanoma and renal cancer as these often metastasise to the brain rapidly. If these genes were not known to be frequently 
methylated in breast tumours (that metastasise to the brain with a longer lag period), they were considered as good candidates. 
Similarly, a literature review included candidate genes downregulated in EMT. In addition, bioinformatic analyses of Genome 
wide 450K methylation data for primary lung and breast tumours from the TCGA were carried out to identify novel candidate 
genes. The identified genes were further screened in BBM samples using CoBRA and those that were frequently methylated in 
BBM samples were screened for methylation in primary breast tumours. Those that were frequently methylated in BBM samples 
and infrequently methylated in primary breast tumours were analysed for their expression in BBM samples and other functional 
roles.   
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2.4.  Study of metastatic potential of candidate genes silenced or downregulated in 
BBM due to promoter hypermethylation 
To achieve this aim, two independent sets of experiments were carried out. 
2.4.1 Wound healing assay 
In a wound-healing assay the breast cancer cell lines knocked down with siRNA 
nucleotide oligos against a respective gene being studied were seeded as a monolayer in 
6 well plates (figure 2.5A). The wound/gap was created using 200µl pipette tip (section 
3.6.3). The migratory potential of the cells was determined based on the distance 
travelled by cells towards the gap using statistical measurement (chapter 6). 
 
2.4.2 Invasion assay 
 
In a transwell assay, the breast cancer cell lines knocked down with siRNA oligos 
against respective gene were seeded as serum free media in a upper surface of a trans 
well contained in 6 well plates (figure 2.5B). The transwell experiment was prepared by 
coating an 8µm pore basement membrane with matrigel (section 3.6.4). The invasive 
potential of the cell lines were determined based on the number of cells invaded through 
the matrigel coated base membrane (section 6).  
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Figure 2.5: The experiments to investigate metastatic potential of breast cancer cell 
following the knockdown of candidate genes. The breast cancer cell lines knocked 
down with siRNA oligos against the candidate gene were used in a wound healing 
assay (A) and a trans well invasion assay (B) to investigate migratory and invasive 
potential of breast cancer cell lines respectively. 
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2.5 Identification of novel candidate genes by genome wide analyses of aberration 
in DNA methylation contributing to BBM 
This aim was achieved by Illumina BeadChip Genome Wide 450K methylation analysis 
using 24 BBM samples (section 3.7.1). This analysis identified novel candidate genes, 
which are either hypomethylated or hypermethylated in BBM compared to primary 
breast tumours from the patients (chapter 7).  
 
2.6 Investigate whether the genomic dysregulation in BBM is an early or a late 
event during the evolution of BBM in individual patients 
 
The genetic dysregulation in the process of metastases is either an early or a late event 
(section 2.1, figure 2.1).  This aim was achieved by determining the methylation status 
of candidate genes in primary tumours and their corresponding BBM samples in 
individual patients (chapter 4, 5 and 7).  
 
2.7 Investigate whether the candidate genes identified (metastatic suppressor or 
metastatic promoter) genes could be used as prognostic biomarkers for BBM 
To achieve this aim the methylation status of a panel of potential candidate genes 
(prognostic markers) was determined using Methylation Specific PCR (MSP) using 
tumour-free circulating DNA (section 3.3.4.2) isolated from individual patients’ plasma 
(section 3.2.2) taken at the time of BBM surgery. The methylation status of these genes 
in plasma samples and BBM samples was used to determine if this panel of genescould 
potentially be used as prognostic biomarkers for BBM (chapter 7).  
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CHAPTER 3 
Materials and Methods 
 
 3.1 Patients and Samples 
 
3.1.1 Breast to brain metastases (BBM) samples  
 
The Walton Research Tissue Bank (WRTB), Liverpool and Brain Tumour North West 
(BTNW), Preston provided fresh frozen metastatic brain tumour samples that had 
originated from breast, lung, melanoma, Renal Cell Carcinoma (RCC) and colorectal 
cancer. Genomic DNA was extracted from all the tumours collected. The metastatic 
brain tumour samples from breast, lung, melanoma and RCC were designated as BBM, 
LBM, MBM and RBM respectively. A list of brain metastases samples is given in 
Appendix A1.  
 
3.1.2 Matched primary breast tumours  
 
Twelve Formalin-Fixed Paraffin Embedded (FFPE) matched primary breast tumours 
corresponding to metastatic brain tumours were provided by BTNW tissue bank, 
Preston. The list of FFPE matched primary tumours and normal breast is given in table 
3.1.  
 
National research ethics committee approved tissues from the research banks and 
informed consent was obtained from each patient. This study was conducted according 
to the principles expressed in the Declaration of Helsinki. 
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Table 3.1: The matched pairs of tumours; BBM, primary breast tumours (BP) and 
normal breast tissues (BN) from individual patients. Eleven primary tumours and 
only three normal breast tissues were available from individual BBM patients.  
 
3.1.3 Genomic DNA from primary breast tumour 
 
A cohort of 60 independent primary breast tumours were provided by Ivan Bièche 
(Department of Genetics, Institute Curie, Paris) and Farida Latif (Department of 
medical genetics, University of Birmingham). The primary breast tumours are denoted 
as BP for convenience. The list of primary tumours is given in appendix A2.  
 
3.1.4 Plasma/serum of patients from BBM 
 
Ten plasma and serum samples, collected at the time of surgery of BBM, were provided 
by BTNW. A list of Plasma/Serum Samples collected is given in table 3.2.  
Breast'to'
brain'
metastases'
(BBM)'code
Primary'
breast'
tumour'
code
Normal'
breast'
tissue
BM1 BP1 BN1
BM2 BP2 BN2
BM3 BP3
BM5 BP5
BM8 BP8 BN8
BM10 BP10
BM11 BP11
BM12 BP12
BM13 BP13
BM14 BP14
BM15 BP15
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Local research committees approved collection of samples and informed consent was 
obtained from each patient. This study was conducted according to the principles 
expressed in the Declaration of Helsinki. 
 
Table 3.2: A cohort of patients’ serum and their corresponding breast to brain 
metastases samples from individual patients. These serum samples were collected 
at the time of brain tumour surgery from the patients, which were used to carry 
out MSP to find if the methylation status of the BBM samples correlates with the 
serum samples (chapter 7).  
 
3.1.5 Breast cancer cell lines 
 
Five breast cancer cell lines (MCF7, T74D, MDA-MB231, BT549 and ZR75) were 
used for tissues culture purposes and to carry out experiments. Prof. Weiguang Wang at 
the Research Institute of Healthcare Sciences (RIHS), University of Wolverhampton 
provided these cell lines. They were routinely maintained in DMEM (Sigma, UK) 
supplemented with 10% FCS at 37°C, and 5% CO2.  
 
 
 
Breast'to'brain'
metastases'
(BBM)'code
patient'serum'
code
BM1 SD1
BM2 SD2
BM5 SD5
BM6 SD6
BM7 SD7
BM8 SD8
BM10 SD10
BM11 SD11
BM12 SD12
BM13 SD13
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3.2 Nucleic Acid Extractions and Preparation  
 
3.2.1 Genomic DNA Extraction  
 
Genomic DNA was extracted from fresh-frozen metastatic brain tumours, FFPE 
samples for matched primary tumours and also from patients’ plasma taken at the time 
of metastatic brain tumour surgery.  
 
3.2.1.1 Genomic DNA extraction from fresh frozen metastatic brain tumours 
 
Genomic DNA was extracted from fresh-frozen metastatic brain tumours using DNA 
isolation kit from cells and tissues (Roche, Germany). 25mg of fresh frozen tissue was 
ground with a mortar and pestle in dry ice and 500µl of lysis buffer was added 
immediately to lyse the cells. The samples were homogenized using a syringe until the 
fine suspension was obtained and incubated at 37°C for 30 minutes. 1µl of Proteinase K 
solution was added to each sample, vortexed to mix, and incubated at 65°C in order to 
degrade proteins. 25µl of RNase solution was added to each sample, vortexed to mix 
and was incubated at 37°C for 30 minutes to ensure the degradation of RNA. 250µl of 
protein precipitation solution was added to each sample, vortexed thoroughly for 5-10 
seconds, placed on ice for 5 minutes and each sample was centrifuged at 17000g for 30 
minutes at room temperature. Supernatant containing DNA was transferred carefully to 
a new tube, 0.7 volumes of isopropanol was added to the sample to precipitate followed 
by centrifugation at 1370g for 10 minutes. Precipitated gDNA was washed with 1.5 ml 
of ice cold 70% ethanol, centrifuged at 1370g for 5 minutes and the supernatant was 
discarded. The DNA pellet was air-dried until the ethanol was fully evaporated. DNA 
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was dissolved in an appropriate amount of water (50-100 µl) and was quantified using a 
Nanodrop 2000 spectrophotometer (Thermo scientific, USA).  
 
3.2.1.2 Genomic DNA extraction from Formalin fixed FFPE tumour samples 
 
Genomic DNA from FFPE samples was extracted using QIAamp DNA FFPE tissue kit 
(Qiagen, USA). Small blocks of samples embedded with paraffin were cut into eight 
sections (5 –10 µm thick) and excess paraffin was removed using a scalpel. These 
sections were immediately placed in a sterile 1.5 ml microcentrifuge tube, mixed with 1 
ml xylene, vortexed vigorously for 10 seconds in order to dissolve paraffin and 
centrifuged at 17000g for 2 minutes at room temperature. The supernatant was 
discarded by pipetting and the pellet was dissolved with 1ml of 96-100 % ethanol, 
vortexed and centrifuged again for 2 minutes at room temperature. The supernatant was 
discarded; the tubes were air dried until all the residual ethanol was evaporated. The 
pellet was resuspended in 180µl buffer ATL followed by the addition of 20ul proteinase 
K, vortexed and incubated at 56°C for 1 hour. The samples were then incubated at 90°C 
for an additional 1 hour to make sure that the samples were completely lysed. The lysate 
was transferred to a QIAamp MinElute column (in a 2 ml collection tube), centrifuged 
at 6000g for 1 minute and the flow through was discarded. 500 µl Buffer AW1 was 
added to each QIAamp MinElute column, centrifuged at 6000g for 1 minute followed 
by an addition of 500 buffer AW2, and centrifuged again at 6000g for 1 minute. Each 
QIAamp MinElute column was centrifuged at 17000g for 3 minutes to remove any 
residual buffer from the column and transferred to clean 1.5 ml microcentrifuge tube. 
20–100 µl of elution buffer (depending on the size of the pellet obtained) was added on 
each QIAamp MinElute column, incubated at room temperature for 5 minutes and 
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centrifuged at 17000g for 1 minute. The DNA was quantified using Nanodrop 2000 
spectrophotometer (Thermo Scientific, USA). 
 
3.2.2 Extraction of tumour free circulating DNA from patients plasma 
 
Tumour-free circulating DNA from the patients’ serum was extracted using ZR serum 
DNA kit (Zymo research, USA). 2 ml plasma from each patient was transferred to a 
conical shaped 50 ml universal tube. 8 ml of genomic lysis buffer and 10µl of 
zymoBeads were added to and placed in a shaker for two hours at room temperature in 
order to mix the sample completely. The samples were centrifuged for 1-2 minutes; the 
pellet was resuspended in 500µl of DNA wash buffer, and transferred to a sterile 1.5 ml 
microcentrifuge tube. The samples were centrifuged at room temperature for 1 minute at 
6000g, and the pellet was resuspended again in another 500µl of DNA wash buffer. The 
samples were centrifuged again at room temperature for 1 minute at 60000g to remove 
any residual buffer, and the pellet was air dried for 15 minutes. 30 µl of DNA elution 
buffer was added to the pellet (containing ZymoBeads), resuspended by repeated 
pipetting and was centrifuged at 10000g for 1 minute. The supernatant containing 
purified DNA was collected and was quantified using Nanodrop2000 
spectrophotometer (Thermo Scientific, USA). 
 
3.2.3 Total RNA extraction 
 
Total RNA was extracted using the EZ-RNA extraction kit (Biological Industries, Israel) 
from the fresh frozen metastatic brain tumours and breast cancer cell lines. 
Approximately 50 µg of the fresh frozen metastatic brain tumours were ground using 
66 
 
and pestle and mortar in dry ice, which were homogenized using 500 µl of denaturing 
solution to lyse the cells. The samples were vortexed and left at room temperature to 
make sure that the cells were lysed completely. 500 µl of extraction solution was added 
to each sample, vortexed and incubated at room temperature for 10 minutes followed by 
centrifugation at 17000g for 15 minutes at 4°C. This centrifugation step produced three 
phases containing RNA at the upper aqueous phase, DNA and protein in intermediate 
and lower phase respectively. The upper phase containing total RNA was carefully 
transferred to sterile RNAse free tubes, mixed with 500 µl of isopropanol, stored over 
night at -20°C and centrifuged at 17000g for 10 minutes at 4°C. The supernatant was 
removed; The RNA pellet was washed with 1 ml 75% alcohol (v/v), and centrifuged at 
10000g for 5 minutes at 4°C. RNA pellet was air dried and dissolved with an 
appropriate amount (30-80 µl) of RNAse free water based on the size of the pellet.  
 
To extract total RNA from the cell lines, respective cell lines were trypsinized using 1x 
300µl trypsin to detach them from the flask when they were 80% confluent, and mixed 
with 1ml DMEM immediately to quench the trypsin.  The cell suspension was 
centrifuged at 1500g for 5 minutes. The cell pellet was resuspended in PBS and re-
centrifuged. RNA was extracted from the resulting pellet using the protocol for total 
RNA extraction. 
 
Total RNA concentration was measured using a Nanodrop2000 Spectrophotometer 
(Thermo Scientific, USA). 
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3.2.4 Quantification of nucleic acid preparations 
The concentration of genomic DNA and total RNA was determined using Nano Drop 
2000 Spectrophotometer (Thermo Scientific, USA). 2µl of water or the solution used to 
elute nucleic acids during preparation was used as a reference for zero absorbance 
(blank).  2µl of nucleic acid preparation was then used to quantify each sample. Nano 
Drop output readings consisted of a 260/280 and 260/230 ratio and a concentration in 
ng/µl. Purity of the DNA and RNA preparations was assessed using the 260/280 and 
260/230 ratios. Both the DNA and RNA were considered to be pure if the ratio was in a 
range of ~1.8 to ~2.0. The ng/µl ratio was calculated by the spectrophotometer based on 
the modified Beer-Lambert equation i.e. c = (A*e)/b, where c denotes for nucleic acid 
concentration in ng/µl, A denotes for absorbance at 260nm, and e is the wavelength 
dependent extinction coefficient in ng-cm/µl for either double stranded DNA (50ng-
cm/µl) or single stranded RNA (40ng-cm/µl). 
3.2.4 Protein Extraction and quantification 
Protein extraction was carried out from cell pellets derived from cancer cell lines. The 
cell pellets were lysed in RIPA buffer (25mM HCl, 0.1%SDS, 1% TritonX 100, 0.15M 
NaCl, pH 7.4) containing phosphatase and protease inhibitor (Roche, Germany). The 
lysate was transferred into a 1.5 ml microfuge tube, sonicated for 1 minute to further 
disrupt the cell wall and centrifuged at 4°C for 15 minutes. The supernatant containing 
protein was transferred to a new 1.5 ml microfuge tube.  
Protein concentration was quantified using a modified Lowry method i.e. Bio-Rad 
detergent-compatible protein assay (Bio-Rad, United Kingdom). 5µl of each protein 
sample (in duplicates) was loaded to a 96-well plate. 20 µl of reagent S for every ml of 
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reagent A (an alkaline tartrate solution) was mixed in a separate tube, and 25 µl of that 
mix was added into each protein sample. 200 µl of reagent B (A dilute Folin reagent) 
was added to each protein sample and the plate was incubated at room temperature for 
10 minutes to allow colorimetric reaction. The plate was read on a spectrophotometer 
(Thermo Scientific, USA) at 650nm.  
 
3.3 DNA Methylation Analyses 
 
3.3.1. DNA methyltransferase modification of DNA to create fully methylated 
positive controls 
 
Fully methylated positive control DNA was generated by incubating genomic DNA 
with DNA methyltransferase in the presence of S-adenosyl methionine (SAM) (New 
England Biolab, USA). SAM acts as a donor (source) for a methyl group whereas DNA 
methyltransferase (DNMTs) catalyzes the transfer of methyl group to cytosine residues. 
The 50µl of reaction mixture contained 5µg of genomic DNA, 5 µl NEB buffer, 2µl of 
32mM SAM, 2µl (4 units) of DNMT and sterile distilled water. The reaction mixture 
was incubated for 2 hours at 37°C resulting in 100ng/µl of fully methylated DNA.  
 
3.3.2 Bisulphite Conversion of DNA  
 
Bisulphite conversion of genomic DNA from tumour samples was carried out using EZ 
DNA methylation kit (Zymo Research Corp. USA) whereas, Bisulphite conversion of 
tumour free DNA from plasma was carried out using EpiTect bisulphite kit (Qiagen, 
USA) 
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3.3.2.1 Bisulphite conversion of genomic DNA  
  
500ng of genomic DNA and 1000ng (1µg) of of fully methylated positive controls were 
bisulphite converted using the EZ DNA methylation kit (Zymo Research Corp. USA). 
5µl of M-dilution buffer and water was added to each sample to make a total volume of 
50µl. The samples were incubated at 37°C for 15 minutes. 100µl of CT conversion 
reagent was added to each sample, mixed by pipetting and were incubated at 50°C for 
12-16 hours. The samples were kept on ice for 10 minutes after the incubation was over. 
400µl of M-binding buffer applied to each zymo spin column with collection tube, and 
the samples were added and mixed by inverting the column 4-6 times. The columns 
were centrifuged, washed using 100µl of M-wash buffer and centrifuged again. 200µl of 
M-disulfonation buffer was added to each column, incubated at room temperature for 
15-20 minutes and centrifuged to ensure the removal of excess bisulphite salts by 
disulfonation. Each column was washed twice, using 200µl of M-wash buffer and 
centrifuged at full speed for 1 minute. The bisulphite converted DNA was eluted using 
30 µl of elution buffer and was stored at -20°C.  
 
3.3.2.2 Bisulphite conversion of tumour free circulating DNA from patients’ 
plasma 
 
Epitect Bisulfite kit (Qiagen, USA) was used for bisulphite conversion of tumour-free 
circulating DNA from patients’ plasma. 200ng of serum or plasma DNA were added to 
200µl sterile PCR tube, the final volume was made up to 20µl with RNase free water. 
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85µl bisulphite conversion reagent (bisulphite mix) and 85µl DNA protect buffer was 
added to the samples making up total volume of 140 µl. 
The samples were incubated in a thermal cycler for three rounds of denaturation and 
inubation at 95°C and 60°C respectively. Each denaturation steps consisted of 5 minutes 
whereas incubation time varied in each cycle. First round of denaturation and incubation 
consisted of 5 minutes and 25 minutes, 2nd round consisted of 5 minutes and 85 
minutes and where as third cycle consisted of 5 minutes and 175 minutes (2 hour 55 
minutes) respectively. The bisulphite converted DNA was transferred to a sterile 1.5 ml 
microcentrifuge tube and 560µl of freshly prepared buffer BL containing 10 µg/ml 
carrier RNA was added to each tube in order to ensure binding of DNA with the 
column. The samples were transferred to EpiTect spin columns with collection tubes 
and were centrifuged for 1 minute at room temperature. The columns were washed with 
500 µl of buffer BW and the sample were desulfonated by adding 500µl of buffer BD to 
each column, incubated at room temperature for 15 minutes, and were centrifuged for 1 
minute at room temperature. The columns were washed twice by the addition of 500 µl 
of buffer BW and centrifugation for 1 minute at room temperature. The columns were 
transferred to a new sterile 1.5 ml microcentrifuge tube, 20µl buffer EB was added to 
each column and centrifuged for 1 minute in order to elute DNA. Another 20 µl buffer 
EB was also added to column and centrifuged again to increase the yield of DNA 
eluted. 
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3.3.3 Combined Bisulphite and Restriction Analysis 
 
3.3.3.1 CoBRA primer design 
 
CoBRA PCR was carried out using semi nested and nested primers. The primers were 
designed to amplify up to 550bp of a promoter region CpG Island. CpG islands 
associated with candidate genes were identified on the human genome browser 
(http://genome.ucsc.edu/cgi-bin/hgGateway). Primers were designed using criteria to 
maximize the specificity and effectiveness of the primers designed; (i) The 5’end of the 
primers preferably started with a G nucleotide and the 3’ end of the primers preferably 
ended with ACC, or CAC in unmodified DNA resulting in ATT or TAT in bisulphite 
modified DNA in order to provide a strong initial binding point and a high specificity to 
bisulphite modified DNA. ii) Primers didnot preferably contain strings of As, Ts, or Cs 
in them to prevent formation of hairpin structures. It was important to ensure that 
CoBRA primers were unbiased towards methylation status. The incorporation of CG 
dinucleotide within the primer was avoided wherever possible to ensure that the primers 
designed were unbiased on methylation status of the region amplified. However if this 
was unavoidable, C nucleotides were designated as Y (either C if methylated or T if not 
methylated, to make a 50:50 ratio of C or T nucleotide incorporation) in forward 
primers. Similarly, C nucleotide was designated as R (either G, if methylated or A if not 
methylated, to make a 50:50 ratio of G or A nucleotide incorporation) in reverse primers. 
The incorporation of BstUI restriction sites (CGCG) or TaqI restriction sites (TCGA) 
within primers were avoided. Annealing temperatures of primers were calculated using 
the equation: [(% C or G x 0.41) + 64.9 - (600/N)] where % C or G is calculated from 
the total number of C or G in the primer (Y and R is counted as 0.5) and N is the total 
72 
 
number of nucleotides with in the primer (length of the primer). All primers were 
manually designed.  
 The CoBRA primers designed are listed in appendix A3.1.  
3.3.3.2 CoBRA PCR 
Semi nested or nested primers were used in all CoBRA PCR reactions, therefore, two 
rounds of PCR were carried out per PCR.  Both the nested PCR (first round) and semi-
nested (second round) reactions contained 2.5 µl 10X PCR buffer containing 
magnesium chloride (pH 8.3), 2.5mM dNTP mix (Bioline, UK), 20µM of forward and 
reverse primer and 6.25 units or 7.5 units (for primary or secondary reactions 
respectively) of FastStart Taq DNA polymerase (Roche, Germany). Reactions were 
made up to 25µl or 50µl for primary and secondary reactions respectively with distilled 
water. 2µl of bisulphite converted DNA was used as starting material in the first 
nested/seminested PCR and 2µl of this PCR product was used as starting material for 
the second round of nested/semi nested PCR. The reagents and concentration of nested 
and semi nested PCR is given in table 3.3. 
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Table 3.3: Reagents used to set up nested and semi nested PCR reaction. Master 
mix was prepared with the required reagents. 2 µ l of bisulphite converted DNA 
(for the first round) was transferred into a sterile 200 µ l PCR tube and 23 µ l of 
master mix was added on the DNA. For the semi-nested PCR, 2 µ l of nested PCR 
product was transferred to a new sterile 200 µ l PCR tube followed by 48 µ l master 
mix  
 
 
 
 
 
Reagent Initial 
Concentration 
Volume used 
First round 
Volume used 
Second round 
PCR buffer with 
MgCl2  
10X 2.5µl  5µl 
dNTPs  2.5 mM 2.5µl 5µl 
Forward Primer 20µM 1.25µl 1.5µl 
Reverse Primer 20µM 1.25µl 1.5µl 
Taq polymerase 5 U/µl 0.25µl 0.25µl 
DNA Bisulfite 
converted DNA 
2µl 2µl from the 
first round 
Double-distilled 
water 
- 15.3µl 34.75µl 
Total - 25µ l 50µ l 
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Both nested and semi-nested PCR were carried out using touchdown PCR, see tables 
3.4 for program details.  
 
 
 
 
 
 
 
 
 
 
 
Table 3.4: Touchdown PCR program. Touchdown PCR program starts at a higher 
temperature than the annealing temperature (Tm) of the primers. The program 
was designed to run first two cycles at Tm+4°C, the next two cycles at Tm+2°C, the 
next two cycles at Tm. Finally, the reaction mixture was run for 32 cycles at 
touchdown temperature (Tm-2°C). .  
 
3.3.4. Methylation Specific PCR (MSP)  
3.3.4.1. MSP primer design 
MSP primers were designed for those genes which methylation status suggested clinical 
significance and deserved further investigation. MSP product sizes ranged from 120-
250bp in length and were located within the region analysed by CoBRA  (to avoid 
biases in methylation analysis of the same region). For MSP, two sets of forward and 
Temperature Duration Step Description/cycle 
94°C 3 minutes Initial denaturation  
94°C 45 seconds Denaturation  2 cycles 
Tm +4°C 45 seconds Annealing 
72°C 45 seconds Extension 
94°C 45 seconds Denaturation  2 cycles 
Tm +2°C 45 seconds Annealing 
72°C 45 seconds Extension 
94°C 45 seconds Denaturation  2cycles 
Tm  45 seconds Annealing 
72°C 45 seconds Extension 
94°C 45 seconds Denaturation 32 cycles 
Tm -2°C (TD) 45 seconds Annealing 
72°C 45 seconds Extension 
72°C 5 minutes Final extension  
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reverse primers were designed i.e. Unmethylated Specific PCR (USP) and MSP primers. 
USP primers were specific for unmethylated sequences and MSP primers were specific 
for methylated sequences. They are designed with the following criteria and guidelines 
for designing MSP primers; i) In contrast to CoBRA primers, MSP primer sequence 
contained at least 2-3 CG dinucleotide to provide specificity and to avoid biases in 
methylation status analysis., ii) Primers were 25-35 base pairs in length iv), As there are 
less C or Gs in USP primers than MSP primers, they are often longer to accommodate 
additional  Gs in their 5’end to ensure their annealing temperature is in a same range as 
in MSP. In addition, primer-designing criteria from CoBRA primers were considered 
(section 3.3.3.1). All primers were manually designed.  
The MSP primers designed are listed in appendix A3.2.  
3.3.4.2 MSP in brain metastases and patients serum 
 
MSP was used to analyse free circulating DNA isolated from patients’ serum and brain 
metastases. MSP in brain metastases was carried out to ensure that the MSP primers 
designed for each gene are able to amplify the region of interested before carrying out 
MSP/QMSP in patients’ serum. Each 25µl MSP reaction contained 2.5µl of 10X PCR 
buffer containing magnesium chloride (pH 8.3), 2.5mM dNTPs mix (Bioline, UK), 
20µM forward and reverse primer each and 6.25 units of FastStart Taq DNA 
polymerase (Roche, Germany). (Table 3.3). A touch down PCR program was used to 
amplify the sample using either MSP or USP primers (table 3.4).  
 
 
3.3.5 Quantitative Methylation Analysis by Bisulphite Sequencing 
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3.3.5.1 Purification of PCR Products 
 
PCR products selected for cloning were first purified from agarose gels using a Gel 
Extraction Kit (Qiagen, USA). PCR products were run on 1% agarose gel 
electrophoresis. The products were cut out of the gel using a scalpel and transferred to 
1.5ml microcentrifuge tubes. Gel slices were weighed and 3 times mass (mg) in volume 
(µl) of buffer QG was added to samples and was incubated at 50 ̊C for 10 minutes with 
intermittent vortexing in every 2-3 minutes to dissolve the agarose gel. 1 x mass (mg) in 
volume (µl) of 100% isopropanol was added to the solution, mixed and was transferred 
to transferred to a QIAquick spin column and centrifuged at room temperature for 1 
minute at 17000g. The flow-through was discarded, 500µl buffer QG was added and 
was centrifuged again. Flow-through was again discarded, 500µl buffer PE was added 
to the column and the samples were centrifuged again for 1 minute at 17000g at room 
temperature. The samples were centrifuged again to remove residual ethanol. The 
columns were placed in a fresh 1.5ml microcentrifuge tube, 30µl distilled water was 
added directly to the column membrane and was incubated at room temperature for 1 
minute. The tubes were centrifuged at room temperature to elute the purified DNA from 
the column. The purified PCR product was either used immediately or stored at -20°C. 
3.3.5.2 Ligation of PCR products into plasmid vector 
The PCR products were ligated in the pGEM-T Easy vector system (Promega, USA) in 
order to introduce PCR products into bacterial cells for cloning. The ligation reaction 
was set up with 0.5µl pGEM vector, 1µl T4 DNA ligase and 5µl 2X ligation buffer. 
This was then added to 3.5µl purified PCR product. Samples were left to incubate at 4 ̊C 
overnight for maximum ligation efficiency.  
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3.5.5.3 Preparation of ampicillin containing (Amp+) agar plates and LB Broth 
 
25g of LB (Luria-Bertani) medium (5N NaCl, tryptone and yeast extract, pH 7) (Sigma, 
UK) and 15g of agar were dissolved in 1 litre distilled water and were autoclaved. 
Ampicillin was mixed to give a final concentration of 100µg/ml.  Agar was then 
immediately poured into the sterile petri dishes, allowed to cool and set, and were 
transferred to 4°C for storage. For LB broth, 25g/L of LB was dissolved in distilled 
water without agar and was autoclaved, it was stored at 4°C. a small aliquot was 
transferred to a sterile tube and ampicillin was added to it to give a final concentration 
of 100µg/ml. 
3.5.5.4 Transformation of PCR product ligated into the pGEM-T easy vector into 
the bacterial cells 
Ligated PCR products were mixed with 50µl DH5α competent cells (Life Technologies, 
UK) by gentle shaking. The cells were heat shocked for 1 minute at 42 ̊C and were then 
incubated on ice for 5 minutes. 1 ml of SOC media (2% w/v, trypton, 0.5%w/v yeast 
extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM glucose) (Invitrogen, USA) 
was added to the cells, which, were then incubated for one hour at 37 ̊C. The cells were 
centrifuged at 2000g for 3 minutes, and two-third of supernatant was gently drained off 
from the tube. The pellet was resuspended in the remaining supernatant. These cells 
were plated on Amp+ LB agar plate and were incubated overnight (or up to 16 hours at 
37 ̊C). 
3.5.5.5 Single colony PCR 
To ensure the greatest chance of picking colonies containing the insert, only white 
colonies were picked, transferred to 20µl distilled water and heated to 95 ̊C for 5 
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minutes to rupture all the cellular membranes. Once cooled, 7µl was used as starting 
material in a PCR reaction (see table 3.3 for protocol), which contained 1x 5X GC rich 
solution, 25µl with distilled water. The Single-colony PCR reactions were carried out 
using a touchdown PCR program (table 3.4) 
3.3.5.6 PCR product clean-up for sequencing 
 
Single colony PCR products were cleaned-up using a combination of FastAP alkaline 
phosphatase (AP) (Fermentas, USA) to remove excess dNTPs, and ExonucleaseI (ExoI) 
(New England Biolabs, USA) to remove excess single stranded primer. A reaction 
mixture contained 10µl PCR product, 1U FastAP, 0.01U ExoI and 10x FastAP buffer 
(100mM Tris-HCL (pH8), 50mM magnesium chloride, 1M potassium chloride, 0.02% 
Triton X-100 and 1mg/ml bovine serum albumin (BSA)). Samples were incubated for 
30 minutes at 37 ̊C followed by an enzyme inactivation step for 20 minutes at 80 ̊C. 
3.5.5.7 Sequencing reaction 
 
Sequencing reactions were carried out using Big Dye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, UK). 5µl cleaned up PCR product was added to a 
20 pmol forward or reverse primer, 0.5µl Big Dye, 2µl 5X buffer and made up to a total 
volume of 10µl with distilled water. The sequencing reaction contained initial 
denaturation at 94 ̊C for four minutes followed by 35 cycles, each of which contained 
three temperatures (94 ̊C for 25 seconds, 50 ̊C for 25 seconds and 60 ̊C for four 
minutes). Samples were wrapped in foil following the sequencing reaction and stored at 
-20 ̊C until precipitated and prepared to be read on the sequencer. 
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3.5.5.8 Ethanol precipitation following sequencing reaction 
 
After the sequencing reaction, 3.5µl precipitation buffer (1.5M sodium acetate, 1.5M 
EDTA) and 100µl of 95% (v/v) ethanol and were centrifuged at 2,254g for 30 minutes 
at 4 ̊C. The supernatant was carefully removed and the samples were then briefly pulsed 
at 23g upside down and were washed with 200µl 70% (v/v) ethanol and centrifuged 
again at 2,254g for 30 minutes at 4 ̊C for. The supernatant was removed and samples 
were pulsed again at 23g upside down, washed with 200µl 70% (v/v) ethanol and were 
centrifuged again at 2,254g for 30 minutes at 4 ̊C. The supernatant was removed and 
samples pulsed at 23g upside down and were allowed to air dry. 
For sequencing, pellets were resuspended in 10µl Hi-Di Formamide (Applied 
Biosystems, UK) and denatured at 95 ̊C for 5 minutes. Samples were run on a 3730 
DNA Analyzer (Applied Biosystems, UK) and output files analysed using sequencing 
analysis 5.2 (Applied Biosystems, UK). 
3.4 Expression analyses of selected genes 
 
3.4.1 Synthesis of complementary DNA (cDNA) from total RNA 
 
Complementary DNA (cDNA) synthesis was carried out using high fidelity cDNA kit 
(Roche, Germany). 1µg of total RNA was mixed with 1µl of oligos dT primers 
(50pmol/µl) and PCR grade water to make 11.6µl volume. The samples were incubated 
at 50°C PCR grade water to make 11.6µl volume. During the incubation time, 8.6µl of 
master mix containing 0.5µl (20 units) of RNAse inhibitor, 2µl of dNTP mix (10mM), 
1µl DDT (5mM), 1.1µl of reverse transcriptase (22 units) were prepared and added to 
each sample to make total volume of 20µl. The samples were incubated at 50°C for 30 
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minutes followed by 85°C for 5 minutes, samples were then immediately placed an ice 
to stop the reaction.  
 
3.4.2 Reverse transcription polymerase chain reaction (RT-PCR) primer design 
RT primers were designed from primary transcripts of the genes of interest. Exon 
sequences of candidate genes were retrieved from Ensembl Genome Browser 
(http://www.ensembl.org/index.html). RT primers were designed in such a way that the 
product encompasses more than one exon, thus ensuring the amplification product was 
not derived from any contaminating gDNA. Primers were designed manually within 
certain guidelines; 1) primers were 18-25 base pairs long (mostly around 20 base pairs), 
2) primers start with G or C to ensure binding specificity of the primers with template 
cDNA, 3) there is even distribution of C and G nucleotide as C and G nucleotide 
determines annealing temperature of the primers which affects the annealing of the 
primers with the template cDNA, 4) long stretches of any nucleotide is avoided to 
prevent formation of hairpin or secondary structure, 5) the product size is around 300-
500 base pairs. Annealing temperatures of primers were calculated using the equation: 
[(% CG x 0.41) + 64.9 - (600/N)] where % CG is calculated from the total number of C 
and G in the primer and N is the total number of nucleotides with in the primer (length 
of the primer).  All primers were manually designed.  
The RT primers designed are listed in appendix A3.3.  
3.4.3 Reverse transcription (RT) PCR 
1µl of prepared cDNA was used to carry out RT PCR to investigate the expression of 
genes in breast cancer cell lines and in metastatic brain tumours. 25µl volume of RT-
PCR reaction contained 2.5µl 10X PCR buffer containing MgCl2 (pH 8.3), 2.5mM 
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dNTPs mix, 1.25 µM forward primer, 1.25 µM reverse primer, 0.5U Fast Start Taq 
DNA polymerase (Roche, Germany), and 16.3 µl distilled water. RT-PCR reactions 
were carried out using a touchdown PCR (3.4). The β-actin gene was used as a positive 
housekeeping control with the same conditions except that the number of cycles was 
reduced (20 cycles) to compare the expression level of the samples being used (28 
cycles). 
3.4.4 Quantification of gene expression 
Quantification of gene expression was carried out using a densitometry program from 
the genetool software to investigate if methylation correlates with expression for three 
genes (BNC1, CCDC8 and GALNT9). Each of the RT PCR products for respective gene 
run on agarose gel electrophoresis was quantified using densitometry on genetool 
software. The PCR product for each sample was also quantified for β-actin gene. The 
expression level of each sample for respective genes was calculated by comparison with 
expression level of β-actin gene.   
3.4.5 Western blotting 
Protein extraction and western blotting of extracts from breast cancer cell lines 
transfected with control oligos/siRNA against candidate genes or transfection ready 
DNA (cDNA clone) for BNC1, CCDC8 and GALNT9 were performed. The western blot 
was performed as follows.  
 
Sample preparation and loading in a gel:  
70µg of each protein extract (section 3.2.4, for protein extraction and quantification) 
was transferred to 0.5ml microcentrifuge tube and 6µl 4x loading buffer, (106 mM Tris 
82 
 
HCl, 141 mM Tris Base, 2% SDS, 10% Glycerol, 0.51 mM EDTA, 0.22 mM SERVA 
Blue G250, 0.175 mM Phenol Red at pH 8.5), 1µl DDT and water was added to make a 
final volume of 25µl. The samples were placed at 96°C for 10 minutes in order to 
denature protein.  
Samples were loaded on 6-10% polyacrylamide gels (PAG) based on the protein size. 
Each gel consisted of a resolving and a stacking gel. 6% resolving polyacrylamide gels 
were used for the proteins above 100 KD and 10% polyacrylamide gels were used for 
the proteins below 100 KD. A polyacrylamide resolving gel was poured between mini 
western mini apparatus (Biorad, UK) to a depth of ~5.0 cm, topped with water to get a 
uniform surface and was left to polymerise for 10-15 minutes. Stacking gel was poured 
to the top of the plates, a 1mm comb with 10 lanes was placed immediately and the gel 
was left to polymerise for another 10-15 minutes. The samples prepared were loaded 
and gel was run in 1x SDS PAGE running buffer (Gene flow, UK) at 200V for 60-75 
minutes or until the smallest marker (11KD) on the protein ladder (geneflow, UK) 
reached to the bottom of the gel in a vertical electrophoresis unit.  
 
The gel was removed from a glass plate carefully and was placed in 1x transfer buffer 
(Geneflow, UK) containing 20% methanol (v/v). Polyvinyl difloride (PVDF) transfer 
membrane (GE healthcare, United Kingdom) was first soaked in methanol followed by 
1x transfer buffer. The gel was placed in a membrane sandwiched between 3 sheets of 
3MM blotting papers on each side. Transfer was carried out in a blotting Unit for 1.5 
hours at 20V and 200mA.  
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Probing with antibody 
 
The membrane was then blocked in blocking buffer (1x TBS, 1% Tween and 5% milk) 
for 30 minutes followed by probing with rabbit primary antibody against the protein 
being analysed at 1-2.5µg/mL (Table 3.5) at 4°C overnight. The membrane was washed 
twice with 1xTBS-T i.e. containing 1% tween X-100 (Sigma, UK) for 10 minutes. 
Signals were detected by probing the membrane using horseradish peroxidase–
conjugated anti-rabbit antibody (GE healthcare, United Kingdom) at 1µl/5mL in 5% 
milk at room temperature for 2 hours. The membrane was washed again for 10 minutes 
twice in 1x TBST. Equal volume of ECL reagent A (luminol) and B (enhancer) was 
mixed from an ECL Chemoluminescence kit (Biological Industries, Israel) and applied 
to a membrane. The membrane was incubated at room temperature for 5 minutes; 
excess reagent was drained off and was covered by cling film in a cassette. The image 
was exposed to a Carestream Kodak BioMax MR film (Sigma, UK) in a dark room for 
a suitable time period (protein dependent), generally 5-15 minutes and immediately 
dipped in developer solution for up to 1 minute. The image was then dipped in a 
fixative solution to fix the image. The membranes were again washed in 1xTBST for 10 
minutes and stained with 1µl/1ml (v/v) India ink (Winsor and Newton, United 
Kingdom) for comparison of loading. 
 
Table 3.5: Concentration of primary antibody and secondary antibody, exposure 
time and molecular weight of proteins BNC1, CCDC8 and GALNT9 analysed by 
Protein
primay,
antibody,
conc.,
secondary,
antibody,
conc.
exposure,
time
Molecular,
weight,(KD)
BNC1 2.5μg/ml 2μL/ml 20,minutes 105
CCDC8 1μg/ml 1μL/ml 10,minutes 64
GALNT9 1μg/ml 1μL/ml 15,minutes 68
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western blotting.  Generally, higher concentration of antibodies and exposure time 
were needed for BNC1 compared to CCDC8 and GALNT9.   
 
3.5 Tissue Culture 
A class-two laminar airflow hood was used to carry out tissue culture using  sterile 
technique at all times. Laminar airflow hoods were cleaned using 1x trigene followed 
by 70% ethanol (v/v). All other equipment was wiped down with 70% ethanol (v/v) 
before use in the hood. Five breast cancer cell lines (see section 3.1.5) were grown in 
this study. 
3.5.1 Preparation of growth media 
Breast cancer cell lines used for this study were routinely maintained in Dulbecco’s 
Modified Eagles Media (DMEM) (Sigma, UK) containing L-Glutamine supplemented 
with 10% (v/v) fetal bovine serum (FBS) (Thermo scientific, USA), penicillin and 
streptomycin (100ᴜ/ml (Lonza, Switzerland). 
3.5.2 Revival of cell lines 
Cell lines frozen stored in liquid nitrogen were removed and defrosted carefully and 
were transferred to 12-15 ml pre-warmed (37 ̊C) DMEM in T75 (75cm2) tissue culture 
flask supplemented with 10% FCS, 5% CO2, and 500 U/ml penicillin-streptomycin.  
Freshly revived cells were maintained at 37 ̊C, 5% carbon dioxide.  
 
3.5.3 Maintenance and passaging of cell lines 
Medium from the cell lines were replaced with fresh pre warmed medium every 3-4 
days. The medium from the flask was first removed, cells washed with 10 ml buffered 
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saline (PBS) and fresh medium was added to the flask. Cell lines were passaged into a 
new flask with a ratio of 1:3, 1:5 or 1:10 when they reached approximately 70%-90% 
confluency depending on the growth rate of the cell lines or the requirement to carry out 
further functional work. After the removal of media, cell lines were washed with 10 ml 
PBS, and 2 ml pre-warmed 1x Trypsin-EDTA (Lonza, Switzerland) was added to the 
flask drop by drop ensuring spreading and reaching of trypsin uniformly in order to 
detach the cells from the flask. After 1-2 minute incubation or at 37 ̊C when the cells 
were completely dislodged from the flask surface, cells were resuspended in 10 ml 
media and split with the desired ratio to ensure the right volume of cells were 
maintained in the flask. The unwanted cells were discarded and the cells in the flask 
were topped up with media to a final volume of 15 ml. 
 
3.5.4 Counting of cells using a Haemocytometer 
Cells were fully trypsinised as described in section 3.5.3 and resuspended in 8 ml fresh 
media. A coverslip was placed firmly onto the Haemocytometer and 10µl of cell 
suspension was applied to both sides of the heaemocytomer underneath the coverslip 
ensuring the cells suspension was uniformly placed in the Haemocytometer chamber. 
The cells in each side were counted under a microscope and an average cell count was 
taken.  
3.5.5 Treatment of cell lines with 5-aza-2’deoxycitidine 
5-AZA-2’deoxycitidne (5-AZA-dC), a global demethylation agent, was used to 
demethylate cell line genomic DNA to enable comparison of methylation status of 
selected genes. 5’Aza-dC incorporates methyl groups to genomic DNA during its 
replication in dividing cells. Therefore, routinely maintained five breast cancer cell lines 
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were plated to make 30-50% confluent based on their doubling time to ensure that both 
control and 5’AZA-dC-treated cells lines were approximately 75 % confluent at the 
time of RNA extraction. 5-AZA-dC was freshly prepared in double distilled water and 
filter sterilized. 24 hours after seeding, cells were treated with 5µM 5–AZA-dC 
supplemented medium. Cells were treated with fresh 5µM 5-AZA-dC three times a 
week on alternate days. After 7 days, cells were washed with PBS and cell pellets 
prepared as describe in section 3.5.6 
3.5.6 Preparation of cell pellets 
To prepare the cell pellet, medium from the cells was aspirated, washed with PBS and 
trypsinised. After the cells were fully dislodged, 8 ml of medium was added to suspend 
the cells.  Cells were resuspended in culture media, transferred to a 25ml universal tube 
and were centrifuged at 1200g at room temperature for 5 minutes. Supernatant was 
aspirated carefully; cell pellets were resuspended with 3ml PBS (equal volume of 
media) and centrifuged at 1200g for 5 minutes. The supernatant was removed and the 
pellets were immediately placed on ice for DNA/RNA/Protein extraction. For long-term 
storage, pellets were snap frozen in liquid nitrogen before transferring to -80 ̊C for long-
term storage.  
3.5.7 Freezing-down cell lines  
After the cells reached 80-90% confluency, they were first washed with PBS, 
trypsinised, and resuspended in 8ml of media described in sections 3.5.3 and 3.5.6. The 
cells were then transferred to a 25ml universal tube, centrifuged at 1200g at room 
temperature for 5 minutes, washed with PBS and centrifuged again. The cell pellet was 
resuspended in 1 ml freezing buffer (10% dimethyl sulphoxide, v/v (DMSO) in FBS) to 
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act as a cryopreservant during storage. The cell suspension was transferred to a cryo-
vial, wrapped in tissue paper and immediately transferred to -80 ̊C, such that under 
these conditions the temperature goes down at approximately a -1 ̊C per minute. Vials 
were transferred to liquid nitrogen for long-term storage.  
3.6 Functional Analysis of Genes/Proteins 
 
3.6.1 RNA Interference (RNAi) assays and over-expression of genes in breast 
cancer cell lines 
 
RNAi was carried out to transiently knockdown genes using siRNA nucleotide oligos 
(Ambion, USA) in breast cancer cell lines. The breast cancer cell lines T47D, MCF7 or 
MDA-MB231 were washed, trypsinised and counted as described in section 3.5.4. Cells 
were seeded into six-well plates containing DMEM with 10 % FBS at a density of 0.5x 
106. After overnight incubation, candidate genes were knocked down by transfection of 
RNAi ‘silencer select’ oligos against respective genes. Control cells were transfected 
with ‘silencer select’ control Oligo no. 1 (Ambion, USA). For each well, 250 µl of 
optimem media and 4µl of Lipofectamine 2000 reagent (Life Technologies, UK) were 
mixed in a 10ml tube and, 250µl of optimem medium and 20 pmol of siRNA oligos 
were mixed in another 10ml tube. After five minutes incubation at RT, both the tubes 
were mixed together. This mixture was incubated for 15-20 minutes at room 
temperature. During the incubation time, the cells were washed with PBS and media 
replaced with 1 ml of Optimem medium. The reaction mix was added to each well drop-
by-drop and shaking forward and backward. The plated cells were returned back the 
incubator. After 4-6 hours, 1ml of antibiotic free DMEM medium was added to each 
well and returned to the incubator (37°C). 48 hours after knockdown, cells were 
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collected and isolated as described in section 3.5.6. The transfection/knockdown was 
carried out in triplicates. Total RNA and protein was extracted to validate knockdown 
of genes and proteins using RT-PCR and western blotting.  
 
3.6.2 Migration assay 
 
The selected genes/proteins from the breast tumour cell lines were knocked down using 
siRNA oligos as described in section 3.6.2. 24 hours after the transfection, DMEM with 
10 % FBS was replaced with fresh DMEM without FBS and incubated at 37°C for 
another 24 hours. The confluent monolayer of cells in each well was “scratched” with 
the tip of a 200 µl pipette. The cells were washed with PBS and replaced with the fresh 
serum free media. Images were taken of each well/“scratch” this was considered the 
beginning of the experiment and referred to as 0 hour. The extent of migration of cells 
was observed after 24 hours and 48 hours of initial scratching. The regions captured 
were marked to ensure that the same region is observed after 24 hours and 48 hours 
under the microscope to avoid biasness. In addition, similar transfection experiments 
were set up in parallel and cells were collected after 48 hours to perform RT-PCR and 
Western blot analysis to determine the knockdown efficiency in these cells. The 
distance migrated by cells towards the gap was examined using Image J software 
(Schneider et al., 2012). Assays were performed in triplicate for each knockdown to 
minimize experimental biases. Statistical analyses were carried out using Microsoft 
Excel and p values were calculated using t tests from graphpad prism as described in 
section 3.8.1.  
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3.6.3 Invasion assay 
Invasion assays were carried out to determine the invasive potential of the cancer cell 
lines following knockdown and silencing of candidate genes. This was done by trans-
well assay using 24 well plates containing inserts with 8µm pores (Corning, USA). 
Knockdown was carried out as described in section 3.6.2. 24 hours after the 
knockdown, DMEM with 10 % FBS was replaced with fresh DMEM without FBS and 
incubated at 37°C for another 24 hours. 200µl of matrigel matrix (Becton Dickinson 
Labware, USA) diluted 10-fold with DMEM without FBS was applied to 24-well 9-mm 
inserts containing polyethylene terephthalate (PET) membranes with 8µm pores 
(Corning, USA). The inserts were placed in sterile 24 well plates and incubated at 37°C 
for 30 min to settle. During the incubation period, the breast cancer cell lines knocked 
down with respective oligos were harvested and resuspended in serum free medium and 
counted using a haemocytometer as described in section 3.5.4. The cell density was 
maintained at 1x105/ml with addition of appropriate volume of serum free media in each 
tube to minimize experimental biasness. 300µl of the cells (150,000 cells) were applied 
to the matrigel invasion chamber. 500 µl of DMEM containing 10% FBS was placed in 
the lower chamber (in 24-well plate) as a chemo-attractant. The plates were incubated at 
37°C for 48 hours with 5% CO2. After 48 hours, medium from the lower and upper 
chamber was carefully removed without disturbing the cells. Cells from the upper 
surface were removed by wiping with a cotton bud and the inserts were transferred to a 
new 24 well plate containing 400µl crystal violet and were incubated for 10 minutes to 
stain invasive cells on the lower layer. The inserts were washed with water, air-dried at 
room temperature and three fields from each insert were counted at 200X magnification. 
Extraction solution (Cell biolabs, USA) was applied to the plates and left for 10 
minutes. 100µl of cell solution was transferred to fresh 96-well plate to determine the 
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optical density of each well at 540 nm. Assays were performed in triplicates for each 
knockdown. Statistical analyses were carried out as described in section 3.8.1. 
  
3.7. Illumina Infinium HumanMethylation450k Data Analyses 
3.7.1 Analyses of the 450K Methylation data from The Cancer Genome Atlas  
In order to identify novel candidate metastatic suppressor genes, Illumina 
HumanMethylation450K BeadChip array data from The Cancer Genome Atlas (TCGA) 
was analysed. To ensure that the genuine promoter-associated CpG islands only those 
probes that are located in the 5’ region of the gene or up to 1500 base pairs from the 
transcription start site (TSS, TSS200, TSS1500) and 5’ UTR were selected. Methylation 
array data for 20 primary lung tumours and 20 primary breast tumours (with no 
evidence of metastasis) were downloaded from the TCGA (Table 3.6) and were 
compared for the methylation status of individual probes across the genome. 
Comparison was carried out between individual probes that are not methylated (β value 
≤ 0.25) in 75% (15/20) in primary breast tumours and methylated (β value ≥ 0.60) in 
primary lung tumours, in at least 50% (10/20) of the samples. Common genes in these 
lists were identified. This analysis identified four candidates that were frequently 
methylated in lung tumours and infrequently methylated in breast tumours. The details 
of the probes and genes are explained in section 5.  
91 
 
 
 
Table 3.6: A list of primary breast tumours (BRCA) and primary lung tumours 
(LUAD) downloaded from The Cancer Genome Atlas (TCGA) to carry out 
bioinformatic analyses of genome wide 450K methylation data to identify novel 
candidate genes that may contribute to breast cancer metastases to brain (BBM). 
The details of the analyses are given in section 5. 
3.7.2 Analyses of the 450K Methylation data for breast cancer brain metastases 
Genomic DNA from 24 breast to brain metastases (BM1-BM30) was extracted (see 
section 3.2.1.1) and prepared at a final concentration of 50ng/µl. This DNA was used to 
interrogate Illumina Infinium 450K methylation Beadchip arrays. Bisulphite 
modification of these samples, array hybridisation and preliminary data analysis was 
carried out by Cambridge genome services, United Kingdom. Raw data was provided as 
Tumour&
Code
Tumour&barcode& Tumour&
Code
Tumour&barcode&
B1 TCGA.AC.A23H.01A.11D.A161.05 L1 TCGA.38.4631.01A.01D.1756.05
B2 TCGA.BH.A204.01A.11D.A161.05 L2 TCGA.38.4632.01A.01D.1756.05
B3 TCGA.BH.A208.01A.11D.A161.05 L3 TCGA.44.6144.01A.11D.1756.05
B4 TCGA.BH.A209.01A.11D.A161.05 L4 TCGA.44.6145.01A.11D.1756.05
B5 TCGA.E2.A1LI.01A.12D.A161.05 L5 TCGA.44.6146.01A.11D.1756.05
B6 TCGA.E2.A1LS.01A.12D.A161.05 L6 TCGA.44.6147.01A.11D.1756.05
B7 TCGA.E9.A1RB.01A.11D.A161.05 L7 TCGA.44.6148.01A.11D.1756.05
B8 TCGA.E9.A1RC.01A.11D.A161.05 L8 TCGA.49.4488.01A.01D.1756.05
B9 TCGA.E9.A1RD.01A.11D.A161.05 L9 TCGA.50.5930.01A.11D.1756.05
B10 TCGA.E9.A1RF.01A.11D.A161.05 L10 TCGA.50.5931.01A.11D.1756.05
B11 TCGA.A2.A3KC.01A.11D.A212.05 L11 TCGA.53.7813.01A.11D.2168.05
B12 TCGA.A2.A3KD.01A.12D.A212.05 L12 TCGA.55.7724.01A.11D.2168.05
B13 TCGA.A7.A3IZ.01A.11D.A212.05 L13 TCGA.55.7725.01A.11D.2168.05
B14 TCGA.A7.A3J0.01A.11D.A212.05 L14 TCGA.55.7726.01A.11D.2168.05
B15 TCGA.A7.A3J1.01A.11D.A212.05 L15 TCGA.55.7727.01A.11D.2168.05
B16 TCGA.AC.A23G.01A.11D.A212.05 L16 TCGA.55.7815.01A.11D.2168.05
B17 TCGA.AC.A3HN.01A.11D.A212.05 L17 TCGA.55.7816.01A.11D.2168.05
B18 TCGA.C8.A3M8.01A.11D.A212.05 L18 TCGA.55.7903.01A.11D.2168.05
B19 TCGA.E2.A3DX.01A.21D.A212.05 L19 TCGA.55.7907.01A.11D.2168.05
B20 TCGA.E9.A3HO.01A.11D.A212.05 L20 TCGA.55.7910.01A.11D.2168.05
BRCA LUAD
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β-values that represented methylation levels of ~485K genomic probe-hybridising 
regions. β-values range from 0 (designating no methylation) to 1 (Designating complete 
methylation). β-values of each individual probes for breast to brain metastases samples 
were compared to normal breast tissues and primary breast tumours from TCGA to 
identify probes which are either hypomethylated or hypermethylated in breast 
metastases compared to normal breast tissues and primary breast tumours.  
3.8 Statistical Methods:  
3.8.1 Fisher’s exact test, t test and p value calculation 
Fisher’s exact test was used to determine the significance of the frequency of 
methylated samples in a particular group such as the primary breast tumours or the 
metastatic brain tumours from the graphpad prism (http://graphpad.com). In Fisher’s 
exact test, p<0.05 was considered statistically significant. Initially, Fisher’s exact test 
was carried out to investigate the statistical significance of methylation status between 
primary breast tumours (n=20) and BBM (n=15), and those genes, which are 
statistically significant, is further analysed in another cohort of primary breast tumours 
(n=40) and BBM (n=30). Similarly, t test was used to calculate p value in migration and 
invasion assay.  
3.8.2 Kaplan-Meier analysis 
Kaplan-Meier analysis (Mizuno et al., 2009) was carried out using the prognoscan 
database (http://www.prognoscan.org) to determine if the down-regulation of selected 
genes was associated with patients outcome such as, overall survival (OS),  poor 
relapse-free survival (RPS) or disease free survival (DFS). OS refers to the time a 
patient survives after certain date of event such as surgery or a particular treatment with 
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or without any disease or disease recurrence (Chua, 2005). Similarly, DFS that is also 
called RFS, refers to the time a patient survives without having any disease or a disease 
recurrence (after the disease has been fully removed by a surgery and treated with 
adjuvant therapy) (Chua, 2005). DFS is generally calculated in every three years, which 
then serves as a secondary point for OS, which is calculated in five years durations if 
patients alive.  As in other statistical test, p<0.05 was considered statistically significant. 
Prognoscan database utilizes cancer microarray data based on the published studies 
around the world mainly from Gene Expression Omnibus (GEO) datasets enabling to 
assess the risk of downregulation or upregulation of a gene in large number of patients 
(Mizuno et al., 2009).  Kaplan-Meier analysis was utilised for BNC1, CCDC8 and 
GALNT9 in independent datasets to identify if downregulation of these genes in primary 
breast cancer is associated with relapse free or disease free survival. 
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CHAPTER 4 
 
DNA methylation analyses to identify metastatic suppressor genes 
dysregulated in BBM  
 
4.1 Introduction 
Formation of brain metastasis follows the multistep metastatic cascade (Hu et al., 2009) 
in which cancer cells escape from the tumour-site, enter the surrounding tissues through 
invasion, flows through the lymph or blood vessels (intravasation), escape out of blood 
capillaries (extravasation), and finally invade into the brain and proliferate (Joyce & 
Pollard, 2009; Fidler et al., 2010; Eichler et al., 2011). Each of these stages is 
inefficient and rate limiting; only a minority of the tumour cells make it to the new 
destination. Therefore, successful metastatic outgrowth is a result of the cumulative 
ability of a cancer cell to find suitable unique microenvironment at each step in the 
metastatic cascade (Joyce & Pollard, 2009). 
The spread of breast cancer to other distant organs takes place in an organized fashion 
first through the lymphatic system and then through the blood.  The micrometastatic 
paradigm states that there may be an existence of micrometastatic lesions in breast 
cancer patients before the diagnosis of breast cancer that will later develop as a 
metastatic disease (Cianfrocca & Goldstein, 2004). It is known that the risk of BBM 
occurring early (<2 years after primary diagnosis) is associated with early onset tumours 
charaxterised by oestrogen receptor negative (ER-ve), human epidermal growth factor 
receptor 2 overexpression (HER2+ve) and triple negative (ER-ve/PR-ve/HER2-ve) 
phenotypes (van 't Veer et al., 2002; Ryberg et al., 2005; Sanna et al., 2007; Metzger et 
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al., 2011). However, more than 50% of BBMs occur over five years after the primary 
tumour was diagnosed. Many of these late recurring brain metastases are derived from 
ER+ primary tumours (Kennecke et al., 2007; Sperduto et al., 2010; Zhang et al., 2013). 
Genomic alterations that provide the potential for metastatic growth can be 
characterised as either those that also drive primary tumour growth advantage, those 
that provide potential for dissemination and infiltration (such as those that drive EMT 
(Wang & Shang, 2013)) or those that enable continued growth within the 
microenvironment of the new organ (Joyce & Pollard, 2009). The common long lag-
time between primary tumour diagnosis and recurrence of a detectable secondary 
tumour suggests that cells from these breast tumours undergo a period of dormancy 
(Aguirre-Ghiso, 2007; Lim et al., 2012). These dormant cells are often found as 
micrometastases in bone marrow (Klein, 2003; Pantel et al., 2008) and a number of 
genetic and epigenetic alterations acquired by breast tumour micrometastases of the 
bone have been characterised (Mundy, 2002; Park et al., 2007). However, the presence 
of these micrometastases is not in itself a strong prognostic indicator for later metastatic 
disease (Klein, 2003; Pantel et al., 2008). Moreover, very little is known about specific 
genomic alterations that facilitate the dissemination and colonisation of primary breast 
tumours in to the brain. 
 
The most frequently metastasising tumours to brain are breast, lung, melanoma and RCC 
(Soffietti et al., 2008).  We selected genes that are frequently methylated in one of these 
tumour types. In addition, we selected genes downregulated in EMT that may contribute 
to BBM. Based on our hypothesis section 2.2.1 those genes dysregulated either in lung, 
RCC or melanoma may be commonly dysregulated in BBM. Therefore, we carried out a 
screen of candidate genes to investigate if these genes are frequently dysregulated 
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through promoter hypermethylation in BBM. It is likely that some genes, which are 
methylated in BBM are “passengers” in relation to metastasis and, as such, will also be 
methylated in primary breast tumours, contributing to primary breast tumorigenesis. 
Therefore, to identify genes, which are specifically dysregulated in breast tumours that 
metastasises to the brain we also determined the methylation status of these genes in a 
cohort of unrelated primary breast tumours and in matched pairs of breast tumours and 
BBM from the same patients (Figure 4.1).  Therefore, we identified candidate genes that 
are either dysregulated early in tumour evolution (methylation is common to primary 
tumour and resulting BBM) or at a later stage only after the metastasising cells have left 
the breast and have probably reached to the brain (methylation occurs only in BBM).  
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Figure 4.1: Summary of screening methodology and experimental analyses to 
identify genes dysregulated in BBM. Screening of genes from two independent 
approaches generated 78 candidate metastatic suppressor genes; Experimental 
analyses of the promoter regions of these 78 genes identified 20 genes that are 
frequently methylated in BBM samples, of which two genes were also infrequently 
methylated in a cohort of unrelated primary tumours.  
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4.2 Results 
 
4.2.1 Screening of candidate metastatic suppressor genes in BBM 
 
We have used two independent candidate gene approaches to identify genes 
dysregulated in breast tumours that metastasise to the brain. For the first approach, we 
carried out a comprehensive literature review to identify genes epigenetically 
dysregulated either in lung, breast, melanoma or renal tumours. This review generated 
independent lists of genes frequently methylated in lung, breast, melanoma and renal 
tumours. However, there were candidate genes that were commonly methylated in more 
than two or all tumours types including breast tumours. As we wished to identify genes 
uniquely dysregulated in BBM but not in primary breast tumours, we discarded the 
genes which were frequently methylated in primary breast tumours regardless of their 
methylation status in other tumour types. Careful screening of the long lists of genes 
generated 42 genes, which were methylated either in melanoma, lung or renal tumours. 
Moreover, we confirmed the methylation status of all these 42 genes in primary breast 
tumours using the 450K-methylation data from TCGA.  
In a second approach, we included genes that have been downregulated in EMT 
regardless of their methylation status in primary tumours. However, we ensured that the 
genes identified are downregulated in EMT and have not been reported to be methylated 
in primary breast tumours. These candidate metastatic suppressor genes associated with 
EMT included claudins, keratins, tumour suppressor microRNAs, and other metastatic 
candidate genes. We identified 10 claudins, 9 keratins and 6 tumour suppressor 
microRNAs.  
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From both of these approaches, we generated a list of 78 genes with well-defined CpG 
islands. A full list of these genes and their biological function including associated 
references is given in appendix B1.  
 
4.2.2 Identification of frequently methylated genes in metastatic brain tumours  
 
We determined the methylation status of 78 candidate genes by CoBRA in up to 30 
BBM samples. To ensure clinical significance, it is important that the genes we intend to 
identify are enriched in methylation status in the population of patients with BBM. 
Therefore, as an initial screening, 15 BBM tumours were analysed and those genes, 
which were methylated in less then 1/3rd of 15 BBM (5 of 15) samples were discarded. 
As we imposed a cut-off value for frequent methylation of a gene as ≥50% in BBM 
samples, it was unlikely that the genes which were methylated in less than 5/15 tumours 
in the first cohort, will be methylated sufficiently frequently in a second cohort to make 
up a frequency of ≥50% methylation in a total of 30 samples. Those genes that were 
methylated in more than 30% in the first cohort of 15 BBM samples were selected for 
methylation analysis in a second cohort of 20 unrelated primary breast tumours (section 
4.2.3). Only those genes, which were infrequently methylated in this cohort of 20 
primary tumours, were then investigated for their methylation status in a second cohort 
of 15 BBM samples.  
From our panel of 42 candidate genes from the literature review, we identified 10 genes 
that were frequently methylated (>50%) in 15 BBM samples. These were HOXD3 
(100%), CCDC8 (73%), HOXB13 (80%), ABCB1 (80%), PENK (80%), BNC1 (68%), 
PCDH8 (53%), STAT3 (67%), TNFRSF10D (60%) and WIF1 (53%) (table 4.1, (figure, 
4.3, figure 4.4, appendix B2.). In addition, SFRP2 was methylated in 47% of the BBM 
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samples. Therefore, we also considered screening its methylation in a cohort of 20 
unrelated primary tumours.  
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Table 4.1: Promoter methylation status of 42 candidate metastatic suppressor genes 
in BBM. Initially, a cohort of 15 BBM samples was used to investigate the methylation 
status of the genes. Ten genes (highlighted in gray) were frequently methylated (50% of 
the samples) in BBM.  Red box indicates methylated samples, green box indicates 
BM1 BM2 BM3 BM4 BM5 BM6 BM7 BM8 BM9 BM10 BM11 BM12 BM13 BM14 BM15
HOXD3 100
HOXB13 93
CCDC8 87
ABCB1
80
PENK
80
BNC1 73
PCDH8
67
STAT3 67
TNFRSF10D
60
WIF1 53
SFRP2 47
BOLL
13
COL14A1
13
DAPK1
13
TNFRSF10C
13
DGKI 13
CDKN11A 7
GREM1
7
AK5 0
ALDH1A3 0
ANK3 0
ATM 0
CD44
0
DLC1
0
FBN2 0
GATA5
0
HK2
0
ICAM5 0
IGFBP3
0
KLHL35
0
MMP2 0
NRCAM
0
PBRM1
0
PTEN 0
PYCARD
0
QPCT
0
RBP1
0
SDHD
0
SULF2
0
TMEF2
0
TSC1
0
UCHL1
0
Gene
Breast2to2Brain2metastases2(BBM)2samples2(n=15)
%2Meth2
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unmethylated samples and white box indicates samples that were not successfully 
amplified during CoBRA PCR.  
 
In addition, from a panel of 36 genes downregulated in EMT, we identified 10 genes 
frequently methylated (>50%) in 15 BBM samples. These were CLDN18 (100%), 
KRT85 (100%), MIR127 (100%), MIR433 (100%), MIR23b (92%), KRT83 (84%), 
MST1R (78%), BVES (64%), CLDN6 (55%) and HOXD10 (55%) (table 4.2). In addition, 
we also considered four other genes CLDN5 (47%), KRT72 (42%), MIR124-1 (36%) and 
MIR34B (33%) to analyse their methylation status in a cohort of unrelated primary 
breast tumours.  
 
From both the panels, 20 genes were found to be frequently methylated in 15 BBM 
samples. The basic information (accession and full name) and the biological functions of 
these genes are given in table 4.3. We proceeded to determine the methylation status of 
these 20 genes and another five genes, with methylation frequency of ≥35%, (SFRP2, 
CLDN5, KRT72, MIR124-1 and MIR34B) in a cohort of unrelated 20 primary breast 
tumours.  
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Table 4.2: Methylation status of candidate metastatic suppressor genes in BBM  
 
BM1 BM2 BM3 BM4 BM5 BM6 BM7 BM8 BM9 BM10 BM11 BM12 BM13 BM14 BM15
CLDN18
100
KRT85
100
MIR127 100
MIR433 100
MIR23B 92
KRT83 84
MST1R 78
BVES 64
CLDN6 55
HOXD10 55
CLDN5 47
KRT72 42
MIR124:1 36
MIR34b 33
CLDN1 20
MIR34a 10
CLDN3 0
CLDN4 0
CLDN7 0
CLDN9 0
CLDN11 0
CLDN23 0
CSNK1A1 0
CMTM8 0
DSP 0
FBXL14 0
KRT7 0
KRT18 0
KRT19 0
KRT28 0
KRT81 0
OCLN 0
PNN 0
TJP1 0
TSPAN13 0
Gene
Breast4to4Brain4metastases4(BBM)4samples4(n=15)
%,Meth,
(n=15)
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Table 4.2: Promoter methylation status of 36 candidate genes, which are down 
regulated in Epithelial Mesenchymal Transition (EMT). Initially, a cohort of 15 
BBM samples was used to investigate the methylation status of the genes. Ten genes 
(shaded in grey) were frequently methylated (50% of the samples) in BBM. Red 
box indicates methylated samples, green box indicates unmethylated samples and 
white box indicates samples that were not successfully amplified during CoBRA 
PCR.  
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Table 4.3: Genes frequently methylated in BBM samples and their functions.  
Gene symbol Accession  Gene name  % of tumours  
methylated 
Function  
CLDN18 NM_016369.3 Claudin 18 100 Intercellular adhesion 
molecule responsible 
for tight junction strand 
formation (Tsukita & 
Furuse, 2000) 
KRT85 NM_002283.3  Keratin 85 100 Component of 
intermediate filament 
in epithelial cells 
contributing to cell-cell 
adhesion (Magin et al., 
2007; Bragulla & 
Homberger, 2009; 
Shimomura et al., 
2010) 
MIR127 NR_029696.1 microRNA 127 100 Regulator of cell 
proliferation and 
senescence (Chen et 
al., 2013) 
MIR433 NR_029966.1 microRNA 433 100 Deregulated in gastric 
cancer, regulator of cell 
migration and drug 
response (Luo et al., 
2009; Symmans, 2010) 
HOXD3 NM_006898.4 HomeoboxD3 100  Proangiogenic 
transcription factor 
(Chen et al., 2004) 
MIR23B  NR_029664.1 microRNA 23b 92 Involved in 
cytoskeleton 
modelling, motility and 
metastasis (Majid et al., 
2012; Zaman et al., 
2012; Jin et al., 2013; 
Pellegrino et al., 2013) 
CCDC8 NM_032040.4 Coil coiled 
domain 
containing 8 
87   Mutated in patients 
with 3M syndrome 
(Hanson et al., 2011). 
Loss is associated with 
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genomic instability and 
aneuploidy (Yan et al., 
2014). 
KRT83 NM_002282.3 Keratin 83 84 Component of 
intermediate filament, 
contributes to cell to 
cell adhesion (Magin et 
al., 2007; Bragulla & 
Homberger, 2009) 
HOXB13 NM_006361.5 Homeobox B13 80  TSG for prostate 
cancer, inhibits 
androgen mediated 
signalling (Fidler et al., 
2010) 
ABCB1 NM_000927.4 ATP-binding 
cassette sub-
family B 
member 1 
80 Controls efflux of 
substances across 
plasma membranes, 
associated with 
multidrug resistance 
(Muggerud et al., 2010) 
PENK NM_006211.3 Proenkephalin 80   Promotes RNA 
splicing in osteoblasts 
and neural cells, plays 
role in bone 
development (Rosen et 
al., 2013b) 
MST1R NM_002447.2 macrophage 
stimulating 1 
receptor 
78 Involved in 
intracellular signalling 
cascades leading to 
cellular growth, 
motility and invasion 
(Wagh et al., 2008) 
BNC1 NM_001717.3 Basonuclin 1 73  Zink finger 
transcription factor, 
regulator of EMT 
(Feuerborn et al., 2014) 
PCDH8 NM_002590.3 Procadhern 8 73 Helps in cell to cell 
adhesion (Sabine et al., 
1998) 
STAT3 NM_139276.2 Signal 67  Involved in embryonic 
107 
 
transducer and 
activator of 
transcription 3 
stem cell regulation, 
somatic cell growth 
(KIYOSHI et al., 1997; 
Hitoshi et al., 1998; 
Akira) 
BVES NM_007073.4 Blood vessel 
epicardial 
substance 
64 Involved in inter-
cellular interaction and 
cell adhesion. (Osler et 
al., 2006) 
TNFRSF10D NM_003840.4 Tumour 
Necrosis Factor 
receptor 
superfamily 10 
D 
60 Member of 
TNF(Tumour Necrosis 
Factor) receptor 
superfamily, promotes 
apoptosis in cancer 
cells (Hill et al., 2011) 
CLDN6 NM_021195.4  Claudin 6 55 Intercellular adhesion 
molecules responsible 
for tight junction strand 
formation, its 
epigenetic silencing is 
associated with 
migration and 
invasiveness of breast 
cancer (Tsukita & 
Furuse, 2000; Osanai et 
al., 2007) 
HOXD10 NM_002148.3 Homeobox D10 55 Maintain epithelial cell 
plasticity and 
contributes to stability 
of extracellular matrix 
(Carrio et al., 2005) 
WIF1 NM_007191.4 Wnt inhibitory 
factor-1 gene 
53  Inhibitor of Wnt-
signalling (Ai et al., 
2006; Veeck et al., 
2009) 
Table 4.3: Genes frequently methylated in breast to brain metastases. 20 genes are 
frequently methylated in brain metastases (n=15). These genes were further 
analysed in 20 primary breast samples (n=40 in total) and 15 breast to brain 
metastases (n=30 in total).  
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4.2.3 Determination of methylation status of 20 genes in a cohort of unrelated 
primary breast tumours  
We screened primary breast tumours for promoter methylation status of the genes that 
were frequently methylated (>30%) in BBM. To ensure that genes identified in this 
study are clinically significant, we imposed a relatively low cut off frequency of ≤45% 
for methylation in primary breast tumours. This fits our hypothesis that genes 
deregulated in the process of BBM will either occur early in tumour evolution and be 
detectable in the primary tumours that eventually metastasise (BBM occurs in 18-30% 
of breast tumours (Weil et al., 2005; Gori et al., 2007; Kennecke et al., 2007; Tosoni et 
al., 2008)) or it occurs later in tumour evolution and will not be detectable in the primary 
tumour. The clinical information of unrelated primary tumours used for this analysis is 
given in appendix B4.  
 
From a panel of 10 genes frequently methylated in brain metastases (from our literature 
review candidates), we identified that 8 of these genes are also frequently methylated in 
primary breast tumours. These are HOXD3 (81%), HOXB13 (53%), ABCB1 (68%), 
PCDH8 (54%), PENK (79%), STAT3 (57%) TNFRSF10D (75%) and WIFI (55%) (table 
4.4, appendix B5). In addition, SFRP2, which was methylated in 47% of the BBM 
samples, was methylated in 90% of the primary breast tumour samples (appendix B5). 
This suggests that SFRP2 is hypomethylated in BBM compared to unrelated primary 
breast tumours and also frequently methylated in both the primary tumours and BBM. 
This suggests that these genes are not uniquely epigenetically dysregulated during the 
process of BBM. Only two genes, BNC1 (21%) and CCDC8 (40%) were infrequently 
methylated in these unrelated primary tumours. Therefore, these two genes were further 
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investigated for their methylation status in a further 20 unrelated primary tumours (40 
primary tumours in total). It is worth noting that to our knowledge this is the first time 
that promoter methylation in CCDC8, HOXD3, PCDH8, PENK, STAT3, SFRP2 and 
WIFI has been described in primary breast tumours. 
Promoter methylation of BNC1 (21%) and CCDC8 (40%) in primary breast tumours 
was infrequent (≤45%), and was statistically significantly lower than the frequency of 
methylation in BBM (p=0.0001, p=0.01 respectively) (figure 4.2, figure 4.3 and figure 
4.4).  
 
From a panel of 10 genes down regulated in EMT that are frequently methylated in 
brain metastases, we found all 10 genes also to be frequently methylated in primary 
breast tumours i.e. CLDN18 (100%), KRT85 (100%), MIR127 (100%), MIR433 (100%), 
KRT83 (100%), MIR23b (60%), MST1R (60%), BVES (60%), CLDN6 (50%), HOXD10 
(55%) (table 4.4). The high frequency of methylation in primary tumours indicates that 
epigenetic deregulation of these genes is not driving BBM. This is the first time that 
promoter methylation has been described for all of these 10 genes. 
 
In addition, MIR34B is also methylated in 60% of the primary tumours. However, it was 
methylated in 33% of the BBM samples. KRT72 was methylated in 25% of the primary 
tumours, which was lower than its methylation in BBM (42%), However this was not 
statistically significant (p=0.26). The other two genes CLDN5, and MIR124-1 were 
methylated in 17% and 19% of the primary tumours respectively. Due to their relatively 
infrequent methylation in primary tumours compared to BBM (47% and 36% 
respectively), we also analysed these genes in a second cohort of 15 BBM to investigate 
if their differential methylation statuses are statistically significant.  
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Table 4.4: methylation status of candidate metastatic suppressor genes in primary 
breast tumours 
 
Table 4.4: Promoter methylation status of 20 candidate metastatic suppressor genes, 
which were frequently methylated in BBM samples, were analysed in an unrelated 
cohort of 20 primary breast tumours. Five other genes were also analysed in 
primary breast tumours to investigate their methylation status (section 4.2.3). Only 
two genes; BNC1 and CCDC8 are differentially methylated in BBM (frequently 
methylated) and primary breast tumours (infrequently methylated). They were 
BP136 BP137 BP138 BP139 BP140 BP141 BP142 BP143 BP144 BP145 BP146 BP147 BP149 BP150 BP151 BP153 BP167 BP170 BP188 BP194
BNC1 20
CCDC8 47
PCDH8 54
STAT3 57
PENK 79
ABCB1 68
HOXB13 53
HOXD3 81
WIF1 55
TNFRSF10D6 75
CLDN18 100
KRT85 100
MIR127 100
MIR433 100
KRT83 100
MIR23B 60
MST1R 61
BVES 60
CLDN6 60
HOXD10 55
SFRP2 90
MIR34b 60
KRT72 25
MIR124@1 19
CLDN5 17
BP152 BP154 BP155 BP156 BP157 BP158 BP159 BP160 BP161 BP162 BP163 BP164 BP165 BP168 BP169 BP171 BP172 BP173 BP174
%.Meth.
(n=40)
BNC1 21
CCDC8 40
Methylation.status.of.the.genes.primary.breast.tumours.which.were.infrequently.methylated.in.BBM.samples
Methylation.status.of.genes.(which.were.frequently.methylated.in.BBM.samples).in.unrelated.primary.breast.tumours,.(n=20)
Gene %.Meth.
Methylation.Status.of.BNC1 .and.CCDC8.in.second.cohort.of.unrelated.primary.breast.tumours.(n=20)
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further analysed in a second cohort of 20 unrelated primary breast tumours, 
making up to a total of 40 primary tumours.  The red box indicates methylated 
samples, green box indicates unmethylated samples and white box indicates 
samples that were not successfully amplified during CoBRA PCR.  
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The four genes; BNC1, CCDC8, CLDN5 and MIR124-1 were further analysed in a 
second cohort of 15 BBM samples (table 4.5). CLDN5 and MIR124-1 were analysed in 
a second cohort of 15 BBM samples due to their differences in the methylation in BBM 
and primary tumours. The aim of this project was to identify genes, which were 
frequently methylated in BBM and infrequently methylated in primary tumours. The 
methylation frequency of CLDN5 and MIR124-1 is higher in BBM (40% and 36% 
respectively) than in primary breast tumours (17% and 19% respectively), however they 
were infrequently methylated both in primary breast tumours and BBM. The genes are 
enriched in methylation in BBM, but this is not statistically significant (p=0.07 and 0.17 
respectively); therefore, we excluded these genes from further investigation.  
   
Taken together, from the list of 78 candidate metastatic suppressor genes based on our 
broad-ranging screen of BBM candidate genes, only two genes with significantly 
differing methylation status in primary breast tumours and BBM were identified. The 
significant difference in frequency of methylation of BNC1 (figure 4.3) and CCDC8 
(figure 4.4) in primary breast tumours and BBM may be an indication that these genes 
may contribute to BBM and are good candidates for further investigation. 
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Table 4.5: Promoter methylation status of candidate metastatic suppressor genes in 
a second cohort of 16 BBM samples. Two of these genes BNC1 and CCDC8 are 
frequently methylated in 31 BBM samples and infrequently methylated in 40 
unrelated primary breast tumours. The methylation frequency of CLDN5 and 
MIR124-2 was higher in the initial cohort of 15 BBM samples. This analysis 
confirmed that CLDN5 and MIR124-2 are infrequently methylated in both BBM 
and primary tumours. However, they are enriched in methylation in BBM 
compared to primary breast tumours. Red box indicates methylated samples, green 
box indicates unmethylated samples and white box indicates samples that were not 
successfully amplified during CoBRA PCR.   
 
 
 
 
 
 
 
 
 
 
Gene BM16 BM17 BM18 BM19 BM20 BM21 BM22 BM23 BM24 BM25 BM26 BM27 BM28 BM29 BM30 BM31
%1meth1
(n=31)
BNC1 68
CCDC8 73
CLDN5 40
MIR124.1 36
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Figure 4.2: Methylation frequency of candidate metastatic suppressor genes in breast-to-brain metastases (BBM) (n=30) versus 
primary breast tumours (n=40). Out of 20 genes that are frequently methylated in brain metastases, two genes (BNC1 and CCDC8) 
are infrequently methylated in a cohort of independent primary tumours with statistical significance (***: p≤ 0.0001 and **: p 
≤0.01).  
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Figure 4.3: Methylation status of BNC1 in the first and second cohort of BBM 
samples (A and B respectively) and in the first and second cohort of unrelated 
primary breast tumours (C and D respectively). BNC1 is frequently methylated 
(68%) in metastatic brain tumours and is infrequently methylated (21%) in 
primary breast tumours. SAM: Fully methylated positive control, BM: Brain 
metastases, BP: primary breast tumours U: Uncut/control sample, C: cut by 
restriction enzyme,  *: methylated samples  
 
 
 
 
 
 
 
D
N
A
 L
ad
de
r 
Sa
m
 D
N
A
 
U C
Sa
m
 D
N
A
 
U C
B
M
28
 
U C
B
M
24
 
U C
* 
B
M
25
 
U C
* 
B
M
27
 
U C
* 
B
M
31
 
U C
 B
M
29
 
U C
* 
B
M
30
 
U C
* 
B
M
22
 
U C
* 
B
M
16
 
U C
 B
M
19
 
U C
B
M
21
 
U C
B
M
23
 
U C
B
M
20
 
U C
* 
B
M
17
 
U C
* 
B
M
18
 
U C
* 
B
M
26
 
U C
*
B)#
Sa
m
 D
N
A
 
U C
Sa
m
 D
N
A
 
U C
B
M
5 
U C
B
M
1 
U C
* 
B
M
2 
U C
* 
B
M
4 
U C
* 
B
M
8 
U C
* 
B
M
3 
U C
* 
 B
M
6 
U C
* 
B
M
7 
U C
* 
B
M
11
 
U C
B
M
10
 
U C
B
M
14
 
U C
* 
B
M
9 
U C
* 
 B
M
12
 
U C
* 
B
M
13
 
U C
B
M
15
 
U C
A)# * 
Sa
m
 D
N
A
 
U CD
N
A
 L
ad
de
r 
B
P1
56
 
U C
B
P1
59
 
U C
B
P1
55
 
U C
* 
B
P1
58
 
U C
B
P1
57
 
U C
B
P1
54
 
U C
B
P1
51
 
U C
B
P1
62
 
U C
B
P1
68
 
U C
B
P1
63
 
U C
B
P1
64
 
U C
* 
B
P1
60
 
U C
* 
B
P1
65
 
U C
B
P1
71
 
U C
B
P1
72
 
U C
B
P1
73
 
U C
B
P1
74
 
U C
B
P1
69
 
U C
B
P1
52
 
U C
* 
B
P1
61
 
U C
B
P1
41
 
U C
B
P1
50
 
U C
B
P1
36
 
U C
B
P1
40
 
U C
* 
B
P1
46
 
U C
B
P1
45
 
U C
* 
D
N
A
 L
ad
de
r 
B
P1
39
 
U C
B
P1
37
 
U C
* 
B
P1
38
 
U C
B
P1
46
 
U C
B
P1
47
 
U C
B
P1
49
 
U C
B
P1
50
 
U C
B
P1
53
 
U C
B
P1
67
 
U C
* 
B
P1
88
 
U C
B
P1
94
 
U C
B
P1
70
 
U C
C)#
D)#
118 
 
 
 
Figure 4.4: Methylation status of CCDC8 in the first and second cohort of BBM 
samples (A and B respectively) and in first and second cohort of unrelated primary 
breast tumours (C and D respectively). CCDC8 is frequently methylated (73%) in 
BBM (n=30) and is infrequently methylated (40%) in primary breast tumours 
(n=35). SAM: Fully methylated positive control, BM: Brain metastases, BP: 
Primary breast tumours, U: Uncut/control sample, C: cut by restriction enzyme,  
*: methylated samples.  
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4.2.4.  Expression analysis of BNC1 and CCDC8 in metastatic brain tumours 
 
Having identified two candidate genes that are differentially methylated in primary 
breast tumours and metastatic brain tumours we proceeded to determine if this promoter 
methylation correlated to gene expression.  
Total RNA was extracted from 15 metastatic brain tumours to determine the expression 
of BNC1 and CCDC8, by RT-PCR. BNC1 and CCDC8 were frequently downregulated 
or silenced in these tumours and reduced expression correlated to promoter methylation 
(Figure 4.5). Of 15 metastatic brain tumours, BNC1 was methylated and silenced or 
downregulated in 10 tumours. BNC1 was expressed in two unmethylated samples 
(BM11 and BM23); downregulated in two partially methylated samples (BM12 and 
BM18) and are silenced in seven methylated samples (BM13, BM24, BM17, BM20, 
BM27, BM29 and BM30). BNC1 is also silenced in three unmethylated tumours (BM13, 
BM16 and BM28). Similarly, out of 15 available tumours for expression analysis, 
CCDC8 was methylated and silenced or downregulated in 10 samples. CCDC8 is 
expressed in four unmethylated samples (BM16, BM23, BM28 and BM29); down 
regulated in two partially methylated samples (BM20 and BM30) and silenced in 6 
methylated samples (BM3, BM11, BM12, BM14, BM15 and BM18). CCDC8 is also 
expressed in two methylated samples (BM13 and BM17). CCDC8 is silenced in one 
unmethylated sample (BM27). 
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Figure 4.5: Gel electrophoresis of reverse transcription PCR (RT-PCR) of BNC1 and CCDC8 in BBM. Expression analysis using 
RT-PCR shows that the expression of BNC1 and CCDC8 correlates with its promoter methylation in BBM. BNC1 and CCDC8 are 
expressed in unmethylated (U), down regulated in partially methylated (*), and is silenced in fully methylated (**) tumours. (See 
figure 4.3 and 4.4 for methylation analysis). Expression of β-actin was determined to ensure equal loading for all samples.  Of 15 
BBM samples available for expression analysis, BNC1 is expressed in two unmethylated samples (BM11 and BM23); 
downregulated in two partially methylated samples (BM12 and BM18) and are silenced in six methylated samples (BM3, BM17, 
BM20, BM27, BM29 and BM30). BNC1 is also silenced in three unmethylated tumours (BM13, BM16 and BM28). Similarly, 
CCDC8 is expressed in four unmethylated samples (BM16, BM23, BM28 and BM29); down regulated in two partially methylated 
samples (BM20 and BM30) and are silenced in six methylated samples (BM3, BM11, BM12, BM14, BM15 and BM18). CCDC8 is 
also expressed in two methylated samples (BM13 and BM17). CCDC8 is silenced in one unmethylated sample (BM27). M: 
Methylated samples, U: Unmethylated samples.  
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4.2.5 Promoter methylation status of BNC1 and CCDC8 in brain metastases and 
associated primary breast tumours from individual patients       
  
We analysed the methylation status of two genes BNC1 and CCDC8 in matched pairs of 
tumours i.e. metastatic brain tumours and corresponding primary tumours from 
individual patients. We have 10 of these pairs, however, some loci in the primary 
tumour DNA proved refractive to amplification. Out of 8 matched pairs, where the 
BNC1 promoter region was successfully amplified, the region is methylated in all 8 of 
the brain metastases. However, it is only methylated in one corresponding primary 
tumour (Figure 4.6A). In contrast, out of 11 matched pairs, CCDC8 is commonly 
methylated in 10 corresponding primary tumours (Figure 4.6B). 
 
These results suggest that BNC1 promoter methylation occurs at a late stage in the 
evolution of metastatic brain tumours, possibly after they have metastasised to the brain. 
Alternatively, methylation of these genes may occur in a small subset of cells within the 
primary tumour (below the detection threshold of this assay) and these cells are 
enriched in the metastatic tumour. In contrast, CCDC8 promoter methylation is 
detectable in most primary tumours that metastasise to the brain, suggesting that it may 
play an important role in the early stages of primary tumour metastasis.  
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Figure 4.6: Methylation status of BNC1 and CCDC8 in metastatic brain tumours and their corresponding originating primary 
breast tumours from individual patients. CoBRA was used to determine the methylation status; small, digested PCR products in 
the BstuI cut (C) lane compared to the undigested (U) lane indicates promoter methylation in a sample. BNC1 was frequently 
methylated (*) in metastatic brain tumours (BM) and NOT methylated in the originating breast primary (BP) tumours. Of 8 
matched pairs analysed, BNC1 is methylated in 6 metastatic brain tumours (see patient 2, 3, 8, 12 and 15), whereas it is methylated 
in only one of the corresponding primary tumour (patient 12). Similarly, CCDC8 was frequently methylated (*) in metastatic brain 
tumours (BM) and their originating breast primary (BP) tumours. Of 11 matched pairs analysed, CCDC8 is methylated in 10 
metastatic brain tumours (see patient 2, 10, 11, 12, 13, 14, 15, 1, 2, and 8) and all 11 corresponding primary tumours. Interestingly, 
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CCDC8 is also methylated in one primary tumour (patient 5) where its corresponding BBM is not methylated.  BP: Breast Primary 
tumour, BM: Metastatic Brain tumour, BN: adjacent Normal Breast tissue, U: Uncut/Control sample, C: cut by methylation 
specific restriction enzyme, *: Methylated samples, Sam DNA: fully methylated positive control. 
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4.3 Discussion:  
Metastasis to the brain is an increasingly common event in the progression of breast 
cancer (Sperduto et al., 2010). This trend is likely to continue as primary tumour 
management improves. Given the extremely poor clinical outcome following a 
diagnosis of BBM (Sperduto et al., 2010). it is imperative that the underlying molecular 
biology that drives tumour evolution to the colonization of the brain is revealed. An 
improved understanding of these events will identify novel therapeutic targets and 
prognostic markers. 
To date some progress has been made to identify prognostic markers for breast cancer 
metastasis by gene expression profiling (Paik et al., 2004). However, prediction of site 
specific-metastasis remains poor (Weigelt et al., 2005).   
   
The importance of gene dysregulation by promoter methylation as a mechanism of 
tumour evolution is now well established (Cock-Rada & Weitzman, 2013). Indeed, 
genome wide methylation analysis of many hundreds of primary breast tumours has 
allowed the definition of specific sub-categories of breast tumours (Curtis et al., 2012; 
TCGA, 2012) and our increasing understanding of the molecular basis of these subtypes 
has improved our ability to predict early metastatic recurrence (Metzger et al., 2011; 
Stephens et al., 2012). However, late recurrence, a common feature of BBM or indeed 
any site specific recurrence has proven difficult to predict (Burstein & Griggs, 2012). 
 
We carried out a broad candidate approach to identify genes that are dysregulated in 
BBM. This approach consisted of identifying two separated candidate gene lists. The 
first cohort of candidate genes was chosen after considering the observation that the 
period between diagnosis of primary breast tumour and brain metastasis is often very 
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much longer than that of lung, renal or melanoma tumours (Eichler et al., 2011). We 
hypothesized that epigenetic events that are common in lung, renal and melanoma 
tumours and drive early tumour development may also contribute to brain metastasis. 
However, these changes may not contribute to primary breast tumour formation but do 
have the capacity to contribute to BBM. Thus, the genes that contribute to BBM and are 
infrequently methylated in primary breast tumours (and commonly methylated in other 
primary tumours) will be frequently methylated in BBM. We carried out a literature 
review for genes methylated in these tumour types and selected only those genes that 
were also infrequently methylated in primary breast tumours according to Illumina 
HumanMethylation 450k data from TCGA. From our resulting candidate list of 42 
genes, we identified BNC1 and CCDC8 as differentially methylated in primary breast 
tumours and BBM, and the methylation of these genes was associated with silencing.  
 
In addition, we screened a selection of genes that have previously been shown to be 
dysregulated during the process of epithelial to mesenchymal transition, a well-
established mechanism during the process of metastasis (Thiery, 2002; Yang & 
Weinberg, 2008). However, following analysis of these genes, we found no significant 
difference between the promoter methylation status of those genes in BBM or primary 
breast tumours; genes found to be frequently methylated in BBM were also frequently 
methylated in primary breast tumours. This suggests that none of these frequently 
methylated genes are involved in the specific process of BBM. However, it is possible 
that frequently methylated genes may be involved in the process of breast cancer 
metastasis to other sites such as bone, lungs or liver. Moreover, these genes could 
possibly be involved in the formation of micrometastases (Hanssens et al., 2011) in 
other body sites such as bone or lung and, other additional genetic and epigenetic 
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alterations may further contribute to those micrometastases to metastasise into the brain.  
Therefore, further analyses may be useful to understand the role of these genes in the 
process of breast cancer metastases and BBM. Therefore, these genes could possibly be 
involved both in primary tumours and BBMs. Cells that disseminate from primary 
tumours through the process of EMT often revert back to an epithelial phenotype once 
they have infiltrated the site of metastasis through a process of Mesenchymal to 
epithelial transition (MET) (Yang & Weinberg, 2008). It will require subtle 
experimental models to track such changes through the process of tumour evolution. 
 
We identified 42 genes that had previously been reported to be frequently methylated in 
either Lung, renal, or melanoma tumours but 450K methylation array analysis (using 
data from TCGA) showed these genes were infrequently methylated in primary breast 
tumours that had, at the time of diagnosis, shown no indication of metastasis. However, 
our independent analysis of a second cohort of 40 unrelated primary breast tumours 
revealed that, contrary to our analysis of genome-wide array data, many of these genes 
were frequently methylated in both BBM and the primary breast tumours. This analysis 
identified two genes (BNC1 and CCDC8,) that are differentially methylated in primary 
breast tumours and BBM and merit further investigation. 
 
We predicted that our analysis of unrelated primary breast tumours and BBM would 
identify two different classes of genes that contribute to BBM. We hypothesised that 
epigenetic silencing of BBM associated genes would either occur as a) early events in 
tumour evolution that may be involved in processes such as local invasion and 
intravasion (Chambers et al., 2002; Gupta & Massague, 2006) or these early events may 
be required for specific distant site metastasis but also contribute to primary tumour 
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development. Or, b) late events that play no significant role in the initial evolution of 
the primary tumour but contribute to the development of the secondary brain metastasis, 
either by promoting invasion or improving the capacity for these foreign cells to survive 
in the novel microenvironment of the brain. 
 
The existence of early and late events has previously been proposed by Nguyen et. al. 
(Nguyen et al., 2009), they classified deregulated genes as either involved in: (i) 
Metastasis initiation (e.g. EMT regulators), these will be detectable in the primary 
tumour. (ii) Metastasis progression genes that are important for survival in the 
circulation or required for extravasation, these may be detectable in the primary tumour, 
however they may occur once metastasising cells have left the primary site, or (iii) 
metastasis virulence genes that allow the cancer cells to survive in a foreign tissue 
environment. These are likely to occur as a consequence of the selection pressure 
provided by the novel environment the metastasised tumour cells find themselves in and 
as such will be a late event in metastasis evolution. Metastasis progression genes may 
have different functions in the primary tumour and distant metastasis, for example 
MMP-1 promotes vascular re-modelling in primary breast tumours and also contributes 
to lung extravasation (Minn et al., 2005a). An example of known metastasis virulence 
genes that does not contribute to primary tumour growth is interleukin-11, which 
promotes breast tumour metastasis to the bone but does not provide any advantage to 
the primary tumour (Kang et al., 2003). 
 
Both early and late methylation events will appear similarly in our initial analysis; the 
genes will be frequently methylated in BBM and infrequently methylated in unrelated 
primary breast tumours. However a comparison of primary tumours and BBM from the 
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same patient should reveal if specific gene methylation occurs early or late in the 
process of tumour evolution.   
 
BNC1 is mainly expressed in basal keratinocytes, squamous epithelium and in 
reproductive cells (Yang et al., 1997). BNC1 is known to function as a transcription 
factor in the synthesis of ribosomal RNA by interacting with rRNA gene promoter 
(Zhang et al., 2007). It is a zinc finger transcription factor that interacts with the 
promoters of both RNA polymerases I and II (Zhang et al., 2007). BNC1 target genes 
have been implicated in a broad range of functions including chromatin structure, 
transcription/ DNA-binding, adhesion, signal transduction, and intracellular transport 
(Ma et al., 2006; Wang et al., 2006; Zhang et al., 2007). It is expressed in a broad range 
of tissue types and is highly expressed in the testis (Safran et al., 2010). 
BNC1 has previously been shown to be silenced by promoter methylation in lung 
(Shames et al., 2006b) renal, (Morris et al., 2010), pancreatic (Yi et al., 2013), prostate 
(Devaney et al., 2013) and leukemic cancers (Dunwell et al., 2009a). In vitro assays 
have shown that loss of BNC1 expression is associated with an increased malignant 
phenotype (Morris et al., 2010). Consistent with this study, analysis of 
HumanMethylation 27K and 450K array data from The Cancer Genome Atlas indicates 
that BNC1 Promoter methylation is an infrequent event in primary breast tumours 
TCGA (2012). However, frequent BNC1 promoter methylation  (>60%) in a small 
cohort of breast tumours has previously been reported (Shames et al., 2006b) Cancer-
associated BNC1 mutations or copy number changes are rare (TCGA, 2012). 
Expression of BNC1 is induced by transforming growth factor-β1 signalling and, in turn, 
it acts as a transcription factor for a number of modulators of epithelial dedifferentiation 
during the process of EMT (Feuerborn et al., 2014). Moreover, loss of BNC1 
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expression results in a reduced EMT phenotype. These findings suggest that the 
expression of BNC1 would enhance the process of metastasis via EMT. Our findings 
are consistent with this; we find that BNC1 is infrequently methylated in primary breast 
tumours (17%) and frequently methylated and silenced in BBMs (73%). Moreover, we 
have shown that BNC1 promoter methylation is a late event in tumour evolution, only 
occurring in the brain metastasis of a BBM patient and not in the associated primary 
tumour. It is plausible that BNC1 expression is commonly required for EMT to occur 
during metastasis and, once these cells have metastasised to the brain, loss of BNC1 
expression contributes to mesenchymal to epithelial transition (MET).  
An in vitro screen that consisted of multiple rounds of breast cancer cell line injection 
into nude mice and re-culturing of the resulting brain metastases showed that BNC1 was 
among 373 genes that were differentially expressed (Guo et al., 2011).  However, 
contrary to the results presented here, BNC1 was overexpressed in the cells recovered 
from the mouse brain metastases. This apparent difference in expression may be as a 
consequence of the model used, or the specific expression profile of the cell line used 
(GI-101A). Alternatively, it may represent important differences in the process of 
aggressive early metastasis (as nude mouse cell line injection models represent) and 
slower metastatic evolution, where tumour cells proceed through a phase of latency or 
micrometastasis. As is often the case for brain metastases removed by surgery (Sperduto 
et al., 2010; Jenkinson et al., 2011), many of the brain metastases in our study were 
identified several years after initial breast cancer diagnosis (Paired primary and BBM 
samples were excised between 2-10 years apart). 
 
CCDC8 encodes a coiled-coil domain containing protein (CCDC8) that is one of three 
proteins that are, mutually exclusively, mutated in patients with 3M syndrome (Hanson 
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et al., 2011). 3M syndrome is an autosomal recessive disorder characterised by short 
stature, skeletal abnormalities, reduced male hormone and blood vessel bulges (Huber et 
al., 2005; Maksimova et al., 2007; Huber et al., 2009) CCDC8 is mutated in ∼5% of 3M 
cases, the other genes, CUL7 and OBSL1 are mutated in ∼65% and ∼30% of cases 
respectively (Hanson et al., 2011; Huber et al., 2011). It has recently been shown that 
these three proteins form a complex (the 3M complex) and that loss of expression of 
any one protein disrupts microtubule dynamics resulting in dysregulated mitosis and 
cytokinesis and associated genomic instability and aneuploidy (Yan et al., 2014). 
Moreover, it was shown that loss of any 3M complex protein significantly altered the 
interphase microtubule network (Yan et al., 2014). The core 3M-protein complex 
interacts with CUL9, which has been proposed to mediate the functions of the 3M 
complex via the ubiquitylation and degradation of survivin (Li et al., 2014). The 3M-
complex also interacts with the F box protein FBXW8, ROC1 and the tumour 
suppressor p53 (Yan et al., 2014) suggesting it may contribute to correct cellular 
physiology through multiple mechanisms. In addition, mutations in OBSL1, CUL7 and 
CCDC8 are associated with altered IGFBP3 and IGF-1 signalling pathways suggesting 
the roles of 3M-complex in cellular growth (Hanson et al., 2011). Interestingly, CCDC8 
expression level was not significantly affected in wild type fibroblasts and those 
affected by 3M-syndrome with CUL7 and OBSL1 mutations suggesting that OBSL1 
and CUL7 do not control the expression of CCDC8 indicating its crucial role in cellular 
growth (Hanson et al., 2011). In addition, CCDC8 is known to uniquely regulate p53 
mediated apoptotic process (Murray et al.). p53 is regulated by Tip60 acetylation 
without affecting the expression of p21 that is required for p53 mediated growth arrest 
(Dai et al., 2011). p21 itself is not affected by CCDC8 knockdown; however, its 
knockdown represses the effect of PUMA, a P53 regulator of upregulated modulator of 
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apoptosis. Moreover, CCDC8 stimulates Lys120 acetylation of p53 by interacting with 
Tip60, suggesting the role of CCDC8 as an upstream regulator on interaction of Tip60-
P53 (Dai et al., 2011). This further underlines that CCDC8 is required to regulate 
apoptosis mediated by p53. Taken together, CCDC8, an important component of 3M-
complex, regulates microtubule dynamics and genome stability, cellular growth and 
growth signalling pathways as well as P53 mediated apoptosis.  
 
The findings presented here indicate that epigenetic dysregulation of BNC1 or CCDC8 
in breast tumours may contribute to metastasis to the brain and possibly other distant 
organs. CCDC8 dysregulation occurs early during tumour evolution, in addition to 
being a potential therapeutic target this early inactivation has the potential to be utilised 
as a prognostic biomarker. Further analysis will be required including studies with 
larger sample numbers and studies to determine if such epigenetic markers can be 
discerned via non-invasive means such as analysis of circulating tumour material in the 
patients blood. BNC1 promoter methylation and associated silencing is common in 
BBM but does not occur frequently in the originating breast tumours suggesting that 
their dysregulation may not necessarily benefit the primary tumour but are required for 
successful colonization of the brain. Further studies will be required to determine if 
these changes are detectable in circulating tumour cells, micrometastases, in other 
reservoir sites or only in macroscopic brain metastases. Our current understanding of 
the cellular function of these genes is far from complete. However, what is known about 
these two genes suggests that their dysregulation may be prognostic biomarker for BBM 
and are functionally significant, which could possibly represent novel therapeutic 
targets.  
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We investigated the association between the methylation status of BNC1 and CCDC8 
with ER/PR/HER2 status of the primary tumours, which have metastasised to the brain 
in individual patients. BNC1 was methylated in 6/8 BBM in matched pairs of samples 
(patient, 2, 3, 8, 12, 14 and 15) whereas it was methylated in only one of these 
associated primary tumours in individual patients i.e. patient 12 (Table 4.6). Some of 
these primary breast tumour patients where BNC1 is not methylated are 
ER+/PR+/HER2- (such as patient 2, 3, and 12), ER+/PR-/HER2- (patient 10) and triple 
negative i.e. ER-/PR-/HER2- (patient 14). In this very small group of samples no 
association of BNC1 methylation with the receptor status of the patients was observed. 
Before any conclusions are made regarding this, further analysis with larger number of 
patients will be required.  In addition, lymph node or vascular invasion and the stage of 
primary tumours do not follow any specific patterns of BNC1 methylation. Interestingly, 
the two BBM tumours (patient 5 and 11) where BNC1 is not methylated, took a 
relatively longer time to metastasise (i.e. Brain metastases surgery was taken place after 
10 and 6 years from the removal of primary breast tumour respectively). This could 
possibly imply that the BNC1 methylation may give metastasised tumours a growth 
advantage in the brain microenvironment. Methylation of BNC1 in 6/8 BBM samples 
and its methylation in only one of the primary tumours in individual patients supports 
the idea that BNC1 is not dysregulated in primary tumours to contribute to the process 
of metastatic evolution. However, its dysregulation due its promoter methylation may 
be crucial for survival of metastasised tumours in the brain (late event). Similarly, 
CCDC8 was methylated in 10/11 BBM patients and all of their corresponding primary 
breast tumours. CCDC8 methylation has occurred in the primary breast cancer patients 
regardless of their receptor status, tumour grade and lymph node or vascular invasion 
(Table 4.6). This supports our findings that the CCDC8 methylation is an early event in 
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the process of BBM regardless of the clinical characteristics of the metastasising 
tumours.   
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Table 4.6: Clinical information of originating primary breast tumours and methylation status BNC1 and CCDC8. 
 
Meth%
in%PB
Meth%
in%BBM
Meth%
in%PB
Meth%
in%BBM
Patient'1 Positive Negative Negative
Grade'I,'Invasive'Ductal'
adenocarcinoma,'
Vascular'
invasion'noted 5'years'
Patient2
Positive'
(5=10%),
'Positive'
(5=10%),' Negative Infiltrating'adenocarcinoma NA 10'years
Patient'3 Positive Positive Negative,' Grade'III,'IDC,'metastatic,'
Lymphovascular'
invasion' 2'years
Patient'5 Positive' Negative Negative NA 10'years
Patient'8 NA NA NA
Grade'II,'IDC,'Advanced'
metastatic'carcinoma,' NA 2'years' '
Patient'10 Negative Negative NA
Grade'III'IDC,'infiltrating'non=
small'cell'carcinoma,' NA 3'years
Patient'11 NA NA 1+'
(negative)'
Grade'III,'infiltrating'ductal'
carcinoma NA 6'years
Patient'12 Positive Positive 1+'
(negative)'
Grade'II,'infiltrating'ductal'
carcinoma
Lymphovascular'
invasion 5'years'
Patient'13 Negative Negative Negative
Grade'III,'infiltrating'ductal'
carcinoma NA 3'years
Patient'14 Negative Negative Negative Grade'III,'breast'duct'origin NA 4'years
Patient'15 NA NA NA
Grade'III,'infiltrating'Ductal'
carcinoma
Lymphovascular'
invasion' 2'years'
BNC1 CCDC8
Patient ER%%%%%%
status
PR%%%
status
HER2%%%%%%
status%
Grade%and%type Lymph/Vascular%
Invasion
Duration%
between%
primary%and%
BBM%surgery
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Table 4.6: Clinical information of the primary breast tumours which metastasised to the brain. BNC1 (methylated in 6/8 BBM) and 
CCDC8 (methylated in 10/11 BBM) are frequently methylated in BBM patients. However, regardless of the clinical characteristics, 
BNC1 is methylated in only one of the corresponding primary tumours whereas CCDC8 is commonly methylated in all the primary 
tumours in individual patients. This suggests the methylation status of BNC1 and CCDC8 may be independent of the clinical 
characteristics of the primary tumours. However, analyses of methylation in more patients are necessary to reach to this conclusion.  
 
 
 
 
 
 
 
 
 
4.4 Conclusion 
This analysis has identified two candidate metastatic suppressor genes (BNC1 and 
CCDC8), which were frequently methylated and silenced in BBM, and infrequently 
methylated in unrelated primary breast tumours. These genes were identified from a 
screen of 85 candidate genes generated from a literature review. CCDC8 was 
commonly methylated in BBM and their associated primary tumours in individual 
patients whereas BNC1 was methylated in BBM and was not methylated in their 
associated primary tumours in individual patients. This suggests that dysregulation of 
CCDC8, that occurs in primary tumours (early events), could be a driver for 
metastasis of breast tumour cells to the brain whereas of BNC1 dysregulation occurs 
after the tumour cells metastasised to the brain (late event) that contribute to survival 
of tumour cells in the brain microenvironment. The data suggests that CCDC8 (a 
regulator of microtubule dynamics) and BNC1 (a transcription factor with various 
target genes) could be used as prognostic markers or as therapeutic targets for BBM.  
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CHAPTER 5 
 
Identifying novel candidate genes dysregulated in BBM by analyses of 
Genome wide 450K methylation array data from TCGA  
  
5.1 Introduction 
 
A comprehensive literature review generated a list of candidates, which are associated 
with one of the tumour types that readily metastases to the brain i.e. RCC, melanoma, 
breast and lung tumours (section 2.2.1) The main aim of the literature review was to 
identify candidate metastatic suppressor genes, which are methylated in either of the 
tumour types readily metastasising to the brain but not methylated in primary breast 
tumours. Hence, these genes may be infrequently methylated in primary breast tumours 
but are frequently methylated in RCC, melanoma or lung tumours. However, It is likely 
that genes identified by a literature review will not identify all potential candidate genes. 
 
Among the primary tumours that metastasise to the brain, lung and breast metastasise to 
the brain more frequently (Soffietti et al., 2002). Moreover, lung tumours metastasise 
more readily than the primary breast tumours (Feld et al., 1984; Zhang et al., 2013). We 
hypothesised that the genetic dysregulation responsible for the brain metastases may be 
commonly frequent in primary lung tumours and infrequent in primary breast tumours. 
In this regard, we hypothesised that genes that are infrequently methylated in non-
metastasising breast tumours and frequently methylated in primary lung tumours (that 
readily metastasis to the brain) (Eichler et al., 2011) may be found to be commonly 
methylated in metastatic brain tumours that derive from both lung and breast tumours 
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(Pangeni et al., 2015). 
The epigenetic events that are commonly frequent in lung, renal and melanoma tumours 
and drive early tumour development may also contribute to brain metastasis. However, 
as these events are rare in primary breast tumours they may not contribute to primary 
breast tumour formation but may contribute to BBM. Therefore, screening for genes 
frequently methylated in primary lung tumours and frequently methylated in breast 
tumours from TCGA was carried out to identify novel candidate genes dysregulated in 
BBM.  
 
TCGA is a public repository of data on DNA copy number arrays, DNA methylation, 
exome sequencing, expression arrays, microRNA sequencing, single nucleotide 
polymorphisms  (SNPs) of multiple cancer types (Cancer Genome Atlas Research, 
2013). Many hundreds of human tumours have been investigated by TCGA to uncover 
molecular abnormalities at the genomic, transcriptomic, proteomic and epigenetic level 
resulting in an integrated picture of similarities and differences among tumour lineages 
(Cancer Genome Atlas, 2012). The analysis of TCGA data has revealed that breast 
cancers show novel gene dysregulation that contribute to tumour heterogeneity and 
clinically observable plasticity within the tumour populations (Cancer Genome Atlas 
Research, 2013). In this regard, it is possible that the genes screened by TCGA data 
analyses would identify potential candidate genes that contribute to breast cancer 
metastases to the brain.  
 
The Infinium Methylation 450K BeadChip array has been designed to include over 
485K CpG dinucleotides distributed across the genome, covering over 96% of CpG 
islands and 99% of the RefSeq genes from the UCSC database (Bibikova et al., 2011; 
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Dedeurwaerder et al., 2011). According to the HumanMethylation 450K array design, 
each gene is divided into a gene body, the 5’ UTR, the first exon, gene body and the 3’ 
UTR regions. The promoter region is further divided into TSS200 and TSS1500 located 
200 and 1500 base pairs upstream of the transcription start site (TSS) (Bibikova et al., 
2011). The candidate gene approach described in Chapter 4 has been limited to those 
candidate genes which are known to be associated with primary tumours. Therefore, the 
analysis of the TCGA data was carried out to find additional, novel candidate metastatic 
suppressor genes that may contribute to BBM.  
Unlike the candidate gene approach which identified known candidate genes already 
associated with primary tumour types (section 4), this analysis was intended to identify 
novel candidate metastatic suppressor genes distributed across the genome. To ensure 
that promoter-associated CpG islands (see 1.2.1.1 for CpG islands details) were 
identified, only those probes that are located in the 5’ region of the gene  (5’UTR) or up 
to 1500 base pairs from the transcription start site (TSS, TSS200, TSS1500) were 
selected. The analysis was carried out from the methylation array data for each of 20 
primary lung and breast tumours (with no evidence of metastasis) downloaded from the 
TCGA (see section 3.7.1, table 3.6). The methylation status of individual probes for 
each sample was compared between primary lung and breast tumours. Probes that are 
not methylated (β value ≤ 0.25) in primary breast tumours and methylated (β value ≥ 
0.60) in primary lung tumours identified 4 candidates that were further validated using 
CoBRA.   
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5.2 Results:  
 
5.2.1 Bioinformatic analyses of breast and lung tumours from TCGA 
 
The objective of this study was to identify genes dysregulated due to promoter 
hypermethylation. Therefore the probes which are not associated with promoter region, 
were discarded. The selection of probes that are located in and around the promoter 
region of the gene (TSS-TSS1500), generated a list of 199590 probes. β value of 0.5 in a 
gene denotes that at least one of its allele is methylated. Therefore, to be statistically 
stringent, only those probes with β≥0.75 were considered as methylated (for lung 
tumours). Similarly, only those probes with β value ≤ 0.25 were considered as 
unmethylated (for breast tumours) to make sure that neither of the alleles of a gene is 
methylated. Therefore, screening of only those probes unmethylated (β value ≤ 0.25) at 
least in 15/20 (75%) of primary breast tumours generated a long list of 97155 probes. 
Similarly, screening of only probes methylated (β value ≥0.75) in at least 15/20 lung 
tumours generated a list of 24052 probes. Comparison of these two sets of probes i.e. 
commonly unmethylated in primary breast tumours and methylated in lung tumours 
generated no probes in common. Therefore, multiple rounds of analyses were carried out 
to generate three independent lists of probes for lung tumours by considering β value of 
≥0.70, ≥0.65 and ≥0.60 in 15/20 (75%) of tumours that generated a long list of 28396, 
32584 and 36652 probes respectively (Figure 5.1).  
 
Multiple rounds of analyses were carried out to identify probes common in lung and 
breast tumours (Figure 5.1). Comparison of 97155 unmethylated probes in breast 
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tumours and 36652 methylated probes in lung tumours, (β value of ≥0.60) generated 
only eight probes in common that corresponded to six genes (GALNT9, KRT222, 
PLEKHA6, TFAP2A, TSPAN4 and ZNF808) (Figure 5.1 and table 5.1). One of these 
genes KRT222 did not have a well-defined CpG island (Gardiner-Garden, 1987). 
Therefore, this genome wide approach identified five candidate genes (GALNT9, 
TFAP2A, TSPAN4, PLEKHA6 and ZNF808), which were analysed further using CoBRA 
in an initial cohort of 15 BBM samples.  
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Figure 5.1: Bioinformatic analyses of TCGA data. Analyses of 450K methylation 
array data for 20 primary breast tumours (Breast Invasive Carcinoma; BRCA) 
and 20 primary tumours (Lung Adenocarcinoma; LUAD) were carried out. The 
analysis was carried out to screen probes/genes, which are unmethylated in 
primary breast tumours (β  value ≤  0.25 in 10/20 tumours) and methylated in 
primary lung tumours (β  value ≥0.75 in 15/20 tumours) in common. The analyses 
identified 6 genes (8 probes), which were then analysed independently in the 
laboratory. 
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PROMOTER'REGION'
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15/20'TUMOURS'
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β'VALUE'≥0.75'
PROBES'WITH'
β'VALUE'≥0.70'
PROBES'WITH'
β'VALUE'≥0.65'
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Table 5.1: Genes identified from TCGA data analyses that may contribute to breast to brain metastases (BBM) 
BeadChip 
Probe 
Gene 
symbol 
Accession Probe position 
relative to gene 
Synonyms Full name Function 
cg09879122 
cg27483007 
GALNT9 NM_001122636.1 TSS200 GalNAc 
TRANSFERASE 9; 
GalNAcT9 
N-acetyl 
galactosaminyl 
transferase 9 
Catalyzes O-glycosylation (Shinya et al., 2000; 
Berois et al., 2013) 
cg11641791 
 
KRT222 NM_152349.2 TSS200 KA21; KRT222P Keratin 222, 
Keratin like 
protein 222 
Structural component of cytoskeleton 
(Rappaport et al., 2014) 
cg25407979 
 
PLEKHA6 NM_014935.4 5'UTR PEPP3; PEPP-3 pleckstrin 
homology domain 
containing, family 
A member 6 
Involved in cellular signalling and cytoskeleton 
organisation (Spellmann et al., 2014) 
cg10899301 
cg24902920 
TFAP2A NM_003220.2 TSS1500 AP-2; BOFS; AP2TF; 
TFAP2; AP-2alpha 
TF activating 
enhancer binding 
protein 2 alpha 
Required for neural crest induction (Li & 
Cornell, 2007) 
Development and differential, cellular and 
pathological process, reduced function causes 
development diseases, abnormal expression in 
various human cancer,  
cg14277925 
 
TSPAN4 NM_001025237.1 5'UTR NAG2; NAG-2; 
TM4SF7; TSPAN-4; 
TETRASPAN 
tetraspanin 4 Cellular growth, adhesion and differentiation 
(Todd et al., 1998a) 
cg22455450 
 
ZNF808 NM_001039886.3 5'UTR  Zink Finger 
protein 808 
Zinc finger protein, may be involved in 
transcriptional regulation (Lancet et al., 2013) 
 
Table 5.1: Probes/Genes identified from bioinformatics analysis of TCGA data to screen novel genes that may contribute to BBM. 
The analyses identified eight probes (six genes) in common that are unmethylated in primary breast tumours and methylated in 
primary lung tumours. The genes identified are involved in various biological functions such as posttranslational modifications, 
cellular signaling, cytoskeleton, and transcriptional regulations and are associated with human cancers.  
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5.2.2 Methylation analyses of five BBM candidate genes  
 
CoBRA was carried out to investigate the methylation status of five genes (GALNT9, 
TFAP2A, TSPAN4, PLEKHA6 and ZNF808) in an initial cohort of 15 BBM samples. 
Only those genes, which were frequently methylated in an initial cohort of 15 BBM 
samples, were used for further analyses.  GALNT9 was frequently methylated (8/15 
(55%)) in BBM samples, the other four genes TFAP2A, TSPAN4, PLEKHA6 and 
ZNF808 were not methylated in any of the BBM samples, and were excluded from 
further analysis.  
The CoBRA primers used to amplify promoter region of these genes are listed in 
appendix A3.1. 
Promoter methylation status of GALNT9 was carried out in a second cohort of 15 BBM 
samples. Therefore, methylation status of GALNT9 was determined in a total of 30 
BBM samples. However, no amplified PCR product could be generated for two of the 
BBM. GALNT9 was methylated in 16/29 (55%) of the BBM samples (figure 5.2). The 
observed high frequency of methylation merited further analysis of GALNT9 promoter 
methylation status in a cohort of unrelated primary breast tumours. A quantitative 
methylation analysis of GALNT9 is given in section 5.2.6. 
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Figure 5.2: Methylation status of GALNT9 in BBM.  GALNT9 is methylated in 
17/29 (58%) of BBM samples. Promoter region methylation in of 15 samples (A 
and B) was carried out using CoBRA. Sam DNA: fully methylated positive control, 
BM: Brain metastases, U: Uncut/control sample, C: cut by restriction enzyme,  *: 
methylated samples.  
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5.2.3 Methylation analyses of GALNT9 in unrelated primary breast tumours 
 
Methylation status of GALNT9 in an independent cohort of 40 primary breast tumours 
with no evidence of distant metastases was carried out. The clinical information on 
these primary tumours is given in appendix B4. It was not possible to amplify GALNT9 
in seven of the primary samples. GALNT9 (which was methylated in 58% of BBM) was 
not methylated in any of the 33 primary breast tumours analysed (Figure 5.3). Therefore, 
there was a significant difference in promoter methylation status of GALNT9 between 
unrelated primary breast tumours and BBM (p=0.0001).  
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Table 5.2: Methylation status of genes identified from TCGA data analyses in breast to brain metastases (BBM) 
 
Table 5.2: Promoter methylation status of five candidate genes identified from TCGA data analyse. Initially, a cohort of 15 BBM 
samples was used to investigate the methylation status of the genes. Only GALNT9 was frequently methylated in these BBM 
samples, following analysis of a further 15 samples the promoter methylation frequency of GALNT9 was determined to be 58% (17 
of 29 samples).    
BM1 BM2 BM3 BM4 BM5 BM6 BM7 BM8 BM9 BM10 BM11 BM12 BM13 BM14 BM15
GALTN9 53
PLEKHA 0
TFAP2A 0
TSPAN4 0
ZNF808 0
Gene BM16 BM17 BM18 BM19 BM20 BM21 BM22 BM23 BM24 BM25 BM26 BM27 BM28 BM29 BM30 BM31 Meth
%3meth3
(n=29)
GALNT9 9 58
Gene
Breast3to3Brain3metastases3(BBM)3samples3(n=15)
Methylation3Status3of3GALNT9 3in3second3cohort3of3BBM3samples3(n=15)
%3Meth3
(n=15)
Meth
8
0
0
0
0
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Figure 5.3: Methylation status of GALNT9 in primary breast tumours.  GALNT9 is 
NOT methylated in any of the primary tumours.  Promoter region methylation in 
40 unrelated primary breast tumours was carried out using CoBRA. Sam DNA: 
fully methylated positive control, BP: primary breast tumours, U: Uncut/control 
sample, C: cut by restriction enzyme, *: methylated samples. 
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5.2.4 Expression analysis of GALNT9 in metastatic brain tumours 
 
As GALNT9 was frequently methylated in BBM the next task was to investigate if 
promoter methylation of GALNT9 was associated with its gene silencing. Only 15 BBM 
samples were available for RNA extraction among 30 breast to brain metastases. Total 
RNA was extracted from these samples to determine the expression of GALNT9 by RT-
PCR (Figure 5.4). RT-PCR shows that the expression of GALNT9 correlates with its 
promoter methylation in BBM. GALNT9 is frequently silenced (**) in 5 methylated 
tumours (BM12, BM20, BM27, BM28 and BM29), downregulated (*) in 3 methylated 
tumours (BM13, BM17 and BM30), and is expressed in 4 unmethylated tumours  
(BM11, BM14, BM18 and BM23). However, GALNT9 is silenced in three BBM 
samples in which its promoter is unmethylated (BM3, BM15 and BM16). The silencing 
of GALNT9 in unmethylated samples could be due to the genetic alteration other than 
the DNA methylation such as deletion. (See section 5.4 for quantitative methylation and 
expression analyses).  
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Figure 5.4: Gel electrophoresis of reverse transcription PCR (RT-PCR) of GALNT9 in BBM. Expression analysis using RT-PCR 
shows that the expression of GALNT9 correlates with its promoter methylation in BBM. GALNT9 is expressed in unmethylated (U), 
downregulated (*) in partially methylated, and is silenced (**) in fully methylated tumours. (See figure 5.2 for methylation 
analysis). Expression of β-actin was determined to ensure equal loading for all samples.  Of 15 BBM samples available for 
expression analysis, four unmethylated samples (BM11, BM14, BM18 and BM23) are expressed; three partially methylated 
samples (BM13, BM17 and BM30) are downregulated and five methylated samples (BM12, BM20, BM27, BM28 and BM29) are 
silenced.  Three unmethylated samples (BM3, BM15 and BM16) are also silenced which could be due to other genetic aberrations 
such as deletion or dysregulation on complex network of the gene on those samples. (See section 5.4 for quantitative expression 
analysis)
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5.2.5 Promoter methylation status of GALNT9 in brain metastases and associated 
primary breast tumours from individual patients 
 
We analysed the methylation status of GALNT9 in matched pairs of tumours i.e. 
metastatic brain tumours and corresponding primary tumours from individual patients. 
We have 10 of these pairs, however, some loci in the primary tumour DNA proved 
refractive to amplification. It was possible to amplify the GALNT9 promoter region in 
6 of these samples. Methylation was observed in 0/6 of these primary breast tumour 
samples and in 4/6 of the resulting brain metastases (Figure 5.5). These results 
suggest that GALNT9 promoter methylation occurs at a late stage in the evolution of 
metastatic brain tumours, possibly after the primary tumour cells have metastasised to 
the brain. Alternatively, methylation of these genes may occur in a small subset of 
cells within the primary tumour (below the detection threshold of this assay) and these 
cells are enriched in the metastatic tumour.  
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Figure 5.5: Methylation status of GALNT9 in metastatic brain tumours and their corresponding originating primary breast 
tumours from individual patients. CoBRA was used to determine the methylation status; small, digested PCR products in the BstuI 
cut (C) lane compared to the undigested (U) lane indicates promoter methylation in a sample. GALNT9 was frequently methylated 
(*) in metastatic brain tumours (BM) and are NOT methylated in the originating breast primary (BP) tumours. Of 5 matched pairs 
analysed, GALNT9 is methylated in 4 metastatic brain tumours (see patient 1, 2, 8 and 12), whereas it is methylated in only one of 
the corresponding primary tumour (patient 8). Sam DNA: fully methylated positive control, BP: Breast Primary tumour, BM: 
Metastatic Brain tumour, BN: adjacent Normal Breast tissue, U: Uncut/Control sample, C: cut by methylation specific restriction 
enzyme, *: Methylated sample 
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5.2.6 Quantitative methylation analysis for BNC1, CCDC8 and GALNT9 
 
Quantitative methylation analyses for BNC1, CCDC8 and GALNT9 were carried out 
to ensure that that CoBRA digests were representative of high methylation status in 
tumours. For this purpose, the promoter region amplified by CoBRA was cloned  (see 
section 3.3.5 for detailed methodology) and sequenced to carry out base-resolution 
analysis of promoter region methylation for these genes. The sequencing was used to 
determine the bisulphite-modified alleles in each individual tumour. Based on the 
methylation status of individual CpG dinucleotides in each allele, the methylation 
index (MI) of CpG islands  (see figure 5.6 for the CpG island region amplified) for 
individual tumours was determined. MI is defined as the total number of methylated 
CpG dinucleotides given as a percentage of all CpGs analysed. The MI for promoter 
regions, which were determined by CoBRA as methylated ranged from 60 to 91 % 
whereas those promoters deemed not to be methylated by CoBRA, had MIs ranging 
between 0 and 36 %. From this analysis, we have defined that, for these samples, 
physiologically significant methylation levels are those of ≥60 % MI and lack of 
physiologically significant methylation is defined as <40 % MI (figure 5.7). The 
detailed sequencing of alleles in individual tumours, are given in appendix C1.  
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Figure 5.6: The promoter region/CpG islands of BNC1, CCDC8 and GALNT9. The 
region amplified for CoBRA analysis is found between the Internal Forward 
primer and the Reverse primer. CpG dinucleotides are highlighted in bold. CpG 
dinucleotides analysed by cloning and sequencing of individual alleles are 
numbered. An arrow indicates the transcription start site. 
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Figure 5.7: Bisulphite sequencing of individual alleles from tumours. Tumours 
were analysed by cloning and sequencing bisulphite-PCR products to determine 
the extent of methylation within the region analysed by CoBRA. 10 clones/alleles 
were sequenced for each tumour and the methylation index (MI) for each tumour 
determined. (A) A representative example of tumours that were determined to 
A"
B"
C"
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have significant CCDC8 promoter methylation by CoBRA having methylation 
index of only 6%. Similarly, the same tumour has a methylation index of 36% for 
BNC1 (B), and a representative example of tumours that has methylation index of 
91% for GALNT9 (C). MI is defined as the total number of methylated CpG 
dinucleotides given as a percentage of all CpGs analysed. The details sequencing of 
the region amplified for these genes for individual tumour is given in C1. 
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5.2.7 The Quantitative Expression analyses for BNC1, CCDC8 and GALNT9 
The expression level of each gene was quantified in relation to the expression of β-actin, 
in tumours with unmethylated promoters (MI = 0–25 %). The maximum expression of 
these genes was 49, 23 and 33 % that of β-actin, respectively. BNC1, CCDC8 and 
GALNT9 were frequently downregulated or silenced in these tumours and reduced 
expression correlated to promoter methylation as determined by CoBRA and base-
resolution sequencing (see figure 5.8 and appendix C2). These genes were also 
commonly silenced in breast cancer cell lines; this silencing was reversed following 
treatment with 5-Aza- 2′-deoxycytidine an inhibitor of DNA methyltransferase enzymes 
(Patra & Bettuzzi, 2009).   
This common CCDC8 methylation in primary breast tumour and resulting brain 
metastasis was confirmed by sequencing individual alleles for pairs of tumours from 
two patients, patient 11 and 15 (BM11, Primary BP 11 and BM15, Primary BP 15). 
Both primary tumour DNA and BM DNA were found to have MIs above 73 % 
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Figure 5.8: Expression levels of each gene were quantified in relation to the 
expression of β-actin. The methylation status was determined by either CoBRA or 
sequencing of individual alleles to determine the methylation index (MI) for 
individual tumours. High levels of expression were not associated with high levels 
of methylation in the region analysed. (BM brain metastasis, M methylated, U 
unmethylated, ‘-’analysis was not done). For full set of expression, see appendix C2. 
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5.2.8 Methylation status of BNC1, CCDC8 and GALNT9 in metastatic and non-
metastatic primary breast tumours from the TCGA 
 
We downloaded all the clinical information available for the metastatic primary breast 
tumours from TCGA. Clinical information from TCGA (table 5.3) revealed that there 
were only 21 primary breast tumours (BRCA), which were predicted to be metastatic to 
distant sites such as lung, breast, liver and skin. However, methylation data was 
available for only 14 of these metastatic tumours (Table 5.4). The methylation status of 
probes that are located within the promoter region amplified for each gene (BNC1, 
CCDC8 and GALNT9) were investigated in the clinical samples from TCGA. There 
were only two probes for BNC1 that were within the region amplified (Figure 5.9A).  
One of these probes (cg18560204) was methylated ((β value ≥ 0.70) in only one of 14 
metastatic tumours i.e. tumour M12 (table 5.5) where as the second probe (cg27304406) 
was not methylated in any of the metastatic tumours. Similarly, there are two probes for 
GALNT9 within a promoter region amplified (figure 5.9C); these probes are not 
methylated in primary tumours (with an exception of a probe, cg12075445 methylated 
in a single tumour). Therefore, this supports our findings that GALNT9 methylation 
occurs late only in brain metastases. Furthermore, there were two probes for CCDC8 
located within the promoter region (Figure 5.9B); however, the methylation data was 
available only for a probe (cg06747432). This probe cg06747432 for CCDC8 is 
methylated in 4/14 tumours; M1, M8, M11 and M12. M1 and M8 are stage III and stage 
II tumours with unknown distance metastases respectively. Methylation of CCDC8 in 
these primary tumours may be an early event for general metastasis, or possibly brain 
specific metastases (metastases in the brain might not have been evaluated or detected). 
Moreover, M11 and M12 are stage IV and stage III tumours with liver and bone 
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metastases respectively. These tumours initially might have metastasised to the 
liver/bone and have evolved as a detectable macrometastases at the time of surgery. 
There could possibly be undetectable micrometastases in the brain. It is important to 
note that there might have been different genomic alterations in these primary breast 
tumours (M11 and M12) responsible for liver and bone metastases respectively (not 
CCDC8 methylation) in a small subset of tumour cells due to the heterogeneous nature 
of a tumour and CCDC8 methylation might have occurred in another subset of tumour 
cells with an advantage (such as gaining metastatic potential due to CCDC8 
methylation) to invade into the brain. These data supports our finding that CCDC8 
methylation occurs in primary breast tumours that eventually evolve into brain 
metastases.  
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Figure 5.9: CoBRA primers designed for BNC1, CCDC8 and GALNT9 to 
investigate the methylation status of promoter region of each gene. The probes 
from 450K methylation array that are located within the region amplified in these 
genes have been identified to determine the methylation status of individual probes. 
CCTGAGAAGAGCGCCAGAGAACTTCAGAGCGTTTCGCCCTTCCCCGGGAGAGGCAAACAC 
CGACACGTCTGTGTCTTTTACCAACAAGTGCCTTCAAGCCCGGCGGGGGCAGACACCTCC 
GCGCCGGCCGCCGGCGAGGTCTCCGCGGTCTGCGGGGGCCACGGCCTCGCCTCAGCTGCG 
CTGATTTAGGGCGTTATCCGGTCCCGGGGCGGGAGGCGGCCTCCCGGGCGGCGAAGCAGC 
GCCCGCGGCGTGGGGCGACCGCGCGGTGGGCGGAGGGGCAGGGGGAGGGGCGGAGAGGCG 
TCCCCGGGGCGCAGGGGGCGGGCGTGCGGGCACACGCGGTGCGCGGCGGGGGCGGCCATC 
GTGCTGCGCAGCCTGGGCGCTTGGGGAGCCGCCCACTTCGCCGGGTCGCGCCCCGACGGC 
Forward Primer Internal Forward Primer Reverse Primer 
cg27304406 cg18560204 
A)#BNC1%
GCTGACGTGGGCCACTGCCGCTTCGCTGGGAAGCAATGGGCCCAGCTAGGCCCGGGGCGC 
GGCCACACCCCTGTGGGGGAGGGGAAGGAGGCCGCCCCGAAGGGAGTGGACAGCCCCCCT 
GTCAGTCTTCCAGAGTCTGGGAGTGTAAGATGAGACGGGGGAAGGTGGGCCTCATTCTGG 
CGGAGGGCGAGGAGGAACTTCCTGCCCGCGCGCTCCACGGTGCAGAGCTCTAAGCGCGCG 
GGCTGGCAGGCTGCGGCGCGTCAAGGTCAGCCTGGAGCTGGGTGGCGGCCTGCCTGGGGG 
CGGGGGACCCTACTGGAGGCCCGGGCTGGGGCCTCCCAGCGCCTCGGCCATATTGAATAG 
CTTCGACTGGACCGTCTTTGTCTGCGAAGTCCTGTCCCAAGTTCCAGCCGCGTCCCTGGG 
GCCTGGGGCAGGAAGAGTCGCTGGCAGCCCGCGCGCCCCAACTTGGAGCTGGGACACCAC 
GTTTCCAGCTTGGAGTGGGCCTTGAGCCTTGGGACTGACCTCGCCCCCGGCTCACGTAGG 
B)#CCDC8%
cg06747432 
Forward Primer Internal Forward Primer Reverse Primer 
cg25987744 
CGCGGTTGCAGATGAGGTGAGGTGAGGCCGCGTCACTCTGCACCGGCGCGGTGGCTGCGG 
GGCGGGCAGGACAGGAGCCGGCACAGACACCGAGCGCCGCCCGCCCGCGCCTTCCCCGCC 
GCCCCCCGGCGCCCCCGGCCCCCCTCACCGCTCCCCGGGGCGGGGCCGCGCCCTCTGAGC 
GGGGGATGCCGGCCGCGCCCCGCGACCCCAGCCCCGGGCAGCCCTCTGCGCTCTGGGGGA 
CCCCCGGCGGCCGTGGCCCGGCGCGCTGAGCTGGTGCTGAAGGGACAGCTCCGGCCGAGC 
CCCGCAGCCCCCGCAGCCCCGGGCGGCTCATGGTCCCCGAAGCCGAAGCTGAAGCCCAGG 
CCCGGGCGGGGATGCTGGGGATGCCCCGCGGGTGAGGCCCCCGCTGCAGCCGTGTTCATG 
GCGGTGGCCAGGAAGATCCGAACTTTGCTGACGGTGAACATCCTGGTGTTCGTGGGCATC 
C)#GALNT9%
cg12075445 
Forward Primer Internal Forward Primer Reverse Primer 
cg2228111 
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The central CG for each probe is marked in a circle (purple). Other independent 
CpGs (CGs) are shaded purple. The primers are shaded in green. The transcripts 
are underlined.  
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Table 5.3:  Clinical information of metastatic primary breast tumours from TCGA. 
 
Table& 5.3:& Clinical& information& of& metastatic& BRCA& samples& from& TCGA& has& shown& that& the& distant& metastasis& of& primary& breast&
tumours& (in& the&data& sets& available& so& far)& has& taken&place&only& in& the& lungs,& bone& and& liver.&No&metastasis& to& the&brain& has& been&
specified.&The&methylation&data& for&BNC1,&CCDC8&and&GALNT9&on& these& tumours& is&given& in&Table&5.6.& (Stages& I:& local&and&generally&
curable,&Stage& II&and& III:& local&and& involvement&of& lymph&node,&Stage& IV& Inoperable&or&metastatic,&M0:&No&distance&metastasis,&M1:&
Distance&metastasis,&MX:&Distance&metastasis& cannot&be&evaluated,&N0:&No&regional& lymph&node&metastasis,&N1ON3:& regional& lymph&
node&metastasis).&
 
Tumour&
Code
Patient's&
age ER&STATUS PR&STATUS
HER2&
Status
micrometast
asis
distant&
metastasis
Distant&metastasis&
sites
Tumour&
stage
Pathological&
stage&
(metastasis)
Pathological&
stage&(Lymph&
node)&
M1 62 Negative Negative NA YES YES NA Stage0IIIA M0 N2a
M2 58 Negative Negative NA NO YES Lung/Bone/Liver Stage0IIIC M0 N1mi
M3 68 Negative Negative 2+ NO YES Lung Stage0IIIC M0 N00(iB)
M4 55 Negative Negative 2+ NA YES Bon/Liver Stage0III M0 N1b
M5 69 Positive Positive NA YES YES Bone Stage0I M0 N3
M6 46 Positive Positive 2+ NO YES Bone Stage0IIB MX N3b
M7 87 NA NA NA YES YES Other Stage0IIB M0 N3b
M8 55 Positive Negative NA NO YES NA Stage0IIB MX N1b
M9 47 Positive Negative NA NA YES Bone NA NA NA
M10 82 Positive Negative NA NO NA Liver Stage0IV M1 N2a
M11 66 Negative Negative 0 NO NA Liver Stage0IV M1 N2
M12 43 Positive Positive 2+ NA NA Bone Stage0IIIA M1 N3
M13 47 Positive Positive 1+ NO NA Bone/Liver Stage0IIIA M0 N2
M14 63 Positive Positive 2+ NO NA Bone Stage0IV M0 N2
 175 
Table 5.4: Methylation status of BNC1, CCDC8 and GALNT9 in primary breast tumours from TCGA.  
 
Table 5.4:  The methylation status of BNC1 and GALNT9 in metastatic primary breast tumours from TCGA shows that these three 
genes are infrequently methylated (β value ≥ 0.70) in metastatic primary tumours, which have metastasised to the distant sites 
other than the brain such as bone, breast and lungs. CCDC8 is methylated (β value ≥ 0.70) in 4/10 metastatic primary breast 
tumours from the TCGA. Two of these samples metastasised to liver and bone whereas the metastasis of the other two samples is 
not known.  
 
 
Gene Probes M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14
No.6of6tumours6
with6β6value6
≥0.70)
cg18560204 0.6441 0.5102 0.2708 0.4231 0.6217 0.5687 0.6609 0.5915 0.3703 0.547 0.099 0.7931 0.6854 0.6424 1
cg27304406 0.4978 0.3186 0.1607 0.2732 0.4874 0.2298 0.5352 0.6478 0.2044 0.3267 0.0307 0.6101 0.5479 0.4283 0
CCDC8 cg06747432 0.713 0.6201 0.0826 0.1719 0.5959 0.0241 0.6847 0.7195 0.2004 0.0319 0.7821 0.8391 0.6941 0.6542 4
cg02228111 0.1542 0.0347 0.2402 0.219 0.106 0.1097 0.6694 0.0392 0.0526 0.1273 0.0383 0.5663 0.4731 0.088 0
cg12075445 0.0769 0.0309 0.1638 0.071 0.5271 0.0366 0.7334 0.0296 0.0219 0.1324 0.1901 0.4157 0.356 0.3577 1
GALNT9
β6value6of6the6probes6in6METASTATIC6primary6breast6tumours6from6TCGA6that6are6associated6with6an6analysed6CpG6island6promoter6region6of66the6genes6
BNC1
BNC1, CCDC8 and GALNT9 are infrequently methylated in the 20 non-metastatic 
tumours from TCGA that were analysed (table 5.5), one of the probes (cg18560204; 
BNC1) is methylated in two tumours and another probe (cg18592647; BNC1) is 
methylated in only of one of the 20 tumours. Similarly, CCDC8, a potential early 
indicator for metastasising primary breast tumours to the brain, is not methylated in 
any of the 20 non-metastatic breast tumours analysed from the TCGA. Similarly, 
GALNT9 is not methylated in any of the 20 non-metastatic primary tumours analysed.  
 
We carried out functional analyses to investigate the role of BNC1, CCDC8 and 
GALNT9 in the metastatic potential of breast cancer cell lines, these are described in 
chapter 6.  
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Table: 5.5 Methylation statuses of BNC1, CCDC8 and GALNT9 in non-metastatic breast tumours from TCGA.  
 
 
Table 5.5: BNC1, CCDC8 and GALNT9 are infrequently methylated in non-metastatic primary breast tumours from TCGA. This 
data suggests that BNC1, CCDC8 and GALNT9 are dysregulated specifically in metastatic primary tumours (Methylation: β value 
≥ 0.70).
Gene Probe NM1 NM2 NM3 NM4 NM5/ NM6 NM7 NM8 NM9 NM10 NM11 NM12 NM13 NM14 NM15 NM16 NM17 NM18 NM19 NM20
No./of/tumours/
with/β/value/
≥0.70)
cg18560204 0.483 0.609 0.434 0.513 0.148 0.301 0.499 0.485 0.519 0.651 0.61 0.498 0.587 0.442 0.705 0.504 0.714 0.328 0.184 0.561 2
cg27304406 0.285 0.379 0.224 0.361 0.042 0.261 0.306 0.319 0.277 0.588 0.413 0.108 0.393 0.229 0.56 0.357 0.619 0.335 0.034 0.453 0
CCDC8 cg06747432 0.51 0.67 0.163 0.07 0.581 0.187 0.061 0.383 0.566 0.04 0.456 0.018 0.231 0.521 0.657 0.305 0.148 0.057 0.028 0.374 0
cg02228111 0.027 0.322 0.04 0.043 0.061 0.031 0.39 0.024 0.126 0.155 0.138 0.083 0.323 0.176 0.048 0.476 0.088 0.039 0.046 0.455 0
cg12075445 0.416 0.018 0.464 0.017 0.142 0.018 0.046 0.016 0.521 0.691 0.27 0.016 0.447 0.024 0.427 0.521 0.025 0.021 0.018 0.589 0
BNC1
GALNT9
β/value/of/the/probes/in/NONFMETASTATIC/primary/breast/tumours/from/TCGA/that/are/associated/with/an/analysed/CpG/island/promoter/region/of//the/genes/////////////////
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5.3 Discussion 
We hypothesized that gene methylation that may contribute to BBM will occur 
commonly in primary lung tumours, as these often metastasise to the brain in a short 
time period relative to initial diagnosis (Eichler et al., 2011). Shorter time period of 
lung tumours to metastasise to the brain may be due to the frequent genomic alterations 
that give advantages to the lung tumours to invade and/or to proliferate into the brain 
against the selective pressure of the brain microenvironment. Similarly, breast tumours 
take a relatively long time to metastasise to the brain compared to the lung tumours 
(Feld et al., 1984; Zhang et al., 2013).  These metastasising breast tumours may have 
genomic alterations common to lung tumours that are responsible for BBM. In order to 
identify such novel candidate genes that contributes to BBM, analyses of genome wide 
450K methylation array data was carried out.  
 
Our main aim was to identify candidate genes, which are silenced due to promoter 
hypermethylation and contribute to BBM. Therefore, the 450K-methylation array 
probes that are not associated with promoter region (those located in gene body and 3’ 
UTR) were discarded. Stringent statistical criteria were used to generate a list of 
candidate genes from the analyses, which identified six genes i.e. GALNT9, KRT222, 
PLEKHA6, TFAP2A, TSPAN4 and ZNF808. Methylation analysis of five genes except 
KRT222 (which has no well-defined CpG island) in BBM samples identified only 
GALNT9 as frequently methylated in 55% (16/29) of BBM samples, and was NOT 
methylated in any samples from an independent cohort of 33 unrelated primary breast 
tumours. Moreover, methylation of GALNT9 correlated to loss of expression of the gene 
in BBM, suggesting that the methylation of GALNT9 in BBM contributes to its 
silencing. GALNT9 was further investigated for its methylation status in BBM samples 
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and their corresponding primary tumours from the same patients to investigate if 
GALNT9 methylation occurs early or late in the process of tumour evolution.   
 
As described in section 4.3 we predicted that our analysis of unrelated primary breast 
tumours and BBM would identify two different classes of genes that contribute to BBM. 
We hypothesized that epigenetic silencing of BBM associated genes would either occur 
as a) early events (Chambers et al., 2002; Gupta & Massague, 2006) or as b) late events. 
The dysregulated genes as either involved in: (i) Metastasis initiation (e.g. EMT 
regulators), (ii) Metastasis progression genes or (iii) metastasis virulence gene. 
Metastatic virulence gene may allow the cancer cells to survive in a foreign tissue 
environment (Nguyen & Massague, 2007). These are likely to occur as a consequence 
of the selection pressure provided by the novel environment the metastasised tumour 
cells find themselves in and as such will be a late event in metastasis evolution e.g. 
BNC1 (section 4.3). GALNT9 may promote BBM by providing selective advantage to 
metastasised tumour cells in the brain microenvironment. Whereas there may be no 
advantage in its silencing during the formation of the primary tumour.  
 
GALNT9 encodes a member of the UDP-N-acetyl-α-D-galactosamine:polypeptide N- 
acetylgalactosaminyltransferase family of enzymes that catalyze the first step of O-
glycosylation; GALNAC-T9 (Chambers et al., 2002). GALNT9 is expressed most 
abundantly in the brain and other CNS tissues. It is also expressed, at lower levels, in a 
number of other tissues including normal breast (Safran et al., 2010). 
 
The GALNAC-T proteins initiate mucin type O-linked glycosylation in the golgi 
apparatus by the covalent linkage of an α-N-acetylgalactosamine (GalNAc) to Ser and 
 181 
Thr residues (Hanisch, 2001). O-Glycans play an important role in cell adhesion and 
cell-cell communication and dysregulated glycosylation is a common characteristic of 
tumour cells (Brockhausen, 2006). A recent screen of GALNAC-T protein expression in 
a neuroblastoma model, cell lines and tumours found that loss of GALNT9 expression 
was linked to a highly malignant phenotype and associated with poor overall and 
disease free survival (Berois et al., 2013). These findings suggest GALNT9 
glycosylates a very specific group of substrates and this may indicate a subtle regulation 
of transmembrane protein function. Our findings of GALNT9 promoter methylation, and 
associated loss of expression, in BBM, but not in primary breast tumours suggest that 
this proposed subtle change in transmembrane protein function may be a common 
occurrence in the later stages of the evolution of breast tumour brain metastasis. This is 
the first time that GALNT9 has been shown to be dysregulated in cancer by promoter 
methylation. However, conserved mutations have been identified in approximately 2% 
of microsatellite instable colorectal cancers (Tuupanen et al., 2014) and GALNT9 is also 
mutated, infrequently (<1%), in astrocytoma (Brennan et al., 2013) and lung tumours 
(Cancer Genome Atlas Research, 2012; Cancer Genome Atlas Research, 2014) and 
infrequently lost through CNV in breast tumours (Cancer Genome Atlas Research, 
2012; TCGA, 2012). 
In a small number of samples with clinical information (6 pairs), methylation status of 
GALNT9 is not associated with ER/PR/HER2 status of the primary tumours, which have 
metastasised to the brain in individual patients. The analysis of more samples is needed 
to determine if GALNT9 methylation is independent of other clinical features (as in the 
case in this very small cohort).  GALNT9 was methylated in 4/6 BBM in matched pairs 
of samples (patient, 1, 2, 8 and 12) whereas it was methylated in only one of the 
associated primary tumours in individual patients i.e. patient 8 (Table 5.6). Patient 2 and 
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12 are ER+/PR+/HER2- whereas patient 1 is ER+/PR-/HER2-. There was no 
information on ER+/PR+/HER2- for patient 8. Looking at the tumours stage as well as 
lymph node and vascular invasion, there is no specific methylation pattern of GALNT9 
that contributes to lymph node or vascular invasion Therefore, it supports the fact that 
the GALNT9 is not dysregulated in primary tumours to contribute to the process of 
invasion/metastasis. However, its dysregulation due its promoter methylation may be 
crucial for survival of metastasised tumours in the brain (late event).  
 
Table: 5.6 Clinical information of originating primary breast tumours and methylation status GALNT9.  
 
Table 5.6: Clinical information of the primary breast tumours which metastasised to the brain. Methylation status of GALNT9 in these 
primary tumours and their corresponding BBM suggests that the methylation status of GALNT9 may be independent of the clinical 
characteristics of the primary tumours. None of the primary tumours, which metastasised the brain, are methylated at GALNT9.  
Patient
ER))))))
status
PR)))
status
HER2))))))
status) Grade)and)type
lymph/Vascular)
Invasion
Duration)
between)
primary)and)
BBM)
surgery
Meth)
in)PB
Meth)
in)BBM
Patient'1 Positive Negative Negative
Grade'I,'Invasive'Ductal'
adenocarcinoma,' vascular'invasion' 5'years'
Patient'2
Positive'
(5<10%),
'Positive'
(5<10%),' Negative Invasive'lobular'carcinoma NA 10'years
Patient'5 Positive' Negative Negative NA 10'years
Patient'8 NA NA NA
Grade'II''IDC,'Advanced'
metastatic'carcinoma NA 2'years'
Patient'11 NA NA 1+'(negative)'
Grade'III,'infiltrating'ductal'
carcinoma NA 6'years
Patient'12 Positive Positive 1+'(negative)'
Grade'II,'infiltrating'ductal'
carcinoma
lymphovascular'
invasion' 5'years
Patient'15 NA NA NA
Grade'III,'infiltrating'Ductal'
carcinoma
'lumphovascular'
invasion' 2'years
The methylation status of BNC1, CCDC8 and GALNT9 in clinical data from TCGA is 
consistent with our independent analyses of BBM and their associated primary 
tumours from individual patients. These data support our findings that the CCDC8 
dysregulation occurs early only in those primary breast tumours which may 
eventually metastasise to the brain where as BNC1 and GALNT9 dysregulation occurs 
late during the process of tumour evolution only after the metastasising tumour cells 
have left the primary tumour.   
 
5.5 Conclusion:  
 
Analyses of the Infinium BeadChip human methylation 450K array data identified 6 
candidate genes that contribute to BBM. We carried out independent experimental 
validation using CoBRA for 6 candidate genes in BBM samples that identified 
GALNT9 as being frequently methylated in BBM tumours. GALNT9 was not 
methylated in any of the unrelated primary breast tumours. Furthermore, GALNT9 
methylation correlated to its expression. GALNT9 was not methylated in any of the 
primary tumours from the individual patients where as it was methylated in their 
metastatic counterparts in BBM. This suggests that, the methylation of GALNT9 
occurs late in the process of metastasis. Analysis of the methylation data from the 
metastatic and non-metastatic tumours from the TCGA was carried out for BNC1 and 
CCDC8 (from candidate gene approach; chapter 4) and GALNT9. Analysis of this 
data supports our findings that the dysregulation of BNC1 and GALNT9 due to 
promoter methylation is a late event whereas the dysregulation of CCDC8 due to 
promoter methylation is an early event during the process of BBM. Functional 
analyses, to determine the contribution of BNC1, CCDC8 and GALNT9 dysregulation 
to the metastatic process have been carried out as described in chapter 6. 
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CHAPTER 6 
 
Functional analyses of BNC1, CCDC8 and GALNT9 to investigate their 
influence on the metastatic potential breast cancer cell lines. 
 
6.1 Introduction 
 
Invasion and metastasis, two important hallmarks of cancer (Hanahan & Weinberg, 
2000), are associated with various complex genetic and epigenetic aberrations allowing 
tumours to disseminate to distant sites through the lymphatic and vascular systems 
(Barekati et al., 2012). The invasion of a tumour from lymphatic and blood vessels 
giveS rise to an eventual colonization of the tumour at a suitable niche and to grow into 
micro (Leong et al., 2011) and macro metastases (Barekati et al., 2012; Kurbasic et al., 
2015). It is important to understand and to identify those genetic and epigenetic 
alterations in primary tumours (such as breast) in order to provide improved prognostic, 
diagnostic and management of metastatic tumours. In the case of primary breast 
tumours, lymph nodes metastases are taken as an important prognostic indicator to 
evaluate the possibility of distance metastases. As recent study has reported epigenetic 
aberrations status of 12 genes in primary breast tumours and the lymph node metastases 
including aberrations in DNA methylation status of BMP6, BRCA1 and P16, which 
could be used as prognostic markers in breast cancer metastases to lymph nodes 
(Barekati et al., 2012). However, epigenetic mechanisms underlying distance metastases 
of breast tumours remain very poor.  
Previous studies have reported dysregulated genes in breast cancer metastases to lungs 
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and bone (Kang et al., 2003; Minn et al., 2005a) and the genes with reduced mRNA 
expression in breast cancer brain metastases (Stark et al., 2005) (see 1.6.4 for details). 
This implies that the metastatic process may involve a group of genes dysregulated in 
selectable subpopulations of primary breast tumours that offer these cells an advantage 
to metastasise to the specific distant site and evolve into metastatic tumours. Consistent 
with this, three potential candidate metastatic suppressor genes; BNC1, CCDC8, and 
GALNT9, which are dysregulated either both in primary and BBM (CCDC8) and or in 
brain metastases (BNC1 and GALNT9) may provide an advantage to the metastasising 
cells to invade the brain or to grow and proliferate within the intracranial environment.  
Cancer cells need to migrate through the blood or lymph to reach a distant site during 
the process of metastasis. Therefore, we have employed in vitro cell migration and 
invasion assays (Kramer et al., 2013) to determine if the silencing of the identified 
genes may contribute to the metastatic process in breast cancers.. We have employed a 
wound-healing assay (a scratch assay) to measure the capacity of cells in a loosely 
connected population to move in any direction without obstructive fiber networks 
towards the wound created. Invasion, a movement of cells through ECM barrier either 
by modifying its own shape or by proteolytic degradation of ECM network, is a crucial 
step in the process of metastasis (Kramer et al., 2013).   Therefore, invasion requires 
ECM remodeling, as cells need to undergo adhesion, proteolytic degradation of ECM 
components and then migration during the process of intravasation and extravasation to 
metastasise into a distant niche. In this regard, migration, a non-destructive and non-
proteolytic movement is a prerequisite for invasion as the cells are able to migrate 
without invasion (Kramer et al., 2013). Therefore, we carried out an invasion assay only 
if the cells exhibited the potential to migrate following the knockdown of BNC1, 
CCDC8 or GALNT9. 
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6.2 Result 
 
 6.2.1 Treatment of breast cancer cell lines with 5-AZA-2-dC 
 
We treated the breast cancer cell lines MCF7, T47D, MDA-MB231, BT549 and ZR75 
with the demethylating agent; 5-AZA-2-dC to investigate the reexpression of BNC1, 
CCDC8, and GALNT9 in these cell lines. Prior to treatment, methylation analyses of the 
genes were carried out on these cell lines. BNC1 was methylated (appendix D1) and 
downregulated in MCF7 (figure 6.1), where as it was methylated and silenced in T47D, 
MDA-MB231, BT549 and ZR75. BNC1 showed an increased level of expression in 
MCF7 and it was reexpressed in T47D and ZR75, after treatment with 5-AZA-2-dC.  
However, there was no evidence of BNC1 expression in MDA-MD231 and BT549. 
Similarly, CCDC8 (appendix D1) was methylated in all the cell lines treated. CCDC8 
was downregulated in MCF7 (figure 6.1) whereas it was silenced in other cell lines 
(T47D, MDA-MD231, BT549 and ZR75). Following treatment with 5-AZA-2-dC, 
CCDC8 was up regulated in MCF7 and was reexpressed fully in ZR75. CCDC8 did not 
re-express in MDA-MB231 and BT549 and was expressed in T47D prior to treatment, 
and the expression level has persisted after the treatment with 5-AZA-2-dC. GALNT9 
(figure 6.1) was downregulated in MCF7, and was silenced in T47D, whereas it was 
expressed in MDA-MD231 and BT549. GALNT9 was up regulated in ZR75 after the 
treatment. However, there was no reexpression or upregulation in T47D or MCF7.  
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Figure 6.1: Global demethylation resulted in the reexpression of BNC1, CCDC8 
and GALNT9 in breast cancer cell lines. Reverse transcription PCR (RT-PCR) 
showed that treatment of breast cancer cell lines with 5-AZA-2-dC, a 
demethylating agent resulted in re-expression of GALNT9, CCDC8 or BNC1 in 
breast cancer cell lines. For comparison, endogenous expression is also shown (-) 
along with the expression after the global demethylation by 5’aza treatment (+). β 
actin was used as a control. The cell lines where BNC1, CCDC8 and GALNT9 are 
expressed i.e. BNC1 in MCF7, CCDC8 in T47D and, GALNT9 in MDA-MB231 and 
BT549 were used in our in vitro knockdown experiments. The experiment was 
carried out in three replicates. 
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6.2.2 Loss of GALNT9, CCDC8 or BNC1 expression increases the motility of breast 
cancer cell lines. 
BNC1, CCDC8 and GALNT9 were knocked down by RNA interference (using siRNA 
oligos) to study the migratory behavior of breast cancer cell lines. BNC1 was knocked 
down in MCF7, CCDC8 was knocked down in T47D and, GALNT9 was knocked down 
in MDA-MB231 and BT549.  The knockdown for these genes was carried out as 
described in section 3.6.2. Before carrying out the migration assay for the genes, the 
knockdown efficiency of each siRNA oligo was determined by RT-PCR (Figure 6.2). 
After determining knockdown efficiency of BNC1, CCDC8 and GALNT9 individually, 
migration assay was set up in triplicates to minimize experimental biases. An identical 
transfection experiment was set up in parallel to ensure the knock-down efficiency at 
the time of migration assay experiments, which were then confirmed by RT-PCR and 
Western blot (Figure 6.5). 
 
Forty-eight hours after initial transfection with siRNA oligos against BNC1, CCDC8 or 
GALNT9 breast cancer cell lines showed loss of specific gene expression. Control 
oligos was used as a control in a respective cell line (Figure 6.2 and 6.3) 
 
Following knockdown, cells were seeded in serum-free media to form confluent 
monolayers. The monolayers were scratched with a 200µl pipette tip to generate 
“Wounds”. Photographs were captured at the time of scratch (labeled as a zero hour) 
and at 48 hours after the initial scratch at 100X magnification using a digital camera 
attached with the microscope. The widths of each scratch were measured at three 
separate points to generate an average distance using Image J software (Schneider et al., 
2012). The difference in the migratory distance at zero and 48 hours was calculated and 
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was compared with a cell line transfected with scrambled control oligos. It was 
observed that the knockdown of any of these three genes increased the migratory 
potential compared to cell lines transfected with control oligos. The increase in motility 
of cell lines following knockdown of BNC1 (Figure 6.3; B), CCDC8 (Figure 6.3; A) or 
GALNT9 (Figure 6.3; C) was statistically significant  (BNC1: p=0.011, CCDC8: 
p=0.001, GALNT9: p= 0.027) compared to control cells (scrambled siRNA transfected).   
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Figure 6.2: Reverse Transcription (RT) PCR to confirm Knockdown of BNC1, 
CCDC8, and GALNT9 in breast cancer cell lines prior to functional assays. RT-
PCR products of BNC1, CCDC8, and GALNT9 transcripts in breast cancer cell 
lines (MDA-MD231, T47D and MCF7 respectively after siRNA knockdown 
compared to transfection with a control siRNA (upper panel). Equal loading was 
confirmed by analysis of β"actin&expression)(lower panel).  
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Figure 6.3: Loss of CCDC8, BNC1 or GALNT9 expression increases the migratory potential of breast cancer cell lines. The breast 
cancer cell lines that expressed CCDC8, BNC1 or GALNT9 were identified; these genes were knocked down by siRNA (see figures 
6.2 and 6.5). (A) T47D cell lines transfected with siRNA oligos against CCDC8; (B) MCF7 cell lines transfected with siRNA oligos 
against BNC1 or (C) MDA-MB231 cell lines transfected with siRNA against GALNT9 exhibited more migratory potential 
compared to respective cell lines transfected with control siRNA oligos. Following siRNA transfection, confluent cells were 
incubated in serum-free media and an artificial wound was scratched through them (0 hrs). 48hrs later the distance migrated was 
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calculated by subtracting the value of non-migrated distance from the initial wound. The distance migrated (in percentage), by 
respective cell lines knocked down with siRNA against CCDC8, BNC1, or GALNT9 compared to the respective cell lines transfected 
with control siRNA oligos, was statistically significant (p=0.001, 0.011 and 0.027 respectively). 
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6.2.3 Reduced expression of BNC1, CCDC8 and GALNT9 increases the invasive 
potential of breast cancer cell lines 
 
BNC1, CCDC8 and GALNT9 were knocked down in breast cancer cell lines by siRNA 
oligos as described in section 3.6.2.  The respective cell lines that were knocked down 
with BNC1, CCDC8 or GALNT9 were applied to matrigel-coated invasion chambers 
with 8-µm polyethylene terephtphalate membrane pores. Forty-eight hours later, cells 
that had “invaded” through the pores were stained with crystal violet and photographs 
were taken at 100X magnification.  
The cells were isolated and the OD was measured at 540nm in order to quantify the 
proportion of cells that had invaded through the matrigel. The number of breast cancer 
cell that invaded through the matrigel coated pores following BNC1 knocked down was 
increased by 40% (p=0.006) compared to cells transfected with control oligos. (Figure 
6.4A). Similarly, following knockdown of CCDC8, 27% more cells invaded through the 
matrigel compared to cells transfected with control oligos (p=0.021) (Figure 6.4B). 
Following knockdown of GALNT9 35% more cells invaded (p=0.025) compared to cell 
transfected with the control-scrambled siRNA (Figure 6.4C).  
 
Increased motility and invasive potential following reduction of expression of these 
genes suggests that these candidates may be involved in the regulation of normal 
cellular physiology and that loss of their expression may contribute the metastatic 
process in breast tumour cells.  
 
 
 195 
 
Figure 6.4: Reduced expression of BNC1, CCDC8 or GALNT9 increases the 
invasive potential of breast cancer cell lines. A trans-well invasion assay was 
carried out following the knockdown of BNC1, CCDC8 or GALNT9 in breast 
cancer cell lines. The invasive capacity of these cells was compared with the same 
cell lines transfected with scrambled control siRNA oligos (control). The numbers 
of cells that had invaded a matrigel coated micropore membrane was determined 
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colourimetrically 48hrs after initial seeding. (A) MCF7 cell lines transfected with 
siRNA oligos against BNC1, (B) T47D cell lines transfected with siRNA oligos 
against CCDC8 and (C) MDA-MB231 cell lines transfected with siRNA oligos 
against GALNT9, exhibited a statistically significant increase in invasiveness 
compared to negative control siRNA transfected cells. p=0.001 (BNC1),  p=0.021 
(CCDC8) and p=0.025 (GALNT9), Invasive potential was calculated as a  
percentage increase above that observed for the control cells (% invasion). 
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Figure 6.5: Knockdown of BNC1, CCDC8, and GALNT9 in breast cancer cell lines 
set up in parallel during migration and invasion assays is confirmed by Reverse 
Transcription (RT) PCR and Western blot. (A) RT-PCR products of BNC1, 
CCDC8, and GALNT9 transcripts in breast cancer cell lines (MDA-MD231, T47D 
and MCF7 respectively), after siRNA knockdown compared to transfection with a 
control siRNA and (B) western blot of GALNT9, CCDC8, and BNC1 proteins to 
confirm their knockdown in each respective cell line. 70 µg of protein was loaded 
in each lane. Equal loading was confirmed by β actin for RT-PCR and by staining 
total protein with India ink for western blot.  
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6.2.4 Association of reduced expression of BNC1, GALNT9 or CCDC8 with poor 
relapse-free survival of patients. 
 
The clinical significance of the expression of BNC1, CCDC8 and GALNT9 was 
analysed using publically available GEO expression profiles using the prognoscan 
database (Mizuno et al., 2009). Given a patient population with varying disease 
outcomes, Prognoscan partitions that population into a high-expression and low-
expression group for each gene by choosing a threshold that maximizes the statistical 
significance of difference in outcome.  It also corrects for multiple testing using the 
method of Miller and Siegmund (Miller & Siegmund, 1982). This analysis 
demonstrated that, in two independent datasets, low CCDC8 expression was 
significantly associated with poor relapse free survival (GSE12276: p=0.001, GSE1456-
GPL97: p=0.004) (Figure 6.6B) and in one data set, low GALNT9 expression was 
associated with poor relapse free survival, (GSE1379: p=0.0029) (Figure 6.6A). There 
was no evidence in any of the datasets analysed that low BNC1 expression correlated 
with poor relapse free survival or any other clinical indicator (Figure 6.6C). The 
survival curves associated with BNC1, CCDC8 and GALNT9 in different datasets are 
given in appendix D2.  
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Figure 6.6: Loss of expression of CCDC8 and GALNT9 correlates with relapse-free 
patient survival. Kaplan-Meier analysis of multiple gene expression studies via the 
prognoscan database revealed that in two separate studies, low expression of (A) 
GALNT9'
A 
CCDC8'
B 
BNC1'
C 
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GALNT9 (p=0.003) and (B) CCDC8 (p=0.001) is associated with poor relapse free 
survival. In contrast to our findings, (C) expression of BNC1 is associated with 
relapse-free survival of patients.  
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6.3 Discussion 
 
Metastasis to the brain is an increasingly common event in the progression of breast 
cancer. Given the extremely poor clinical outcome following a diagnosis of BBM 
(Sperduto et al., 2010), it is imperative that the underlying molecular biology that drives 
tumour evolution to the colonization of the brain is revealed. An improved 
understanding of these events will identify novel therapeutic targets and prognostic 
markers. 
 
To date some progress has been made to identify prognostic markers for breast cancer 
metastasis by gene expression profiling (Paik et al., 2004) (See section 1.6.5). However, 
prediction of site specific-metastasis and a late recurrence, a common feature of BBM, 
or indeed any site-specific recurrence has proven difficult to predict (Weigelt et al., 
2005; Burstein & Griggs, 2012) (see section 1.6.5). 
As described in section 4.2, it is possible that those genes infrequently methylated in 
primary breast tumours and frequently methylated in BBM samples may be involved in 
BBM. In this regard, loss of CCDC8 expression (CCDC8 is commonly methylated both 
in primary tumours and BBMs in the same patient) may provide an advantage to 
primary tumours; contributing to invasion into and to proliferation within the brain (an 
early event). Similarly, BNC1 and GALNT9 are unmethylated in primary tumours and 
frequently methylated in BBM samples from the same patient. Loss of expression of 
these genes may provide survival advantages to tumour cells in the brain (late events).  
Our functional analyses included in vitro models to assess migratory and invasive 
potential of these genes in breast cancer cell lines. Our wound healing assays on 
respective breast cancer cell lines knocked-down with BNC1, CCDC8 or GALNT9 
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showed that these genes increase the migratory potential of the cells significantly 
compared to control cell lines (figure 6.3). Similarly, invasion assays of respective 
breast cancer cell lines knocked down with BNC1, CCDC8 or GALNT9 showed 
significant increases in invasive potential (Figure 6.4).  
 
Kaplan-Meier (K-M) analysis using the Prognoscan databases has been used to 
investigate the survival curves i.e. overall survival (OS) and disease free survival (DFS) 
of the patients due to the downregulation of BNC1, CCDC8 or GALNT9. OS i.e. the 
time a patient survives after certain date of event such as surgery or a particular 
treatment with/out any disease or disease recurrence (Chua, 2005) or RFS i.e the time a 
patient survives without having any disease or a disease recurrence (after the disease has 
been fully removed by a surgery and treated with adjuvant therapy) (Chua, 2005) are 
caulcated using K-M analysis. DFS is generally calculated in every three years, which 
then serves as a secondary point for OS, which is calculated in five years durations if 
patients alive.  Kaplan-Meier analyses demonstrated that low CCDC8 and GALNT9 
expression was significantly associated with poor relapse free survival of the patients. 
This implies that downregulation or silencing of these two genes contributes to disease 
recurrence or the expression of these two genes is important to suppress the chances of 
tumours to recur. In contrast to our findings, there was no evidence that low BNC1 
expression correlated with poor relapse free survival or any other clinical indicator.  
 
Basonuclin 1 (BNC1) is a zinc finger transcription factor that interacts with the 
promoters of both RNA polymerases II and I (Zhang et al., 2007). BNC1 target genes 
have been implicated in a broad range of functions (Ma et al., 2006; Wang et al., 2006; 
Zhang et al., 2007). BNC1 knockdown in mouse oocytes shows that BNC1 may be 
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necessary for embryogenesis and oogenesis (Ma et al., 2006; Vanhoutteghem et al., 
2009) (see section 4.3 for details of BNC1 functions). 
 
Analysis of HumanMethylation 27K and 450K array data from TCGA indicates that 
BNC1 Promoter methylation is an infrequent event in both metastatic and non-
metastatic primary breast tumours (TCGA, 2012) (Section 5.3.1). Expression of BNC1 
is induced by transforming growth factor-β1 (TGFβ1) signalling and, in turn, it acts as a 
transcription factor for a number of modulators of epithelial dedifferentiation during the 
process of EMT (Feuerborn et al., 2014) (Section 4.3). BNC1 may be a component of a 
network of transcription factors that influences epithelial cell plasticity as well as TGF-
β1 signaling and its silencing may contribute to EMT influencing invasion and 
metastasis (Feuerborn et al., 2014). These findings suggest that the expression of BNC1 
would enhance the process of metastasis via EMT. Our findings are consistent with this; 
we find that BNC1 is infrequently methylated in primary breast tumours (17%) and 
frequently methylated and silenced in BBMs (73%). In addition, we have shown that 
BNC1 promoter methylation is a late event in tumour evolution, only occurring in the 
brain metastasis of a BBM patient and not in the associated primary tumour. It is 
plausible that BNC1 expression is commonly required for EMT to occur during 
metastasis and, once these cells have metastasised to the brain, loss of BNC1 expression 
contributes to Mesenchymal to epithelial transition (MET).  
It is important to note that the BNC1 overexpression did not exhibit any differences in 
migration and invasion when it was transfected in pancreatic cell line (Yi et al., 2013). 
According to our findings, BNC1 silencing is a late event during the process BBM. This 
implies that BNC1 contributes to survival of metastasized tumours to the brain. Our in 
vitro wound healing and invasion assays have shown that BNC1 knockdown with RNAi 
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significantly increased the migratory and invasive potential of breast cancer cell lines. 
This suggests that the BNC1 downregulation or silencing may contribute to metastasis 
of breast tumours to other distant sites than the brain, however, in BBM, dysregulation 
of BNC1 occurs late, its dysregulation may be an important factor for tumour cells to 
survive against the selective pressure of the brain microenvironment. In addition, BNC1 
silencing may contribute to local invasion of the tumours inside the brain.  
 
CCDC8 encodes a coiled-coil domain containing protein (CCDC8) that is one of three 
proteins that are, mutually exclusively, mutated in patients with 3M-syndrome (Hanson 
et al., 2011). (Hanson et al., 2011) (Section 4.3). It has been shown that loss of any 3M 
complex protein significantly altered the interphase microtubule network (Yan et al., 
2014). The core 3M-protein complex interacts with CUL9, which has been proposed to 
mediate the functions of the 3M-complex via the ubiquitylation and degradation of 
survivin (Li et al., 2014). The 3M-complex also interacts with the F box protein 
FBXW8, ROC1 and the tumour suppressor p53 (Yan et al., 2014) suggesting it may 
contribute to correct cellular physiology through multiple mechanisms. Taken together, 
these discoveries suggest that CCDC8 downregulation or silencing contributes to 
microtubule damage suggesting its role on microtubule integrity (Yan et al., 2014). 
Microtubules are an important cytoskeleton component that is crucial for spindle fibres 
formation and cytokinesis during mitosis (Yan et al., 2014). Our findings have shown 
that the downregulation or silencing of CCDC8 increases the metastatic (migratory and 
invasive) potential of the cells, which could possible that the silencing of CCDC8 may 
disintegrate microtubule giving an advantage to cancer cells to migrate and invade 
through ECM   contributing to metastases.   
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CCDC8 interacts with Tip60, a protein required for acetylation of p53 and promotes 
p53 acetylation thereby increasing p53 mediated apoptotic response (Dai et al., 2011). 
Therefore, CCDC8 is required specifically in p53 mediated apoptotic process following 
DNA damage and its downregulation reduces the apoptotic response mediated by p53 
(Murray et al., 2013).  It is possible that a decreased apoptotic response mediated by 
P53 due to CCDC8 silencing may influence cellular physiology giving selective 
advantage to cancer cells contributing to their capacity to proliferate and to invade the 
tissue promoting metastases. 
 
GALNT9 encodes a member of the UDP-N-acetyl-α-D-galactosamine:polypeptide N- 
acetylgalactosaminyltransferase family of enzymes that catalyze the first step of O-
glycosylation; GALNAC-T9 (Toba et al., 2000). The first step of mucin type O linked 
glycosylation is the transfer of a α-N-acetylgalactosamine (GalNAc) residue to the 
hydroxyl group of Ser or Thr in target protein in the golgi apparatus (Hanisch, 2001; 
Peng, 2010). GALNT9 is expressed most abundantly in the brain and other CNS tissues. 
It is also expressed, at lower levels, in a number of other tissues including normal breast 
(Safran et al., 2010). 
 
O-Glycans play an important role in cell adhesion and cell-cell communication and 
dysregulated glycosylation is a common characteristic of tumour cells (Brockhausen, 
2006). Mucin 1 (MUC1), in particular, has been identified as a highly O-glycosylated 
transmembrane protein that is dysregulated at the expression and post-translational level 
in multiple tumour types (Brockhausen, 2006). MUC1 is commonly overexpressed but 
under-glycosylated in primary breast tumours (Hayes et al., 1991; Perey et al., 1992) 
and the expression of under-glycosylated MUC1 is associated with high tumour grade, 
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metastatic potential and invasiveness of breast tumours (de Roos et al., 2007; van der 
Vegt et al., 2007; Ghosh et al., 2013) (Section 5.3). 
GALNT9 is a member of a sub family (with GALNT8, 18 and 19) that differ 
significantly in sequence from other GALNAC-T members (Raman et al., 2012) and as 
such does not have catalytic activity towards classic MUC1 variants derivatives 
(MUC1/A, MUC5AC or mono-GalNAc/Thr7thEA2) (Li et al., 2012). Moreover, 
GALNT9 is capable of transferring GalNAc to a very specific subset of synthetic 
peptides (see details on section 5.3) (Zhang et al., 2003). These findings suggest 
GALNT9 glycosylates a very specific group of substrates and this may indicate a subtle 
regulation of transmembrane protein function. Our findings of GALNT9 promoter 
methylation, and associated loss of expression in BBM, but not in primary breast 
tumours suggest that this proposed subtle change in transmembrane protein function 
may be a common occurrence in the later stages of the evolution of breast tumour brain 
metastasis. Hence, changes in simple mucin type-O-glycans could give an advantage to 
metastasised tumour cells to differentiate and to proliferate into a macrometastases.  
This is the first time that GALNT9 has been shown to be dysregulated in cancer by 
promoter methylation. However, conserved mutations have been identified in 
approximately 2% of microsatellite instable colorectal cancers (Tuupanen et al., 2014) 
and GALNT9 is also mutated, infrequently (<1%), in astrocytoma (Brennan et al., 2013) 
and lung tumours (Cancer Genome Atlas Research, 2012; Cancer Genome Atlas 
Research, 2014) and infrequently lost through CNV in breast tumours (Cancer Genome 
Atlas Research, 2012; TCGA, 2012). 
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6.4 Conclusion 
 
Our functional analyses to investigate the role of BNC1, CCDC8 and GALNT9 in BBM 
presented here, indicate that silencing of these in breast tumours may contribute to 
metastasis to the brain and possibly other distant organs. There was a significant 
increase in cell motility and invasiveness following knockdown of BNC1, CCDC8, and 
GALNT9 in breast cancer cell lines.  Downregulation of CCDC8 and GALNT9 is 
associated with poor relapse-free survival of breast cancer patients. Further studies will 
be required to determine if epigenetic changes/dysregulation of these genes are 
detectable in circulating tumour cells, micrometastases, in other reservoir sites or only 
in macroscopic brain metastases. Further functional assessment should be carried out on 
these genes to understand the cellular function and their specific roles on metastases. 
However, our current level of knowledge about these genes suggests that their 
dysregulation is functionally significant and may provide useful prognostic markers for 
BBM and be novel therapeutic targets.     
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CHAPTER 7 
Genome-wide 450K methylation analyses to identify genes 
dysregulated in BBM 
 
7.1 Introduction 
 
One of the keys to identifying prognostic markers specific to BBM is to identify genes 
that are uniquely dysregulated in breast tumours metastasising to the brain. These 
dysregulated genes may either be metastatic promoter genes or be metastatic suppressor 
genes contributing to BBM. The metastatic suppressor genes are infrequently 
methylated or unmethylated in primary breast tumours and frequently methylated in 
BBM whereas the metastatic promoter genes are expected to be frequently methylated 
in primary breast tumours and are subsequently demethylated or hypomethylated in 
BBM. In both cases, the differential methylation of genes may be attained by 
comparison of the methylation status of the genes in primary breast tumours and BBM 
samples.   
 
Our previous strategies in screening genes included identifying genes which were 
methylated in one of the tumour types that readily metastasised to the brain (section 4) 
or to identify those probes (individual CpG sites), that are differentially methylated 
between primary breast and lung tumours by statistical analyses of the 450K 
methylation data from the TCGA (section 5). Those genes that met the criteria were 
experimentally validated in BBM samples and unrelated primary tumours from the 
patients.  
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Only 2% of the human genome consists of protein coding regions. Very little 
information is currently available on the role of non-coding and regulatory regions in 
cancer (Weinhold et al., 2014). It is crucial to explore the non-coding component of the 
cancer genome to identify regulatory regions and other novel targets to improve 
prognosis and clinical outcomes (Weinhold et al., 2014).  
 
To overcome the limitations of candidate gene approaches, we carried out genome-wide 
screening of methylation status in BBM. We used 24 BBM samples from the patients to 
carry out Infinium BeadChip 450K methylation array, which is one of the most accurate, 
comprehensive and highly reproducible technologies available today (Dedeurwaerder et 
al., 2011; Fortin et al., 2014). 450K methylation array takes an account of the CpGs 
located both in CpG-rich islands as well as in non CpG-rich sites (Zhang et al., 2012). 
This technology makes it possible to map individual probes (CpG dinucleotides) with 
differential methylation levels (Bibikova et al., 2009) in primary tumours and BBM. 
This analysis allows both the identification of CpG hypermethylation of candidate 
tumour/metastasis suppressor genes and CpG hypomethylation of candidate proto-
oncogenes/metastasis promoting genes in BBM (Dedeurwaerder et al., 2011).   
  
7.2 Results:  
 
7.2.1. Normalisation of the TCGA data sets  
Before comparing the normal breast tissues, primary breast tumours and BBM samples 
at a genome wide level, normalization of the TCGA methylation data was carried (in the 
same manner as our metastatic tumour data was normalized) out to avoid unwanted 
differences (Fortin et al., 2014) in the array data sets. Normalisation was carried out Dr. 
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David Huen, a bioinformatics lecturer at School of Biology, Chemistry and Forensic 
Sciences, Faculty of Science of Engineering, University of Wolverhampton.  
 
7.2.2. Statistical analyses of the 450K-methylation data to identify genes 
differentially methylated in normal breast tissues and primary breast tumours, 
and BBM samples 
Genome wide 450K methylation data from the TCGA was downloaded for 14 normal 
breast tissues (all that were available) and 20 primary breast tumours (see appendix E1 
for TCGA barcoded identifiers). After the normalization for these data was carried out 
(see section 7.2.1), two independent approaches were used to identify the probes, which 
were differentially methylated between the primary breast tumours and BBM samples. 
As a first approach, an average of the beta value of each probe in all the samples was 
calculated in primary breast tumours and in BBM. Those probes, which had a mean 
differential methylation between primary tumours and BBM, were identified. This 
approach identified 56 genes, of these only 29 genes had differentially methylated 
probes in their promoter region (Appendix E2). Genes where methylated probes were 
not in promoter regions were discarded from further analysis. Of 29 genes, only 9 genes 
consisted significant level of differences in their beta values between primary tumours 
and BBM. These genes are:  HSPB9, MIR1179, LOC154872, EDARADD, DDX52, 
RNF8, SOX5, RBM23 and LMX1B (table 7.1). However, two of these genes i.e. 
MIR1179 and LOC15472 did not have well-defined upstream CpG islands. Therefore, it 
was decided not to carry these two genes forward in the analysis. The methylation status 
of the remaining 7 genes (HSPB9, EDARADD, DDX52, RNF8, SOX5, RBM23 and 
LMX1B) was determined in 15 BBM samples. Only one gene, HSPB9 was frequently 
methylated  (86%) in BBM samples, and none of the other six genes were methylated in 
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any of the BBM samples (table 7.2, Figure 7.1A). Therefore, only HSPB9 was carried 
forward to determine its methylation status in an unrelated cohort of 20 primary breast 
tumours. However, HSPB9 was also frequently methylated (89%) in primary tumours 
(Table 7.2, figure 7.1B). Taken together, none of the genes from the first approach were 
significantly differentially methylated.  
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Table 7.1: Genes identified from the 450K-methylation data analyses based on 
mean β value of all the samples. 
 
Table 7.1: 450K methylation data of the BBM samples and primary tumours from 
the TCGA was analysed to identify probes having differential methylation status 
in BBM compared to primary breast tumours. The mean β value of all the samples 
for each probe was used as a basis to find the differences in the methylation in 
primary and BBM samples. This analysis resulted in 56 probes (genes), of which 
29 probes were located in the promoter regions of the respective gene (appendix 
E2). Only 7 of these probes (genes) were selected based on the differences in the β 
value (greater than 0.25), and the presence of well-defined CpG Island for 
experimental validation of methylation status of these genes using CoBRA (Note, 
β-values have been renormalized for comparison and thus do not sit within the 
range of 0-1).  
 
Gene$Symbol Entrez'ID Chromosome Mean'(β'value)'BBM
Mean'(β'value)'
primary'tumours
Difference
HSPB9 94086 chr17 2.029788864 0.0868493 2.130872037
DDX52 11056 chr17 1.525909178 0.417176197 1.118207247
EDARADD 128178 chr1 0.422072021 0.726856306 1.192213701
RNF8 157360 chr6 0.822653313 0.524739581 0.297913731
SOX5 281485 chr12 0.837062213 0.556376304 0.28068591
RBM23 311885 chr14 0.818144254 0.538907402 0.279236851
LMX1B 224781 chr9 0.826886808 0.54627828 0.280608528
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Table 7.2:  Methylation status of the genes in BBM and in a cohort of unrelated primary breast tumour samples  
 
Table 7.2: Promoter methylation status of seven candidate genes in a cohort of BBM and unrelated primary breast tumour samples. 
These genes were identified from the 450K-methylation array data analysis based on the differences between mean methylation (β 
value) in BBM compared to primary breast tumours from the TCGA. 15 BBM samples were used to investigate the methylation 
BM1 BM2 BM3 BM4 BM5 BM6 BM7 BM8 BM9 BM10 BM11 BM12 BM13 BM14 BM15
HSPB9
86
DDX52
0
EDARADD
0
SOX5
0
RBM23
0
RNF8
0
LMX1B
0
BP136 BP137 BP138 BP139 BP140 BP141 BP142 BP143 BP144 BP145 BP146 BP147 BP148 BP149 BP150 BP151 BP153 BP167 BP170
HSPB9 89
Gene
Methylation8status8of8HSPB98in8a8cohort8of8unrelated8primary8breast8tumour8samples8(n=19)
%8Meth8
(n=19))
Gene
Breast8to8Brain8metastases8(BBM)8samples8(n=15)
%8Meth8
(n=15)
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status of these genes using CoBRA. Only HSPB9 was frequently methylated in these BBM samples (86%), which was further 
analysed in primary tumours and found to be methylated in 89% of the primary tumours. Red: Methylated samples, Green: 
Unmethylated samples. 
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Figure 7.1: Methylation status of HSPB9 in BBM (A), and in unrelated primary tumours (B). HSPB9 is methylated in 12/14 (85%) 
in BBM samples and 2/17 (89%) i.e. it is methylated frequently both in BBM and primary breast tumours. Promoter region 
methylation was carried out using Combined Bisulphite and Restriction Analysis (CoBRA). Sam DNA: fully methylated positive 
control, BM: Brain metastases, BP: Primary breast tumours, U: Uncut/control sample, C: cut by restriction enzyme,  *: methylated 
samples.   
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For the second approach, methylation status (β value) for each probe in all samples 
(normal breast tissues, primary breast tumours and the BBM) was generated. 
Comparison was carried out taking account of each probe in individual samples to 
determine the frequency of methylation in normal breast, primary breast tumours and 
the BBM sample. For each probe a β value of 0.4 was considered as the cut off value, so 
that a β value of >0.4 was considered as methylated whereas a β value <0.4 was 
considered as unmethylated (figure 7.2). This approach generated a list of 78 probes 
located in promoter regions of the genes that corresponded to 49 genes, of which, 27 
probes (15 genes) were hypermethylated (increased level of methylation) in BBM 
samples compared to normal tissues and primary tumours whereas 56 probes (38) genes 
were hypomethylated (decreased level of methylation) in BBM samples compared to 
normal tissues and primary tumours (Figure 7.2). In addition to the list of probes located 
in promoter region of a gene, another list of differentially methylated probes were 
generated which also included probes both in promoter regions and in other regions of 
the gene such as gene body and 3’UTR in order to identify probes located other than in 
the promoter region of the genes (which could represent regulatory elements). This 
approach generated another list of probes, which are located in other genomic regions 
other than gene promoters. Not surprisingly, many of the probes were common in both 
the lists (as second list included probes in both promoter as well as other regions of a 
gene), therefore, only those probes which are not common with the probes in the 
promoter region and have a significant variations in methylation status (β value) were 
selected i.e. 7 probes (5 genes), of which 6 probes (4 genes) were hypermethylated 
whereas one probe (one gene) was hypomethylated. Therefore, this approach generated 
a long list of 85 probes (54 genes) in total, which are given in appendix E3. However, 
many of these probes (genes) did not have a significant difference in their methylation 
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status (β value) in BBM compared to primary tumours and normal tissues. Only 18 
hypermethylated probes showed a significant difference (β value) in BBM compared to 
normal breast tissues and primary breast tissues, which were selected for experimental 
analyses (table 7.3, figure 7.3). Similarly, of 56 hypomethylated probes (38 genes), 16 
probes (13 genes) showed significant variation in methylation status in normal tissues 
primary tumours compared to BBM samples.  These probes were selected for laboratory 
analyses (Table 7.4 figure 7.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 218 
 
Figure 7.2: Analyses of the 450K-methylation array data identified two classes of genes dysregulated in BBM. A) Metastatic suppressor 
genes which are frequently methylated (β value ≥0.4 in ≥40% of the tumours) in BBM samples compared to normal breast tissues and 
primary breast tumours and B) Metastatic promoter genes which are infrequently methylated (β value < 0.4 in <40%) in BBM samples 
compared to normal breast tissues and primary breast tumours.  The methylation data for the normal breast tissues and the primary 
breast tumours was downloaded from the TCGA where as the 450K-methylation array for BBM was carried out using 24 BBM sample.
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Table 7.3: The list of probes selected for laboratory analyses, which were 
hypermethylated in BBM samples compared to normal breast tissues and 
primary breast tumours 
 
Table 7.3: The list of probers (genes) hypermethylated in BBM samples 
compared to normal breast tissues and primary breast tumours, which were 
selected for laboratory analyses for their methylation status. Methylation status 
of these genes was determined using CoBRA.  Probes, which are located in 
regions other than the promoter of the gene, are shaded grey. 
 
 
cg16736018 ENSG00000237588 RP11$66D17.3 chr1
cg01882471 ENSG00000239795 AC109826.2 chr2
cg158854301 ENSG00000250020 RP11$811I15.1 chr5
cg21532408 ENSG00000134864 A2LD1 chr13
cg126085651
cg05529816
77cg14275842
7cg07834574
7cg09036188
cg14482741
7cg20814095
77cg21071097
cg089570691 ENSG000002211911 AL662890.1 chr6
cg045597791 ENSG000002078161 MIR124−27 chr8
cg2077124011
cg06769296
cg227717591
cg175370731
ENSG00000205710 C17orf107 chr17
ENSG000002546481 RP11$713P17.4 chr11
ENSG000002346271 NUS1P37 chr13
Probes Ensembl+Gene+ID Gene Chomosome
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Table 7.4: The list of probes selected for laboratory analyses, which were 
hypomethylated in BBM samples compared to normal breast tissues and primary 
breast tumours 
 
Table 7.4: The list of probers (genes) hypomethylated in BBM samples compared 
to normal breast tissues and primary breast tumours, which are selected for 
laboratory analyses for their methylation status. Methylation status of these genes 
was determined using CoBRA. Probes, which are located in regions other than the 
promoter of the gene, are shaded grey. 
 
cg25066665' ENSG00000163125' RPRD2% chr1
cg26362491
cg00659878
cg12720965' ENSG00000232192' Unknown chr1
cg26563141 ENSG00000229604 MT−ATP8 chr2
cg13231117 ENSG00000229689' AC009237.8 chr2
cg27612889 ENSG00000138386 NAB1 chr2
cg12494166 ENSG00000251129 RP11C734I18.1 chr4
cg21771528'
cg21806580'
cg23311108' ENSG00000185641' Unknown chr5
cg12949141' ENSG00000249119 MTND6P4 chr5
cg24232869' ENSG00000226138' SENP1/SUMO1 chr12
cg09923107'
cg00494337'
cg23454038' ENSG00000247993' FOXD1 chr5
ENSG00000248693' CTDC2023M8.1 chr5
ENSG00000264395 MIR3193% chr20
ENSG00000229367 HMGN2P19 chr1
Probes Ensembl+Gene+ID Gene Chomosome
!cg16736018)(RP11$66D17.3*))A) cg04559779)(MIR12402)))B)
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Figure 7.3: Representative examples of the probes, which are frequently methylated in BBM samples compared to normal breast 
tissues and primary breast tumours. This class of genes are the potential metastatic suppressor genes with increased level of 
methylation (hypermethylated) in BBM samples i.e. A) cg16736018 that corresponds to a non-protein coding gene RP1166D17.3, 
and B) cg207711240 and 06761296, both of which correspond to a non-protein coding gene RP11-713.4. The upper panel shows the 
β value of a probe in each individual sample whereas the lower panel shows the distribution of the probes based on the β value.  
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cg21771528(cg21806580((CTD$2023M8.1()(A( cg12949141(((MTND6P4!)((B(
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Figure 7.4: Representative examples of the probes, which are infrequently methylated in BBM samples compared to normal breast 
tissues and primary breast tumours. This class of genes are the potential metastatic promoter genes with decreased level of 
methylation (hypomethylated) in BBM samples i.e. A) cg21771528 and cg21806580 both of correspond to a non protein coding gene 
CTD-2023M8.1 and B) cg12949141 that corresponds to a pseudogene of MTND6 (MTND6P4) gene. The upper panel shows the β 
value of a probe in each individual sample whereas the lower panel shows the distribution of the probes based on the β value. The 
lower panel for gene ‘A’ looks different due to presence two probes in the same region. 
 
 
 
 
 
 
 
 
 
 
7.2.3 Validation of candidate Hypomethylated probes in BBM samples 
 
As an initial screening method, only those probe hypomethylated (infrequently 
methylated) in BBM were validated in laboratory using CoBRA. There were 16 
probes (13 genes) that the methylation array analysis identified as significantly 
hypomethylated in BBM samples compared to normal breast tissues and primary 
breast tumours. These included one probe located in regions other than the promoter. 
A cohort of 15 BBM samples were used for initial validation to determine if these 
genes were infrequently methylated in the BBM samples analysed. From the panel of 
13 genes analysed (including one probe hypermethylated), three genes (table 7.5) 
were infrequently methylated (≤40%) in BBM samples i.e. MIR3193 (30%) and CTD-
2023M8.1 (20%) and FOXD1 (20%). Moreover, one gene MTND6P4 (Figure 7.6) 
was not methylated in any of the BBM samples. These four genes were further 
validated in a cohort of 20 unrelated primary breast tumours (with no evidence of 
distant metastasis) to determine if they are frequently methylated (≥45%) (see section 
7.2.4).  
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Table 7.5: Methylation status of candidate genes BBM 
 
Table 7.5: Methylation status of array analysis candidate genes in BBM as 
determined by CoBRA. Of 14 genes analysed in an initial cohort of 15 BBM 
samples (A), seven genes (shaded in grey) were hypomethylated or 
hypermethylated (differentially methylated) in BBM compared to primary 
tumours. The methylation status of the other eight genes was the same in BBM and 
primary tumours. The seven differentially methylated genes were further 
investigated for their methylation status in a second cohort of 16 BBM samples 
(total of 31 BBM samples) (B). Red: methylated samples, Green: unmethylated 
samples, White: tumour samples did not show any product during CoBRA PCR.  
 
 
 
A)#
BM1 BM2 BM3 BM4 BM5 BM6 BM7 BM8 BM9 BM10 BM11 BM12 BM13 BM14 BM15
cg04559779 mir124'2 93
cg06769296++cg20771240 RP11'713P17.4 55
cg17537073+ NUS1P3 40
cg09923107+cg00494337+ MIR31933 33
cg21771528++++cg21806580+ CTD'2023M8.1 20
cg12949141+ MTND6P4 0
cg23454038 FOXD1 33
cg12608565+cg05529816++
cg14275842+cg07834574 C17ORF107 35
cg16736018 RP11'66D17.3 67
cg21532408 AL2D1 100
cg26362491+cg00659878 HMGN2P19 100
cg12494166 RP11'734118.1 100
cg15585430 RP11'811115.1 90
cg24232869 SENP1/SUMO1 100
cg08957069+ AL662890.1 100
BM16 BM17 BM18 BM19 BM20 BM21 BM22 BM23 BM24 BM25 BM26 BM27 BM28 BM29 BM30 BM31
cg04559779 mir124'2 88
cg06769296++cg20771240 RP11'713P17.4 73
cg09923107+cg00494337+ MIR31933 30
cg21771528+ CTD'2023M8.1 26
cg12949141+ MTND6P4 0
cg23454038 FOXD1 29
Gene
#Breast#to#Brain#metastases#(BBM)#samples#(n=15)
%#Meth#
(n=15)
Probe
Probe Gene
Second#cohort#of#BBM#samples#(n=16)
%#Meth#
(n=31)
B)#
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7.2.4 Validation of candidate Hypermethylated of probes in a cohort of unrelated 
primary breast tumours 
 
There were 18 probes (9 genes) hypermethylated in BBM compared to normal breast 
tissues and primary tumours, including 6 probes (4 genes) that were located in regions 
other than the promoter of the gene. These genes showed higher level of methylation 
(higher β value) in BBM samples, therefore, these genes were initially validated in an 
unrelated cohort of 20 primary breast tumours to investigate if they were infrequently 
methylated in primary tumours. Of 18 probes (9 genes), only three genes RP11-
713P17.4, MIR124-2, NUS1P3 (Figure 7.5) were infrequently methylated in primary 
tumours. These genes were further validated in a cohort of 15 BBM samples (see 
section 7.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 7.6: Methylation status the candidate genes in a cohort of unrelated primary tumours 
 
A)#
BP136 BP137 BP138 BP139 BP140 BP141 BP142 BP143 BP144 BP145 BP146 BP147 BP148 BP149 BP150 BP151 BP153 BP167 BP170
cg12608565)cg05529816))
cg14275842)cg07834574
C17ORF07
cg26362491)cg00659878
HMGN2P19
100
cg27612889
NAB1
100
cg21532408
AL2D1 100
cg12494166 RP113734I18.1
100
B)#
BP137 BP138 BP139 BP140 BP141 BP142 BP143 BP146 BP147 BP150 BP151 BP153 BP167 BP170 BP175 BP176 BP178 BP179 BP180
cg04559779 mir12432 54
cg06769296))cg20771240 RP113713P17.4 11
cg17537073) NUS1P3 7
cg23454038 FOXD1 67
C)
BP152 BP154 BP155 BP156 BP157 BP158 BP159 BP160 BP161 BP162 BP163 BP164 BP165 BP168 BP169 BP171 BP172 BP173 BP174
cg09923107)cg00494337) MIR3193? 84
cg21771528) CTD32023M8.1 63
cg12949141) MTND6P4 47
%#Meth#
(n=19)
GeneProbe
Methylation#Status#of#genes#in#a#cohort#of#unrelated#primary#breast#tumours#(n=19)
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Table 7.6: Methylation status of candidate genes in a cohort of non-metastatic unrelated primary tumours to identify if they are 
frequently or infrequently methylated in these tumours.  Seven genes (B, C) are differentially methylated in primary and BBM 
samples. FOXD1 (B), MIR3193, CTD-2023M8.1 and MTND6P4 (C) are frequently methylated in primary tumours and are 
infrequently methylated in BBM samples (see table 7.5 A, C). Similarly, NUS1P3 and RP11-713P17.4  (B) are infrequently 
methylated primary tumours and are frequently methylated in BBM samples (see table 7.5A, C). MIR124-2 (B) is frequently 
methylated both in primary tumours and in BBM (see table 7.5 A, C), however, the frequency of methylation of this gene is much 
higher in BBM samples (100%) compared to primary tumours (54%), which is statistically significant p=0.03). Five genes (A) are 
frequently methylated both in primary breast tumours and in BBM. Red: methylated samples, Green: unmethylated samples, 
White: tumour samples did not show any product during CoBRA PCR.  
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Figure 7.5: Methylation status of potential candidate metastatic suppressor genes 
in BBM versus unrelated primary tumours. MIR124-2 (A, B), RP11-713P17.4 (C, 
D) and NUS1P3 (E, F) are enriched in methylation in BBM samples compared to 
unrelated primary breast tumours. RP11-713P17.4 is frequently methylated in 
BBM (55%) and is infrequently methylated in a cohort of unrelated primary 
breast tumours (11%). MIR12-2 is frequently methylated in BBM  (93%) and 
primary breast tumours (55%), where as NUS1P3 is infrequently methylated both 
in BBM samples (40%) and in primary breast tumours (7%) however, their 
methylation frequency is significantly higher in BBM compared to primary breast 
tumours (p=0.03 and 0.05 respectively). Sam DNA: Fully methylated positive 
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control, BM: Brain metastases, BP: Primary breast tumours, U: Uncut/control 
sample, C: cut by restriction enzyme,  *: methylated samples.  
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Figure 7.6: Methylation status of potential candidate metastatic promoter genes in 
BBM versus unrelated primary tumours. MIR3193 (A, B), CTD-2023M8.1 (C, D), 
MTND6P4 (E, F) and FOXD1 (G, H) have decreased methylation in BBM samples 
compared to unrelated primary breast tumours. MIR3193 is frequently methylated 
in unrelated primary tumours (84%) and is infrequently methylated in BBM 
(30%). CTD-2023M8.1 is frequently methylated in unrelated primary tumours 
(63%) and is infrequently methylated in BBM (20%). MTND6P4 is frequently 
methylated in unrelated primary tumours (47%) where as it is not methylated in 
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any of the BBM samples analysed. FOXD1 is frequently methylated in unrelated 
primary tumours (67%) and is infrequently methylated in BBM (33%). Sam DNA: 
fully methylated positive control, BM: Brain metastases, BP: Primary breast 
tumours, U: Uncut/control sample, C: cut by restriction enzyme,  *: methylated 
samples.   
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Taken together, seven genes differentially methylated in BBM compared to primary 
breast tumours and normal breast tissues were identified (figure 7.7), of which three 
genes (MIR124-2, RP11-713P17.4, and NUS1P3) were hypermethylated in BBM 
(candidate metastatic suppressor genes) whereas four genes (MIR3193, CTD-2023M8.1, 
MTND6P4 and FOXD1) were hypomethylated in BBM (metastatic promoter genes). 
The difference in the methylation of these genes in is statistically significant i.e. 
MIR124-2 (p=0.03), RP11-713P17.4 (p=0.0001) (p, NUS1P3 (p=0.05), MIR3193 
(p=0.01), CTD-2023M8.1 (p=0.0003), MTND6P4 (p=0.01) and MTND6P4 (p=0.0001). 
These genes were further investigated in BBM samples and their corresponding primary 
tumours in individual patients to investigate a possible point at which the epigenetic 
dysregulation occurred during the process of metastatic evolution.  
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Figure 7.7: Methylation array analysis identified seven candidate genes 
differentially methylated in BBM compared to primary breast tumours and 
normal breast tissues, of which three were candidate metastatic suppressor genes 
hypermethylated and silenced in BBM samples whereas other four are candidate 
metastatic promoter genes hypomethylated and expressed in BBM samples. The 
difference in the methylation status of these genes in BBM compared to primary 
breast tumours is statistically significant (*: p≤0.05, **: p≤0.01, ***: p≤0.001). 
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7.2.5 Methylation status of the genes in BBM samples and their corresponding 
primary breast tumours from individual patients 
 
The methylation status of the genes differentially methylated in BBM samples 
compared to normal breast tissues and the primary breast tumours were determined in 
matched pairs of tumours i.e. metastatic brain tumours and corresponding primary 
tumours from individual patients. Only 11 primary tumours were available from the 30 
BBM patients, however, some loci in the primary tumour DNA proved refractive to 
amplification for some genes. 5 of 7 genes i.e. MIR3193, FOXD1, RP11-713P14.4, 
CTD-2023M8.1 and MTND6P4 were successfully amplified in BBM and their 
corresponding primary tumours from individual patients. In the matched samples RP11-
713P17.4 is methylated in 6 of 9 BBM and is commonly methylated in 4 of 9 primary 
breast tumours from these individual patients (Figure 7.7A). Of 9 successfully amplified 
matched pairs, MIR3193 was methylated in only two of the brain metastases. However, 
it was methylated in 4 corresponding primary tumours (Figure 7.7B) Similarly, FOXD1 
was methylated in only 4 out of 11 matched BBM samples from the individual patients. 
However, it was methylated in all of the corresponding primary breast tumours (11/11) 
((Figure 7.8A). CTD-2023M8.1 was amplified in 5 matched pairs. It is methylated in 3 
of 5 matched primary tumours; however, it is not methylated in any of the BBM 
originated from these primary tumours (Figure 7.8B). MTND6P4 is amplified in 5 
matched pairs, and is not methylated in any of the primary and BBM samples from 
individual patients (Figure 7.7C).  
 
RP11-713P17.4 is methylated in 10% in unrelated primary tumours and 55% of the 
BBM. It is methylated in 67% (6/9) BBM samples and 50% (3/6) of the primary breast 
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tumours in which their corresponding BBM samples were methylated in individual 
patients (Figure 7.7A). This suggests that the methylation of RP11-713P17.4 occurs 
early in the primary tumours before the tumours metastasise to the brain and the 
methylation is detectable in most primary tumours that metastasise to the brain, 
suggesting that it may play an important role in the early stages of primary tumour 
metastasis. MIR3193 is methylated in only 3/9 (30%) of the primary breast tumours and 
22% (2/9) in BBM in individual patients, where as it is methylated in 84% (16/19) in a 
cohort of unrelated primary tumours.  This suggests that MIR3193 methylation is 
decreased (hypomethylated) in BBM compared to primary tumours and the 
hypomethylation of MIR3193 is detected in primary tumours from the individual 
patients further implying that the hypomethylation of MIR3193 is an early event in 
BBM. Similarly, MTND6P4 is methylated in 47% of unrelated primary tumours and is 
not methylated in any of the BBM samples. However, it is not methylated in any of the 
primary and BBM tumours in individual patients suggesting that the hypomethylated of 
MTND6P4 occurs early in the primary tumours before the tumours metastasise to the 
brain.  
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Figure 7.8: Methylation status (denoting early events) of RP11-713P14.4 (A), MIR3193 (B) and MTND6P4 (C) in metastatic brain 
tumours and their corresponding originating primary breast tumours from individual patients. CoBRA was used to determine the 
methylation status; small, digested PCR products in the Bstu1 cut (C) lane compared to the undigested (U) lane indicates promoter 
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methylation in a sample. RP11-713P14.4 is methylated in 6 BBM (see patient 2, 11, 12, 13, 14, 15) and all 3 corresponding primary 
tumours. One of the BBM (patient 2) has its only normal breast tissue amplified. Of 9 matched pairs analysed, MIR3193 is 
methylated in only two of its BBM samples (patient 1 and 12) i.e. it is unmethylated in 7/9 BBM samples and is unmethylated in 6/9 
corresponding primary tumours from individual patients. Interestingly, MIR3193 is methylated in patient-1 in BBM and is not 
methylated in its matched primary tumour in contrast to all other samples. MTND6P4 is not methylated in any of the BBM 
samples and their corresponding primary tumours from the individual patients. BP: Breast Primary tumour, BM: Metastatic 
Brain tumour, BN: adjacent Normal Breast tissue, U: Uncut/Control sample, C: cut by methylation specific restriction enzyme, *: 
Methylated samples, Sam DNA: fully methylated positive control.  
 
 
 
 
 
 
In contrast, FOXD1 is methylated in 67% of unrelated primary tumours and 28% of 
the BBM samples whereas it is methylated in all the primary tumours (11/11) and 
36% of the BBM (4/11) from individual patients (Figure 7.8A). This suggests that 
hypomethylation of FOXD1 occurs in the BBM at a late stage in the evolution of 
metastatic brain tumours, possibly after they have metastasised to the brain. Similarly, 
CTD-2023M8.1 is methylated in 63% in unrelated primary tumours and 20% BBM 
samples. It is methylated in 60%  (3/5) in primary tumours and none of the BBM from 
individual patients (Figure 7.8B). This suggests that the hypomethylation of these 
genes takes place at a late stage of tumour evolution in BBM. Alternatively, in these 
genes the genetic dysregulation such as hypomethylation of these genes may occur in 
a small subset of cells within the primary tumour (below the detection threshold of 
this assay) and these cells are enriched in the metastatic tumour. In summary, out of 
five genes that have been analysed in matched pairs in individual patients, 
dysregulation of three genes MIR3193, MTND6P4 and RP11-713P17.4 occurs early 
and is detectable in primary tumours (early events) where as the dysregulation of 
other two genes FOXD1 and CTD-2023M8.1 occurs late only after the primary 
tumour cells have left the primary tumours (late events).  
 
 Figure 7.9: Methylation status (denoting late events) of FOXD1 (A) and CTD-2023M8.1 (B) in metastatic brain tumours and their 
corresponding originating primary breast tumours from individual patients. CoBRA was used to determine the methylation status; 
small, digested PCR products in the Bstu1 cut (C) lane compared to the undigested (U) lane indicates promoter methylation in a sample. 
FOXD1 is methylated in all the primary tumours analysed where as it is methylated in only 4 of 11 of their corresponding BBM from the 
individual patients. Of 5 pairs analysed, CTD-2023M8.1 is not methylated in any of the BBM samples where as it is methylated in their 
corresponding primary tumours from the individual patients. BP: Breast Primary tumour, BM: Metastatic Brain tumour, BN: adjacent 
Normal Breast tissue, U: Uncut/Control sample, C: cut by methylation specific restriction enzyme, *: Methylated samples, Sam DNA: 
fully methylated positive control.  
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7.2.6 Investigating the methylation status of genes in patients’ plasma to determine 
if these genes could be used as prognostic markers for BBM 
 
The 450K-methylation array identified seven genes; MIR3193, FOXD1, MTND6P4, 
CTD-2023M8.1, RP11-713P17.4, MIR124-2 and NUS1P3 that were differentially 
methylated in BBM compared to primary tumours and normal breast tissues. Patients’ 
plasma, collected at the time of BBM surgery was used to investigate if these genes 
could be used as non-invasive prognostic markers. To investigate this, tumour-free 
circulating DNA was extracted from 10 plasma samples to carry out methylation 
specific PCR (MSP) in six of these genes (analysis of NUS1P3 was not carried out due 
to time constraints) (Table 7.7). In addition, MSP was also carried out for CCDC8, 
which was identified as a candidate by literature review (section 4). It was expected that 
the methylation status of the BBM to be similar to that of the serum as it is possible that 
the tumour-free circulating DNA in the patients’ plasma is the results of the DNA 
sloughed off from the BBM (Esteller et al., 1999; Hoque et al., 2006; Lo Nigro et al., 
2013) due to tumour-associated leaky blood brain barrier (Zhang & Yu, 2011). To 
ensure the uniformity in the methodology used, MSP was carried out on BBM samples 
corresponding to those plasma samples from the individual patients.  
 
CCDC8 was methylated in 9/10 (90%) brain metastases according to MSP in BBM 
samples. This gene is methylated in 6/9 (67%) plasma samples in these patients (Figure 
7.9A). There is a variation in methylation status of CCDC8 between BBM and plasma 
samples in three patients (BM8, BM11 and BM13). Methylation status of MIR3193 in 
50% of BBM is identical to the methylation status in serum samples (Figure 7.9B). 
Interestingly, methylation of MIR3193 was detected more frequently in plasma samples 
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(50%) compared to BBM samples. Similarly, CTD-2023M8.1 is methylated in 6/10 
BBM samples. It is methylated in those plasma samples from the patients whose BBM 
were methylated. This showed that the methylation status of CTD-2023M8.1 in BBM 
samples is identical to the methylation status of the free circulating DNA in plasma 
samples in individual patients (Figure 7.9C). RP11-713P17 was methylated in 8/10 
plasma samples with a variation of only one sample between BBM and plasma samples. 
MIR124-2 is methylated in all the BBM samples, and it is methylated in 8/10 plasma 
samples among this patients (Figure 79D). There were two patients BM12 and BM13 
that showed variations in methylation status of MIR124-2 in BBM and plasma samples. 
 
 It will be necessary to carry out MSP of circulating DNA for GALNT9, BNC1 and 
MTND6P4 to get a complete picture of the detectability of tumour methylation in all 
candidate genes in BBM and serum DNA.  
 
This analysis has shown that there is a good correlation between the methylation status 
of circulating DNA in plasma and fresh frozen BBM tumours in individual patients. 
This suggests that it might be possibility to use these genes as a panel of potential 
biomarkers for BBM with suitable quantitative methylation techniques such as QMSP.  
This analysis has furthermore identified a range of novel candidate prognostic markers. 
MIR124-2 (a tumour suppressor microRNA associated with various malignancies), 
RP11-713P17.4 (a novel noncoding RNA gene; ncRNA) and NUS1P3 (a pseudogene of 
its parental pro-apoptotic gene; NUS1) are potential metastatic suppressor genes. 
Similarly, MTN6P4 (a processed pseudogene of its parental gene mitochondrial 
encoded NADH dehydrogenase; MTND6), CTD-2023M8.1 (a novel non protein 
gene/noncoding RNA gene), MIR3193 (a novel microRNA identified by deep 
 244 
sequencing in melanoma) and FOXD1 (a member of forkhead transcriptional factors) 
are potential metastatic suppressor genes. Furthermore, three novel metastatic 
suppressor genes BNC1 (a transcriptional factor), CCDC8 (a regulator of microtubule 
dynamics) and GALNT9 (initiator of o-glycosylation) are potential metastatic 
suppressor genes  see section 4.3 and 5.3 for detailed function of these genes).  
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Table 7.7: Methylation status of candidate prognostic markers in BBM and 
tumour free circulating DNA 
 
Table 7.7: Methylation status of candidate prognostic markers in BBM and serum 
DNA determined by Methylation Specific PCR (MSP). Methylation status of panel 
of 6 candidate prognostic markers in individual patients in their BBM samples 
versus serum DNA has been determined. It is expected that the methylation status 
of each gene in BBM should be identical with the serum in each patient. The 
identity (BBM vs. serum) in methylation has been expressed in percentage for each 
patient in a panel of 6 candidate prognostic markers.  
 
 
 
 
 
 
MSP$
Mets
MSP$ser MSP$
Mets
MSP$ser MSP$
Mets
MSP$ser MSP$
Mets
MSP$ser MSP$
Mets
MSP$ser MSP$
Mets
MSP$ser
1 100
2 100
5 100
6 67
7 75
8 83
10 83
11 50
12 75
13 50
Methylation$
status$mets$vs$
serum$(%$
identity)
Patient
MIR124'2MIR3193CCDC8 CTD FOXD1 RP11
 Figure 7.10: Methylation status of candidate prognostic markers (genes) CCDC8 (A, B), MIR3193 (C, D), CTD-2023M8.1 (E, F) and 
MIR124-2 (G, H), in BBM versus tumour free serum DNA. Methylation status of BBM is similar to serum DNA in individual patients in 
majority of the samples suggesting that serum the methylation status of serum DNA could possible used as prognostic markers for BBM.  
BM: Brain Metastases, SM: Serum DNA U: USP, M: MSP, *: Methylation 
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7.3 Discussion  
 
In recent years, a wide range of epigenetic studies, especially those concerning the DNA 
methylation status of primary breast tumours have been carried out (Yuan et al., 2003; 
Huang et al., 2011; Moelans et al., 2011; Park et al., 2011; Zeng et al., 2012; Kar et al., 
2014; Shenker et al., 2015).  However, due to the poor clinical outcomes of breast 
cancer patients, there is an urgent need to understand the process of BBM and to 
identify a way of prognosis or to find novel targeted therapies (Salhia et al., 2014). Due 
to the challenges associated with the treatment of brain tumours such as drug access via 
the blood brain barrier and other related problems (Fazakas et al., 2011), it is crucial to 
find novel prognostic markers that will inform the clinical management of breast cancer 
patients.  
There are very few prognostic procedures available for BBM; however, these are 
primarily based on the various factors including ethnicity, ER/PR/HER receptor status 
and presence of germline mutations BRCA1 gene (Salhia et al., 2014). However, there 
are not many genome-wide studies carried out to find rare epigenetic determinants 
contributing to BBM.  Salhiya et al (Salhia et al., 2014) carried out copy number 
analyses, mRNA expression profiling and 27K methylation studies to find dysregulated 
gene in BBM which however, did not identify any potential prognostic biomarkers or 
key regulators that were significantly differentially dysregulated in BBM compared to 
primary tumours and normal breast tissues.  
This study aims to find dysregulated genes, by genome-wide analyses that are involved 
in the process of BBM. For this purpose, Illumina BeadChip 450K human methylation 
arrays were carried out using 24 fresh frozen samples from patients with BBM. In 
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addition, genome wide 450k methylation data for primary breast tumours and normal 
breast tissues was downloaded from the TCGA to identify differentially methylated 
probes/genes in BBM compared to normal tissues and primary tumours.  
This methylation array analyses generated a long list of 78 probes located in promoter 
regions as well as 7 probes located other than the promoter regions. Of 85 probes in 
total, only 34 probes (21 genes), showed clear differences in methylation in BBM 
compared to primary tumours and normal breast tissues. Experimental validation of 
methylation of these genes identified only 7 genes (MIR3193, FOXD1, MTND6P4, 
CTD-2023M8.1, RP11-713P17.4, MIR124-2 and NUS1P3) that were differentially 
methylated in BBM compared to primary tumours and normal breast tissues. Of these 7 
genes, RP11-713P17.4, MIR124-2 and NUS1P3 were frequently methylated in BBM, 
and infrequently methylated in primary breast tumours and normal breast tissues where 
as MIR3193, FOXD1, MTND6P4 and CTD-2023M8.1 were frequently methylated in 
normal breast tissues and primary tumours, and infrequently methylated in BBM. 
One of the important findings of this study is the identification of novel regulatory 
elements and microRNAs dysregulated in BBM. Of 7 genes identified, there were two 
microRNAs (MIR3193 and MIR124-2), four non-coding genes that included two long 
intergenic non-coding RNA (lincRNA) genes (RP11-713P17.4 and CTD-2023M8.1) 
and two non-protein coding genes or the pseudogenes (MTND6P4 and NUS1P3).  
FOXD1 codes for a protein forkhead box protein D1, a member of a family of forkhead 
transcriptional factors containing distinct forkhead domain (Ernstsson et al., 1996; 
Lancet et al., 2013). FOXD1 is identified as a mediator and indicator of gene expression 
changes during the cell reprogramming process (Koga et al., 2014). The population of 
induced pluoripotent stem cells (iPSCs) is reduced after FOXD1 is knockdown.  DAX1, 
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which is a component in autoregulatory network of maintenance of pluripotency in the 
cells is inhibited by knockdown of FOXD1, and furthermore, the iPSCs colonies are a 
result of FOXD1 expression, revealing that FOXD1 contributes to iPSCs populations for 
cell programming process (Koga et al., 2014).  It has been shown that the forkhead 
genes are associated with nervous system development, tumorigenesis as well as in gene 
expression in liver and lung tissues (Ernstsson et al., 1996). It is expressed in temporal 
regions of the developing chick retina, determining the temporal specificity of retina 
(Takahashi et al., 2009; Carreres et al., 2011). Moreover, FOXD1 is known to act as a 
transcriptional repressor of downstream gene in retinal development (Takahashi et al., 
2009).  Interestingly, co-transfection of FOXD1 with p53 has revealed that, in presence 
of p53, FOXD1 gene inhibits the transcription of genes, which otherwise would be 
activated by it in absence of p53 suggesting that FOXD1 regulation is associated with 
p53 (Ernstsson et al., 1996). In addition, co-transfection of WT-1 with p53 has produced 
similar results showing that WT-1 is regulated by p53 and a binding site for WT-1 is 
found in in FOXD1. These experiments have demonstrated that the two genes p53 and 
WT-1 regulate the FOXD1 gene (Ernstsson et al., 1996). These data are consistent with 
our findings that FOXD1 is a metastatic promoter gene silenced in normal breast tissues 
and primary breast tumours through promoter methylation. In addition, the two tumour 
suppressor genes WT-1 and p53 may provide an additional layer of control on this gene. 
FOXD1 is unmethylated in BBM and is methylated in primary tumours in the individual 
patients suggesting that the hypomethylation and expression of FOXD1 gene takes place 
only after the tumours have metastasised to the brain. FOXD1 could possibly contribute 
to the tumour survival in the brain by promoting tumour cell proliferation through 
pluoripotent stem cells (PSC) or by stimulating DAX1, which helps to maintain PSC and 
helps in cell reprogramming.  
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MIR124-2 is one of the MIR124 precursor gene located in chromosome 8 (Deo et al., 
2006; Wang et al., 2014b). There are three independent precursors of MIRNA124 gene 
i.e. MIR124-1, MIR124-2, and MIR124-3 located on chromosome 8, 8 and 20 
respectively (Conaco et al., 2006; Deo et al., 2006; Kozomara & Griffiths-Jones, 2014; 
Neo et al., 2014; Wang et al., 2014b), which are processed to form MIR124.  MIR124 is 
one of the most abundantly expressed and conserved microRNAs in the nervous system 
(Deo et al., 2006; Makeyev et al., 2007). Interestingly, expression of mir124 is specific 
to neurons and its expression level increases as nervous system develops. Moreover, 
neuronal cell differentiation is activated where as glial cell differentiation is repressed 
by MIR124. MIR124 promotes neurogenesis by down-regulating SCP1 (small C-
terminal domain phosphatase 1), which has an anti-neural function during neural 
development (Visvanathan et al., 2007). Therefore, MIR124 is involved in regulation of 
intricate nervous system network specific alternative splicing and plays a crucial role in 
progenitor cells differentiation into the mature neurons (Deo et al., 2006; Makeyev et 
al., 2007). MIR124, furthermore, down regulates non-neuronal mRNA when introduced 
into neuronal cells, suggesting its specific role in promoting neuronal and inhibiting role 
in non-neuronal cell differentiation (Makeyev et al., 2007). MIR124-2, one of the 
genomic loci of MIR124 is downregulated due to promoter hypermethylation in 
hepatocellular carcinoma (HCC) cell lines (Furuta et al., 2010). In addition, restoration 
of MIR124 in two different HCC cell lines had suppressive effects on cell proliferations 
suggesting that MIR124 supresses cell proliferations. In addition, its expression led to 
decrease in S, G2 and M cells and increase in G0-G1 cells suggesting that MIR124 
contributes to cell cycle arrest at G1-S phase checkpoint possibly due to apoptosis of 
HCC cells. (Furuta et al., 2010). Previous studies (Han et al., 2013) identified that 
MIRNA124 directly targets the 3’UTR region and supresses CD151, which is highly 
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expressed in breast cancers and is associated with TGF-β signalling. CD151 promotes 
motility of breast cancer cell lines contributing to breast cancer migration and invasion 
(Han et al., 2013). Similarly, mimic of MIR124 and knockdown of CD151 together 
leads to the inhibition of breast cancer cell lines through cell cycle arrest (Han et al., 
2013) where as MIR124 mimics alone increases breast cancer motility. Metastases of 
breast cancer cell lines to lung are diminished by knockdown of CD151 and its 
transfection increases the migration and invasion of breast cancer cell lines. In addition, 
motility of breast cancer cell lines is inhibited by overexpression of MIR124 suggesting 
that MIR124 regulates breast cancer metastases and invasion by targeting CD151 (Han 
et al., 2013). Similarly, MIR124 inhibits motility and adhesion properties of oral 
squamous cell carcinoma (OSCC) by targeting ITGB1, which is a crucial factor for 
OSCC progression and metastases (Hunt et al., 2011). Furthermore, reduced expression 
of MIR124 is associated with poor prognosis of colorectal carcinoma (CRC) and poor 
outcome of the patients (Wang et al., 2013b; Jinushi et al., 2014). In vitro and in vivo 
knockdown experiments have shown that MIR124 is expressed in microglia as well as 
the neuronal population of the normal CNS, regulates microglia quiescence restricting 
their proliferation (Ponomarev et al., 2011; Willemen, 2012) (Conaco et al., 2006; Deo 
et al., 2006; Akerblom et al., 2012) and supresses macrophages and monocytes 
differentiation into microglia, which suggests that MIR124 may be a master regulator of 
different cell types in CNS development (Ponomarev et al., 2011). All three MIR124 
genes; MIR124-1, MIR124-2 and MIR124-3 are hypermethylated and silenced in 
pancreatic adenocarcinoma (PDAC) and are associated with migration and invasion of 
PDAC (Wang et al., 2014b). MIR124 is associated with downregulation of its target 
gene RAC1 that is involved in adhesion, migration and invasion of PDAC (Wang et al., 
2014b). Similarly, stable decrease in MIR124 is shown to promote migratory and 
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invasive behaviour of the pulmonary fibroblast cells suggesting the suppressive role of 
MIR124 in migration and invasion of cancer cells (Wang et al., 2014a). Taken together, 
MIR124, which is processed from any of its three genes (MIR124-1, MIR124-2 and 
MIR124-3) is abundantly expressed in neuronal cells and glial cells contributing to glial 
cells quiescence and is involved repression of migration and invasion of various cancers 
through its target. These findings are consistent with our finding that silencing of 
MIR124-2 through promoter methylation in BBM samples may provide a selective 
advantage for metastasised tumours to survive and to proliferate in the brain. In addition, 
it’s silencing in primary breast tumours may contribute to its metastases from the breast 
to brain and other sites in the body. Moreover, it could be possible that MIR124-2 
silencing in BBM may provide a selective advantage to the tumours to proliferate in 
non-neuronal cellular environment such as amongst glial cells. It is important to note 
that methylation of MIR124-1 was higher in BBM compared to primary tumours; 
however, it was infrequently methylated both in BBM and primary breast tumours 
(section 4.2). This suggests that among the members of MIR124 genes (MIR124-1, 
MIR12-2 and MIR124-3), only MIR124-2 is significantly dysregulated in BBM due to 
promoter hypermethylation.  
 
MIR3193 is a novel microRNA molecule, which is one of the 209 micro RNAs 
identified by deep sequencing melanomas (Stark et al., 2010). There is no other 
evidence of MIR3193 dysregulation reported in any cancer types or other diseases. In 
this study, MIR3193 was frequently methylated in non-metastatic primary breast 
tumours and infrequently methylated in BBM samples. In addition, it is commonly 
unmethylated in primary breast tumours and BBM samples in individual patients 
suggesting that the demethylation/hypomethylation of MIR3193 is an early event during 
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the course of tumour evolution. It implies MIR3193 is a metastatic promoter microRNA, 
which is kept silenced in normal breast tissues or in primary breast tumours through the 
methylation. MIR3193 is hypomethylated in those subsets of cells or tumours, which 
metastasises to the brain. The hypomethylation of MIR3193 and its expression in 
primary breast tumours is an early event, which could possibly contribute to the process 
of BBM.  
 
MTND6P4 and NUS1P3 are non-coding genes or processed pseudogenes of its parental 
gene MTND6 and NUS1 respectively. MTND6, which codes for the protein 
mitochondrial encoded NADH dehydrogenase, provides a quinone binding sites of 
complex I in mitochondria in ETS (DeHaan et al., 2004) and is one of the six subunits 
(ND1-ND6) of the complex I in mitochondria (Lancet et al., 2013). Furthermore, 
activating mutations in MTND6 are associated with increase in metastatic potential in 
lung and breast cancer cell lines (Ishikawa et al., 2008). Similarly, NUS1, also known as 
NOGO-B, an isoform of NOGO gene is expressed in central and peripheral nervous 
system including lung, kidney, heart and liver as well as in other tissues (Huber, 2002; 
Schwab, 2010). In contrast to the previous studies which showed that NUS1 is a pro-
apoptotic gene (Li et al., 2001), it has been shown that the NUS1 down regulates 
epithelial markers such as E-cadherin and increases mesenchymal markers contributing 
to EMT in cervical cancer promoting invasion and metastasis (Xiao et al., 2013). In 
addition, NUS1 has been associated with cell cycle progression (Harrison et al., 2011) 
and its expression has been associated with various cancer types (Oertle et al., 2003). 
Similarly, SUN1 expression is associated with proliferation of ER/PR/HER2 positive 
breast tumours (Wang et al., 2013a).  
Previous studies (Poliseno et al., 2010) of the PTEN pseudogene, PTENP1 has revealed 
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that the PTENP1 has highly identical sequence with its ancestral gene PTEN, due to 
which both the PTEN and PTENP1 compete for their miRNA binding for their decoy in 
the cells (Poliseno et al., 2010). Therefore, increase in the expression of PTENP1 led to 
the increase in the PTEN due to increased availability of PTENP1 for miRNA binding 
(Poliseno et al., 2010). It is plausible that such regulation is common and the genes 
identified in this study mediate the regulation of their partner genes this way. 
MTND6P4 is frequently methylated in unrelated primary tumours and infrequently 
methylated in BBM samples. In addition, MTND6P4 is commonly unmethylated in 
BBM patients and their corresponding primary tumours from the individual patients. 
This suggests that MTND6P4 is switched off in the normal breast tissues due to 
methylation and is turned on due to hypomethylation in primary breast tumours. The 
hypomethylation of MTND6P4 and its expression in primary breast tumours is an early 
event, which could possibly contribute to the process of BBM. This is consistent with 
the idea that increase in the expression of MTND6P4 leads to the increase in expression 
MTND6 transcripts and proteins that in turn increases the metastatic potential of the 
primary breast cancer cells contributing to BBM. Similarly, NUS1P3 is infrequently 
methylated in primary tumours suggesting its expression, which possibly could lead to 
increased expression of NUS1. Furthermore, increased expression of NUS1 could 
possibly promote EMT in breast cancer contributing to invasion and metastases to the 
brain. It is possible that the silencing of NUS1P3 in brain lead to silencing of NUS1 
gene that contributes to Mesenchymal to Epithelial Transition (MET). Moreover, NUS1 
expression in CNS and PNS contributes to neuronal proliferation (Huber et al., 2002), 
and its silencing may provide a selective advantage to supporting cells such as glial 
cells in metastatic tumour evolution in the brain microenvironment.   
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CTD-2023M8.1 and RP11-713P17.4 are long intergenic non-coding RNA (lincRNA) 
genes. LincRNA are transcribed into RNA without any protein product and are 
correlated with open chromatic mark such as histone modification sites and epigenetic 
regulation of transcription, RNA stability, and recruitment of protein complexes 
(Marchese & Huarte, 2014; Roberts et al., 2014; O'Leary et al., 2015). These are a 
subclass of long non-coding RNA (lncRNA) with similar biological functions to 
lncRNA but differing in genomic organizations (Roberts et al., 2014). LincRNA differs 
from LncRNA mainly because lincRNAs do not overlap with the protein coding genes 
and are situated between the genes suggesting that the biological roles they played could 
be attributed to their transcript transcribed independently (Roberts et al., 2014). 
Similarly, crucial biological functions such cellular growth and differentiation, 
development and apoptosis are controlled by lincRNAs (Marchese & Huarte, 2014). A 
type of lncRNA known as HOTAIR (HOX Transcript Antisense RNA) is found to 
tumour invasion and metastasis due to epigenetic silencing in oral squamous cell 
carcinoma (Wu et al., 2015). Likewise, LncRNA microarray studies have identified 3 
potential lncRNAs associated with invasion and metastases of hepatocellular carcinoma 
(Gao et al., 2015).  
CTD-2023M8.1, a potential candidate metastatic promoter gene is methylated in 26% in 
metastatic tumours and 63% of unrelated, non-metastatic, primary tumours. It is 
methylated in 80% in matched primary tumours and none of the BBM samples in 
individual patients suggesting that the hypomethylation of CTD-2023M8.1 is a late 
event during the course of evolution of BBM that takes place only in BBM not in 
primary breast tumours. In contract, RP11-713P17.4 is methylated in 11% of the 
unrelated primary tumours and 76% of the BBM tumours. It is methylated in 30% in the 
matched primary tumours and 56% of the corresponding BBM samples in individual 
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patients suggesting that the promoter hypermethylation of RP11-713P17.4 is an early 
event during the course of BBM. These two genes, which have RNA transcripts, could 
possibly regulate genes associated with invasion and metastasis. However, their 
regulatory functions and the target genes have not been reported before. Functional 
studies are required to determine the role of these genes in BBM.  
 MSP in BBM and tumour-free circulating DNA in individual patients has shown some 
promising results. There is only a little variation in methylation status of BBM 
compared to serum DNA in individual patients. Moreover, methylation of each patient 
is identical to BBM and serum DNA in the majority of genes in a panel of six genes i.e. 
CCDC8, MIR3193, CTD2023.8, FOXD1, RP11-713P17 and MIR124-2 (Table 7.7). 
Methylation in BBM is the same as in serum DNA in patients 1, 2 and 5 in a panel of 
genes. In addition, methylation in BBM is >75% identical to serum DNA methylation in 
patients 7, 8,10 and 12. Similarly, methylation in BBM in patients 6, 11 and 13 is 67%, 
50% and 50% identical to serum DNA respectively. These findings suggest that these 
genes could be used as the basis for a panel of non-invasive prognostic biomarkers to 
predict the risk of BBM in patients with breast tumours.  
These findings merit further investigations to develop these potential biomarkers in 
clinical settings. The methylation status of this panel of genes could possibly be used 
during the time of diagnosis of primary tumours either in a serum of patients (non-
invasive method) or in primary tumours if surgery has been carried out. In cases where 
these markers show aberrations in methylation status suggesting the possibility that 
primary tumour cells have already metastasised, some adjuvant therapies such as 
demethylating agent treatment or other suitable epigenetic/genetic therapies could be 
used to prevent or to slow down the growth of the metastases. Similarly, in cases where 
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there are no aberrations in methylation of these genes at the time of diagnosis patients 
could be followed up at regular intervals to investigate the possibility of breast tumour 
metastases. 
There is a need to investigate these genes in a large number of clinical specimens. More 
primary tumours-BBM pairs from individual patients including normal tissues are 
crucial to investigate these genes. Similarly, it is important to follow up if those 
unrelated patients with primary breast tumour (a cohort of unrelated primary breast 
tumours used) developed brain metastases. A number of genes from a panel of genes, 
which were methylated both in BBM, and unrelated primary tumours from the patients 
(section 4.2 and section 7.2), could possibly have a role in breast cancer metastases to 
other secondary sites such as bone, liver and lungs. In this regard, follow up studies in 
those unrelated patients might provide further information about the genes involved in 
breast cancer metastases to other sites than the brain. 
7.4 Conclusion 
 
Analyses of Illumina HumanMethylation 450K BeadChip array on 24 BBM samples in 
comparison to the normal breast tissues and primary breast tumours from TCGA 
identified 7 genes (MIR3193, FOXD1, MTND6P4, CTD-2023M8.1, RP11-713P17.4, 
MIR124-2 and NUS1P3) dysregulated in BBM, which showed statistically significant 
differences in methylation in BBM compared to primary tumours and normal breast 
tissues.  Three of these genes (RP11-713P17.4, MIR124-2 and NUS1P3) were 
hypermethylated in BBM compared to primary breast tumours and normal breast tissues 
whereas other four genes (MIR3193, FOXD1, MTND6P4 and CTD-2023M8.1) were 
hypomethylated in BBM compared to primary breast tumours and normal breast tissues. 
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The genes identified included two microRNAs (MIR3193 and MIR124-2) and four non-
coding RNA (ncRNA) genes such as novel long intergenic non-coding RNA (lincRNA) 
genes (RP11-713P17.4 and CTD-2023M8.1) and two novel non-protein coding genes or 
the pseudogenes (MTND6P4 and NUS1P3).  This suggests that these genes are 
important regulatory elements and their epigenetic aberration (DNA methylation) 
contributes to the dysregulation in crucial steps in genetic network during evolution of 
BBM. Similarly, methylation analyses of these genes in BBM and their corresponding 
primary tumours in individual patients showed that dysregulation of RP11-713P17.4, 
MIR3193, MTND6P4 is an early event whereas dysregulation of FOXD1 and CTD-
2023M8.1 is a late event during the process of BBM. In addition, methylation analyses 
of these genes including CCDC8, BNC1 and GALNT9 (from section 4 and 5) in tumour 
free circulating DNA in patients’ plasma showed that the methylation status of serum 
DNA corresponds to BBM in individual patients suggesting that these genes could 
possibly be potential prognostic biomarkers for BBM or as therapeutic targets.  
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CHAPTER 8 
Final Discussions and Conclusions 
 
8.1 Final Discussion  
 
Cancer metastasis, an extremely complex and multistep process is attributed to 90% of 
the deaths by cancers (Valastyan & Weinberg, 2011). These multistep cascades consist 
of various layers of selective pressures to metastasising tumour cells not limited to 
migration and invasion (Spano et al., 2012). This implies that there should be a complex 
genetic and epigenetic dysregulation, which possibly contribute to the metastatic 
cascades favouring metastasising tumour cells during the process of metastatic 
evolution (Valastyan & Weinberg, 2011). Due to this complex nature of the disease, 
there is a need of preclinical studies and therapeutic intervention to control the 
metastatic process (Sleeman, 2012). However, due to the cost and other challenges 
associated with metastases such as complexity of the diseases, there is an urgent need to 
identifying and developing biomarkers to predict the early risk of cancer metastases. 
Moreover, the presence of micrometastases undetected at the time of diagnosis of 
primary tumours further intensifies an urgent need for developing biomarkers to predict 
the surviving micrometastases into the new microenvironment. There have been 
significant advances in understanding tumour biology especially in terms of primary 
tumours, however, information on primary tumours has not been adequate to make a 
decision relating to metastasis due to the differences between genetic and epigenetic 
dysregulation in primary and metastatic tumours (Guo et al., 2011).  
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The aim of this study was to identify epigenetically dysregulated genes in BBM that 
could be used as prognostic biomarkers in BBM. Breast cancer is a heterogeneous 
population of cells as a result of unstable genetic dysregulation and variations arisen as 
the tumour cell divides (Minn et al., 2005a). Therefore, it is not surprising that primary 
breast tumours, like other metastasising tumours, consist of subpopulations of cells with 
higher metastatic potential to disseminate into distant sites i.e. bone (Kang et al., 2003), 
lung (Minn et al., 2005a), brain (Guo et al., 2011), liver (Minn et al., 2005b) and 
relatively rarely to adrenal glands (Liu et al., 2010). A previous study identified a group 
of genes (IL11, CTGF, CXCR4, and MMP-1), which are overexpressed in a 
subpopulation of breast cancer cell lines (MDA-MB 231) metastasising to the bone 
(Kang et al., 2003). Similarly, Minn et. al (Minn et al., 2005a) used expression profiling 
techniques in a breast cancer cell line (MDA-MB-231) and identified 18 genes, which 
are uniquely dysregulated in breast to lung metastases. In addition, a group of genes 
were identified that provided a selective advantage to the primary breast tumours as 
well as to the metastasised tumour cells in the lung microenvironment (Minn et al., 
2005a). Furthermore, gene expression studies have identified COX2, PTGS2, HBEGF 
and ST6GALNAC5 as involved in the process of BBM (Bos et al., 2009). Frequent large 
chromosomal gains (1q, 5p, 8q, 11q, and 20q) and deletions (8p, 17p, 21p and Xq) were 
reported by Salhia et.al (Salhia et al., 2014) in BBM based on their integrated genetic 
and epigenetic (27K methylation array) studies. A number of genes overexpressed 
(ATAD2, BRAF, DERL1, DNMTRB and NEK2A) and deleted (ATM, CRYAB and 
HSPB2) were reported a study including the genes (AURKA, AURKB and FOXM1) 
enriched in cell cycle and G2/M transition pathways (Salhia et al., 2014). However, the 
identified genes were based on only comparison of unrelated primary breast tumours 
and BBM with non-neoplastic brain and breast tissues. Furthermore, analysis of BBM 
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and their corresponding primary tumours in individual patients is crucial to identify 
unique events in BBM compared to primary tumours (Salhia et al., 2014). In this regard, 
due to the limitations of the Illumina HumanMethylation 27K BeadChip array and lack 
of matched tumours from the individual patients, the study was able to identify only 
basic epigenetics and genetic events in primary breast tumours and BBM (Salhia et al., 
2014). Moreover, comparison was made between the normal brain and BBM (unrelated 
tissues), not BBM and primary breast tumours. Therefore, despite advances in breast 
cancer diagnosis and therapeutic advancements in recent years, roles of epigenetic 
determinants such as DNA methylation on breast cancer metastases to distant sites 
including the brain still remain elusive. The current common predictive methods for 
BBM include factors that increase the risk of BBM i.e. age, ethnicity, receptor ER/PR 
status, HER2 receptor status and germline mutation in the BRCA1 gene (Salhia et al., 
2014).  
 
The genetic dysregulation responsible for the BBM may be common to the genetic 
dysregulation responsible for one of the primary tumours that readily metastasises to the 
brain such as lungs, breast, melanoma and RCC (section 2.2.1, section 4.1).  Based on 
these hypotheses, a comprehensive literature review was carried out to screen genes, 
which were methylated in either lungs, melanoma, RCC but not in primary breast 
tumours. Investigation of methylation status of a long list of 78 genes in BBM identified 
two candidate metastatic suppressor genes (BNC1 and CCDC8), which were frequently 
methylated in BBM and infrequently methylated in unrelated primary tumours (section 
4).  
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Similarly, bioinformatic analyses of 450K methylation data of primary lungs and breast 
tumours from the TCGA were carried out to identify genes that may be dysregulated in 
BBM (section 5). Investigation of methylation status of 5 genes in BBM generated from 
the TCGA data analysis identified GALNT9 as a potential metastatic suppressor gene 
frequently methylated in BBM and infrequently methylated in unrelated primary breast 
tumours. 
 
Study of in vitro metastatic potential (wound healing assay and invasion assay) for 
BNC1, CCDC8 and GALNT9 in breast cancer cell lines showed that the downregulation 
of BNC1, CCDC8 and GALNT9 increases the migratory and invasive potential of MCF7, 
T47D and MDA-MB 231 respectively. 
 
Genome-wide methylation analysis identified 7 candidate genes of which, three genes 
(MIR124-2, RP11-713P14.4 and NUS1P3) are candidate tumour suppressor genes 
whereas four genes (MIR3193, MTND6P4, FOXD1 and CTD-2023M8.1) are metastatic 
promoter genes. Taken together, this entire project identified 10 candidate genes (Figure 
8.1) of which, 6 were metastatic suppressor genes (BNC1, CCDC8, GALNT9, MIR124-2, 
RP11-713P14.4 and NUS1P3) and 4 were metastatic promoter genes (MIR3193, 
MTND6P4, FOXD1 and CTD-2023M8.1). Furthermore, candidate genes identified by 
genome-wide methylation analyses includes two microRNAs (MIR3193, MIR124-2), 
two long intergenic non-coding RNAs (RP11-713P14.4, CTD-2023M8.1) and two non 
protein-coding genes (MTND6P4 and NUS1P3).  
 
 
 
 263 
 
 
 
 
Figure 8.1: A total of 10 genes (candidate prognostic markers) were identified as 
dysregulated in BBM and are differentially methylated in BBM compared to 
primary breast tumours. Six of these genes are candidate metastatic suppressor 
genes hypermethylated and silenced in BBM samples whereas four are candidate 
metastatic promoter genes hypomethylated and expressed in BBM samples. The 
difference in the methylation status of these genes in BBM compared to primary 
breast tumours is statistically significant (*: p≤0.05, **: p≤0.01, *: p≤0.001). 
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We hypothesised that epigenetic dysregulation of BBM associated genes would either 
occur as a) early events or as b) late events in tumour evolution (section 2.1). Consistent 
with our hypothesis, the genes identified in our study are either dysregulated early in the 
primary breast tumours providing selective advantage to the tumour cells to metastasise 
to the brain (CCDC8, RP11-713P14.4, MIR3193, and MTND6P4) or are dysregulated 
late in the process of BBM which, contribute to the survival of metastasize tumours in 
the brain (BNC1, GALNT9, FOXD1 and CTD-2023M8.1). It is important to note that 
both early and late methylation events appear similar in the initial analyses using 
unrelated primary tumours and BBM. However, a comparison of primary breast 
tumours and BBM from the individual patients have revealed whether specific gene 
methylation occurs early or late in the process of tumour evolution.   
 
The investigation of methylation status of the genes in tumour free circulating DNA in 
patients’ plasma using MSP was another exciting aspect of this study. Methylation 
status of a panel of 6 genes (CCDC8, MIR3193, FOXD1, CTD-2023M8.1, RP11-
713P17.4 and MIR124-2) together in BBM and in patients’ plasma was identical in up 
to 90% of cases (gene dependent) for each patient. This initial screening using patients’ 
plasma suggests that these genes could be used as a panel of prognostic biomarkers for 
BBM. However, investigation of methylation in many more serum samples is necessary 
to validate the efficacy of these genes as biomarkers in a clinical setting.  
  
In addition to the ten candidate prognostic biomarkers, this study has identified a 
number of candidate genes, which deserve further investigation to explore their roles in 
breast cancer metastases to distant organs. For instance, from the panel of 20 genes 
frequently methylated in BBM (section 4), 18 genes were frequently methylated both in 
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primary breast tumours and in BBM. In addition, there were five metastatic suppressor 
genes from the genome-wide analysis, which were frequently methylated both in 
primary tumours and BBM. It is possible that these 23 genes are silenced both in 
primary breast tumours and in BBM suggesting their role in primary tumours as well as 
in breast cancer metastases to other sites including brain. Moreover, these genes could 
possibly be passengers for BBM, and a number of them could be specific to other 
distant sites.  These genes were excluded from the further analyses due to the limitation 
of the study at this point. 
 
Nguyen et. al. (Nguyen et al., 2009) proposed the possibility of three different classes 
of genes involved in the process of metastases i.e. 1) metastasis initiator genes, 2) 
metastasis progression genes and 3) metastasis virulence genes (section 4.3.). In this 
regard, there is a possibility that these 23 genes, may fall in one of these three categories. 
It is important to note that these 23 genes primarily play a role in primary tumours and 
may be only a passenger for the metastatic process. However, frequent methylation 
status of these genes both in primary tumours and BBM merits further investigation on 
methylation of these genes in breast to lung, liver and bone metastases. Moreover, 
follow up of these patients for their breast cancer recurrence in any secondary sites and 
investigation of methylation of these genes on those sites could possibly confirm if 
these genes contribute to breast cancer metastases to any other sites of the body.  
 
Likewise, it would be worth investigating the methylation status of these 10 genes, 
(dysregulated in BBM) in breast to lung, bone or liver metastases. It is possible that the 
silencing of these genes may contribute to survival of the metastasised tumours in lungs, 
liver or bone as micrometastases. Furthermore, it may also be possible that methylation 
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of some of the genes may contribute to brain metastases in a later stage from the other 
secondary sites to which breast metastases initially had taken place. Therefore, a 
number of candidate genes dysregulated in primary and BBM also suggests that these 
genes could play an important role in one of the steps of the metastatic cascades of 
breast cancer metastases to BBM.  
 
8.2 Final Conclusions 
 
This study has identified ten candidate genes differentially methylated in BBM 
compared to primary breast tumours. These candidates were identified using three 
independent approaches i.e. broad literature review, bioinformatic analysis of TCGA 
data and genome wide 450K methylation analyses. A broad literature review identified 
BNC1 and CCDC8, analyses of the TCGA data identified GALNT9 and the genome-
wide methylation analyses identified MIR124-2, RP11-713P17.4, NUS1P3, MIR3193, 
MTND6P4, FOXD1 and CTD-2023M8.1. Methylation analyses of these genes in 
unrelated primary breast tumours and BBM samples revealed that six of these genes  
(BNC1, CCDC8, GALNT9, MIR124-2, RP11-713P17.4 and NUS1P3) are metastatic 
suppressor genes hypermethylated and silenced in BBM where as the other four 
(MIR3193, MTND6P4, FOXD1 and CTD-2023M8.1) are metastatic promoter genes 
hypomethylated and expressed in BBM samples. Similarly, methylation analyses of 
these genes in BBM and their corresponding primary breast tumours from the individual 
patients revealed that the dysregulation of CCDC8, RP11-713P17.4 and NUS1P3 
occurs early in primary tumours whereas the dysregulation of MIR3193, MTND6P4, 
FOXD1 and CTD-2023M8.1 occurs late only after the tumour cells has left the primary 
tumours. Study in the in vitro metastatic potential of BNC1, CCDC8 and GALNT9 in 
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breast cancer cell lines showed that the downregulation of BNC1, CCDC8 and GALNT9 
increases the migratory and invasive potential of respective breast cancer cell lines used. 
In addition, methylation status of a panel of six genes (CCDC8, MIR3193, FOXD1, 
CTD-2023M8.1, RP11-713P17.4 and MIR124-2) in patients’ serum has showed that 
these genes could be used as non-invasive prognostic markers to predict the risk of 
BBM. However, analysis of many more patients’ serum samples is necessary to validate 
these markers before taking these candidates into a clinical setting.  
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Appendix 
Appendix A 
Appendix A1:  
 
Appendix A1: A list of brain metastases from breast (BM1-BM31), lungs (LM1-
LM29), melanoma (MM1-MM9), Renal Cell carcinoma or RCC (RM1-RM8) and 
colorectal (CM1-CM7). Genomic DNA was extracted from these tumours. BBM 
samples were used for the methylation analyses. 
 
 
 
 
 
 
 
 
 
Melanoma(
Brain,
metastases
RCC(Brain,
metastases
Colorectal,
Carcinoma(
Brain,
metastases
BM1 BM12 BM22 LM1 LM11 LM21 MM1 RM1 CM1
BM2 BM13 BM23 LM2 LM12 LM22 MM2 RM2 CM2
BM3 BM14 BM24 LM3 LM13 LM23 MM3 RM3 CM3
BM4 BM15 BM25 LM4 LM14 LM24 MM4 RM4 CM4
BM5 BM16 BM26 LM5 LM15 LM25 MM5 RM5 CM5
BM6 BM17 BM27 LM6 LM16 LM26 MM6 RM6 CM6
BM7 BM18 BM28 LM7 LM17 LM27 MM7 RM7 CM7
BM8 BM19 BM29 LM8 LM18 LM28 MM8 RM8
BM9 BM20 BM30 LM9 LM19 LM29 MM9
BM10 BM21 BM31 LM10 LM20
BM11
Breast,to,Brain,metastases Lung,to,brain,metastases
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Appendix A2 
 
Appendix A2: List of unrelated primary breast tumours used in methylation 
analyses.   
 
Appendix A3.1:  
Gene Primer  Sequence (5'-3') 
ABCB1 
F GTG AAG TTT TTT GGT AAG TTT ATG GGG ATT 
IF GTA GYG TTT AAA TYG TAG TGG TAT TGG ATT 
R AAC CAA ATA CAT GAA CCT CAG GCR CRC TAA  
AK5 
F GAG YGG GYG AGT GYG TTT TTA TAA GTT  
IF AYG GGG YGY GGT TGT TTT AAT TYG AAT T  
R AAA ACC ACA ACC CCC RAA AAA AAA CRA AAA 
ALDH1A3 
F TAG TTT TTT GTY GGG TYG GGT GTT TTA GTT  
IF GTT TTT YGG GGA GTT YGT TTA TAG GTA GTT  
R TTT CCA CRA CCC CRT TAA CRA TAA CCA TAA 
ANK3 
F TG GGG ATG GTT AAT GAA ATT TTA TTT AGT AGT T  
IF G AGT TGT TTT TGT TGT TTT TAG TTA TTT TAA GGT  
Primary'
breast'
tumour'code
Primary'
breast'
tumour'code
Primary'
breast'
tumour'code
Primary'
breast'
tumour'code
Primary'
breast'
tumour'code
BP101 BP120 BP139 BP158 BP178
BP102 BP121 BP140 BP159 BP179
BP103 BP122 BP141 BP160 BP180
BP104 BP123 BP142 BP161 BP181
BP105 BP124 BP143 BP162 BP182
BP106 BP125 BP144 BP163 BP183
BP107 BP126 BP145 BP164 BP184
BP108 BP127 BP146 BP165 BP185
BP109 BP128 BP147 BP167 BP186
BP110 BP129 BP148 BP168 BP187
BP111 BP130 BP149 BP169 BP188
BP112 BP131 BP150 BP170 BP189
BP113 BP132 BP151 BP171 BP190
BP114 BP133 BP152 BP172 BP191
BP115 BP134 BP153 BP173 BP192
BP116 BP135 BP154 BP174 BP193
BP117 BP136 BP155 BP175 BP194
BP118 BP137 BP156 BP176 BP195
BP119 BP138 BP157 BP177 BP196
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R CCT CRA ACC TCC AAA CRT AAA ACT TCT TAA  
ATM 
F GGA TAG ATT GGG TYG TAT AYG ATT GAA TTT TT 
IF GAA GTY GTT GYG TTG TTT TYG YGT TTT TAT T  
R ATA AAA ACC CCA AAA CCC RAA CCR AAA A  
BNC1 
F GGT YGA ATT ATT TTT TGA GAA GAG YGT TAG AGA AT 
IF GAG AGG TAA ATA TYG ATA YGT TTG TGT TTT TTA TT 
R CCA AAC RCC CAA ACT ACR CAA CAC RAT AA 
BOLL 
F GGY GAT TTT AAG GTT GTT GAA GGT TGA AAT 
IF TGG TTT YGT TTY GGA TTT TTT TAG AGG TTG TGT  
R CTC TCC TCC ACT TAA AAA AAA TCR ACC TCT AA 
BVES 
F GGT AGT GTT TTG TTT AYG ATG GAG GGT T  
IF GTA TYG TTT GGG ATT GTT AGT TTY GGT TAA GTA TT  
R TCR CCT CRC TAC AAA ATT CTA TCC TTA TTT AA 
CCDC8 
F GTT ATT GTY GTT TYG TTG GGA AGT AAT GGG TT 
IF GGT YGT TTY GAA GGG AGT GGA TAG TT  
R CCC AAA ACT CAA AAC CCA CTC CAA ACT AA  
CDKN1A 
F ATA GTG GYG TAA AGG ATT TGA ATT TGG GAT T  
IF GGG YGG YGT AGA TTG GAT TTT AGA GTT ATT  
R CTC RAC TTA CRC ACA CRA TAT CTC TAA ATA 
CD44 
F TTA GYG GGA AAG GAG AGG TTA AAG GTT GAA TT 
IF TGG TGT AAG GTT TTA YGG TTY GGT TAT TT                                                
R CCR AAC CTA ACA AAA ACT AAA ATC CRC TAA  
CLDN1 
F GYG TGA AAY GTT TTA TAG GAG YGA GAA GAT TT  
IF GTA GGG AYG TAG TTT TGG TGT TTG GTT T  
R CC TCC ACT AAA ACA AAA CAA TAC TAA CRA TAA   
CLDN3 
F GTT TAG TTA GGT TTA AGG GTA TTT TTT GGG TAT T 
IF GGT TTT TGG GTT TAG TAA TTT TTG GGT TGG AT  
R AAC CTA AAA ACA ATA ACR TAA CCC CTA CC  
CLDN4 
F GTY  GGT  TGG  AAG   GAA  TTG  GTT  TGT  TTA T  
IF GGT TTT ATT TTT TGA TTT AYG GTG TAA AGG TGT AT  
R C CAT AAA CCC TCC CAA ATA ATC TAC RAA ATA  
CLDN5 
F GAY GGG GTG GGG GGT TTT TGT AAA TT   
IF GGA GTT GGT TYG AGT GGA AGA GAT T    
R CC AAC TCC TAC CRA AAA ATA CCC TCT TTA   
CLDN6 
F GTG  GTG AAG YGG AGT TTT AAG TTT TGT TTT ATT  
IF GGG TGA GTT TGG AYG TTT GTT AGT T 
R CCR AAA AAC CCT ATC ACC TCR AAA ACT TAA 
CLDN7 
F GGA AAT TTA GTT YGG AGG GGT TGA T  
IF GAG TTT GGG ATT TTT GGG GAG TTA T 
R CCC AAA ATA TCC TAA ACT ATA AAT CCR AAA CTA 
CLDN9 
F GTA GGT YGT AYG TGT TTT TTG TGT TAT TGT T  
IF GTT GGT TTT GTT TGG TTT TTT GGT GGT T  
R CAA AAA AAC CCC CCR CCC AAC ATA AAC AAT A 
CLDN11 
F GG TYG GAG YGG AAT GGA TAT TTA GAG AT 
IF GAT GAG AGA GGG GTT ATA AGA AGA GAA ATT 
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R CTC ACR ACT ATA CCT AAA CCT AAA CTA AAC AAT A 
CLDN18 
F GGA GAG TAG ATA AGT GTT TTT AGG GTT 
IF GAA TTA GGA GYG AAA TTG AGT TAT TTA AGG AAA AT 
R CAA CTC CTC CAA AAC CCT TCR TAC TAA 
CLDN23 
F GA TAY GTT TTT GGA TTG GGT GGG TTT TTG TAT 
IF GYG AGT GGT TGT AAG TTG TAG AGT AAA TT 
R CAA CCR AAC RAC TAA ACC ACR CCT AA 
CMTM8 
F GYG GAG TTT TTG GAG GTT TGG GTT TTT  
IF GTT TTY GAT TYG TTT AGG TGG AAG GAA AT  
R CTC CCR AAC TAC RCT AAA ACC CTA AAA A  
COL14A1 
F GTATATAGTATTTGAGAATAGGAGGGTTYGAGAT 
IF GGGTTTGGTTTGGGAGTTTGTAGTAGT 
R CTAAAACTACCTCCRCCTCTCCAACTAA 
CSNK1A1 
F GGT GAT TTT TTT AAA TAT TAA GGT YGG GGG GTT  
IF GGG TTY GAG GYG AGT AAT AGG TAA TAT  
R CTA CCA CCA CTA CCR CCR ACT CC  
DAPK1 
F GAA GTT TTY GTT TAG AYG GTA YGY GTT TTA T  
IF TTG YGG TAA YGG TGG TAT TTT YGY GTT ATT 
R CAA CTT TTA CTT TCC CAA CCA AAA CRC RAT AA  
DGKI 
F GTT TTA YGG TGT AGG ATT TAG GGY GYG GTT  
IF G TTT TGG YGT TTT TAG TTY GGG GTY GTA GTT  
R CAA ACR ACR CCR CTA CAA AAA CCR AAC RAA CTA  
DLC1 
F TTG YGT GTT TGT TTG YGG YGT TGY GTT TTT  
IF GGT TAT TTG GAT TGT TTT TGA AGG GAA GAT T  
R ACC RCA AAC TAT CRC CTA CCT TCA AAA AA  
DSP 
F GTY GGG TTA YGT ATT TTT AGT TYG AGA GGT T  
IR GAG GTT TTA GYG TAG AGY GTA GTA GTT  
R CTA ACA CTA AAC RCC TAA ACC ACA CCT AA  
FBLX14 
F GAT AGT TGT YGT TTT TTT GTG GYG TTT AT 
IF GGG TTA AAA ATT AGG GGT TAY GGG ATT 
R CCR CCR CCC AAA CRA AAA AAC CAA A 
FBN2 
F TGY GTY GGT TTT TTA GTT YGG GTT GAG TT 
IF TGT GGA YGG TYG YGT TTT TAT TGA TAG T  
R ATT CCC RTA CAC TCC RAA AAC RAA TAT TAA  
GALNT9 
F GGT GAG GTG AGG TYG YGT TAT TTT GTA T  
IF GGT AGG ATA GGA GTY GGT ATA GAT AT 
R CAC CRT CAA CAA AAT TCR AAT CTT CCT AA  
GATA5 
F TGY GGA GTT TTA GYG GTT YGG GTT TTT  
IF GTY GTT TTT TTT GTT YGT TGG TGA GTG TTT T  
R CAT CCT CCC AAA CRT AAT CTT AAC CTA CAA A  
GREM1 
F TAG TAG AGG TTG GTT ATT TGT YGT TYG TTT  
IF GYG TAG GTA AAT AAA YGT TAA GTT GGG GTA TT  
R TAA CRC CRA ACA ACR ACC ACC RAC TAA  
HK2 
F GTG GGA GTT TTT TAT ATG ATT TYG AGA TGT T  
IF TAT AGG GYG TGT GTT GGT TTA GAG GTT  
R CTC CTA CRC CRA AAT TTC ATA CAA CAA TAT AA  
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HOXB13 
F GTT GGG GTA AAG TAT TTT YGT AGT TTT TGT T 
IR CTC CCA ACA AAC CTT CRA TAT CCT TAA 
R CAA ACA TCA ACR TAA ACR CCR CTA AAT AAC TAA 
HOXD3 
F GTG GYG  GTT   TYG  GGT  GAT  TTT T TA  ATT  TAG  T  
IR CAA AAT CCC CCT CTT ACA TCT ACC CTA TA 
R CAA CRA ATA ACC ACC CCC CRT CAA ATA  
HOXD10 
F GAG GTT TTT TYG TAT TAG AGG TTG GTT T 
IF GAT AAG YGT AAT AAA TTT ATT TYG GTY GAG GTT T 
R CTC TCC ACC TAA AAA ACT TTA ATA AAC TCC TAA 
ICAM5 
F GYG GGG TTY GGA GTT TAG TTT ATT ATT ATG GT  
IF GTA GGG GTT TGG GAA GGG TAA TTT AGT ATT T  
R CCC CAA ACC CAA AAC AAC CCA AAA A  
IGFBP3 
F YGA TAT YGG TTY GTY GTA GGG AGA TTT TAT T 
IF GGG TGT TGA GTT GGT TAG GAG TGA T 
R CAA CRC CCA ACC RCA ATA CTC RCA TCT AAA 
KLHL35 
F GYGGAGYGGTATTTTTATYGAYGTGGTGT 
IF GTTTAGYGYGGGTAGYGTTTATTTTYGTAGT 
R CRTAACRCRCCACCTCRACRAAACCTA 
KRT7 
F GGG ATG GYG TTT TTG TTT ATT TYG GAT T  
  GGT TTG GTA GTA GAG AAA GGT GGT T  
  CAA CCR CAA CRA AAC CAA CAA ACT CTA A  
KRT18 
F GTT TTG AAA GTA GTT TYG AGG GTT AAT AAT AT  
IF GTT GTY GTG TTT ATG TTY GGT TGG TTA T 
R CCT AAA CAA AAC CCA AAA ACC RAT AAT TAA TA  
KRT19 
F GTT TTT GGT TTT TGG GAG GGG AGG GAA TTG ATT 
IR GGG GAG AGA GTT TAT ATT TGT TTT TAG GAG TT 
R CAC CTT ATC CAA ATA AAA AAC CAA ACR ATC RTT A 
KRT28 
F GAT TGA GTG TGA ATT TGT AAT GTT TTT AAA GTT AT    
IF G AAA ATC TAC AAA ATA CRC CTC ATC TCR ATA         
R CT AAC CTT CRC TAT CAC CTA CCR TAA               
KRT72 
F GG ATT TAT GGG GAG TTT AYG GTG GAA T  
IF GGT TTT AAG GGA TTT AAA AGG TGT TGT YGA TAT AT 
R CTA CCC CCA AAA CAA AAA AAA CTC TTA CTA 
KRT81 
F GTA GGY GGA AGA AAA AGA TGA ATT TTY GGG AT 
IF GAT TAT TAG GAA AGG TTA TAG AGA GAG ATT 
R CTC CCR CTA AAC RAA TCT AAA AAC CTC TAA 
KRT83 
F GGA AAT TTT AGT TGT GTT TTT GTT TGY GGG TT 
IF CT  ATT AAA AAA CTT AAT CTA CTC CTT CTC CTC CTA 
R CCA AAA CRA CAC CCA CCT TAT CRA TA  
KRT85 
F GGA TGY GGG GTT ATT AGG AAT TTT AGT  
IF GTG GTT TTT AAA ATT GGT AAT YGT TGT TGT ATT  
R CTT AAT CTA CTC CTT CTC CTC CTA  
KRT86 
F GGT TTA TAG GGT GTA AGT AGT GAA YGT T  
IF CCA TCC TTA ATA CCC RAC CCT AAC TAT A  
R CTA TAT ATC TAT ATA CCT CRC CCA TCA AAC TAA 
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MIR23B  
F GGA GGA TGA GAG ATT ATT TGA TTT TAA GGA TGT AT  
IF GTT GGG AAT GTT AGT TAT GTA TTG AGT TT  
R CTC RAC TCC TAT TCC TAC TAA ACT AAA CCA ATA  
MIR34a 
F GAG ATA ATA GGT TTT GAT TYG GGA TAG ATT TTA T  
IF GGG TTT TTT TTT TTT TTT AGG YGA GAG GTT  
R CCT AAC CTC RAC CTA AAA CRC AAA TAC RAT A  
MIR34b 
F GAG TTA GTT TTA GGG TTT GGG TTT GGG AAT  
IF GTT TGG YGT GAA GGA AGT GGG AGT T  
R CCA CCA CAA TAC AAT CAA CTA ATA ACA CTA 
MIR124-1 
F GA TAG GTA GTY GGA GGG AGC TTT AGA TT  
IF GG YGT TTG GTT YGG TYG GTY GTT TT  
R CCC CTC CRC TTT ACA AAA AAA AAC CTA A  
MIR127 
F GGY GGG YGG AAG TAG TTT TTT AGG T 
IF G AGT GGA AGG TGT AGY GGT TTT TGA TTT  
R C CTA AAT CRA CTC ACC TAC TCC AAA AAA ATA  
MIR433 
F GGA GTA GAA AGY GTA GTA GGT TTT TTT GT  
IF GTT TTT AAG TAG AAT GGG TTT TGG GGT 
R CCA TCA TAA CAA AAT ACC CTA CCC CTA A  
MMP2 
F GTT TAG TYG GTT ATA TTT GGY YGT TGT T  
IF GGA GGT TGY GTA TTT GGG GTT TTA AAT 
R CAA ACA ACC CAA AAA ACA AAA CRC CCT CAA A  
MST1R 
F AYG TTA GGT GAA GGT ATA GGA GTT AGG TT 
IR GAG GGT TTG GGT TAG GTT AAG TTT TTT 
R CCT ATA CCA AAC CTC CRA CRA AAA AAC TAA  
NRCAM 
F TAG TTT TTY GAG GYG TYG GYG GTT GGA GTT 
IF TAG TAG TAG GGT AAG AGG GGG TTG GTT 
R CAA CTC TAA CRC RAC TAC CCA AAA CCC TAA 
OCLN 
F TAT TTT AAG GTT TTA TTY GAA GTA GGY GGA GTA T  
IF GAG GAY GTG TTT TTT TTA TTA AAG TGT TGA GTG TT  
R CCR ACT CCT CRA CRC TCT AAA CCT AA  
PBRM1 
F GATYGTYGTAGGGATTTTTAATTTTYGGTTTTATT 
IF AGGGTTAAGGTTTAYGYGTAGGTTTTTATT 
R CRTAACCRCCACRACTACTACTATTA 
PCDH8 
F GTG TTG ATA AGA AAA GGG GGA AAA AGT  
IF CAA AAA CTA CCC CAA CRC CTC ACA AA 
R G TTT TTT TAT ATT AAA GGG ATT GTT AGA GGT AGG 
PENK 
F AYG GTG TAA TTT TAG TGA TTT TAT GYG GAG AAA T 
IF GTT TGT TAT TTG GTY GTG TGG GGA GTT 
R AAA CRA ACC CRA ATA TAC TAA CRA ACR TAA AAC C 
PNN 
F ATT TTG YGT TAG TAG YGG GAT TTA GGT ATT  
IF TAG TTA ATT GGG GAG GGA GAT GAT TGT T    
R TCT CAT CCA CRT TCT TAA AAC TCT CTT TAA  
PTEN 
F GTA GAG TAA GGA GTG AGT TTT AGG TTT TAG TTT  
IF GYG AGG AGT GGT ATT AGT TTG GGG AT  
R CTT TCC AAA TTC CCA CTC CCC AAT A  
PYCARD F TGG TGT AAG TTT AGA GAT AAG TAG GYG TTA TT  
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IF GYG GTT TTT TTT YGG GYT TTA TTT YGT AGG TT  
R CTT AAA CTT CTT AAA CTC CTC RAC RAT CAA A  
QPCT 
F GTT GTG GGT ATA TTT TTA GGY GTA TTT YGT ATT  
IF ACR ACT CTA ATC CRA TAC RAA AAC CCC TAA  
R CCA AAA AAA TCA ATC CRA ATA CCT CAA CCT AA 
RBP1 
F GTG AGA AGT TAA TGG YGT TTG AAG GAA ATT T  
IR CCA ATT AAC CAC AAA CRA ACR AAA CRA CTA A  
R CAA CAT CTT CCA ATA CCC AAT AAA ATC RAC TAA 
SDHD 
F AAT GGG ATG TAG TYG GGA TYG AGT ATT 
IF GTG TAT AGA TTT TYG AGY TGT TTT AGG ATT ATT 
R CCR CCA TCT CRT TCC TAA AAA CTC AAA A 
SFRP2 
F TAT TGT GGG GGY GTA GYG GTT AGG TTT TTT 
IF ATT TAG GGG AGG GGG TGT AGT TAG AAT TTT  
R CTA AAT ACR ACT CRA AAC CCC RAA AAA CTA A  
STAT3 
F TAG ATA TTY GGT GGT GGT TGT AGG GTT  
IF GTG ATA ATG TAG GGA AAG GYG TTT TAA TT  
R ACC AAT CCC TAC TAT CRC TAA AAC CCT TAA 
SULF2 
F AGG GAT AGY GGA AAT TAY GGT AGA TAG TAT 
IF TAA TTT TTY GGG GAG TTT TYG GGY GYG TAT 
R CRC TTT CTT CTT CTC CTC TCT CRA AAC TAA 
TFAP2A 
F GGG TTG GTA GAG TTA GAT TYG TTA AGG TT 
IF GGG AYG GYG ATT TGT TTT TAT TGT GTT T  
R CAC CAA CAT CTC ACC TTT TCA TAA AAA ACT AA  
TJP1 
F GGT ATR GGT TTT GTR GGT TTT TTT AGT RGT AT 
IF GTG GAT AAG TTT TTT AAG GAA AGT TTT GGT GTA T 
R CTA CCR ACC CRA CCC ACT AAA CAT A  
TMEFF2 
F GGT TAA AGA GTG TGT TTA ATT GTT TGA AGA ATG T 
IF GTT TGA AGA ATG TAG TAG AYG GAA GGY GGG TTT 
R TCC AAC CCR TAA CCT ATT AAT ATA TCC ACC TAA 
TNFRSF10C 
F GGG TAG TTA GGG GGA TYG TTT TTT TGT TTT 
IF GTY GGG TTT TTT TTG TTT AGT TYG GGG ATT  
R TAA AAA CAA AAC RCC CCR ACC ACC TAA TAA 
TNFRSF10D 
F TYG TTG TYG GAA AGA GTT AGT TTT TGT TYG TTT  
IF GTT TTT TTG GAG GTG TTG GGG GAG ATT 
R TCT AAT TCC CRA CRC TAT CCT AAC TCC TAA 
TSC1 
F GGT TTT TTA TTT AYG YGG GTT TTA GTA GTT TT  
IF TYG TTG TTT TGA GGT YGT TTA TAG AGA GAT T  
R CCR AAA AAA AAA AAC TCT TCC ACT CAT AAC TAA 
TSPAN4 
F GGT GAT AAG AYG TTT GYG ATT TGY TAG GTT   
IF GGG GAT AAG GTT TTT TYG AAA GTA GAT TAT  
R CAT AAT CAT CCC TAT ACR CTA CTT CAC TTA TA 
TSPAN13 
F GTT AGY GTG GAT TTT TTT YGA GTT TYG TTT TTT  
IF GGT YGT YGT TTT GGT TTG GGG TTT T  
R CCC TAA CAA CTA CTT TAT CCT TAC CTT TAA  
UCHL1 
F TTG GAA TAG GAG TTT AGG GAG TAG GTA TT  
IR AAT AAC RCT TCR TAA ACR TAC TAA AAC TAA  
R CCT CTC CRC AAA TAC TAT CCC RAC TAA  
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WIF1 
F AAA GGG AGA YGA AGG GTA ATT TGY GTT  
IF AGY GTY GGA GGA GGA ATA GGA GTT ATT ATT  
R CTT AAA CRA CCR CCA CTT AAA AAC RCT ATA A  
Primers designed for gene in genome wide methylation analyses 
ZNF808 
F GTT TTA GAT AAT TTT AGG GTT TTG GAA TTA TGT T  
IR CAC RTC CCA AAA ACA AAA ACR ACR AAA ACC TAA 
R CCT CTC ACT AAA CTA TCT CAA TTT ACT CTA A  
HSPB9 
F GTT TTA GGT TTG GTT TTT AGA AGG TAA GAT AGT T  
IF GGT TTG GTT TGG TYG TGG ATT TAG TTT T  
R CTC TAC ATC CRA ATC AAC AAC TAA CTA CTA  
DDX52 
F GAG ATY GAG ATG GGA GGA TTA TTT GAG TT  
IF GYG TTT TAG TTT GGG YGA TAG AGA GAG ATT  
R CCA ACA ACR AAT TCA TTC CCR AAC TCC TA  
EDARADD 
F GYG TGT GTT ATT ATG TAG YGG TAG AGT T  
IF GTA TTT TAG TTT AGG TTT GTG TAA GGG GAG TTT  
R CTT CCA CRA ACT CAC TTC CTA CTT TAA  
SOX5 
F GGA AGA AGT TGA TAA AGG GAT TTG ATT AAA T  
IF GAT GYG AGT TTT ATY GAG ATT TAG AGA TAT TT  
R CAT AAA ACA ACT TCA AAA ACA AAC AAC ACA ATA  
RBM23 
F GTG GTY GGG AAG GTT GTT TAG GTA GT  
IF GTT TAG AAY GGG GAT TTY GAG TTT AGT ATT T  
R CAA AAC CTC CTC TTC CCR CAA AAT AA  
RNF8 
F GGA AAG TTT AAA GTT GTT TAA AAG TGG GT  
IF GGT TTT AGT TTG GGG YGG TTA GGA T  
R CCC TAA CCT AAA TTC TAA CTA CCT CTA TA  
LMX1B 
F GGA TTG ATA AGT AGG TGA TAG AGG AGT  
IF CAT ATC CTA CAA ACC CAT TTC CTT TAT CCR TTA A 
R CTT ACR ACC CTC TAA CRA TCA CTC CAA A  
mir124-2 
F GTT TTG GTA GAT GTG TTA GAG ATG AGT  
IF GAG ATA GGA GTT GGG TTT ATG AGT TAT GAT  
R CAC AAA CRA AAA CTA CTA CTC TCC AAA CAA CTA  
RP11-
713P17.4 
F GTY GAG AAG AGT YGA GAA GAG YGG AT  
IF GTG TYG TTT TTA AGG GGT AGT TTT GGT GTT AT  
R CCT CAA TCC CRA ACA AAT CAA TTA CCR CTA  
NUS1P3 
F GAT TAA GAG GTT AGG AGA TYG AGA TTA TTT TGG T  
IF GGT GGY GGG AGT TTG TAG TTT TAG TTA T  
R CCC ATA CRC ACA AAC AAC TTC TCC AAA  
MIR3193  
F GAG AGG GYG TGG GYG TTT GTA TTA T 
IF GTA TTT GGT TAT GYG GGG GTG TTT AAG GAG TT  
R CAA TAC CTC AAC CTC AAC CCC AAA CTA A  
CTD-
2023M8.1 
F GGA GGA AAA TAT TGG GTA ATT GTG GGT TAT 
IF CTT ACC CTC CTA ACC AAA AAA TTC TTA AAC TCA AA 
R CAT ATA CAA AAA TCT TCA AAT AAC CTC CCC ATT TA 
MTND6P4 F GAA GGA TAT TTG GTT TTA TGG GAG GAT ATA GTT 
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IF GTT GTT ATA GTT GTA AGT AGG AGG ATG ATG TT  
R CCC CAA TAC RCA AAA TTA ACC CCT TA  
FOXD1 
F GGG GAT TTT GTA TTA AGG GAT TGT TTT GTT T  
IF CTT CCT CCC TAC CCC AAA TCR AAA ATT AA  
R CTA CCA AAC RTC AAA AAA ACC TCT AAT ACC TAA  
C17ORF107 
F GAA AAT ATY GGG GTG GGT TTT AGG AGT T  
IF CCA AAC TCC TCA AAT TCC TTA TTT TCR TCA TAA  
R CCA ACC CAT ACC AAA AAA AAC CRT ATT TA  
AL2D1 
F GAT TTG TGT TTT TYG GAG AGA TAG AAG TGT TAT 
IF CAA ACT CAC AAA CRA CTC CAC AAA CTT AA 
R CAC TCA AAC TCA AAC CCC RAC TAC ATA A  
HMGN2P19 
  GTA TAA TGT GAA GAA AAA GAG GYG AGA AYG ATT  
  CCA ACA ACA ACT TTT CCC TTT TTC CCT TTA A 
  CTC CAA CAC CTT CAA CTT TCT ATA CCT AA 
RP11-
734118.1 
  GAG GGG AGT TTT TAG ATA AAG GYG AGA TAT 
  GAA AGG TGA TAG YGT GTT GGT AGT TT 
R CTA CCC TAC RAA AAA ACA ACT AAA ACC CRA TA  
AL662890.1 
F GYG GGT AGT GTT AAA GAT AGG GAT GTT  
IF GAT TTY GGG GTT AGA AGT TGA GGA T  
R CCC CTA CAC CTA AAA CTA TTT ATT TCC TTA  
 
Appendix A3.1: A list of CoBRA primers designed to amplify promoter region of 
candidate genes (chapter 4, 5 and 7).  Y: C or T in a forward sequence; R: G or A 
in a reverse sequence. 
 
Appendix A3.2 
Gene Primer type Primer Primer sequence 
        
BNC1 
USP 
F G GTG GTT TTT TGG GTG GTG AAG TAG T   
R CAA AAT AAA CAA CTC CCC AAA CAC CC 
MSP 
F CG GTT TTT CGG GCG GCG AAG TAG T 
R CGA AAT AAA CGA CTC CCC AAA CGC C   
CCDC8 
USP 
F GGT GAG GAG GAA TTT TTT GTT TGT GTG T 
R C CAA AAC ACT AAA AAA CCC CAA CCC AAA  
MSP 
F C GAG GAG GAA TTT TTT GTT CGC GCG T  
R CGA AAC GCT AAA AAA CCC CAA CCC GAA  
CTD-
2023M8.1 
USP 
  GTG ATA AGT ATG GTT GTT AGA TTT AAG ATA TGG  
  CTC ACT ATA CCA TAA TCT CAA CTA AAT CAA TA  
MSP   GCG ATA AGT ATG GTT GTT AGA TTT AAG ATA CGG  
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  CTC GCA ATA CCA TAA TCT CGA CTA AAT CAA TA  
FOXD1 
USP 
F GTT AGT GTG TTT GAG GAA GAA GGT AGG AAT TT  
R CCC ACA AAA CCA AAA AAC ACA CCC AAA CTA  
MSP 
F GC GCG TTC GAG GAA GAA GGT AGG AAT TT 
R C GCA AAA CCA AAA AAC GCG CCC GAA CTA   
GALNT9 
USP 
F GTT TTG GGT AGT TTT TTG TGT TTT GGG GGA  
R CAC AAC TAC AAC AAA AAC CTC ACC CAC AAA  
MSP 
F CG GGT AGT TTT TTG CGT TTT GGG GGA  
R C GAC TAC AAC GAA AAC CTC ACC CAC GAA  
MIR124-2 
USP 
F GTA TGT GGT GAA TGT TAA GAG TGG AGT T  
R CCT CAA AAA TTT ACC TAC AAA TTT CCA CAA CTA  
MSP 
F CGC GGT GAA TGT TAA GAG CGG AGT T  
R CGA AAA TTT ACC TAC GAA TTT CCG CGA CTA  
MIR3193 
USP 
F G TGT TTT TTT GTT GTG TTT TTT GGG GAA G  
R CTT CAA CAA CAC AAA ATA CAA TCA TCC ACA AA  
MSP 
F CGT TTT TTC GTC GTG TTT TTT GGG GAA G  
R CGA CAC AAA ATA CGA TCG TCC GCA AA  
MTND6P4 
USP 
F TGT TAT TGG TGT GAA GGT AGT GGA TGA TTT  
R CT CCA CAT AAT AAA ACT TCA ACT CAC TTC TTA A  
MSP 
F CGT TAT TGG CGT GAA GGT AGC GGA TGA TTT  
R CCG CAT AAT AAA ACT TCG ACT CAC TTC TTA A  
RP11-713 
USP 
F GAA GTT TTT TGG TTG AGT TGT GGT ATT TAT GT 
R CTA ACC TAA AAA TAC CAA AAC AAG CCT AA  
MSP 
F GTT TTT CGG TCG AGT TGT GGT ATT TAC GT  
R CC TAA AAA TAC CGA AAC GAC CCT AA  
Appendix A3.2: Methylation Specific PCR (MSP) primers used to amplify 
promoter region of selected genes in BBM and in patients serum DNA. 
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Appendix A3.3  
 
Appendix A3.3: Primers designed for selected genes to carry out Reverse 
transcription PCR (RT-PCR).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Primer Primer sequence
CCDC8 F AGG GCT ACA GTA GTT TGT TGG G
R GGC GGG CTT AGA GAT GAC T
BNC1 F CAC TAC TTC ACA CCT GGG ATG 
R GTT TGA GCT GTG TCT GTC TCT G 
GALNT9 F CAT CCC CAT GTC GAA CCC AG 
R CAG ACA CTT GGA CTC AGG CAA G 
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Appendi
x B 
Gene 
symbol 
Accession  Gene name  % of 
tumours 
methylated 
Function  
ABCB1 NM_000927.4 ATP-binding 
cassette sub-
family B 
member 1 
80 Controls efflux of 
substances across 
plasma membranes, 
associated with 
multidrug resistance 
(Muggerud et al., 
2010) 
AK5 NM_174858.2 Adenylate 
kinase 
0  Involved in 
phosphoryl exchange 
(Solaroli et al., 2009) 
ALDH1A3 NM_000693.2 Aldehyde 
dehydrogena
se 
0  Retinal oxidation 
(Vasiliou et al., 2000) 
ANK3 NM_020987.3 Ankyrin-3/G 0 Regulate voltage gated 
sodium channel 
(Ferreira et al., 2008) 
ATM NM_000051.3 Ataxia 
telangiectasi
a mutated 
0  Key regulator in 
multiple signalling 
cascades (Rotman & 
Shiloh, 1998) 
BNC1 NM_001717.3 Basonuclin 1 73  Zink finger 
transcription factor, 
regulator of EMT 
(Feuerborn et al., 2014) 
BOLL NM_197970.2 boule-like 13  Associated with 
spermatogenesis 
(Westerveld et al., 
2005)  
BVES NM_007073.4 Blood vessel 
epicardial 
substance 
64 Involved in inter-
cellular interaction and 
cell adhesion. (Osler et 
al., 2006) 
CCDC8 NM_032040.4 Coil coiled 
domain 
containing 8 
87  Mutated in patients 
with 3M syndrome 
(Hanson et al., 2011). 
Loss is associated with 
genomic instability and 
aneuploidy (Yan et al., 
2014). 
CD44 NM_000610.3 CD44 
molecule 
0  Main receptor for 
extracellular matrix 
component Hyaluronan 
(HA), associated in 
metastatic spread in 
various cancers 
(Gvozdenovic et al., 
2013) 
CDKN1A 
 
NM_000389.4  Cyclin-
Dependent 
7  Important component 
to regulate cell cycle 
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Kinase 
Inhibitor 1A 
(Shiozaki et al., 2013) 
CLDN1 NM_021101.4  Claudin 1  20 Intercellular adhesion 
molecule responsible 
for tight junction strand 
formation, its 
down/upregulation is 
associated with various 
cancers (Krämer et al., 
2000; Tsukita & 
Furuse, 2000; Fritzsche 
et al., 2008; Myal et 
al., 2010) 
CLDN11 NM_005602.5 Claudin 11  0 Intercellular adhesion 
molecule responsible 
for tight junction strand 
formation (Tsukita & 
Furuse, 2000) 
CLDN18 NM_016369.3 Claudin 18 100 Intercellular adhesion 
molecule responsible 
for tight junction strand 
formation (Tsukita & 
Furuse, 2000) 
CLDN23 NM_194284.2  Claudin 23 0 Intercellular adhesion 
molecule responsible 
for tight junction strand 
formation, 
downregulated in 
various cancers 
(Tsukita & Furuse, 
2000; Turksen & Troy, 
2004) 
CLDN3 NM_001306.3 Claudin 3 0 Intercellular adhesion 
molecule responsible 
for tight junction strand 
formation, its 
down/upregulation is 
associated with various 
cancers (Tsukita & 
Furuse, 2000; Turksen 
& Troy, 2004) 
CLDN4 NM_001305.4  Claudin 4 0 Intercellular adhesion 
molecule responsible 
for tight junction strand 
formation, associated 
with various cancers 
and metastasis (Tsukita 
& Furuse, 2000; 
Turksen & Troy, 2004) 
CLDN5 NM_0011308
61.1 
Claudin 5 47 Intercellular adhesion 
molecule responsible 
for tight junction strand 
formation, involved in 
breast cancer 
metastasis, its loss 
affects blood brain 
barrier selectivity 
(Tsukita & Furuse, 
2000; Nitta et al., 
2003; Escudero-
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Esparza et al., 2012) 
CLDN6 NM_021195.4  Claudin 6 55 Intercellular adhesion 
molecules responsible 
for tight junction strand 
formation, its 
epigenetic silencing is 
associated with 
migration and 
invasiveness of breast 
cancer (Tsukita & 
Furuse, 2000; Osanai et 
al., 2007) 
CLDN7 NM_0011850
22.1 
Claudin 7 0 Intercellular adhesion 
molecule responsible 
for tight junction strand 
formation, its loss is 
associated with breast 
cancer progression 
(Tsukita & Furuse, 
2000; Kominsky et al., 
2003) 
CLDN9 NM_020982.3  Claudin 9 0 Intercellular adhesion 
molecule responsible 
for tight junction strand 
formation (Tsukita & 
Furuse, 2000) 
CMTM8 NM_178868.3 CKLF-like 
MARVEL 
transmembr
ane domain 
containing 8 
0 Negative regulator of 
EGM induced 
signalling, induces 
apoptosis (Jin et al., 
2007) 
COL14A1 NM_021110.2 Collagen, 
type XIV, 
alpha-1 
13  Interacts with 
extracellular matrix 
components, play roles 
in cell adhesion (Bauer 
et al., 1997) 
CSNK1A1 NM_0010251
05.2 
Casein 
kinase 1, 
alpha 1 
0 Serine/Threonine 
kinase plays role in 
cellular senescence 
(Sarasqueta et al., 
2013) 
DAPK NM_004938.3 Death 
Associated 
protein 
kinase 
13  Serine/threonine 
kinase involved in 
apoptotic system 
(Pulling et al., 2009) 
(Toyooka et al., 2003) 
DGKI NM_004717.2 Diacylglycer
ol kinase 
13  Activator of various 
signalling proteins 
(Regier et al., 2005) 
DLC1 NM_182643 Deleted in 
Liver 
Cancer 
0 GTPase activating 
protein plays roles in 
signalling pathways 
(Wong et al., 2003) 
DSP NM_004415.2 Desmoplakin 0 Inhibits Wnt/Beta 
catenin pathway, 
involved in cancers and 
metastasis (Davies et 
al., 1999; Pang et al., 
2004; Chun & 
Hanahan, 2010; Yang 
 282 
et al., 2012) 
FBN2 NM_001999.3 fibrillin 2 0  Associated with 
formation of 
microfibrils and elastic 
fibrillogenesis 
(Chaudhry et al., 2001) 
FBXL14 NM_152441.2  F-box and 
leucine-rich 
repeat 
protein 14 
0 Involved with hypoxia 
and cancer 
development (Vinas-
Castells et al., 2010; 
Zheng et al., 2012) 
GALNT9 NM_0011226
36.1 
N-
acetylgalact
osaminyltran
sferase 9 
55 Catalyzes O-
glycosylation (Shinya 
et al., 2000; Berois et 
al., 2013) 
 
GATA5 NM_080473.4 GATA 
binding 
protein 5 
0  Transcription factor, 
activates anti-tumour 
genes and act as TSG 
(Akiyama et al., 2003)  
GREM1 NM_013372.6 Gremlin1 7  Plays role in tissue 
modelling and 
angiogenesis (Mulvihill 
et al., 2012) 
HK2 NM_000189.4 Hexokinase 0.  First rate limiting 
enzyme of glycolysis, 
involved in pancreatic 
carcinogenesis Dong et 
al. (2011) (Fang et al., 
2012) 
HOXB13 NM_006361.5 Homeobox 
B13 
80  TSG for prostate 
cancer, inhibits 
androgen mediated 
signalling (Fidler et al., 
2010) 
HOXD10 NM_002148.3 Homeobox 
D10 
55 Maintain epithelial cell 
plasticity and 
contributes to stability 
of extracellular matrix 
(Carrio et al., 2005) 
HOXD3 NM_006898.4 HomeoboxD
3 
100  Proangiogenic 
transcription factor 
(Chen et al., 2004) 
ICAM5 NM_003259.3 intercellular 
adhesion 
molecule 5 
0  Involved in dendritic 
outgrowth, associated 
with prostate cancer 
(Griffith & Swartz, 
2006) 
IGFBP3 
 
NM_000598.4 Insulin-like 
growth 
factor-
binding 
protein 3 
0  Supresses tumour 
growth and induce 
apoptosis (Regel et al., 
2012) 
KLHL35 NM_0010395
48.2 
Kelch –like 
35 
0 Associated with 
Mendalian diseases and 
cancers (Dhanoa et al., 
2013) 
KRT18 NM_000224.2  Keratin 18 0 Component of 
intermediate filament 
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in epithelial cells 
contributing to cell to 
cell adhesions, 
involved in apoptosis 
and is associated with 
invasiveness of breast 
cancer  
(Magin et al., 2007; 
Bragulla & Homberger, 
2009; Iyer et al., 2013) 
(Oshima, 2002) 
KRT19 NM_002276.4  Keratin 19 0 Component of 
intermediate filament 
in epithelial cells 
contributing to cell to 
cell adhesion (Magin et 
al., 2007; Bragulla & 
Homberger, 2009) 
 
KRT28 NM_181535.3 Keratin 28 0 Component of 
intermediate filament 
in epithelial cells 
contributing to cell to 
cell adhesions (Magin 
et al., 2007; Bragulla & 
Homberger, 2009) 
KRT7 NM_005556.3 Keratin 7 0 Component of 
intermediate filament 
in epithelial cells 
contributing to cell to 
cell adhesions (Magin 
et al., 2007; Bragulla & 
Homberger, 2009) 
KRT72 NM_080747.2 Keratin 72 42 Component of 
intermediate filament 
in epithelial cells in 
contributing to cell to 
cell adhesion (Magin et 
al., 2007; Bragulla & 
Homberger, 2009) 
KRT81 NM_002281.3 Keratin 81 0 Component of 
intermediate filament 
in epithelial cells 
contributing to cell to 
cell adhesions (Magin 
et al., 2007; Bragulla & 
Homberger, 2009) 
KRT83 NM_002282.3 Keratin 83 84 Component of 
intermediate filament, 
contributes to cell to 
cell adhesion (Magin et 
al., 2007; Bragulla & 
Homberger, 2009) 
KRT85 NM_002283.3  Keratin 85 100 Component of 
intermediate filament 
in epithelial cells 
contributing to cell-cell 
adhesion (Magin et al., 
2007; Bragulla & 
Homberger, 2009; 
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Shimomura et al., 
2010) 
KRT86 NM_002284.3  Keratin 86 0 Component of 
intermediate filament 
in epithelial cells 
contributing to cell to 
cell adhesions (Magin 
et al., 2007; Bragulla & 
Homberger, 2009) 
MIR124-1 NR_029668.1 microRNA 
124-1 
36 miRNA with tumour 
suppressor activity, 
epigenetically 
deregulated in various 
cancers (Wilting et al., 
2010; Wong et al., 
2011; Shi et al., 2013) 
MIR127 NR_029696.1 microRNA 
127 
100 Regulator of cell 
proliferation and 
senescence (Chen et 
al., 2013) 
MIR23B  NR_029664.1 microRNA 
23b 
92 Involved in 
cytoskeleton 
modelling, motility and 
metastasis (Majid et 
al., 2012; Zaman et al., 
2012; Jin et al., 2013; 
Pellegrino et al., 2013) 
MIR34a NR_029610.1  microRNA 
34 
10 Transcriptional target 
of p53 associated with 
various cancers, 
apoptosis and 
metastasis (Rokhlin et 
al., 2008; Yamakuchi 
et al., 2008; 
Hermeking, 2010; Roy 
et al., 2012) 
MIR34b NR_029839.1 microRNA 
34b 
30 Tumour suppressor 
miRNA, associated 
with p53 regulation, 
cancer and apoptosis 
(Hermeking, 2010) 
MIR433 NR_029966.1 microRNA 
433 
100 Deregulated in gastric 
cancer, regulator of cell 
migration and drug 
response (Luo et al., 
2009; Symmans, 2010) 
MMP2 NM_004530.4
  
Matrix 
metallopepti
dase 2 
0 A type of extracellular 
enzymes that digests 
extracellular 
membranes and 
promotes cell 
migration/ and 
promotes tumour 
development invasion 
of (Somiari et al., 
2006) 
MST1R NM_002447.2 macrophage 
stimulating 1 
receptor 
78 Involved in 
intracellular signalling 
cascades leading to 
cellular growth, 
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motility and invasion 
(Wagh et al., 2008) 
NRCAM NM_0010371
32.2 
Neuronal 
cell 
adhesion 
molecule 
0 Functions as neural-
glial cell adhesion 
molecule, plays role in 
neural proliferation, 
proliferation and 
signalling pathways 
(Sakurai, 2012) 
OCLN NM_002538.3 Occludin 0 Tight junction 
associated integral 
protein, (Martin et al., 
2010) 
PBRM1 NM_018313.4 polybromo 1 0 Regulates embryonic 
development associated 
with renal cell 
carcinoma (Varela et 
al., 2011b) 
PCDH8 NM_002590.3 Procadhern 
8 
73 Helps in cell to cell 
adhesion (Sabine et al., 
1998) 
PENK NM_006211.3 Proenkephal
in 
80   Promotes RNA 
splicing in osteoblasts 
and neural cells, plays 
role in bone 
development (Rosen et 
al., 2013a) 
PNN NM_002687.3 pinin, 
desmosome 
associated 
protein 
0 Associated with linking 
intermediate filaments 
to desmosome in 
epithelial cells 
(Ouyang & Sugrue, 
1996) 
PTEN NM_000314 Phosphatase 
and tensin 
homolog 
0  Modulates cell 
signalling, growth, 
migration and 
apoptosis, regulates 
Pi3K pathway (Wu et 
al., 1998; Yamada & 
Araki, 2001) 
PYCARD NM_013258.4 Apoptosis-
associated 
speck-like 
protein 
containing a 
CARD 
0  Pro-apoptotic TSG 
(Siraj et al., 2011) 
QPCT NM_012413.3 Glutaminyl-
peptide 
cyclotransfer
ase 
0  CCL2 signalling, may 
be involved in thyroid 
carcinoma (Kehlen et 
al., 2012) 
RBP1 NM_002899.3 retinol 
binding 
protein 1 
0  Involved in retinol 
transport and 
metabolism, associated 
with ovarian cancer 
(Stephens et al., 2012) 
SDHD NM_0012765
03.1 
Succinate 
dehydrogena
se complex, 
subunit D 
0  Encodes respiratory 
chain protein, 
associated with 
paraganglioma 
(Gimenez-Roqueplo et 
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al., 2001) 
SFRP2 NM_003013.2 Secreted 
frizzled-
related 
protein 2 
47  Regulator of canonical 
Wnt pathway (Veeck et 
al., 2008) 
STAT3 NM_139276.2 Signal 
transducer 
and 
activator of 
transcription 
3 
67  Involved in embryonic 
stem cell regulation, 
somatic cell growth 
(KIYOSHI et al., 1997; 
Hitoshi et al., 1998; 
Akira, 2000) 
SULF2 NM_018837.3  sulfatase 2 0  Modulates various 
signalling proteins and 
inhibit tumour growth 
(Chau et al., 2009) 
TFAP2A NM_003220.2 Transcriptio
n factor AP-
2 alpha 
0 Required for neural 
crest induction (Li & 
Cornell, 2007) 
TJP1 NM_003257.3 tight 
junction 
protein 1  
0 Plays role in tight 
junction organization 
and assembly (D'Atri et 
al., 2002) 
TMEFF2 
 
NM_016192.2 Transmembr
ane protein 
with EGF-
like and two 
follistatin-
like domains 
2 
0  Transmembrane 
protein, suppresses 
prostate tumour (Gery 
& Koeffler, 2003) 
TNFRSF10C NM_003841.3 Tumour 
Necrosis 
Factor 
receptor 
superfamily 
10C 
13  Cell surface protein, 
modulates multiple 
biological networks 
(Degli-Esposti et al., 
1997) 
TNFRSF10D NM_003840.4 Tumour 
Necrosis 
Factor 
receptor 
superfamily 
10 D 
60 Member of 
TNF(Tumour Necrosis 
Factor) receptor 
superfamily, promotes 
apoptosis in cancer 
cells (Hill et al., 2011) 
TSC1 NM_000368.4 Tuberous 
Sclerosis 1 
0  May be involved in 
tumour suppression 
(Miloloza et al., 2000) 
TSPAN13 NM_014399.3  Tetraspanin 
13 
0 Transmembrane 
protein, inhibits 
cellular growth and 
invasion (Arencibia et 
al., 2009) 
TSPAN4 NM_0010252
37.1 
Tetraspanin
4 
0 Cellular growth, 
adhesion and 
differentiation (Todd et 
al., 1998b) 
UCHL1 
 
NM_004181.4 Ubiquitin 
carboxyl-
terminal 
esterase L1 
0  Neuron specific 
ubiquitinating enzyme, 
associated with early 
onset of progressive 
neurodegeneration(Bilg
uvar et al., 2012)  
WIF1 NM_007191.4 Wnt 53  Inhibitor of Wnt-
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inhibitory 
factor-1 
gene 
signalling (Ai et al., 
2006; Veeck et al., 
2009) 
ZNF808 NM_0010398
86.3 
Zink finger 
protein 808 
0 Zink finger protein, 
may be involved in 
transcriptional 
regulation (Lancet et 
al., 2013) 
 288 
Appendix B1: A list of all genes screened for methylation status in BBM 
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Appendix B2: Gel electrophoresis images of some additional genes, which were 
frequently methylated in BBM samples.  
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Appendix B4:  
 
Appendix B4: Clinical information of unrelated primary tumours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Estrogen)
receptor)
status
Progesterone)
receptor)
status
HER2)
status
Date)of)
surgery)
Age)at)
diagnosis))
Date)of)
investigation)
for)metastasis
Metastasis
Bone)
metastasis
Lung)
metastasis
Cutaneous)
metastasis))
Multiples)
metastases
Hepatic)
metastasis))
Brain)
metastasis
Lymph)
node
P P N 1978 37 1981 1 1 0 0 0 1 0
N N N 1984 59 1999 0 0 0 0 0 0 0 0
N N N 1984 71 2001 0 0 0 0 0 0 0 0
P P N 1985 79 1991 0 0 0 0 0 0 0 0
P N N 1985 73 1988 1 0 0 0 0 1 0
N N P 1986 83 1992 0 0 0 0 0 0 0 0
P P N 1991 72 1998 1 1 1 0 1 1 0
P P P 1987 50 2013 0 0 0 0 0 0 0 0
N N P 1987 63 2008 0 0 0 0 0 0 0 0
P P N 1989 64 2004 1 1 0 0 0 0 0
P P N 1987 66 1995 0 0 0 0 0 0 0 0
P P P 1987 43 2006 0 0 0 0 0 0 0 0
N N P 1987 75 2000 0 0 0 0 0 0 0 0
P P N 1990 81 2000 1 0 0 0 0 1 0
P P N 11981 68 1989 1 0 0 1 0 0 0
P P N 1991 78 1999 0 0 0 0 0 0 0 0
P P N 1991 80 2002 0 0 0 0 0 0 0 0
P N N 1992 70 1999 0 0 0 0 0 0 0 0
P P N 1992 59 1997 0 0 0 0 0 0 0 0
P P N 1984 62 1998 0 0 0 0 0 0 0 0
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Appendix B5: Gel electrophoresis images of some additional genes frequently 
methylated in unrelated primary breast tumour 
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Appendix B7  
 
Appendix B7: Clinical information on matched primaries that have metastasised 
to the brain. 
 
Appendix C 
 
Appendix C1: Clone sequencing images 
Appendix C1. 1 
Tumour
Estrogen,
receptor,
status
Progesterone,
receptor,
status
HER2,status
Lymph/Vascular,
Invasion
Duration,between,
primary,breast,
tumours,and,BBM,
surgery
BP1 Positive Negative Negative
Vascular2invasion2
noted
52years2
BP2 Positive2 2Positive2 Negative NA 102years
BP3 Positive Positive Negative,2
Lymphovascular2
invasion2
22years
BP5 Positive2 Negative Negative NA 102years
BP8 NA NA NA NA 22years2
BP10 Negative Negative NA NA 32years
BP11 NA NA 1+2(negative)2 NA 62years
BP12 Positive Positive 1+2(negative)2
Lymphovascular2
invasion
52years2
BP13 Negative Negative Negative NA 32years
BP14 Positive Negative Negative NA 42years
BP15 NA NA NA
Lymphovascular2
invasion2
22years2
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Appendix C1.1: Clone sequencing: BNC1 methylation in individual alleles 
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C1.2 Clone sequencing of CCDC8 methylation in individual alleles 
 
 
C1.3 Clone sequencing: GALNT9 methylation in individual alleles 
 
 295 
 
 
C1.4 Region of analysis of base pair resolution of methylation in individual alleles 
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Appendix C2 Quantitative expression of three genes BNC1, CCDC8 and GALNT9 
in BBM samples 
 297 
 
Appendix C3: Metastatic and non-metastatic primary tumours from the TCGA 
used for clinical information. 
 
 
 
 
 
 
 
 
 
 
 
 
Tumour&
Code
Tumour&barcode& Tumour&
Code
Tumour&barcode&
M1 TCGA'A2'A3XS'01A'11D'A230'05 NM1 TCGA'D8'A1X6'01A'11D'A14N'05
M2 TCGA'EW'A1P8'01A'11D'A145'05 NM2 TCGA'D8'A1XJ'01A'11D'A14N'05
M3 TCGA'EW'A1P1'01A'31D'A14H'05 NM3 TCGA'D8'A1XM'01A'21D'A14N'05
M4 TCGA'AR'A2LH'01A'31D'A18O'05 NM4 TCGA'D8'A1XO'01A'11D'A14N'05
M5 TCGA'GM'A2D9'01A'11D'A18O'05 NM5 TCGA'D8'A1XQ'01A'11D'A14N'05
M6 TCGA'GM'A2DA'01A'11D'A18O'05 NM6 TCGA'D8'A1XR'01A'11D'A14N'05
M7 TCGA'AC'A2FM'01A'11D'A19Z'05 NM7 TCGA'D8'A1XS'01A'11D'A14N'05
M8 TCGA'EW'A1P0'01A'11D'A145'05 NM8 TCGA'D8'A1XT'01A'11D'A14N'05
M9 TCGA'BH'A1FH'01A'12D'A13K'05 NM9 TCGA'D8'A1XU'01A'11D'A14N'05
M10 TCGA'A2'A0SW'01A'11D'A10P'05 NM10 TCGA'D8'A1XV'01A'11D'A14N'05
M11 TCGA'A2'A0T2'01A'11D'A10P'05 NM11 TCGA'D8'A1XW'01A'11D'A14N'05
M12 TCGA'AR'A0TZ'01A'12D'A10P'05 NM12 TCGA'D8'A1XY'01A'11D'A14N'05
M13 TCGA'AR'A0U2'01A'11D'A10A'05 NM13 TCGA'D8'A1XZ'01A'11D'A14N'05
M14 TCGA'A2'A0SV'01A'11D'A10P'05 NM14 TCGA'D8'A1Y0'01A'11D'A14N'05
BRCA&&METASTATIC&tumours&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&BRCA &NON&METASTATIC&tumours&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&
Metastatic&and&Non&metastatic&primary&breast&tumours&from&the&TCGA&used&for&the&
clinical&information&
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Appendix D 
 
Appendix D1: cobra methylation for cell lines. CL1: MCF7, CL2: T47D, CL3: 
MDA-MB231, CL4: BT549, CL5: ZR75, U: Uncut (control), C: Cut by restriction 
enzyme (BstU1/TaqI), *: methylated cell line 
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Appendix D2: Survival curves for three genes BNC1, CCDC8 and GALNT9 in 
different data sets 
 
 
 
 
 
 
 
 
 
 Relapse free survival  
(GSE9195, p=0.06 
Distance metastasis free 
survival 
GSE9195, p=0.02 
 Relapse free survival  
(GSE12276, p=0.004 
Overall survival 
GSE1456-GPL97, p=0.02 
Distance metastasis free 
survival 
GSE1456-GPL97, p=0.02 
 Relapse free survival  
(GSE1379, p=0.003 
Overall survival 
GSE9893, p=0.12 
Distance metastasis free 
survival 
GSE6532-GPL570, p=0.02 
BNC1% CCDC8% GALNT9%
Overall survival 
GSE3143, p=0.18 
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Appendix E 
 
E1: TCGA Barcode identifiers of normal tissues and primary tumours used in 
analyses of 450K methylation data in BBM 
 
 
 
 
 
 
 
 
 
 
 
Tumour&barcode&
TCGA%AC%A23H%11A%12D%A161%05 TCGA%D8%A1X6%01A%11D%A14N%05
TCGA%BH%A204%11A%53D%A161%05 TCGA%D8%A1XJ%01A%11D%A14N%05
TCGA%BH%A209%11A%42D%A161%05 TCGA%D8%A1XM%01A%21D%A14N%05
TCGA%E9%A1RB%11A%33D%A161%05 TCGA%D8%A1XO%01A%11D%A14N%05
TCGA%E2%A1LI%11A%23D%A161%05 TCGA%D8%A1XQ%01A%11D%A14N%05
TCGA%E2%A1LS%11A%32D%A161%05 TCGA%D8%A1XR%01A%11D%A14N%05
TCGA%E9%A1RC%11A%33D%A161%05 TCGA%D8%A1XS%01A%11D%A14N%05
TCGA%E9%A1RD%11A%33D%A161%05 TCGA%D8%A1XT%01A%11D%A14N%05
TCGA%BH%A208%11A%51D%A161%05 TCGA%D8%A1XU%01A%11D%A14N%05
TCGA%E9%A1RF%11A%32D%A161%05 TCGA%D8%A1XV%01A%11D%A14N%05
TCGA%AC%A23H%11A%12D%A161%05 TCGA%D8%A1XW%01A%11D%A14N%05
TCGA%AC%A23H%11A%12D%A161%05 TCGA%D8%A1XY%01A%11D%A14N%05
TCGA%D8%A1XZ%01A%11D%A14N%05
TCGA%D8%A1Y0%01A%11D%A14N%05
Primary&breast&tissues&from&the&TCGANormal&breast&tissues&from&the&TCGA
Tumour&barcode&
NormalHbreastHtissuesHandHprimaryHbreastHtumoursH(InvasiveHbreastHcarcinomaH
BRCA)HusedHforHcomparingHwithHBBMHdataHtoHscreenHcandidatesHforHBBMH
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Appendix E2: list of probes generated, which are differentially methylated in BBM 
compared in primary breast tumours from TCGA (based on mean β values of all 
tumours) 
Gene$Symbol Entrez$ID Chromosome Mean$(β$value)$BBM
Mean$(β$value)$
primary$tumours
Difference Promoter
HSPB9 94086 chr17 2.029788864 0.0868493 2.130872037 TRUE
DDX52 11056 chr17 1.525909178 0.417176197 1.118207247 TRUE
EDARADD 128178 chr1 0.422072021 0.726856306 1.192213701 TRUE
RNF8 157360 chr6 0.822653313 0.524739581 0.297913731 TRUE
SOX5 281485 chr12 0.837062213 0.556376304 0.28068591 TRUE
RBM23 311885 chr14 0.818144254 0.538907402 0.279236851 TRUE
LMX1B 224781 chr9 0.826886808 0.54627828 0.280608528 TRUE
OTX1 5013 chr2 32.052294171 30.963869274 31.459176341 TRUE
NDUFS6 4726 chr5 32.363352982 31.068901118 31.715868344 TRUE
MEIS2 4212 chr15 32.262082477 31.023659256 31.504283882 TRUE
NR2F1 7025 chr5 31.67850661 30.204925415 31.473581195 TRUE
MIR1178 100302274 chr12 1.752820322 0.458007976 1.403570235 TRUE
SLITRK5 26050 chr13 32.779276933 31.879359928 31.057982323 TRUE
CSRP2 1466 chr12 32.542994118 31.651557161 31.194480426 TRUE
LOC154872 154872 chr7 30.076256492 31.326517102 1.461613651 TRUE
RPS6KA2 6196 chr6 32.629307437 31.685474923 31.111214542 TRUE
BCL9 607 chr1 31.710535721 30.699173354 31.06067673 TRUE
KCNA2 3737 chr1 31.87471767 30.88162023 31.035807156 TRUE
PANK1 53354 chr10 32.660896875 31.6144809 31.046415975 TRUE
PIP5K1A 8394 chr1 31.924748424 31.088080394 31.167612619 TRUE
FLJ22447 400221 chr14 32.16613857 31.09760256 31.06853601 TRUE
ALDHL1 89880 chr3 0.615892326 0.255782622 0.360109704 TRUE
SCAND3 114821 chr6 2.052172389 0.801862888 1.250309501 FALSE
UNKL 64718 chr16 31.066310228 0.164519429 31.709470409 FALSE
PRDM2 7799 chr1 32.241456505 31.140906534 31.100549971 FALSE
MIR5580 100847076 chr14 32.21502181 31.096813745 31.425877581 FALSE
PAX9 5083 chr14 32.548073287 31.39339006 31.568435629 FALSE
ZNF331 55422 chr19 32.114654599 31.142370508 31.034999342 FALSE
LOC388942 388942 chr2 32.654429853 31.753323924 31.079412215 FALSE
MNX1 3110 chr7 30.917992399 0.52934354 31.829976908 FALSE
RNF220 55182 chr1 32.518476022 31.043731152 31.669193455 FALSE
SCD 6319 chr10 31.669775868 30.698550507 31.09810695 FALSE
GNG4 2786 chr1 31.504077952 30.478997596 31.097389678 FALSE
GATA3 2625 chr10 2.813936505 1.576045434 1.237891071 FALSE
PARG 8505 chr10 31.553188052 30.526076947 31.027111105 FALSE
TLR3 7098 chr4 2.158430487 1.183355862 1.031898906 FALSE
FGF9 2254 chr13 32.57297787 31.450151353 31.122826518 FALSE
UNQ6975 400952 chr2 32.136015239 31.002047522 31.133967718 FALSE
NFIB 4781 chr9 32.778820565 31.465912041 31.390347762 FALSE
ARID3A 1820 chr19 32.097062072 31.046837775 31.093688548 FALSE
OSR2 116039 chr8 32.764144155 31.371592925 31.44085651 FALSE
MECOM 2122 chr3 32.497820446 31.461679264 31.278761723 FALSE
EFNA2 1943 chr19 1.977663492 2.995766323 31.018102831 FALSE
KCTD8 386617 chr4 30.871676426 0.157637684 31.02931411 FALSE
HHIP 64399 chr4 32.97240584 31.918370607 31.209099267 FALSE
PYY 5697 chr17 32.96844562 32.094559227 31.059136332 FALSE
C1orf216 127703 chr1 32.60973537 31.600226301 31.009509069 FALSE
SRSF7 6432 chr2 30.321410898 0.937379935 31.258790833 FALSE
SLC35F3 148641 chr1 1.990232239 0.930531034 1.059701205 FALSE
OR10AD1 121275 chr12 31.157595374 0.32176395 31.54475007 FALSE
DNAJB6 10049 chr7 30.643603812 0.37155827 31.106530684 FALSE
BNIP3 664 chr10 31.514194422 30.093777042 31.420417379 FALSE
LINC00476 100128782 chr9 2.224419525 1.226652806 1.029069023 FALSE
MRGPRX1 259249 chr11 1.71317044 0.685085961 1.028084478 FALSE
TRABD 80305 chr22 30.928343052 32.14998339 1.221640338 FALSE
MARCKS 4082 chr6 32.81590301 31.574430944 31.347103793 FALSE
SLC12A9 56996 chr7 31.028879937 30.086277383 31.008520316 FALSE
ARMC2 84071 chr6 2.843974028 1.841212414 1.002761614 FALSE
CCDC80 151887 chr3 2.198874929 1.065549344 1.169874992 FALSE
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cg25066665 ENSG00000163125 RPRD2 chr1
cg16736018 ENSG00000237588 RP11-66D17.3 chr1
cg13052638 ENSG00000261000 Unknown chr1
cg26362491 ENSG00000229367 HMGN2P19 chr1
cg00659878 ENSG00000229367 HMGN2P19 chr1
cg24339574 ENSG00000224939 LINC00184 chr1
cg12720965 ENSG00000232192 Unknown chr1
cg19749001 ENSG00000264010 MIR4429 chr2
 cg25785303 ENSG00000264010 MIR4429 chr2
cg26563141 ENSG00000229604 MT−ATP8 chr2
cg13231117 ENSG00000229689 AC009237.8 chr2
cg01882471 ENSG00000239795 AC109826.2 chr2
cg27612889 ENSG00000138386 NAB1 chr2
cg17974460 ENSG00000222972 Unknown chr2
cg14731570 ENSG00000261829 Unknown chr2
cg01070987 ENSG00000206199 ANKUB1 chr3
cg10636490 ENSG00000206199 ANKUB1 chr3
cg09406615 ENSG00000114200 BCHE chr3
cg12494166 ENSG00000251129 RP11-734I18.1 chr4
cg15885430 ENSG00000250020 RP11-811I15.1 chr5
cg03512172 ENSG00000251532 Unknown chr5
cg11599887 ENSG00000251532 Unknown chr5
cg27039593 ENSG00000251532 Unknown chr5
cg08808615 ENSG00000251532 Unknown chr5
cg18634758 ENSG00000251532 Unknown chr5
cg16292885 ENSG00000251532 Unknown chr5
cg18262197 ENSG00000251532 Unknown chr5
cg18895088 ENSG00000251532 Unknown chr5
cg21129181 ENSG00000251532 Unknown chr5
cg21771528 ENSG00000248693 CTD-2023M8.1 chr5
cg21806580 ENSG00000248693 CTD-2023M8.1 chr5
cg22422937 ENSG00000251675 Unknown chr5
cg23311108 ENSG00000185641 Unknown chr5
cg12949141 ENSG00000249119 MTND6P4 chr5
cg06793849   ENSG00000253925 Unknown chr5
cg11061434 ENSG00000253925 Unknown chr5
cg10647925 ENSG00000253925 Unknown chr5
cg22871227 ENSG00000249031/SUMO2P6 chr5
cg14429919 ENSG00000229282 Unknown ch6
 cg00660009 ENSG00000229282 Unknown ch6
cg24395504 ENSG00000220181 Unknown ch6
cg01196858 ENSG00000227014 Unknown chr7
cg06133110 ENSG00000227014 Unknown chr7
cg14399183 ENSG00000235865 GSN−AS1 chr9
cg12867448 ENSG00000136811 ODF2 chr9
cg09337049 ENSG00000242853 Unknown chr10
cg24232869 ENSG00000226138 SENP1/SUMO1 chr12
cg16264616  ENSG00000250133 HOXC−AS2 chr12
cg19794507 ENSG00000250133 HOXC−AS2 chr12
cg09941406 ENSG00000250133 HOXC−AS2 chr12
cg20340866 ENSG00000250133 HOXC−AS2 chr12
cg06208615 ENSG00000257342 Unknown chr12
cg11899507 ENSG00000200135 Unknown chr12
cg21532408 ENSG00000134864 A2LD1 chr13
cg10256726 ENSG00000151327 FAM177A1 chr14
cg19664425 ENSG00000258377 Unknown chr14
cg13704629  ENSG00000176043 Unknown chr14
cg24043861 ENSG00000176043 Unknown chr14
cg13158272 ENSG00000156030 C14orf43 chr14
cg10356657 ENSG00000258749 Unknown chr14
cg06897120 ENSG00000261612 SUB1P3 chr16
cg20438687 ENSG00000230201 ATP6V0CP1 chr17
cg12608565 ENSG00000205710 C17orf107 chr17
cg05529816 ENSG00000205710 C17orf107 chr17
  cg14275842 ENSG00000205710 C17orf107 chr17
 cg07834574 ENSG00000205710 C17orf107 chr17
 cg09036188 ENSG00000205710 C17orf107 chr17
cg14482741 ENSG00000205710 C17orf107 chr17
 cg20814095 ENSG00000205710 C17orf107 chr17
  cg21071097 ENSG00000205710 C17orf107 chr17
cg12323063 ENSG00000267653 Unknown chr17
cg24449629 ENSG00000243680 Unknown chr19
cg09923107 ENSG00000264395 MIR3193 chr20
cg00494337 ENSG00000264395 MIR3193 chr20
cg17499729 ENSG00000214889 RPS9P1 chr21
cg20341238 ENSG00000188660 LINC00319 chr21
cg23454038 * ENSG00000247993 FOXD1 chr5
cg08957069 * ENSG00000221191 AL662890.1 chr6
cg04559779 * ENSG00000207816 MIR124−2 chr8
cg20771240  *
cg06769296*
cg22771759 *
cg17537073 *
ENSG00000254648 RP11-713P17.4 chr11
ENSG00000234627 NUS1P3 chr13
Probes Ensembl Gene ID Gene Chomosome
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Appendix E3: A list of probes, which are either hypermethylated (shaded grey) or 
hypomethylated in BBM compared to primary breast tumours and normal breast 
tissues. * Indicates probes located in regions other than the gene promoter. 
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Abstract
Background: Tumour metastasis to the brain is a common and deadly development in certain cancers; 18–30 %
of breast tumours metastasise to the brain. The contribution that gene silencing through epigenetic mechanisms
plays in these metastatic tumours is not well understood.
Results: We have carried out a bioinformatic screen of genome-wide breast tumour methylation data available at
The Cancer Genome Atlas (TCGA) and a broad literature review to identify candidate genes that may contribute
to breast to brain metastasis (BBM). This analysis identified 82 candidates. We investigated the methylation status
of these genes using Combined Bisulfite and Restriction Analysis (CoBRA) and identified 21 genes frequently
methylated in BBM. We have identified three genes, GALNT9, CCDC8 and BNC1, that were frequently methylated
(55, 73 and 71 %, respectively) and silenced in BBM and infrequently methylated in primary breast tumours. CCDC8
was commonly methylated in brain metastases and their associated primary tumours whereas GALNT9 and BNC1
were methylated and silenced only in brain metastases, but not in the associated primary breast tumours from
individual patients. This suggests differing roles for these genes in the evolution of metastatic tumours; CCDC8
methylation occurs at an early stage of metastatic evolution whereas methylation of GANLT9 and BNC1 occurs
at a later stage of tumour evolution. Knockdown of these genes by RNAi resulted in a significant increase in
the migratory and invasive potential of breast cancer cell lines.
Conclusions: These findings indicate that GALNT9 (an initiator of O-glycosylation), CCDC8 (a regulator of microtubule
dynamics) and BNC1 (a transcription factor with a broad range of targets) may play a role in the progression of primary
breast tumours to brain metastases. These genes may be useful as prognostic markers and their products may provide
novel therapeutic targets.
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Background
Brain metastases account for up to 40 % of all secondary
tumours, with an estimated 27,000 new cases every year
in the UK [1, 2]. Current estimates suggest that 18–30 %
of patients with breast cancer eventually develop brain
metastases [3–6]. The frequency of metastatic brain
tumours is rising; this increased incidence is due, in part,
to an ageing population, improved neuroimaging and
increased patient survival following primary tumour treat-
ment [7]. Currently, brain metastases are treated by whole
brain radiotherapy, stereotactic radiosurgery and surgical
resection either individually or in combination [8].
However, following treatment, patient prognosis remains
poor; both morbidity and mortality are high and the
median survival is approximately 7 months [9].
Evidence indicating that tumours originating in specific
organs favour certain sites of metastasis has existed for
over 50 years [10]. However, the underlying mechanisms
of this organotropism towards specific secondary sites
such as the brain are still poorly understood. Although the
genetic basis of primary tumour formation is becoming
increasingly clear [11], it is still unclear which of the many
hundreds of tumour-associated alterations found in
primary breast cancer [12, 13] contribute to metastasis
and moreover, metastasis to specific secondary sites
such as the brain. The primary tumour types that most
frequently metastasise to the brain are lung, breast,
melanoma and renal cancers. However, the speed at which
these secondary tumours develop varies greatly with
breast to brain metastases (BBM) occurring relatively
slowly [7]. This specificity indicates that, at least in part,
genomic alterations that drive tumour formation in these
primary organs provide the potential for colonization of a
distinct subset of secondary organ sites.
There is little in the way of prognostic markers for
BBM. It is known that the risk of BBM occurring early
(<2 years after primary diagnosis) is associated with early
onset tumours, estrogen receptor negative (ER-ve),
human epidermal growth factor receptor 2 overexpression
(HER2 + ve) and triple negative (ER-ve/PR-ve/HER2-ve)
phenotypes [14–17]. However, more than 50 % of BBMs
occur over 5 years after the primary tumour was diagnosed.
Many of these late recurring brain metastases are derived
from ER+ primary tumours [4, 9, 18]. The common long
lag-time between primary tumour diagnosis and recurrence
of a detectable secondary tumour suggests that cells from
these breast tumours undergo a period of dormancy
[19, 20]. These dormant cells are often found as microme-
tastases in bone marrow. However, the presence of these
micrometastases is not in itself a strong prognostic indica-
tor for later metastatic disease [21, 22]. It is possible that
brain micrometastases are common, and these require
further genomic alterations to occur before sustained
proliferation and growth occurs.
Genomic alterations that provide the potential for meta-
static growth can be characterised as either those that
also drive primary tumour growth advantage, those
that provide potential for dissemination and infiltration
[23] or those that enable continued growth within the
microenvironment of the new organ [24]. A number
of genetic and epigenetic alterations acquired by breast
tumour micrometastases of the bone have been charac-
terised [25, 26]. However, very little is known about
specific genomic alterations that facilitate colonisation
in the brain.
We have carried out a screen to identify genes frequently
dysregulated through promoter hypermethylation in BBM.
This analysis has identified candidate genes that are either
dysregulated early in tumour evolution (methylation is
common to primary tumour and resulting BBM) or at a
later stage, once the cells that will evolve into the BBM have
disseminated from the primary tumour. We hope that this
preliminary analysis may provide initial evidence of
novel targets that can be utilised in the development of
prognostic screens and new rational therapeutic approaches
for breast tumours and brain metastases.
Methods
Selection of candidate metastatic suppressor genes
For an overview of our candidate selection strategies see
Additional file 1: Figure S1. We utilized the Illumina
HumanMethylation 450 K BeadChip methylation array
data from The Cancer Genome Atlas (TCGA) to identify
candidate genes (Additional file 2: Table S1 for TCGA
tumour barcodes). To ensure we were selecting genuine
promoter-associated CpG islands, we selected only those
probes that are located in the 5′ region of the gene or
up to 1500 base pairs from the transcription start site
(identified in the array annotation as TSS, TSS200,
TSS1500). We identified individual probes that are not
methylated (β value ≤ 0.25) in 75 % (15/20) of primary
breast tumours and methylated (β value ≥ 0.60) in primary
lung tumours, in at least 50 % (10/20) of the samples.
This analysis generated four candidates that were then
characterised in the laboratory.
In addition to our bioinformatic analysis, we carried
out a broad literature review to identify candidate
genes. We generated a long-list of genes that had pre-
viously been identified as hypermethylated in one of
the primary tumours types that readily metastasise to
the brain (lung, melanoma or renal [7]). We expanded this
long-list by selecting genes that are downregulated in
epithelial-mesenchymal transition (EMT) and that
possess a well-defined promoter region CpG island.
By interrogating all the available breast tumour methyla-
tion data in the TCGA by using their data portal
(https://tcga-data.nci.nih.gov/tcga/), we shortlisted only
those genes that were infrequently methylated in primary
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breast tumours. This analysis generated 78 candidates that
were then characterised in the laboratory.
Patients and samples
Thirty-one fresh-frozen metastatic brain tumours ori-
ginating from primary breast tumours were provided
by The Walton Research Tissue Bank, Liverpool and Brain
Tumour North West (BTNW) Tissue Bank, Preston.
Eleven pairs of formalin fixed paraffin embedded (FFPE)
primary breast tumours corresponding to matched
metastatic brain tumours were provided by BTNW
tissue bank. Receptor status information is available
for 9 of the 11 primary tumour pairs, six of these are
ER + ve, one is triple negative. The time between primary
tumour surgery and removal of the brain metastasis
ranges from 2 to 10 years (Additional file 3: Table S2a).
A cohort of 40 independent primary breast tumours
was also analysed. All breast tumours from this cohort
were ducal carcinomas; their clinical characteristics are
described in [27]. Molecular characterisation was available
for 20 of these tumours, 15 of these are ER + ve and three
are triple negative. No brain metastases were observed in
any of these patients, nine patients had been screened
for metastasis 10 years or more post-primary tumour
surgery and 17 of the 20 after more than 5 years
(Additional file 3: Table S2b).
Tissues were obtained from National research Ethics
committee approved research tissue banks, and informed
consent was obtained from each patient. This study was
conducted according to the principles expressed in the
Declaration of Helsinki.
Breast cancer cell Lines and 5-Aza-2′–deoxycytidine
treatment
Five breast cancer cell lines (MCF7, T74D, MDA-MB231,
BT549 and ZR75) were routinely maintained in DMEM
(Sigma, UK) supplemented with 10 % FCS at 37 °C and 5 %
CO2. Cells were plated according to their doubling time to
ensure that both control and 5-AZA-2′-deoxycytidine
(5-AZA-dC; Sigma, UK)-treated cells lines were approxi-
mately 75 % confluent at the time of RNA extraction.
5-AZA-dC was freshly prepared in ddH2O and filter
sterilized. Twenty-four hours after seeding, cells were
treated with 5 μM 5-AZA-dC. Cells were treated with
fresh 5 μM 5-AZA-dC three times a week on alternate days.
After 7 days, the cells were collected using 1 % trypsin; cell
pellets were washed with PBS.
Genomic DNA/RNA extraction
Genomic DNA was extracted from fresh-frozen metastatic
brain tumours using The DNA isolation kit from cells and
tissues (Roche, Germany). Briefly, 25 mg of tissue was
homogenised using lysis buffer and incubated at 37 °C
for 30 min followed by addition of Proteinase K and
RNase solution. The samples were then centrifuged and
processed according to manufacturer’s instructions. For
FFPE samples, a FFPE DNA extraction kit (Qiagen, USA)
was used. Briefly, a small block of samples embedded with
paraffin was cut into thin sections and mixed with xylene
followed by 100 % ethanol. The samples were then proc-
essed according to manufacturer’s instructions. Similarly,
total RNA was extracted using the EZ-RNA extraction kit
(Biological Industries, Israel). Briefly, fresh-frozen tumours
were homogenized using lysis buffer followed by addition
of extraction solution. The samples were then centrifuged
and processed according to manufacturer’s instructions.
DNA concentration was measured using a nanodrop2000
(Thermo Scientific, USA).
Bisulfite conversion of DNA
Bisulfite conversion of genomic DNA from metastatic
brain tumours (500 ng) and positive controls was carried
out using the EZ DNA methylation kit (Zymo Research
Corp., USA) according to manufacturer’s instruction. Fully
methylated, positive controls were generated by incubating
gDNA with DNA methyltransferase, in the presence of
S-Adenosyl methionine (SAM) (New England bio lab, USA)
for 2 h at 37 °C prior to bisulfite conversion.
Promoter methylation analysis
Primers used to amplify promoter regions from bisulfite-
modified DNA can be found in Additional file 4: Table S3.
Primers were designed based on standard bisulfite DNA
primer designing criteria [28]. These primers were used to
amplify bisulfite converted DNA. DNA methylation was de-
termined by digesting Combined Bisulfite and Restriction
Analysis (CoBRA) PCR products with the BstUI and TaqI
restriction enzymes (Fementas, UK).
Quantitative methylation analysis of tumour DNA was
carried out by cloning bisulfite-PCR products (individual
alleles) into pGEM plasmid (Promega, UK) followed by
sequencing of individual clones using primers to M13.
The CpG island regions of BNC1, CCDC8 and GALNT9
are presented in Additional file 5: Figure S2, details of PCR
primer sites and individual CpG dinucleotides analysed by
sequencing are provided.
Migration assay
Candidate genes were knocked down in breast cancer
cell lines by transfection of RNAi ‘silencer select’ oligos
against CCDC8 (s228331), BNC1 (s2012) or GALNT9
(s27040), control cells were transfected with control
oligo no. 1 (Ambion, Austin, TX, USA). After 24 h,
DMEM with 10 % FBS was replaced with fresh DMEM
without FBS and incubated at 37 °C for 24 h. Confluent
monolayer of cells in each well was scratched with the
tip of a 200 μl pipette tip. The extent of migration of
cells was observed after 24 and 48 h.
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Invasion assay
Two hundred microlitres of matrigel matrix (Becton
Dickinson, NJ, USA) was applied to 24-well 9-mm inserts
containing polyethylene terephthalate (PET) membranes
with 8-um pores (Corning, USA). One hundred fifty
thousand cells were applied to the invasion chamber.
DMEM containing 10 % FBS was placed in the lower
chamber as a chemoattractant. The plates were incubated
at 37 °C for 48 h with 5 % CO2. Cells from the lower layer
were stained with crystal violet. The optical density at
540 nm for each well was determined.
Western blotting
Cells were lysed in RIPA buffer (25 mM HCL, 0.1 %
SDS, 1 % triton 100, 0.15 M NaCl) containing phosphatase
and protease inhibitor (Roche, Germany). Seventy micro-
grams of each extract was resolved on polyacrylamide gels
and probed with anti-rabbit primary antibody against
CCDC8 (ab170233), BNC1 (ab123645) or GALNT9
(ab173682) (Abcam, USA). Signals were detected with
horseradish peroxidase-conjugated anti-rabbit antibody
(GE Healthcare, UK) and enhanced chemiluminescence
(Biological Industries, Israel). Membranes were stained
with India ink (Winsor and Newton, UK) for comparison
of loading.
Results
Screening of candidate BBM suppressor genes
We have used a candidate gene approach to identify
genes deregulated in breast tumours that metastasise
to the brain. See Additional file 6: Table S4 for details
of genes.
Bioinformatic analysis of primary tumour genome-wide
methylation arrays identified four candidate BBM
suppressor genes
We have compared the methylation status (β value) of
array probes in TCGA data sets from 20 primary breast
tumours (with no evidence of metastatic disease) and
20 primary lung tumours. We hypothesised that genes
that are infrequently methylated in non-metastasising
breast tumours and frequently methylated in primary
lung tumours that readily metastasis to the brain
(metastases are identified relatively soon after primary
tumour diagnosis) [29] may be commonly methylated
in metastatic brain tumours that derive from both lung
and breast tumours.
We filtered probes in primary breast tumours to
identify those that are infrequently methylated, (having a
β value ≤ 0.25 in at least 15/20 (75 %)). This resulted
in 97,155 probes. Filtering of frequently methylated
probes, (having a β value ≥ 0.60 in at least 50 % (10/20)) in
lung tumours resulted in 45,382 probes. Comparison of
the probes between breast and lung tumours identified
eight probes that corresponded to six genes (GALNT9,
KRT222, PLEKHA6, TFAP2A, TSPAN4 and ZNF808).
Two of these genes (KRT222 and PLEKHA6) do not have
well-defined CpG islands. In total, this genome wide
approach identified four candidate genes (GALNT9,
TFAP2A, TSPAN4 and ZNF808) for further analysis.
A literature review identified 78 candidates BBM
suppressor genes
We have screened genes that have previously been
shown to be frequently methylated and silenced in at
least one of the primary tumours types that rapidly
(relative to many breast tumours) metastasise to the
brain, i.e. lung, melanoma and renal cell carcinoma
(RCC) [7]. We then interrogated TCGA to determine the
methylation status of these genes in primary breast
tumours. This screen identified 42 candidate meta-
static suppressor genes that are infrequently methylated
in primary breast cancer and frequently methylated in pri-
mary lung, melanoma or renal tumours (Additional file 6:
Table S4 and references therein).
In addition, we selected 36 metastasis suppressor candi-
dates that are downregulated during EMT (Additional file 6:
Table S4 and references therein).
Identification of frequently methylated genes in
metastatic brain tumours
The methylation status of 82 candidate genes was de-
termined by CoBRA [28] in 30 BBM. To ensure that
we were identifying genes which are enriched in the
population of patients with BBM that are most likely
to be clinically significant, we have imposed a high
cut-off of ≥50 % of all metastatic tumours being
methylated for a gene to be considered as frequently
methylated. For this preliminary screening, we have deter-
mined that a significant proportion of the promoters
within the tumour sample is methylated if there are clearly
observed digest products following restriction analysis.
From the panel of four genes selected from our
analyses of HumanMethylation 450 K BeadChip arrays
obtained from TCGA, only one gene, GALNT9, was
frequently methylated (55 %) in metastatic brain tumours
originating from primary breast tumours (see Table 1,
Fig. 1a, Additional file 7: Figure S3).
From our panel of 42 literature review candidate genes,
we identified ten genes that are frequently methylated
in brain metastases. These were HOXD3 (100 %),
CCDC8 (73 %), HOXB13 (80 %), ABCB1 (80 %),
PENK (80 %), BNC1 (71 %), PCDH8 (53 %), STAT3
(67 %), TNFRSF10D (60 %) and WIF1 (53 %) (see Table 1,
Fig. 1a, Additional file 7: Figure S3).
We proceeded to determine the methylation status of
these ten genes in an independent cohort of primary
breast tumours.
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In addition, from a panel of 36 genes downregulated
in EMT, we identified 10 genes frequently methylated in
metastatic brain tumours originated from primary breast
tumours. These were CLDN18 (100 %), KRT85 (100 %),
MIR127 (100 %), MIR433 (100 %), MIR23b (92 %),
KRT83 (84 %), MST1R (78 %), BVES (64 %), CLDN6
(55 %) and HOXD10 (55 %) (see Table 1, Fig. 1a). We
proceeded to determine the methylation status of these
ten genes in an independent cohort of primary breast
tumours.
A graphical overview of our candidate selection
process and results is presented in Additional file 1:
Figure S1.
GALNT9, BNC1 and CCDC8 are differentially methylated in
primary breast tumours and BBM
We have screened primary breast tumours for the pres-
ence of methylation in the genes that are frequently
methylated in BBM. To ensure that genes identified in
this study are clinically significant, we have imposed a
Table 1 Genes frequently methylated in breast to brain metastases. Twenty-one genes are frequently methylated in brain
metastases (n = 15) of which 18 genes are also frequently methylated in primary breast tumours (n = 20). Three genes, CCDC8,
BNC1 and GALNT9 (highlighted in grey), are infrequently methylated in primary breast tumours. These genes were further analysed
in 20 primary breast samples (n = 40 in total) and 15 breast to brain metastases (n = 30 in total)
Gene symbol Accession Gene name % of metastatic
tumours methylated
Function
CLDN18 NM_016369.3 Claudin 18 100 Intercellular adhesion molecule responsible for tight
junction strand formation [77]
KRT85 NM_002283.3 Keratin 85 100 Component of intermediate filament in epithelial cells
contributing to cell-cell adhesion [78–80]
MIR127 NR_029696.1 microRNA 127 100 Regulator of cell proliferation and senescence [81]
MIR433 NR_029966.1 microRNA 433 100 Deregulated in gastric cancer, regulator of cell migration
and drug response [82, 83]
HOXD3 NM_006898.4 HomeoboxD3 100 Proangiogenic transcription factor [84]
MIR23B NR_029664.1 microRNA 23b 92 Involved in cytoskeleton modelling, motility and
metastasis [85–88]
CCDC8 NM_032040.4 Coil coiled domain containing 8 73 Mutated in patients with 3 M syndrome [70]. Loss is
associated with genomic instability and aneuploidy [75].
KRT83 NM_002282.3 Keratin 83 84 Component of intermediate filament, contributes to cell
to cell adhesion [78, 80]
HOXB13 NM_006361.5 Homeobox B13 80 TSG for prostate cancer, inhibits androgen mediated
signalling [89]
ABCB1 NM_000927.4 ATP-binding cassette
sub-family B member 1
80 Controls efflux of substances across plasma membranes,
associated with multidrug resistance [90]
PENK NM_006211.3 Proenkephalin 80 Promotes RNA splicing in osteoblasts and neural
cells, plays role in bone development [91]
MST1R NM_002447.2 Macrophage stimulating
1 receptor
78 Involved in intracellular signalling cascades leading to
cellular growth, motility and invasion [92]
BNC1 NM_001717.3 Basonuclin 1 71 Zink finger transcription factor, regulator of EMT [68]
PCDH8 NM_002590.3 Procadhern 8 73 Helps in cell to cell adhesion [93]
STAT3 NM_139276.2 Signal transducer and
activator of transcription 3
67 Involved in embryonic stem cell regulation, somatic cell
growth [94–96]
BVES NM_007073.4 Blood vessel epicardial substance 64 Involved in inter-cellular interaction and cell adhesion [97]
TNFRSF10D NM_003840.4 Tumour Necrosis Factor
receptor superfamily 10 D
60 Member of TNF (Tumour Necrosis Factor) receptor
superfamily, promotes apoptosis in cancer cells [98]
CLDN6 NM_021195.4 Claudin 6 55 Intercellular adhesion molecules responsible for tight
junction strand formation, its epigenetic silencing is
associated with migration and invasiveness of breast
cancer [77, 99]
HOXD10 NM_002148.3 Homeobox D10 55 Maintain epithelial cell plasticity and contributes to
stability of extracellular matrix [100]
GALNT9 NM_001122636.1 N-acetyl galactosaminyl
transferase 9
55 Catalyzes O-glycosylation [53, 101]
WIF1 NM_007191.4 Wnt inhibitory factor-1 gene 53 Inhibitor of Wnt-signalling [102, 103]
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relatively low cut-off frequency of ≤45 % for methylation
in primary breast tumours.
We analysed the 21 genes that were frequently methylated
in BBM in a cohort of 40 primary breast tumours (unrelated
to the brain metastasis cohort [27]).
We found GALNT9 to be frequently methylated in
BBM (55 %) and not methylated in any of the 40 primary
breast tumours (p = 0.0001).
From a panel of ten genes frequently methylated in
brain metastases (from our literature review candidates),
we identified that eight of these genes were also frequently
methylated in primary breast tumours. These are HOXD3
(81 %), HOXB13 (53 %), ABCB1 (68 %), PCDH8 (54 %),
PENK (79 %), STAT3 (57 %),TNFRSF10D (75 %) andWIFI
(55 %) (Fig. 1a). This suggests that these genes are not
uniquely epigenetically deregulated during the process of
BBM. However, it is worth noting that to our knowledge
this is the first time that promoter methylation in CCDC8,
HOXD3, PCDH8, PENK, STAT3, SFRP2 and WIFI has
been described in primary breast tumours.
Promoter methylation of BNC1 (17 %) and CCDC8
(40 %) in primary breast tumours was infrequent (≤45 %),
and statistically significantly lower than that of the
frequency of methylation in BBM (p = 0.0001 and
0.01, respectively) (Fig. 1a). The low frequency of
methylation in primary tumours indicates that BNC1 and
CCDC8 may contribute to BBM and are good candidates
for further investigation.
We found that all ten EMT-related genes were frequently
methylated in primary breast tumours, i.e. CLDN18
(100 %), KRT85 (100 %),MIR127 (100 %),MIR433 (100 %),
MIR23b (60 %), KRT83 (100 %), MST1R (60 %), BVES
(60 %), CLDN6 (50 %) and HOXD10 (55 %) (Fig. 1a). The
high frequency of methylation in primary tumours
indicates that epigenetic deregulation of these genes is not
driving BBM.
From our broad-ranging screens, we have identified
GALNT9, BNC1 and CCDC8 as frequently methylated in
BBM and significantly less frequently methylated in primary
breast tumours (Fig. 1, Additional file 8: Figure S4).
To ensure that CoBRA digests were representative of
high methylation status in tumours, we carried out base-
resolution analysis of promoter region methylation for
BNC1, CCDC8 and GALNT9 by cloning and sequencing
individual bisulfite-modified alleles from select tumours
(Additional file 9: Figure S5). This analysis was used
to determine the methylation index (MI) of CpG
islands for individual tumours. MI is defined as the
total number of methylated CpG dinucleotides given as a
percentage of all CpGs analysed. The MI for regions
determined to be methylated by CoBRA ranged from
60 to 91 % whereas those promoters deemed not to
be methylated by CoBRA had MIs ranging between 0 and
36 %. From this analysis, we have defined that, for these
samples, physiologically significant methylation levels are
those of ≥60 % MI and lack of physiologically significant
methylation is defined as <40 % MI.
Expression analysis of BNC1, CCDC8 and GALNT9 in
metastatic brain tumours
Having identified three candidate genes that are differen-
tially methylated in primary breast tumours and metastatic
brain tumours, we proceeded to determine if this promoter
methylation correlated to gene expression.
Total RNA was extracted from 15 metastatic brain
tumours to determine the expression of BNC1, CCDC8
and GALNT9 by RT-PCR. The expression level of each
gene was quantified in relation to the expression of
β-actin, in tumours with unmethylated promoters
(MI = 0–25 %). The maximum expression of these
genes was 49, 23 and 33 % that of β-actin, respectively.
BNC1, CCDC8 and GALNT9 were frequently downregu-
lated or silenced in these tumours and reduced expression
correlated to promoter methylation as determined by
CoBRA and base-resolution sequencing (Fig. 1b and c,
Additional file 10: Figure S6). These genes were also
commonly silenced in breast cancer cell lines, this
silencing was reversed following treatment with 5-Aza-
2′-deoxycytidine an inhibitor of DNA methyltransferase
enzymes [30] (Additional file 11: Figure S7).
Promoter methylation status of BNC1, CCDC8 and GALNT9
in brain metastases and associated primary breast
tumours from individual patients
We analysed the methylation status BNC1, CCDC8 and
GALNT9 in metastatic brain tumours and corresponding
(See figure on previous page.)
Fig. 1 a Methylation frequency of candidate metastatic suppressor genes in breast-to-brain metastases (BBM) (n = 30) versus primary breast
tumours (n = 40). Out of the 25 genes that were frequently methylated in brain metastases, three genes (GALNT9, CCDC8 and BNC1) were
infrequently methylated in a cohort of independent primary tumours with statistical significance (p = 0.0001, 0.01 and 0.0001, respectively).
b, c Expression of GALNT9, CCDC8 and BNC1 correlates with promoter methylation in BBM. Reverse transcription PCR (RT-PCR) for GALNT9,
CCDC8 and BNC1 in BBM shows that these genes were expressed in tumours where their promoters are unmethylated (U) and silenced in
methylated (M) tumours (see Additional file 7: Figs S3 and Additional file 9: Figure S5 for representative methylation analysis). Expression of
β-actin was determined to ensure equal loading for all samples. c Expression levels of each gene were quantified in relation to the expression
of β-actin. The methylation status was determined by either CoBRA or sequencing of individual alleles to determine the methylation index
(MI) for individual tumours. High levels of expression were not associated with high levels of methylation in the region analysed. A full set of methylation/
expression analysis can be seen in Additional file 10: Figure S6 (BM brain metastasis, Mmethylated, U unmethylated, − analysis was not done)
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primary tumours from individual patients. We had ten
pairs, however, some loci in the primary tumour DNA
proved refractive to amplification. Of eight matched
pairs, where the BNC1 promoter region was successfully
amplified, the region was methylated in all eight of the
brain metastases. However, it was only methylated in one
corresponding primary tumour (Fig. 2a). The GALNT9
promoter was methylated in 3/5 brain metastases and not
methylated in any of the corresponding primary breast
tumours (Fig. 2b). In contrast, out of 11 matched pairs,
CCDC8 was commonly methylated in 10 correspond-
ing primary tumours (Fig. 2c). This common CCDC8
Fig. 2 Methylation status of GALNT9, CCDC8 and BNC1 in metastatic brain tumours and their corresponding originating primary breast tumours
from individual patients. CoBRA was used to determine methylation status; small, digested PCR products in the Bstu1 cut (C) lane compared to
the undigested (U) lane indicates promoter methylation in a sample. a GALNT9, b CCDC8 and c BNC1 were frequently methylated (*) in metastatic
brain tumours (BM). However, GALNT9 and BNC1 were not commonly methylated in the originating breast primary (BP) tumours (a, c). CCDC8
promoter was methylated in both the originating primary tumours (BP) and the associated brain metastases (BM) from individual patients (b). Of
eight matched pairs analysed, BNC1 was methylated in all metastatic brain tumours whereas it was methylated in only one of the corresponding
primary tumours (for example, see patients 2, 3 and 8). Of six matched pairs analysed, GALNT9 was methylated in three metastatic brain tumours
(see patients 1 and 12), whereas it was not methylated in any of the corresponding primary tumours. Of 11 matched pairs analysed, CCDC8 was
methylated in ten metastatic tumours and all corresponding primary tumours (for example, see patients 1, 3 and 5). However, it was not
methylated in normal tissue (BN) adjacent to the primary breast tumour (see patient 1). (BP breast primary tumour, BM metastatic brain tumour,
BN adjacent normal breast tissue, U uncut/control sample, C cut by methylation specific restriction enzyme, *methylated samples)
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methylation in primary breast tumour and resulting brain
metastasis was confirmed by sequencing individual alleles
for pairs of tumours from two patients (patient 11 and 15
(BM11, Primary BT 11 and BM15, Primary BT 15)). Both
primary tumour DNA and BM DNA were found to have
MIs above 73 % (Additional file 9: Figure S5a).
These results suggest that BNC1 and GALNT9 pro-
moter methylation occurs at a late stage in the evolution
of metastatic brain tumours, possibly after they have
metastasised to the brain. Alternatively, methylation of
these genes may occur in a small subset of cells within
the primary tumour (below the detection threshold of
this assay), and these cells are enriched in the metastatic
tumour. In contrast, CCDC8 promoter methylation is
detectable in most primary tumours that metastasise to
the brain, suggesting that it may play an important role
in the early stages of primary tumour metastasis.
Loss of GALNT9, CCDC8 or BNC1 expression increases
metastatic potential
We have identified that CCDC8 is dysregulated at an early
point of BBM, and its promoter methylation is detectable
in the primary tumours that proceed to metastases.
GALNT9 and BNC1 methylation is uncommon in primary
breast tumours and is often not detectable in the tumours
that metastasise. These differences suggest that loss of
these genes confers metastatic potential though alter-
native mechanisms. However, loss of BNC1 or CCDC8
expression has previously been shown to increase the
clonagenic potential of RCC cell lines [31, 32]. Loss
of GALNT9 has yet to be directly linked with increased
malignancy. We have investigated the effect that loss of
these genes has on metastasis-related properties of breast
cancer cell lines.
Loss of GALNT9, CCDC8 or BNC1 expression increases
breast cancer cell line cell motility
Forty-eight hours after initial transfection with siRNA
oligos against BNC1, CCDC8 or GALNT9 breast cancer
cell lines showed loss of specific gene expression
(Additional file 12: Figure S8).
In a wound-healing assay, knockdown of these genes
increased migratory potential compared to cell lines
transfected with control oligos. The increase in motility of
cell lines following knockdown of BNC1 (Fig. 3a), CCDC8
(Fig. 3b) or GALNT9 (Fig. 3c) was statistically significant
compared to control cells (scrambled siRNA transfected)
Fig. 3 Loss of CCDC8, BNC1 or GALNT9 expression increases the migratory potential of breast cancer cell lines. Breast cancer cell lines that
expressed CCDC8, BNC1 or GALNT9 were identified; the expression of these genes was knocked down by siRNA (see Additional file 11: Figure S7
and Additonal file 12: Fig. S8). a T47D cell lines transfected with siRNA oligos against CCDC8; b MCF7 cell lines transfected with siRNA oligos
against BNC1 or c MDA-MB231 cell lines transfected with siRNA against GALNT9 exhibited more migratory potential compared to respective cell
lines transfected with control siRNA oligos. Following siRNA transfection, confluent cells were incubated in serum-free media and an artificial wound
was scratched through them (0 h). Forty eight hours later the distance migrated was calculated by subtracting the value of non-migrated distance
from the initial would. The distance migrated (in percentage) by respective cell lines knocked down with siRNA against CCDC8, BNC1 or GALNT9 in
compared to the respective cell lines transfected with control siRNA oligos was statistically significant (p = 0.001, 0.011 and 0.027, respectively)
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(BNC1, p = 0.011; CCDC8, p = 0.001; GALNT9, p = 0.027).
All experiments were repeated in triplicate.
Reduced expression of GALNT9, CCDC8 or BNC1 increases
invasive potential
GALNT9, BNC1 and CCDC8 were knocked down in breast
cancer cell lines by siRNA and applied to matrigel-coated
invasion chambers as described in the methods.
Forty-eight hours later, cells that had ‘invaded’ were
isolated and quantified.
Following knockdown of GALNT9, 35 % more cells
invaded (p = 0.025) compared to cell transfected with the
control scrambled siRNA (Fig. 4a). Following knockdown
of CCDC8, 27 % more cells invaded, (p = 0.021) (Fig. 4b).
The number of breast cancer cell that invaded following
BNC1 knocked down was increased by 40 % (p = 0.006)
(Fig. 4c).
Increased motility and invasive potential following re-
duction of expression of these genes suggests that these
candidates may be involved in the regulation of normal
cellular physiology and that loss of their expression may
contribute the metastatic process.
Reduced expression of GALNT9 or CCDC8 is significantly
associated with poor relapse-free survival
The clinical significance of the expression of BNC1,
CCDC8 and GALNT9 was analysed using publically
available GEO expression profiles using the prognoscan
database [33]. Prognoscan partitions a patient population
into high-expressor and low-expressor group for each
gene by choosing a threshold that maximises the statis-
tical significance of difference in outcome. It corrects
for multiple testing using the method of Miller and
Siegmund [34]. In two independent datasets, low CCDC8
expression was significantly associated with poor relapse
free survival (GSE12276, p = 0.001; GSE1456-GPL97,
p = 0.004) (Fig. 5a), and in one data set, low GALNT9
expression was associated with poor relapse free survival,
(GSE1379, p = 0.0029) (Fig. 5b). There was no evidence in
any of the datasets analysed that low BNC1 expression
correlated with poor relapse free survival or any other
clinical indicator.
Discussion
Given the extremely poor clinical outcome following a
diagnosis of BBM [9], it is imperative that the underlying
molecular biology that drives tumour evolution to the
colonization of the brain is elucidated.
To date, some progress has been made to identify
prognostic markers for breast cancer metastasis by
gene expression profiling [35]. However, prediction of
site-specific metastasis remains poor [36].
The importance of gene dysregulation by promoter
methylation as a mechanism of tumour evolution is now
well established [37]. Indeed, genome wide methylation
analysis of many hundreds of primary breast tumours
has allowed the definition of specific sub-categories of
breast tumours [12, 13], and our increasing understanding
of the molecular basis of these subtypes has improved our
ability to predict early metastatic recurrence [14, 38].
However, late recurrence, a common feature of BBM has
proven difficult to predict [39].
We have carried out a broad candidate approach
to identify genes that are dysregulated in BBM
(Additional file 1: Figure S1). This analysis has identi-
fied three genes (BNC1, CCDC8 and GALNT9) that
are differentially methylated in primary breast tumours
and BBM.
We predicted that our analysis of unrelated primary
breast tumours and BBM would identify two different
classes of genes that contribute to BBM, epigenetic si-
lencing of BBM associated genes would either occur
as (i) early events in tumour evolution that may be
involved in processes such as local invasion and intra-
vasion [40, 41] or these early events may be required
for specific distant site metastasis but also contribute
to primary tumour development or (ii) late events
that play no significant role in the initial evolution of
the primary tumour but contribute to the development of
the secondary brain metastasis, perhaps by improving the
capacity of these cells to survive in the foreign micro-
environment of the brain.
The existence of early and late events had previously
been proposed by Nguyen et al. [42], they classified
deregulated genes as either involved in (i) metastasis
initiation, detectable in the primary tumour, (ii) metastasis
progression genes, important for survival in the circulation
or required for extravasation, while occasionally present
in the primary tumour, they may also occur once metasta-
sising cells have left the primary site, or (iii) metastasis
virulence genes that allow the cancer cells to survive in a
foreign tissue environment. These are likely to occur as a
consequence of the selection pressure provided by the
novel environment the metastasised tumour cells find
themselves in. Metastasis progression genes may have
different functions in the primary tumour and distant
metastasis, for example, MMP-1 promotes vascular re-
modelling in primary breast tumours and also contributes
to lung extravasation [43]. An example of a known metas-
tasis virulence genes that does not contribute to primary
tumour growth is interleukin-11, which promotes breast
tumour metastasis to the bone but does not provide any
advantage to the primary tumour [44].
Both early and late methylation events will appear
similarly in our initial analysis; the genes will be fre-
quently methylated in BBM and infrequently methylated
in unrelated primary breast tumours, this is the case
for BNC1, CCDC8 and GALNT9 (Fig. 1). However, a
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comparison of primary tumours and BBM from the
same patient should reveal if specific gene methylation
occurs early or late in the process of tumour evolution.
Our analysis of such tumour pairs (Fig. 2) identified that
BNC1 and GALNT9 are not frequently methylated in any
breast tumours, even those that will eventually develop
into brain metastases where these genes are methylated.
Their methylation appears to be a late event in tumour
evolution/metastasis. However, the CCDC8 promoter
was commonly methylated in primary breast tumours
that eventually develop brain metastases and as such it
can be categorised as an early event in tumour evolution/
metastasis.
GALNT9 encodes a member of the UDP-N-acetyl-
α-D-galactosamine:polypeptide N-acetylgalactosaminyl-
transferase family of enzymes that catalyze the first step
of O-glycosylation; GALNAC-T9. GLANT9 is expressed
most abundantly in the brain and other CNS tissues. It is
also expressed, at lower levels, in a number of other
tissues including normal breast (GeneCards) [45].
Fig. 5 Loss of expression of CCDC8 and GALNT9 correlates with relapse-free patient survival. Kaplan–Meier analysis of multiple gene expression
studies via the prognoscan database revealed that in two separate studies low expression of a CCDC8 (p = 0.001) and b GALNT9 (p = 0.003) was
associated with poor relapse free survival
(See figure on previous page.)
Fig. 4 Reduced expression of GALNT9, CCDC8 or BNC1 increases the invasive potential of breast cancer cell lines. Trans-well invasion assays were
carried out following the knockdown of of GALNT9, CCDC8 or BNC1 in breast cancer cell lines. The invasive capacity of these cells was compared
with the same cell lines transfected with control siRNA oligos (control). The numbers of cells that had invaded a matrigel-coated micropore
membrane was determined colourimetrically 48 h after initial seeding. a MDA-MB231 cell lines transfected with siRNA oligos against GALNT9,
b T47D cell lines transfected with siRNA oligos against CCDC8 and c MCF7 cell lines transfected with siRNA oligos against BNC1 exhibited a
statistically significant increase in invasiveness compared to negative control siRNA transfected cells. p = 0.025 (GALNT9), p = 0.021 (CCDC8)
and p = 0.001 (BNC1). Invasive potential was calculated as a percentage increase above that observed for the control cells (% invasion)
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The GALNAC-T proteins initiate mucin type O-linked
glycosylation in the golgi apparatus by the covalent linkage
of an α-N-acetylgalactosamine (GalNAc) to Ser and Thr
residues [46]. O-Glycans play an important role in cell
adhesion and cell-cell communication, and dysregulated
glycosylation is a common characteristic of tumour cells
[47]. Mucin 1 (MUC1), in particular, has been identified
as a highly O-glycosylated transmembrane protein that is
dysregulated at the expression and posttranslational
level in multiple tumour types [47]. MUC1 is commonly
overexpressed but under-glycosylated in primary breast
tumours [48, 49], and the expression of under-glycosylated
MUC1 is associated with high tumour grade, metastatic po-
tential and invasiveness of breast tumours [50–52]. Loss of
GALNT9 expression in neuroblastoma has been linked to
a highly malignant phenotype and associated with poor
overall and disease free survival [53]. GALNT9 is a member
of a sub family (with GALNT8, 18 and 19) that differ
significantly in sequence from other GALNAC-T members
[54] and as such does not have catalytic activity towards
classic MUC1 variants derivatives [55, 56]. This suggests
that GALNT9 glycosylates a specific group of substrates
indicating a subtle regulation of transmembrane protein
function. Our findings of GALNT9 promoter methylation,
and associated loss of expression, in BBM, but not in
primary breast tumours suggest that this change in
transmembrane protein function may be a common
occurrence in the later stages of breast tumour brain
metastasis, and perhaps relates to cell-cell interaction that
the tumour cells must undergo before acquiring a suitable
niche to proliferate within the novel microenvironment of
the brain.
This is the first time that GLANT9 has been shown to be
dysregulated in cancer by promoter methylation. However,
conserved mutations have been identified in approximately
2 % of microsatellite instable colorectal cancers [57]
and GALNT9 is also mutated, infrequently (<1 %), in
astrocytoma [58] and lung tumours [59, 60] and infre-
quently lost through CNV in breast tumours [12, 60].
Basonuclin 1 (BNC1) is a zinc finger transcription
factor that interacts with the promoters of both RNA
polymerases I and II [61]. BNC1 target genes have
been implicated in a broad range of functions includ-
ing chromatin structure, transcription/DNA-binding,
adhesion, signal transduction and intracellular transport
[61–63]. It is expressed in a broad range of tissue types
(GeneCards) [45].
BNC1 has previously been shown to be silenced by
promoter methylation in lung [64], renal [31], pancreatic
[65], prostate [66] and leukemic cancers [67]. In vitro assays
have shown that loss of BNC1 expression is associated with
an increased malignant phenotype [31]. Consistent with
this study, analysis of HumanMethylation 27 and 450 K
array data from The Cancer Genome Atlas indicates that
BNC1 Promoter methylation is an infrequent event in
primary breast tumours [12]. However, frequent BNC1
promoter methylation (>60 %) in a small cohort of breast
tumours has previously been reported [64].
The expression of BNC1 is induced by transforming
growth factor-β1 signalling and, in turn, it acts as a
transcription factor for a number of modulators of
epithelial dedifferentiation during EMT [68]. Moreover,
loss of BNC1 expression results in a reduced EMT pheno-
type. These findings suggest that the expression of BNC1
would enhance the process of metastasis via EMT. Our
findings are consistent with this; we find that BNC1 is
infrequently methylated in primary breast tumours (17 %)
and frequently methylated and silenced in BBMs (73 %).
Moreover, we have shown that BNC1 promoter methyla-
tion is a late event in tumour evolution, only occurring in
the brain metastasis of a BBM patient and not in the associ-
ated primary tumour. It is plausible that BNC1 expression
is commonly required for EMT to occur during metastasis
and, once these cells have metastasised to the brain, loss of
BNC1 expression contributes to mesenchymal to epithelial
transition (MET).
An in vitro screen that consisted of multiple rounds of
breast cancer cell line injection into nude mice and recul-
turing of the resulting brain metastases showed that
BNC1 was among a large number of genes overexpressed
in mouse brain metastases [69]. This apparent difference
to our findings may be as a consequence of the model
used. Alternatively, it may represent important differences
in the process of aggressive early metastasis (as cell line
injection models represent) and slower metastatic evolu-
tion, where tumour cells proceed through a phase of
latency or micrometastasis. Many of the brain metastases
in our study were identified several years after initial
breast cancer diagnosis (Paired primary and BBM samples
were excised between 2 and 10 years apart).
CCDC8 encodes a coiled-coil domain containing
protein (CCDC8) that is one of three proteins that are
mutated in patients with 3 M syndrome [70], an auto-
somal recessive disorder characterised by short stature,
skeletal abnormalities, reduced male hormone and blood
vessel bulges [71–73]. CCDC8 is mutated in ~5 % of 3 M
cases, the other genes, CUL7 and OBSL1 are mutated
in ~65 % and ~30 % of cases, respectively [70, 74].
These three proteins form a complex (the 3 M complex)
and loss of expression of any one protein disrupts
microtubule dynamics resulting in dysregulated mitosis,
cytokinesis, associated genomic instability and aneuploidy
[75]. Moreover, it was shown that loss of any 3 M complex
protein significantly altered the interphase microtubule
network [75]. The core 3 M-protein complex interacts with
CUL9, which has been proposed to mediate the functions
of the 3 M complex via the ubiquitylation and degradation
of survivin [76]. The 3 M-complex also interacts with the F
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box protein FBXW8, ROC1 and the tumour suppressor
p53 [75] suggesting it may contribute to correct cellular
physiology through multiple mechanisms.
Despite the broad range and very different known
functions that these three proteins have it is interesting to
see that, at the level of in vitro assays, reduced expression
of any of them increases metastatic potential (Figs. 3, 4).
Conclusions
Our findings indicate that epigenetic dysregulation of
GALNT9, CCDC8 or BNC1 in breast tumours may
contribute to metastasis to the brain and possibly other
distant organs. CCDC8 dysregulation occurs early during
tumour evolution, in addition to being a potential thera-
peutic target this early inactivation has the potential to be
utilised as a prognostic biomarker. Further analysis will be
required including studies to determine if such epigenetic
markers can be discerned via non-invasive means such as
analysis of circulating tumour material in the patients
blood. GALNT9 and BNC1 promoter methylation and
associated silencing is common in BBM but does not
occur frequently in the originating breast tumours
suggesting that their dysregulation may not necessarily
benefit the primary tumour but are required for successful
colonization of the brain. Further studies will be required
to determine if these changes are detectable in circulating
tumour cells, micrometastases, or only in macroscopic
brain metastases. Our current understanding of the cellular
function of these genes is far from complete. However,
what is known about all three suggests that their dysregula-
tion may be more that just a marker for BBM. As such
these genes may represent novel therapeutic targets.
Additional files
Additional file 1: Figure S1. Graphical overview of methodologies
used and results obtained in this study. (A) A literature review was
carried out to identify genes that are methylated in lung, melanoma
and renal cancer as these often metastasise to the brain rapidly. If these
genes were not known to be frequently methylated in breast tumours
(that metastasise to the brain with a longer lag period) they were
considered as good candidates. (B) A literature review was carried out
to identify genes down regulated in Epithelial to Mesenchmal Transition
(EMT). (C) Analysis of genome-wide methylation data from The Cancer
Genome Atlas identified 4 genes frequently methylated in Lung tumours
and infrequently methylated in breast tumours with no evidence of
distant metastasis. Genes from these candidate lists were screened for
methylation in breast to brain metastases (BBM), those that were frequently
methylated were then screened for methylation in non-metastatic primary
breast tumours. Of the 82 genes analysed BNC1, CCDC8 and GALNT9
were frequently methylated in BBM and infrequently methylated in
non-metastatic primary breast tumours, suggesting a role in the evolution
of metastatic tumours.
Additional file 2: Table S1. TCGA tumour barcodes: Unique barcode of
Breast Invasive Carcinoma (BRCA) and Lung Adenocarcinoma (LUAD)
tumours from The Cancer Genome Atlas (TCGA) downloaded for
bioinformatic analysis to screen for candidate genes, which may
contribute to breast to brain metastases (BBM).
Additional file 3: Table S2. Molecular characteristics and other clinical
information relating to primary breast tumours analyzed in this study.
(A) Primary breast tumours that have metastasised to the brain. These
primary tumours have associated metastases analysed in this study.
(B) Primary breast tumours with no evidence of metastasis to the
brain. These patients have no evidence of developing brain metastases,
see Methods: Patients and samples for further details (N: Negative,
P: Positive; 0: Negative, 1: Positive).
Additional file 4: Table S3. Primers used in CoBRA and
Reverse-Transcription (RT) PCR. CoBRA (Combined Bisulphite and
Restriction Analysis) primers were designed to amplify promoter
regions of 82 genes In addition, RT primers were designed to
amplify transcripts of BNC1, CCDC8 and GALNT9 to investigate their
expression in breast cancer cell lines and breast to brain metastases.
F: Forward primer, IF: Internal Forward primer, IR: Internal Reverse
primer, R: Reverse primer.
Additional file 5: Figure S2. The promoter region/CpG islands of BNC1,
CCDC8 and GALNT9. The region amplified for CoBRA analysis is found
between the Internal Forward primer and the Reverse primer. CpG
dinucleotides are highlighted in bold. CpG dinucleotides analysed by
cloning and sequencing of individual alleles are numbered. An arrow
indicates the transcription start site.
Additional file 6: Table S4. Genes analysed for their methylation status
in breast to brain metastases (BBM) and their function. Methylation status
of CpG island promoter region of 82 genes (4 genes from our
bioinformatic screen and 78 genes from a broad literature review
including genes down regulated in Epithelial- Mesenchymal Transition)
was interrogated using Combined Bisulphite and Restriction Analysis
(CoBRA) in BBM (n=15). 21 genes were frequently methylated in BBM
(light grey background) of which, 3 genes (CCDC8, BNC1 and GALNT9)
(dark grey background) were infrequently methylated in an independent
cohort of primary tumours (n=15). These three genes were further analysed in
20 more primary breast samples (n=30 in total) and 15 more BBM (n=30).
Additional file 7: Figure S3. Methylation analysis of BNC1, CCDC8 and
GALNT9 in Breast to brain metastases. Up to 31 brain metastases (BM)
were analysed by CoBRA, small, digested PCR products in the Bstu1
cut (C) lane compared to the undigested (U) lane indicates promoter
methylation in a sample (SAM DNA: genomic DNA treated with
S-Adenosyl methionine and DNA methyltransferase as a positive control).
Additional file 8: Figure S4. Methylation status of GALNT9, CCDC8 and
BNC1 in metastatic brain tumours from primary breast tumours and a
cohort of unrelated primary breast tumours. (A) GALNT9 was frequently
methylated in metastatic brain tumours (55 %) and (B) was NOT
methylated in any of the primary tumours; (C) CCDC8 was frequently
methylated in metastatic brain tumours (73 %) and (D) infrequently
methylated in primary breast tumours (40 %). (E) BNC1 is frequently
methylated in metastatic brain tumours 68 % and (F) infrequently
methylated in a cohort of unrelated primary breast tumours (17 %). We
have determined that a significant proportion of the promoters within
the tumour sample are methylated if there are clearly observed digest
products following restriction analysis BM: Brain metastases, BP: Primary
breast tumours, U: Uncut/control sample, C: cut by restriction enzyme,
*: methylated samples).
Additional file 9: Figure S5. Bisulphite sequencing of individual alleles
form tumours. Tumours were analysed by cloning and sequencing
bisulphite-PCR products to determine the extent of methylation within
the region analysed by CoBRA. 10 clones/alleles were sequenced for
each tumour and the methylation index (MI) for each tumour determined.
(A) Tumours that were determined to have significant CCDC8 promoter
methylation by CoBRA (BM11, BM15, BM12 and BM14) had methylation
indices ranging from 66 %-90 %. The corresponding primary breast tumours
for BM11 and BM15 were also analyses these both had correspondingly
high MIs (82 % and 74 % respectively). Tumours that had no evidence of
CCDC8 promoter region methylation by CoBRA analysis (BM16, BM23) had
low MIs (8 % and 6 % respectively). (B) Tumours that were determined to
have significant BNC1 promoter methylation by CoBRA (BM13, BM14, BM15
and BM27) had methylation indices ranging from 60 %-86 %. Tumours that
had no evidence of BNC1 promoter region methylation by CoBRA analysis
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(BM11, BM23) had low MIs (0 % and 36 % respectively). (C) Tumours that
were determined to have significant GALNT9 promoter methylation by
CoBRA (BM12, BM20, BM27 and BM28) had methylation indices ranging
from 78 %-91 %. Tumour BM23 that had no evidence of GALNT9 promoter
region methylation by CoBRA analysis had a low MI (25 %). Each circle
represents a CpG island, those shaded black are methylated. MI is
defended as the total number of methylated CpG dinucleotides given
as a percentage of all CpGs analysed.
Additional file 10: Figure S6. Expression levels of BNC1. CCDC8 and
GALNT9 in all tumours analysed. The expression level of each gene was
quantified in relation to the expression of β-actin. Below each bar is the
methylation status of each CpG island as determined by CoBRA and
sequencing of individual alleles (MI) (BM: Brain Metastasis, MI: Methylation
index, M: Methylated, U: Unmethylated, -: analysis was not done).
Additional file 11: Figure S7. Global demethylation resulted in the
re-expression of GALNT9, CCDC8 and BNC1 in breast cancer cell lines. Re-
verse transcription PCR (RT-PCR) showed that treatment of breast
cancer cell lines with 5- 2-deoxycytidine (5-AZA-dC), an inhibitor of DNA
methyltransferase enzymes, resulted in re-expression of (A) GALNT9, (B)
CCDC8 or (C) BNC1 in the breast cancer cell line ZR75. For comparison,
endogenous expression is shown in (A) MDA-MD231, (B) T47D and (C)
MCF7, these, expressing, cell lines were used in our in vitro knock down
experiments.
Additional file 12: Figure S8. Knockdown of GALNT9, CCDC8, and BNC1
in breast cancer cell lines is confirmed by Reverse transcription (RT) PCR
and western blot. (A) RT-PCR of GALNT9, CCDC8, and BNC1 transcripts in
breast cancer cell lines (MDA-MD231, T47D and MCF7 respectively)
following siRNA knockdown compared to transfection with a control
siRNA and (B) western blot of GALNT9, CCDC8, and BNC1 proteins to
confirm their knockdown in each respective cell line. 70 μg of protein
was loaded in each lane. Equal loading was confirmed by staining total
protein with India ink.
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